-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, VfdLom7sTnjBaM0jYKFJxQ0IMSq5p2Pkr/1H3ShXCmzl2BVlqgmOBZ/0q91WLSSx K/biZA9czCUpiIYNSPb0dw== 0001157523-10-003143.txt : 20100513 0001157523-10-003143.hdr.sgml : 20100513 20100513164446 ACCESSION NUMBER: 0001157523-10-003143 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20100404 FILED AS OF DATE: 20100513 DATE AS OF CHANGE: 20100513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PFIZER INC CENTRAL INDEX KEY: 0000078003 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 135315170 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-03619 FILM NUMBER: 10829141 BUSINESS ADDRESS: STREET 1: 235 E 42ND ST CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 2125732323 MAIL ADDRESS: STREET 1: 235 E 42ND ST CITY: NEW YORK STATE: NY ZIP: 10017 FORMER COMPANY: FORMER CONFORMED NAME: PFIZER CHARLES & CO INC DATE OF NAME CHANGE: 19710908 10-Q 1 a6285704.htm PFIZER INC. 10-Q a6285704.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q

x  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended April 4, 2010

OR

TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

COMMISSION FILE NUMBER 1-3619

----
 
 
PFIZER INC.
(Exact name of registrant as specified in its charter)
 
DELAWARE
(State of Incorporation)
13-5315170
(I.R.S. Employer Identification No.)
 
 
235 East 42nd Street, New York, New York  10017
(Address of principal executive offices)  (zip code)
(212) 733-2323
(Registrant’s telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.
 
YES x                 NO o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
 
YES x                 NO o
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act (check one):
 
Large Accelerated filer x Accelerated filer o Non-accelerated filer o Smaller reporting company o
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

YES o                  NO x

At May 10, 2010, 8,066,133,809 shares of the issuer’s voting common stock were outstanding.
 
 

 
 
FORM 10-Q
 
For the Quarter Ended
April 4, 2010
 
Table of Contents
 
Page
   
 
 
 
   
 
3
   
 
4
   
 
5
   
 
6
   
 
20
   
 
 
21
   
 
 
48
   
 
 
48
   
 
 
   
 
 
48
   
 
 
51
   
 
 
51
   
 
 
52
   
 
 
52
   
 
 
52
   
 
53
 
 
2

 
 


CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
 
   
Three Months Ended
 
(millions, except per common share data)
 
April 4,
2010
   
Mar. 29,
2009
 
             
Revenues
  $ 16,750     $ 10,867  
                 
Costs and expenses:
               
Cost of sales(a)
    4,306       1,408  
Selling, informational and administrative expenses(a)
    4,436       2,876  
Research and development expenses(a)
    2,226       1,705  
Amortization of intangible assets
    1,409       578  
Acquisition-related in-process research and development charges
    74        
Restructuring charges and certain acquisition-related costs
    706       554  
Other (income)/deductions––net
    414       (57 )
                 
Income from continuing operations before provision for taxes on income
    3,179       3,803  
                 
Provision for taxes on income
    1,146       1,074  
                 
Income from continuing operations
    2,033       2,729  
                 
Discontinued operations – net of tax
    2       1  
                 
Net income before allocation to noncontrolling interests
    2,035       2,730  
                 
Less:  Net income attributable to noncontrolling interests
    9       1  
                 
Net income attributable to Pfizer Inc.
  $ 2,026     $ 2,729  
                 
Earnings per common share––basic:
               
Income from continuing operations attributable to Pfizer Inc. common shareholders
  $ 0.25     $ 0.41  
Discontinued operations––net of tax
     ––        ––  
Net income attributable to Pfizer Inc. common shareholders
  $ 0.25     $ 0.41  
                 
Earnings per common share––diluted:
               
Income from continuing operations attributable to Pfizer Inc. common shareholders
  $ 0.25     $ 0.40  
Discontinued operations––net of tax
     ––        ––  
Net income attributable to Pfizer Inc. common shareholders
  $ 0.25     $ 0.40  
                 
Weighted-average shares used to calculate earnings per common share:
               
Basic
    8,061       6,723  
Diluted
    8,101       6,753  
                 
Cash dividends paid per common share
  $ 0.18     $ 0.32  
(a)
Exclusive of amortization of intangible assets, except as disclosed in Note 8B. Goodwill and Other Intangible Assets: Other Intangible Assets.

See accompanying Notes to Condensed Consolidated Financial Statements.
 
 
3

 
 
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)

 (millions of dollars)
 
April 4,
2010*
   
Dec. 31,
2009**
 
Assets
           
Cash and cash equivalents
  $ 1,759     $ 1,978  
Short-term investments
    15,503       23,991  
Accounts receivable, less allowance for doubtful accounts
    13,611       14,645  
Short-term loans
    919       1,195  
Inventories
    10,132       12,403  
Current deferred tax assets and other current assets
    7,502       6,962  
Assets held for sale
    490       496  
Total current assets
    49,916       61,670  
Long-term investments and loans
    12,081       13,122  
Property, plant and equipment, less accumulated depreciation
    21,651       22,780  
Goodwill
    42,648       42,376  
Identifiable intangible assets, less accumulated amortization
    64,480       68,015  
Noncurrent deferred tax assets and other noncurrent assets
    4,337       4,986  
Total assets
  $ 195,113     $ 212,949  
                 
Liabilities and Shareholders’ Equity
               
Short-term borrowings, including current portion of long-term debt
  $ 7,769     $ 5,469  
Accounts payable
    3,028       4,370  
Dividends payable
    1       1,454  
Income taxes payable
    765       10,107  
Accrued compensation and related items
    2,060       2,242  
Current deferred tax liabilities and other current liabilities
    12,301       13,583  
Total current liabilities
    25,924       37,225  
                 
Long-term debt
    38,281       43,193  
Pension benefit obligations
    6,119       6,392  
Postretirement benefit obligations
    3,239       3,243  
Noncurrent deferred tax liabilities
    17,460       17,839  
Other taxes payable
    8,338       9,000  
Other noncurrent liabilities
    5,670       5,611  
Total liabilities
    105,031       122,503  
                 
Preferred stock
    58       61  
Common stock
    443       443  
Additional paid-in capital
    70,456       70,497  
Employee benefit trusts
    (89 )     (333 )
Treasury stock
    (21,697 )     (21,632 )
Retained earnings
    42,429       40,426  
Accumulated other comprehensive income/(loss)
    (1,941 )     552  
Total Pfizer Inc. shareholders’ equity
    89,659       90,014  
Equity attributable to noncontrolling interests
    423       432  
Total shareholders’ equity
    90,082       90,446  
Total liabilities and shareholders’ equity
  $ 195,113     $ 212,949  
Unaudited.
** 
Condensed from audited financial statements.

See accompanying Notes to Condensed Consolidated Financial Statements.
 
 
4

 
 
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
 
   
Three Months Ended
 
 
(millions of dollars)
 
April 4,
2010
   
Mar. 29,
2009
 
             
Operating Activities:
           
Net income before allocation to noncontrolling interests
  $ 2,035     $ 2,730  
Adjustments to reconcile net income before allocation to noncontrolling interests to net
   cash (used in)/provided by operating activities:
               
Depreciation and amortization
    2,051       1,008  
Share-based compensation expense
    138       71  
Acquisition-related in-process research and development charges
    74       ––  
Deferred taxes from continuing operations
    840       533  
Other non-cash adjustments
    319       (296 )
Changes in assets and liabilities, net of acquisitions and divestitures
    (11,817 )     (899 )
                 
Net cash (used in)/provided by operating activities
    (6,360 )     3,147  
                 
Investing Activities:
               
Purchases of property, plant and equipment
    (305 )     (253 )
Purchases of short-term investments
    (2,178 )     (17,724 )
Proceeds from redemptions and sales of short-term investments
    11,388       6,711  
Purchases of long-term investments
    (858 )     (3,442 )
Proceeds from redemptions and sales of long-term investments
    1,127       889  
Other investing activities
    220       185  
                 
Net cash provided by/(used in) investing activities
    9,394       (13,634 )
                 
Financing Activities:
               
Increase in short-term borrowings
    1,892       10,774  
Principal payments on short-term borrowings
    (3,663 )     (12,100 )
Proceeds from issuances of long-term debt
    2       13,392  
Principal payments on long-term debt
    (9 )     (303 )
Cash dividends paid
    (1,441 )     (2,133 )
Other financing activities
    8       5  
                 
Net cash (used in)/provided by financing activities
    (3,211 )     9,635  
Effect of exchange-rate changes on cash and cash equivalents
    (42 )     (23 )
Net decrease in cash and cash equivalents
    (219 )     (875 )
Cash and cash equivalents at beginning of period
    1,978       2,122  
                 
Cash and cash equivalents at end of period
  $ 1,759     $ 1,247  
                 
Supplemental Cash Flow Information:
               
Cash paid during the period for:
               
Income taxes
  $ 10,547     $ 454  
Interest
    792       84  

See accompanying Notes to Condensed Consolidated Financial Statements.
 
 
5

 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)


We prepared the condensed consolidated financial statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (U.S. GAAP) can be condensed or omitted. Balance sheet amounts and operating results for subsidiaries operating outside the U.S. are as of and for the three-month periods ended February 28, 2010, and February 22, 2009.

On October 15, 2009, we completed our acquisition of Wyeth and, commencing from the acquisition date, our financial statements include the assets, liabilities, operating results and cash flows of Wyeth. As a result, legacy Wyeth operations are reflected in our results of operations and cash flows for the first quarter of 2010, but not for the first quarter of 2009.

Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.

We are responsible for the unaudited financial statements included in this document.  The financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our financial position and operating results.

The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2009.

 
The provisions of the following new accounting standards were adopted as of January 1, 2010 and did not have a significant impact on our consolidated financial statements:

·
An amendment to the recognition and measurement guidance for the transfers of financial assets.

·
An amendment to the guidelines for determining the primary beneficiary in a variable interest entity.

 
On October 15, 2009 (the acquisition date), we acquired all of the outstanding equity of Wyeth in a cash-and-stock transaction, valued at the acquisition date at approximately $68 billion. While Wyeth now is a wholly-owned subsidiary of Pfizer, the merger of local Pfizer and Wyeth entities may be pending or delayed in various international jurisdictions and integration in these jurisdictions is subject to completion of various local legal and regulatory obligations.
 
Recording of Assets Acquired and Liabilities Assumed

The following table summarizes the provisional amounts recognized for assets acquired and liabilities assumed as of the acquisition date as well as adjustments made in the first quarter of 2010 to the amounts initially recorded in 2009 (measurement period adjustments). The measurement period adjustments did not have a significant impact on our consolidated statements of income, balance sheets or cash flows in any period and, therefore, we have not retrospectively adjusted our financial statements. Certain estimated values are not yet finalized (see below) and are subject to change, which could be significant. We will finalize the amounts recognized as we obtain the information necessary to complete the analyses, but no later than one year from the acquisition date.

 
6

 
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
 

(millions of dollars)
 
Amounts Recognized
as of Acquisition Date
(as previously reported)
   
Measurement
Period
Adjustments
   
Amounts Recognized
as of Acquisition Date
(as adjusted)
 
                   
Working capital, excluding inventories
  $ 16,342     $ ––     $ 16,342  
Inventories
    8,388       (167 )     8,221  
Property, plant and equipment
    10,054       (171 )     9,883  
Identifiable intangible assets, excluding
in-process research and development (a)
    37,595       (452 )     37,143  
In-process research and development (a)
    14,918       (956 )     13,962  
Other noncurrent assets
    2,394       ––       2,394  
Long-term debt
    (11,187 )     ––       (11,187 )
Benefit obligations
    (3,211 )     ––       (3,211 )
Net tax accounts
    (24,773 )     761       (24,012 )
Other noncurrent liabilities
    (1,908 )     ––       (1,908 )
Total identifiable net assets
    48,612       (985 )     47,627  
Goodwill
    19,954       985       20,939  
Net assets acquired
    68,566       ––       68,566  
Less: Amounts attributable to
noncontrolling interests
    (330 )     ––       (330 )
Total consideration transferred
  $ 68,236     $ ––     $ 68,236  
(a)
The measurement period adjustments for Identifiable intangible assets reflect changes in the estimated fair value of certain acquired intangibles, principally in-process research and development assets, primarily to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date.  The measurement period adjustments did not result from intervening events subsequent to the acquisition date.

The recorded amounts are provisional and subject to change. Specifically, the following items are subject to change:

·  
Amounts for intangibles and inventory, pending finalization of valuation efforts.

·  
Amounts for legal contingencies, pending the finalization of our examination and evaluation of the portfolio of filed cases.

·  
Amounts for income tax assets, receivables and liabilities pending the filing of Wyeth pre-acquisition tax returns, including all required disclosures and documentation, as well as the receipt of information from taxing authorities which may change certain estimates and assumptions used.

·  
The allocation of goodwill among reporting units.


We have incurred significant costs in connection with our cost-reduction initiatives (several programs initiated since 2005) and our acquisition of Wyeth on October 15, 2009.

Since the acquisition of Wyeth, our cost-reduction initiatives that were announced on January 26, 2009, but not completed as of December 31, 2009, have been incorporated into a comprehensive plan to integrate Wyeth’s operations, generate cost savings and capture synergies across the combined company. We are focusing our efforts on achieving an appropriate cost structure for the combined company.

 
7

 
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

We incurred the following costs in connection with all of our cost-reduction initiatives and the acquisition of Wyeth:
   
Three Months Ended
 
(millions of dollars)
 
April 4,
2010
   
Mar. 29,
2009
 
             
Transaction costs(a)
  $ 9     $ 369  
Integration costs(b)
    208       28  
Restructuring charges(c)
    489       157  
Restructuring charges and certain acquisition-related costs
    706       554  
Additional depreciation––asset restructuring(d)
    93       90  
Implementation costs(e)
    ––       84  
Total
  $ 799     $ 728  
(a)
Transaction costs represent external costs directly related to effecting the acquisition of Wyeth and primarily include expenditures for banking, legal, accounting and other similar services. Substantially all of the costs incurred in the first quarter of 2009 were fees related to a $22.5 billion bridge term loan credit agreement entered into with certain financial institutions on March 12, 2009 to partially fund our acquisition of Wyeth. The bridge term loan credit agreement was terminated in June 2009 as a result of our issuance of approximately $24.0 billion of senior unsecured notes in the first half of 2009.
(b)
Integration costs represent external, incremental costs directly related to integrating Wyeth and primarily include expenditures for consulting and systems integration.
(c)
Restructuring charges include the following:
   
Costs Incurred
             
   
Three Months Ended
         
Activity
   
Accrual
 
(millions of dollars)
 
April 4,
2010
   
Mar. 29,
2009
      2005-2010    
Through
April 4,
2010(1)
   
As of
April 4,
2010(2)
 
                                 
Employee termination costs
  $ 458     $ 135     $ 8,179     $ 5,276     $ 2,903  
Asset impairments
    6       18       1,458       1,458       ––  
Other
    25       4       735       631       104  
Total restructuring charges
  $ 489     $ 157     $ 10,372     $ 7,365     $ 3,007  
(1) 
Includes adjustments for foreign currency translation.
(2) 
Included in Current deferred tax liabilities and other current liabilities ($2.0 billion) and Other noncurrent liabilities ($1.0 billion).

In the first quarter of 2010, the restructuring charges are related to the integration of Wyeth.  From the beginning of our cost-reduction initiatives in 2005 through April 4, 2010, Employee termination costs represent the expected reduction of the workforce by approximately 45,400 employees, mainly in manufacturing, sales and research, of which approximately 28,100 employees have been terminated as of April 4, 2010. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination. Asset impairments < /font>primarily include charges to write down property, plant and equipment to fair value. Other primarily includes costs to exit certain assets and activities.

(d)
Additional depreciation – asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions and are included in our condensed consolidated statements of income as follows:
   
Three Months Ended
 
(millions of dollars)
 
April 4,
2010
   
Mar. 29,
2009
 
             
Cost of sales
  $ 13     $ 63  
Selling, informational and administrative expenses
    60       6  
Research and development expenses
    20       21  
Total
  $ 93     $ 90  
 
(e)
Implementation costs in the first quarter of 2009 represent external, incremental costs directly related to implementing cost-reduction initiatives prior to our acquisition of Wyeth, and primarily include expenditures related to system and process standardization and the expansion of shared services. For the three months ended March 29, 2009, implementation costs are included in Cost of sales ($13 million), Selling, informational and administrative expenses ($40 million), Research and development expenses ($20 million) and Other (income)/deductions––net ($11 million).

 
8

 
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)


A. Selected Financial Assets and Liabilities

Information about certain of our financial assets and liabilities follows:
(millions of dollars)
 
April 4,
2010
   
Dec. 31,
2009
 
Selected financial assets measured at fair value on a recurring basis (a) :
           
Trading securities (b)
  $ 168     $ 184  
Available-for-sale debt securities(c)
    23,787       32,338  
Available-for-sale money market funds(d)
    1,484       2,569  
Available-for-sale equity securities, excluding money market funds(c)
    243       281  
Derivative financial instruments in receivable positions(e):
               
Foreign currency swaps
    400       798  
Interest rate swaps
    315       276  
Foreign currency forward-exchange contracts
    284       502  
Total
    26,681       36,948  
Other selected financial assets(f):
               
Short-term loans, carried at cost (g)
    919       1,195  
Held-to-maturity debt securities, carried at amortized cost(c)
    642       812  
Private equity securities, carried at cost or equity method (h)
    858       811  
Long-term loans, carried at cost(g)
    782       784  
Total
    3,201       3,602  
Total selected financial assets (i)
  $ 29,882     $ 40,550  
Financial liabilities measured at fair value on a recurring basis(a):
               
Derivative financial instruments in a liability position(j):
               
Foreign currency forward-exchange contracts
  $ 351     $ 237  
Foreign currency swaps
    221       528  
Interest rate swaps
    73       25  
Total
    645       790  
Other financial liabilities (k):
               
Short-term borrowings, carried at historical proceeds, as adjusted(f), (l)
    7,769       5,469  
Long-term debt, carried at historical proceeds, as adjusted(m), (n)
    38,281       43,193  
Total
    46,050       48,662  
Total selected financial liabilities
  $ 46,695     $ 49,452  
(a)
Fair values are determined based on valuation techniques categorized as follows: Level 1 means the use of quoted prices for identical instruments in active markets; Level 2 means the use of quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active or are directly or indirectly observable; Level 3 means the use of unobservable inputs. Virtually all of our financial assets and liabilities measured at fair value on a recurring basis use Level 2 inputs in the calculation of fair value, except that included in available-for-sale equity securities, excluding money market funds, are $93 million as of April 4, 2010 and $77 million as of December 31, 2009 of investments that use Level 1 inputs in the calculation of fair value. None of our financial assets and liabilities measured at fair value on a recurring basis are valued using Level 3 inp uts as of April 4, 2010 or December 31, 2009.
(b)
Trading securities are held in trust for legacy Pharmacia severance benefits.
(c)
Gross unrealized gains and losses are not significant.
(d)
Includes approximately $1.2 billion of money market funds held in escrow to secure certain of Wyeth’s payment obligations under its 1999 Nationwide Class Action Settlement Agreement, which relates to litigation against Wyeth concerning its former weight-loss products, Redux and Pondimin (see Note 5G. Financial Instruments: Guarantee).
(e)
Designated as hedging instruments, except for certain foreign currency contracts used as offsets; namely, foreign currency forward-exchange contracts with fair values of $150 million and foreign currency swaps with fair values of $36 million as of April 4, 2010; and foreign currency swaps with fair values of $106 million and foreign currency forward-exchange contracts with fair values of $100 million at December 31, 2009.
(f)
The differences between the estimated fair values and carrying values of our financial assets and liabilities not measured at fair value on a recurring basis were not significant as of April 4, 2010 or December 31, 2009.
(g)
Our short-term and long-term loans are due from companies with highly rated securities (Standard & Poor’s (S&P) ratings of mostly AA or better).
(h)
Our private equity securities represent investments in the life sciences sector.
(i)
The decrease in selected financial assets is primarily due to the use of proceeds of short-term investments for tax payments made in the first quarter of 2010, associated with certain business decisions executed to finance the Wyeth acquisition.
(j)
 Designated as hedging instruments, except for certain foreign currency contracts used as offsets; namely, foreign currency forward exchange contracts with fair values of $157 million and foreign currency swaps with fair values of $72 million as of April 4, 2010; and foreign currency forward-exchange contracts with fair values of $122 million and foreign currency swaps with fair values of $3 million as of December 31, 2009.
(k)
The carrying amounts may include adjustments for discount or premium amortization or for the effect of interest rate swaps designated as hedges.
 
 
9

 
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
 
(l)
Includes foreign currency borrowings with fair values of $2.3 billion at April 4, 2010 and $1.1 billion as of December 31, 2009, which are used as hedging instruments.
(m)
Includes foreign currency debt with fair value of $754 million as of April 4, 2010 and $2.1 billion as of December 31, 2009, which is used as a hedging instrument.
(n)
The fair value of our long-term debt is $41.7 billion as of April 4, 2010 and $46.2 billion as of December 31, 2009.

We use a market approach to determine the fair value of our financial assets and liabilities and apply the following methods and assumptions:
 
·  
Trading equity securities––quoted market prices.

·  
Trading debt securities––observable market interest rates.

·  
Available-for-sale debt securities––third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and credit-adjusted interest rate curves.

·  
Available-for-sale money market funds––observable prices.

·  
Available-for-sale equity securities, excluding money market funds––third-party pricing services that principally use a composite of observable prices.

·  
Derivative financial instruments (assets and liabilities)–– third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data.  Where applicable, these models discount future cash flow amounts using market-based observable inputs including interest rate curves, foreign exchange rates, and forward and spot prices for currencies.  The credit risk impact to our derivative financial instruments was not significant.

·  
Held-to-maturity debt securities–– third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and credit-adjusted interest rate curves.

·  
Short-term and long-term loans–– third-party model that discounts future cash flows using current interest rates at which similar loans would be made to borrowers with similar credit ratings and for the same remaining maturities.
 
·  
Private equity securities––application of the implied volatility associated with an observable biotech index to the carrying amount of our portfolio and, to a lesser extent, performance multiples of comparable securities adjusted for company-specific information.

·  
Short-term borrowings and long-term debt–– third-party matrix-pricing model that uses significant inputs derived from or collaborated by observable market data and our own credit rating.
 
In addition, we have long-term receivables where the determination of fair value uses discounted future cash flows, using current interest rates at which similar loans would be made to borrowers with similar credit ratings and for the same remaining maturities.
 
These selected financial assets and liabilities are presented in the condensed consolidated balance sheets as follows:
(millions of dollars)
 
April 4,
2010
   
Dec. 31,
2009
 
Assets
           
Cash and cash equivalents
  $ 380     $ 666  
Short-term investments
    15,503       23,991  
Short-term loans
    919       1,195  
Long-term investments and loans
    12,081       13,122  
Current deferred tax assets and other current assets(a)
    313       526  
Noncurrent deferred tax assets and other noncurrent assets(b)
    686       1,050  
Total
  $ 29,882     $ 40,550  
Liabilities
               
Short-term borrowings, including current portion of long-term debt
  $ 7,769     $ 5,469  
Current deferred tax liabilities and other current liabilities(c)
    414       369  
Long-term debt
    38,281       43,193  
Other noncurrent liabilities(d)
    231       421  
Total
  $ 46,695     $ 49,452  
(a)
As of April 4, 2010, derivative instruments at fair value include foreign currency forward-exchange contracts ($284 million) and foreign currency swaps ($29 million) and as of December 31, 2009, include foreign currency forward-exchange contracts ($503 million) and foreign currency swaps ($23 million).
(b)
As of April 4, 2010, derivative instruments at fair value include foreign currency swaps ($371 million) and interest rate swaps ($315 million) and as of December 31, 2009, include foreign currency swaps ($774 million) and interest rate swaps ($276 million).
 
 
10

 
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
 
(c)
As of April 4, 2010, derivative instruments at fair value include foreign currency forward-exchange contracts ($351 million) and foreign currency swaps ($63 million) and as of December 31, 2009, include foreign currency forward-exchange contracts ($237 million) and foreign currency swaps ($132 million).
(d)
As of April 4, 2010, derivative instruments at fair value include foreign currency swaps ($158 million) and interest rate swaps ($73 million) and as of December 31, 2009, include foreign currency swaps ($396 million) and interest rate swaps ($25 million).

We regularly evaluate all of our financial assets for impairment. For investments in debt and equity securities, when a decline in fair value, if any, is determined to be other-than-temporary, an impairment charge is recorded, and a new cost basis in the investment is established. For loans, an impairment charge is recorded if it is probable that we will not be able to collect all amounts due according to the loan agreement. There were no significant impairments recognized in the first quarter of 2010 or the year ended December 31, 2009.

B. Investments in Debt and Equity Securities

The contractual maturities of the available-for-sale and held-to-maturity debt securities as of April 4, 2010, follow:
   
Years
       
(millions of dollars)
 
Within 1
   
Over 1
to 5
   
Total as of
April 4,
2010
 
Available-for-sale debt securities:
                 
Western European and other government debt
  $ 9,157     $ 2,576     $ 11,733  
Western European and other government agency debt
    2,678       266       2,944  
Corporate debt(a)
    996       1,885       2,881  
Federal Home Loan Mortgage Corporation and Federal National Mortgage
        Association asset-backed securities
    102       2,531       2,633  
Reverse repurchase agreements(b)
    1,263       ––       1,263  
U.S. government Federal Deposit Insurance Corporation guaranteed debt
    ––       1,101       1,101  
Supranational debt
    636       386       1,022  
Other asset-backed securities
    33       125       158  
Certificates of deposit
    52       ––       52  
Held-to-maturity debt securities:
                       
Certificates of deposit and other
    636       6       642  
Total debt securities
  $ 15,553     $ 8,876     $ 24,429  
Trading securities
                    168  
Available-for-sale money market funds(c)
                    1,484  
Available-for-sale equity securities, excluding money market funds
                    243  
Total
                  $ 26,324  
(a)
Largely issued by above-investment-grade institutions in the financial services sector.
(b)
Very short-term agreements involving U.S. government securities.
(c)
Consisting of securities issued by the U.S. government and its agencies or instrumentalities and reverse repurchase agreements involving the same investments held.

C. Short-Term Borrowings
Short-term borrowings include amounts for commercial paper of $3.1 billion as of April 4, 2010 and $3.9 billion as of December 31, 2009.

D. Long-Term Debt
In March 2007, we filed a securities registration statement with the SEC. The registration statement was filed under the automatic shelf registration process available to “well-known seasoned issuers” and expired in March 2010. On March 24, 2009, in order to partially finance our acquisition of Wyeth, we issued $13.5 billion of senior unsecured notes under this registration statement. On June 3, 2009, also in order to partially finance our acquisition of Wyeth, we issued approximately $10.5 billion of senior unsecured notes in a private placement pursuant to Regulation S under the Securities Act of 1933, as amended (Securities Act of 1933). The notes have not been and will not be registered under the Securities Act of 1933 and, subject to certain exceptions, may not be sold, offered or delivered within the U.S. to, or for, the account or benefit of U.S. persons.

E. Derivative Financial Instruments and Hedging Activities
Foreign Exchange Risk—A significant portion of our revenues, earnings and net investments in foreign affiliates is exposed to changes in foreign exchange rates. We seek to manage our foreign exchange risk, in part, through operational means,
 
 
11

 
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
 
including managing expected same-currency revenues in relation to same-currency costs and same-currency assets in relation to same-currency liabilities. Depending on market conditions, foreign exchange risk also is managed through the use of derivative financial instruments and foreign currency debt. These financial instruments serve to protect net income and net investments against the impact of the translation into U.S. dollars of certain foreign exchange-denominated transactions. The aggregate notional amount of foreign exchange derivative financial instruments hedging or offsetting foreign currency exposures is $44.8 billion. The derivative financial instruments primarily hedge or offset exposures in euro, Japanese yen and U.K. pound. The maximum length of time over which we are hedging future foreign exchange cash flows relates to ou r $2.4 billion U.K. pound debt maturing in 2038.
 
Interest Rate Risk—Our interest-bearing investments, loans and borrowings are subject to interest rate risk. We seek to invest and loan primarily on a short-term or variable-rate basis; however, in light of current market conditions, we currently borrow primarily on a long-term, fixed-rate basis. From time to time, depending on market conditions, we will change the profile of our outstanding debt by entering into derivative financial instruments like interest rate swaps.
 
We entered into derivative financial instruments to hedge or offset the fixed interest rates on the hedged item, matching the amount and timing of the hedged item. The aggregate notional amount of interest rate derivative financial instruments is $9.2 billion. The derivative financial instruments hedge U.S. dollar and euro fixed-rate debt.

Information about gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk is as follows:
   
Gains/(Losses)
 
   
Three Months Ended
 
(millions of dollars)
 
April 4, 2010
   
Mar. 29, 2009
 
Derivative Financial Instruments in Fair Value Hedge Relationships
           
Interest rate swaps
           
Recognized in OID(a)
  $ ––     $ (284 )
Foreign currency swaps
               
Recognized in OID(a)
    ––       (1 )
Derivative Financial Instruments in Cash Flow Hedge Relationships
               
U.S. Treasury interest rate locks
               
Recognized in OID(a)
  $ ––     $ (11 )
Recognized in OCI(a), (b)
    ––       (15 )
Reclassified from OCI to OID(a), (b)
    ––       ––  
Foreign currency swaps
               
Recognized in OID(a)
    ––       ––  
Recognized in OCI(a), (b)
    (438 )     (19 )
Reclassified from OCI to OID(a), (b)
    (628 )     ––  
Foreign currency forward exchange contracts
               
Recognized in OID(a)
    ––       ––  
Recognized in OCI(a), (b)
    ––       2  
Reclassified from OCI to OID(a), (b)
    1       10  
Derivative Financial Instruments in Net Investment Hedge Relationships
               
Foreign currency swaps
               
Recognized in OID(a)
  $ 1     $ (2 )
Recognized in OCI(a), (b)
    11       53  
Derivative Financial Instruments Not Designated as Hedges
               
Foreign currency swaps
               
Recognized in OID(a)
  $ 4     $ (5 )
Foreign currency forward-exchange contracts
               
Recognized in OID(a)
    (890 )     (255 )
Non-Derivative Financial Instruments in Net Investment Hedge Relationships
               
Foreign currency short-term borrowings
               
Recognized in OID(a)
  $ ––     $ ––  
Recognized in OCI(a), (b)
    31       110  
Foreign currency long-term debt
               
Recognized in OID(a)
    ––       ––  
Recognized in OCI(a), (b)
    16       158  
(a)
OID = Other (income)/deductions––net. OCI = Other comprehensive income/(expense), a balance sheet account.
(b)
Amounts presented represent the effective portion of the gain or loss. For derivative financial instruments in cash flow hedge relationships, the effective portion is included in Other comprehensive income/(expense) – Net unrealized gains/(losses) on derivative financial instruments. For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the effective portion is included in Other comprehensive income/(expense)––Currency translation adjustment.

 
12

 
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
 
For information about the fair value of our derivative financial instruments, and the impact on our Condensed Consolidated Balance Sheets, see Note 5A. Financial Instruments: Selected Financial Assets and Liabilities. Certain of our derivative instruments are covered by associated credit-support agreements that have credit-risk-related contingent features designed to reduce our counterparties’ exposure to our risk of defaulting on amounts owed. The aggregate fair value of these derivative instruments that are in a liability position is $353 million, for which we have posted collateral of $188 million in the normal course of business. These features include the requirement to pay additional collateral in the event of a downgrade in our debt ratings. If there had been a downgrad e to below an A rating by S&P or the equivalent rating by Moody’s Investors Service, on April 4, 2010, we would have been required to post an additional $171 million of collateral to our counterparties. The collateral advanced receivables are reported in Short-term loans.

F. Credit Risk
On an ongoing basis, we review the creditworthiness of counterparties to our foreign exchange and interest rate agreements and do not expect to incur a significant loss from failure of any counterparties to perform under the agreements. There are no significant concentrations of credit risk related to our financial instruments with any individual counterparty. As of April 4, 2010, we had $2.1 billion due from a well-diversified, highly rated group (S&P ratings of primarily A+ or better) of bank counterparties around the world.  See Note 5B. Financial Instruments: Investment in Debt and Equity Securities for a distribution of our investments.

In general, there is no requirement for collateral from customers. However, derivative financial instruments are executed under master netting agreements with financial institutions. These agreements contain provisions that provide for the ability for collateral payments, depending on levels of exposure, our credit rating and the credit rating of the counterparty. As of April 4, 2010, we received cash collateral of $518 million against various counterparties. The collateral primarily supports the approximate fair value of our derivative contracts. The collateral received obligations are reported in Short-term borrowings, including current portion of long-term debt.

G. Guarantee
In April 2010, Wyeth LLC (Wyeth), a wholly owned subsidiary of Pfizer Inc. (Pfizer), entered into the Tenth Amendment (Tenth Amendment) to the 1999 Diet Drug Nationwide Settlement Agreement (Settlement Agreement) related to the litigation against Wyeth concerning its former weight-loss products, Redux and Pondimin. Pursuant to the Tenth Amendment, Pfizer entered into an agreement to guarantee Wyeth's obligation to make certain payments under the Settlement Agreement up to a maximum amount of $1.5 billion (Guarantee). The Guarantee will remain in effect until the termination of Wyeth's long-term obligation to make such payments. The Tenth Amendment and the Guarantee are subject to the approval of the United States District Court for the Eastern District of Pennsylvania and will become effective following such approval.


The components of comprehensive income/(loss) follow:
   
Three Months Ended
 
(millions of dollars)
 
April 4,
 2010
   
Mar. 29,
2009
 
             
Net income before allocation to noncontrolling interests
  $ 2,035     $ 2,730  
Other comprehensive income/(loss):
               
Currency translation adjustment and other
    (2,747 )     (384 )
Net unrealized gains/(losses) on derivative financial instruments
    134       (23 )
Net unrealized gains/(losses) on available-for-sale securities
    (15 )     145  
Benefit plan adjustments
    117       159  
Total other comprehensive loss
    (2,511 )     (103 )
Total comprehensive (loss)/income before allocation to noncontrolling interests
    (476 )     2,627  
Less: Comprehensive (loss)/income attributable to noncontrolling interests
    (9 )     2  
Comprehensive (loss)/income attributable to Pfizer Inc.
  $ (467 )   $ 2,625  
 
 
13

 
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
 

The components of inventories follow:
 (millions of dollars)
 
April 4,
2010
   
Dec. 31,
2009
 
             
Finished goods
  $ 4,535     $ 5,249  
Work-in-process
    4,233       5,776  
Raw materials and supplies
    1,364       1,378  
Total inventories(a)
  $ 10,132     $ 12,403  
(a)
The decrease in total inventories is primarily due to the inventory sold during the first quarter of 2010 that was acquired from Wyeth and had been recorded at fair value, as well as operational reductions and the impact of foreign exchange. Certain amounts of inventories are in excess of one year’s supply.  These excess amounts are primarily attributable to biologics inventory acquired from Wyeth and recorded at fair value and the quantities are generally consistent with the normal operating cycle of such inventory. There are no recoverability issues associated with these quantities.


A. Goodwill

The changes in the carrying amount of goodwill for the three months ended April 4, 2010, follow:
(millions of dollars)
 
Biopharmaceutical
   
Diversified
   
Other
   
Total
 
                         
Balance, December 31, 2009(a)
  $ 22,165     $ 173     $ 20,038     $ 42,376  
Additions
    ––       18       985  (b)     1,003  
Other(c)
    (570 )     (3 )     (158 )     (731 )
Balance, April 4, 2010
  $ 21,595     $ 188     $ 20,865     $ 42,648  
(a)
The Other goodwill relates to our acquisition of Wyeth and is subject to change until we complete the recording of the assets acquired and liabilities assumed from Wyeth (see Note 3. Acquisition of Wyeth). The allocation of Wyeth goodwill among the Biopharmaceutical and Diversified segments has not yet been completed, but will be completed within one year of the acquisition date.
(b)
Reflects the impact of measurement period adjustments (see Note 3. Acquisition of Wyeth).
(c)
Primarily reflects the impact of foreign exchange.

B. Other Intangible Assets

The components of identifiable intangible assets, primarily included in our Biopharmaceutical segment, follow:
   
April 4, 2010
   
December 31, 2009
 
(millions of dollars)
 
Gross
Carrying
Amount
   
Accumulated
Amortization
   
Identifiable
Intangible
Assets, less
Accumulated
Amortization
   
Gross
Carrying
Amount
   
Accumulated
Amortization
   
Identifiable
Intangible
Assets, less Accumulated
Amortization
 
                                     
Finite-lived intangible assets:
                                   
Developed technology rights
  $ 68,416     $ (22,417 )   $ 45,999     $ 68,870     $ (21,223 )   $ 47,647  
Brands
    1,627       (563 )     1,064       1,637       (535 )     1,102  
License agreements
    620       (148 )     472       622       (119 )     503  
Trademarks
    107       (69 )     38       113       (73 )     40  
Other
    425       (228 )     197       488       (231 )     257  
Total amortized finite-lived
                                               
  intangible assets
    71,195       (23,425 )     47,770       71,730       (22,181 )     49,549  
Indefinite-lived intangible assets:
                                               
Brands
    12,462       ––       12,462       12,562       ––       12,562  
In-process research and development (a)
    4,178       ––       4,178       5,834       ––       5,834  
Trademarks
    70       ––       70       70       ––       70  
Total indefinite-lived
                                               
intangible assets
    16,710       ––       16,710       18,466       ––       18,466  
Total identifiable intangible assets(b)
  $ 87,905     $ (23,425 )   $ 64,480     $ 90,196     $ (22,181 )   $ 68,015  
(a)
Decrease is primarily related to the impact of measurement period adjustments (see Note 3. Acquisition of Wyeth).
(b)
Decrease is primarily related to amortization of finite-lived intangible assets, the impact of measurement period adjustments (see Note 3. Acquisition of Wyeth) and the impact of foreign exchange.
 
 
14

 
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
 
Amortization expense related to acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in Amortization of intangible assets as it benefits multiple business functions. Amortization expense related to acquired intangible assets that are associated with a single function is included in Cost of sales, Selling, informational and administrative expenses and Research and development expenses, as appropriate. Total amortization expense for finite-lived intangible assets was $1.4 billion for the first quarter of 2010, and $610 million for the first quarter of 2009.< /font>


The components of net periodic benefit costs of the U.S. and international pension plans and the postretirement plans, which provide medical and life insurance benefits to retirees and their eligible dependents, follow:
   
Pension Plans
       
   
U.S.
Qualified
   
U.S.
Supplemental
(Non-Qualified)
   
International
   
Postretirement
Plans
 
(millions of dollars)
 
April 4,
2010
   
Mar. 29,
2009
   
April 4,
2010
   
Mar. 29,
2009
   
April 4,
2010
   
Mar. 29,
2009
   
April 4,
2010
   
Mar. 29,
2009
 
Three Months Ended:
                                               
Service cost
  $ 94     $ 59     $ 8     $ 5     $ 60     $ 45     $ 22     $ 8  
Interest cost
    191       119       19       13       111       78       54       30  
Expected return on plan assets
    (202 )     (118 )     ––       ––       (112 )     (86 )     (8 )     (6 )
Amortization of:
                                                               
Actuarial losses
    38       57       7       8       17       6       ––       4  
Prior service costs/(credits)
    ––       1       (1 )     (1 )     (1 )     (1 )     (4 )     (1 )
Curtailments and settlements––net
    (33 )     24       (1 )     7       1       2       ––       5  
Special termination benefits
    14       13       90       ––       1       1       6       12  
Net periodic benefit costs
  $ 102     $ 155     $ 122     $ 32     $ 77     $ 45     $ 70     $ 52  

The decrease in net periodic benefit costs in the first three months of 2010 compared to the first three months of 2009 for our U.S. qualified plans was primarily driven by curtailment gains and lower settlement charges associated with Wyeth-related restructuring initiatives.  The acquisition of Wyeth contributed to the increase in certain components of net periodic benefit costs, such as service cost and interest cost, offset by related expected return on plan assets.

The increase in net periodic benefit costs in the first three months of 2010, compared to the first three months of 2009 for our U.S. supplemental (non-qualified) pension plans was primarily driven by special termination benefits recognized for certain executives as part of Wyeth-related restructuring initiatives.

For the first quarter of 2010, we contributed from our general assets $87 million to our international pension plans, $61 million to our U.S. supplemental (non-qualified) pension plans and $60 million to our postretirement plans. Contributions to our U.S. qualified pension plans in the first quarter of 2010 were not significant.

During 2010, we expect to contribute from our general assets, a total of $439 million to our international pension plans, $257 million to our postretirement plans, $205 million to our U.S. supplemental (non-qualified) pension plans and $7 million to our U.S. qualified pension plans. Contributions expected to be made for 2010 are inclusive of amounts contributed during the first quarter of 2010. The international pension plan, postretirement plan and U.S. supplemental (non-qualified) pension plan contributions from our general assets include direct employer benefit payments.

 
15

 
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)


Basic and diluted earnings per share (EPS) were computed using the following data:
   
Three Months Ended
 
(millions)
 
April 4,
2010
   
Mar. 29,
2009
 
             
EPS Numerator––Basic:
           
Income from continuing operations attributable to Pfizer Inc.
  $ 2,024     $ 2,728  
Less: Preferred stock dividends––net of tax
    1       ––  
Income from continuing operations attributable to Pfizer Inc. common shareholders
    2,023       2,728  
Discontinued operations––net of tax
    2       1  
Net income attributable to Pfizer Inc. common shareholders
  $ 2,025     $ 2,729  
                 
EPS Denominator––Basic:
               
Weighted-average number of common shares outstanding
    8,061       6,723  
                 
EPS Numerator––Diluted:
               
Income from continuing operations attributable to Pfizer Inc. common shareholders
  $ 2,024     $ 2,728  
Discontinued operations––net of tax
    2       1  
Net income attributable to Pfizer Inc. common shareholders
  $ 2,026     $ 2,729  
                 
EPS Denominator––Diluted:
               
Weighted-average number of common shares outstanding
    8,061       6,723  
Common-share equivalents: stock options, stock issuable under employee compensation
        plans and convertible preferred stock
    40       30  
Weighted-average number of common shares outstanding and common-share equivalents
    8,101       6,753  
                 
Stock options that had exercise prices greater than the average market price of our common
        stock issuable under employee compensation plans(a)
    366       475  
(a)
These common stock equivalents were outstanding during the first quarters of 2010 and 2009, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.


We operate in the following two distinct commercial organizations, which constitute our two business segments:

·  
Biopharmaceutical consists of the Primary Care, Specialty Care, Oncology, Established Products and Emerging Markets customer-focused units and includes products that prevent and treat cardiovascular and metabolic diseases, central nervous system disorders, arthritis and pain, infectious and respiratory diseases, urogenital conditions, cancer, eye diseases and endocrine disorders, among others. Biopharmaceutical’s segment profit includes costs related to research and development, manufacturing, and sales and marketing activities that are associated with the products in our Biopharmaceutical segment.

·  
Diversified includes Animal Health products that prevent and treat diseases in livestock and companion animals, including vaccines, parasiticides and anti-infectives; Consumer Healthcare products that include over-the-counter healthcare products such as pain management therapies (analgesics and heat wraps), cough/cold/allergy remedies, dietary supplements, hemorrhoidal care and personal care items; Nutrition products such as infant and toddler nutritional products; and Capsugel, which represents our capsule products and services business. Diversified’s segment profit includes costs related to research and development, manufacturing, and sales and marketing activities that are associated with the products in our Diversified segment.

Segment profit/(loss) is measured based on income from continuing operations before provision for taxes on income and income attributable to noncontrolling interests. Certain costs, such as significant impacts of purchase accounting for acquisitions, restructuring and acquisition-related costs and costs related to our cost-reduction initiatives are included in Corporate/Other only. This methodology is utilized by management to evaluate our businesses. Each segment is managed separately and offers different products requiring different marketing and distribution strategies.

 
16

 
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

Revenues and profit/(loss) by segment for the first quarters of 2010 and 2009 follow:
   
Three Months Ended(a)
 
(millions of dollars)
 
April 4,
2010
   
Mar. 29,
2009
 
Revenues
           
Biopharmaceutical
  $ 14,506     $ 10,102  
Diversified
    2,141       691  
Corporate/Other(b)
    103       74  
Total revenues
  $ 16,750     $ 10,867  
                 
Segment profit/(loss)(c)
               
Biopharmaceutical
  $ 7,912     $ 5,407  
Diversified
    510       163  
Corporate/Other(b), (d)
    (5,243 )     (1,767 )
Total profit/(loss)
  $ 3,179     $ 3,803  
(a)
Includes revenues and profit/(loss) from legacy Wyeth products and operations for the three months ended April 4, 2010. Revenues and profit/(loss) from legacy Wyeth products and operations are not included in the three months ended March 29, 2009. Prior-period amounts for Capsugel, which were previously classified in Corporate/Other, are now classified in Diversified.
(b)
Corporate/Other includes Pfizer Centersource, which includes contract manufacturing and bulk pharmaceutical chemical sales. Corporate/Other under Segment profit/(loss) also includes interest income/(expense), corporate expenses (e.g., corporate administration costs), other income/(expense) (e.g., realized gains and losses attributable to our investments in debt and equity securities), certain performance-based and all share-based compensation expenses, significant impacts of purchase accounting for acquisitions, acquisition-related costs, intangible asset impairments and costs related to our cost-reduction initiatives.
(c)
Segment profit/(loss) equals Income from continuing operations before provision for taxes on income. Certain costs, such as significant impacts of purchase accounting for acquisitions, acquisition-related costs and costs related to our cost-reduction initiatives are included in Corporate/Other only. This methodology is utilized by management to evaluate our businesses.
(d)
For the first quarter of 2010, Corporate/Other includes: (i) significant impacts of purchase accounting for acquisitions of $2.8 billion, including intangible asset amortization related to our acquisitions of Wyeth in 2009 and Pharmacia in 2003 and charges related to fair value adjustments of inventory acquired from Wyeth and sold during the period; (ii) restructuring and acquisition-related costs of $799 million, primarily related to our acquisition of Wyeth; (iii) all share-based compensation expense; and (iv) net interest expense of $410 million. For the first quarter of 2009, Corporate/Other includes: (i) significant impacts of purchase accounting for acquisitions of $546 million, including intangible asset amortization and other charges, primarily related to our acquisition of Pharmacia in 2003; (i i) acquisition-related costs of $397 million, primarily related to our acquisition of Wyeth; (iii) restructuring charges and implementation costs associated with our cost-reduction initiatives of $331 million; (iv) all share-based compensation expense; and (v) net interest income of $116.
 
 
17

 
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

Significant product revenues are as follows:
   
Three Months Ended
 
(millions of dollars)
 
April 4,
2010
   
Mar. 29,
2009
 
             
Biopharmaceutical products:
           
Lipitor
  $ 2,757     $ 2,721  
Enbrel(a), (c)
    802       ––  
Lyrica
    723       684  
Effexor(a)
    716       ––  
Celebrex
    570       564  
Prevnar/Prevenar 7(a)
    520       ––  
Viagra
    479       454  
Xalatan/Xalacom
    422       407  
Norvasc
    368       481  
Zyvox
    292       283  
Prevnar/Prevenar 13(a)
    286       ––  
Zosyn/Tazocin(a)
    264       ––  
Detrol/Detrol LA
    261       289  
Sutent
    259       202  
Premarin family(a)
    256       ––  
Geodon/Zeldox
    254       230  
Genotropin
    206       197  
Chantix/Champix
    189       177  
Vfend
    188       179  
BeneFIX(a)
    154       ––  
Caduet
    135       134  
Aromasin
    128       110  
Zoloft
    120       115  
Revatio
    114       113  
Medrol
    109       118  
Cardura
    107       107  
Aricept(b)
    107       95  
Zithromax/Zmax
    103       114  
ReFacto/Xyntha(a)
    90       ––  
All other(d)
    2,523       1,746  
Alliance revenues (Enbrel (in the U.S. and Canada)(a), Aricept, Exforge, Rebif and Spiriva)
    1,004       582  
Total Biopharmaceutical products
    14,506       10,102  
Diversified products:
               
Animal Health products(d)
    846       537  
Consumer Healthcare products(a)
    663       ––  
Nutrition products(a)
    458       ––  
Capsugel(e)
    174       154  
Total Diversified products
    2,141       691  
Corporate/Other
    103       74  
Total revenues
  $ 16,750     $ 10,867  
(a)
Represents legacy Wyeth products for the three months ended April 4, 2010. Legacy Wyeth products are not included in the three months ended March 29, 2009.
(b)
Represents direct sales under license agreement with Eisai. Co. Ltd.
(c)
Outside the U.S. and Canada.
(d)
Includes legacy Pfizer and legacy Wyeth products for the three months ended April 4, 2010 and includes only legacy Pfizer products in the three months ended March 29, 2009.
(e)
Prior-period amounts for Capsugel, which were previously classified in Corporate/Other, are now classified in Diversified.

 
18

 
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

Revenues by geographic area follow:
   
Three Months Ended(a)
 
(millions of dollars)
 
April 4,
2010
   
Mar. 29,
2009
   
% Change
 
                   
Revenues
                 
United States
  $ 7,314     $ 4,969       47  
Europe
    4,785       3,005       59  
Japan/Other Asia
    2,659       1,738       53  
Canada/Latin America/Africa/Middle East
    1,992       1,155       72  
Total Revenues
  $ 16,750     $ 10,867       54  
(a)
Includes revenues from legacy Wyeth products for the three months ended April 4, 2010. Revenues from legacy Wyeth products are not included in the three months ended March 29, 2009.


Our effective tax rate for continuing operations was 36.0% for the first quarter of 2010, compared to 28.2% for the first quarter of 2009. The higher tax rate for the first quarter of 2010 is primarily the result of:

·  
higher amortization charges, primarily related to intangible assets acquired in connection with the acquisition of Wyeth, and the mix of jurisdictions in which those charges were incurred;

·  
the write-off of the deferred tax asset of approximately $270 million related to the Medicare Part D subsidy for retiree prescription drug coverage, resulting from changes in the U.S. healthcare legislation enacted in March 2010 concerning the tax treatment of that subsidy effective for tax years beginning after December 31, 2012;

·  
the expiration of the U.S. research tax credit; and

·  
the increase in non-deductible in-process research and development charges.

These factors were partially offset by $410 million in tax benefits for the resolution of certain tax positions pertaining to prior years with various foreign tax authorities.

 
19

 
 

To the Shareholders and Board of Directors of Pfizer Inc.:

We have reviewed the condensed consolidated balance sheet of Pfizer Inc. and Subsidiary Companies as of April 4, 2010, the related condensed consolidated statements of income for the three-month periods ended April 4, 2010, and March 29, 2009, and the related condensed consolidated statements of cash flows for the three-month periods ended April 4, 2010, and March 29, 2009. These condensed consolidated financial statements are the responsibility of the Company’s management.

We conducted our reviews in accordance with the standards of the Public Company Accounting Oversight Board (United States). A review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the Public Company Accounting Oversight Board (United States), the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our reviews, we are not aware of any material modifications that should be made to the condensed consolidated financial statements referred to above for them to be in conformity with U.S. generally accepted accounting principles.

We have previously audited, in accordance with standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheet of Pfizer Inc. and Subsidiary Companies as of December 31, 2009, and the related consolidated statements of income, shareholders’ equity, and cash flows for the year then ended (not represented herein); and in our report dated February 26, 2010, we expressed an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying condensed consolidated balance sheet as of December 31, 2009, is fairly stated, in all material respects, in relation to the consolidated balance sheet from which it has been derived.





KPMG LLP

New York, New York
May 13, 2010

 
20

 
 

Introduction

Our MD&A is provided in addition to the accompanying condensed consolidated financial statements and footnotes to assist readers in understanding Pfizer’s results of operations, financial condition and cash flows. The MD&A is organized as follows:

·  
Overview of Our Performance and Operating Environment. This section, beginning on page 23, provides information about the following: our business; our performance during the first quarter of 2010; the anticipated impacts of the recently enacted healthcare legislation in the U.S.; our operating environment; and our strategic initiatives.

·  
Acquisition of Wyeth. This section, beginning on page 26, discusses our 2009 acquisition of Wyeth and adjustments made in the first quarter of 2010 to the provisional allocation of the purchase price. For additional information see Notes to Condensed Consolidated Financial Statements––Note 3. Acquisition of Wyeth.

·  
Revenues. This section, beginning on page 27, provides an analysis of our products and revenues for the first quarters of 2010 and 2009, as well as an overview of important product developments.

·  
Costs and Expenses. This section, beginning on page 36, provides a discussion about our costs and expenses.

·  
Provision for Taxes on Income. This section, on page 39, provides a discussion of items impacting our tax provision for the periods presented.

·  
Adjusted Income. This section, beginning on page 39, provides a discussion of an alternative view of performance used by management.

·  
Financial Condition, Liquidity and Capital Resources. This section, beginning on page 43, provides an analysis of our balance sheets as of April 4, 2010 and December 31, 2009 and cash flows for the first quarters of 2010 and 2009, as well as a discussion of our outstanding debt and commitments that existed as of April 4, 2010, and December 31, 2009. Included in the discussion of outstanding debt is a discussion of the amount of financial capacity available to help fund Pfizer’s future activities.

·  
Our Financial Guidance for 2010 and Our Financial Targets for 2012. These sections, beginning on page 45, provide a discussion of our financial guidance for full-year 2010 and our financial targets for full-year 2012.

·  
Forward-Looking Information and Factors That May Affect Future Results. This section, beginning on page 46, provides a description of the risks and uncertainties that could cause actual results to differ materially from those discussed in forward-looking statements set forth in this MD&A relating to our financial results, operations and business plans and prospects. Such forward-looking statements are based on management’s current expectations about future events, which are inherently susceptible to uncertainty and changes in circumstances. Also included in this section is a discussion of legal proceedings and contingencies.

 
21

 
 
Components of the Condensed Consolidated Statements of Income follow:
   
Three Months Ended
 
(millions of dollars, except per common share data)
 
April 4,
2010
   
Mar. 29,
2009
   
% Change
 
                   
Revenues
  $ 16,750     $ 10,867       54  
                         
Cost of sales
    4,306       1,408       206  
% of revenues
    25.7 %     13.0 %        
                         
Selling, informational and administrative expenses
    4,436       2,876       54  
% of revenues
    26.5 %     26.5 %        
                         
Research and development expenses
    2,226       1,705       31  
% of revenues
    13.3 %     15.7 %        
                         
Amortization of intangible assets
    1,409       578       144  
% of revenues
    8.4 %     5.3 %        
                         
Acquisition-related in-process research and development charges
    74       ––       *  
% of revenues
    0.4 %     –– %        
                         
Restructuring charges and certain acquisition-related costs
    706       554       27  
% of revenues
    4.2 %     5.1 %        
                         
Other (income)/deductions––net
    414       (57 )     *  
                         
Income from continuing operations before provision for taxes on income
    3,179       3,803       (16 )
% of revenues
    19.0 %     35.0 %        
                         
Provision for taxes on income
    1,146       1,074       7  
                         
Effective tax rate
    36.0 %     28.2 %        
                         
Income from continuing operations
    2,033       2,729       (26 )
% of revenues
    12.1 %     25.1 %        
                         
Discontinued operations––net of tax
    2       1       35  
                         
Net income before allocation to noncontrolling interests
    2,035       2,730       (26 )
% of revenues
    12.1 %     25.1 %        
                         
Less: Net income attributable to noncontrolling interests
    9       1       *  
                         
Net income attributable to Pfizer Inc.
  $ 2,026     $ 2,729       (26 )
% of revenues
    12.1 %     25.1 %        
                         
Earnings per common share––basic:
                       
Income from continuing operations attributable to Pfizer Inc. common shareholders
  $ 0.25     $ 0.41       (39 )
Discontinued operations––net of tax
    ––       ––       ––  
Net income attributable to Pfizer Inc. common shareholders
  $ 0.25     $ 0.41       (39 )
                         
Earnings per common share––diluted:
                       
Income from continuing operations attributable to Pfizer Inc. common shareholders
  $ 0.25     $ 0.40       (38 )
Discontinued operations––net of tax
    ––       ––       ––  
Net income attributable to Pfizer Inc. common shareholders
  $ 0.25     $ 0.40       (38 )
                         
Cash dividends paid per common share
  $ 0.18     $ 0.32          
Calculation not meaningful.
Certain amounts and percentages may reflect rounding adjustments.
 
 
22

 
 
OVERVIEW OF OUR PERFORMANCE AND OPERATING ENVIRONMENT

Our Business

Our mission is to apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world’s best-known consumer products. Every day, we work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We also collaborate with other biopharmaceutical companies, healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Our revenues ar e derived from the sale of our products, as well as through alliance agreements, under which we co-promote products discovered by other companies.

On October 15, 2009, we completed our acquisition of Wyeth and, commencing from the acquisition date, our financial statements include the assets, liabilities, operating results and cash flows of Wyeth. As a result, legacy Wyeth operations are reflected in our results of operations and cash flows for first-quarter 2010, but not for first-quarter 2009. Legacy Wyeth assets and liabilities are reflected in our balance sheets as of April 4, 2010 and December 31, 2009.

Our First Quarter 2010 Performance

Revenues in the first quarter of 2010 increased 54% to $16.8 billion, compared to $10.9 billion in the same period in 2009, due to:

·  
the inclusion of revenues from legacy Wyeth products of $5.3 billion, which favorably impacted revenues by 48%; and

·  
the favorable impact of foreign exchange, which increased revenues by approximately $733 million, or 7%,

partially offset by:

·  
the net revenue decrease from legacy Pfizer products of $137 million, or 1%.

Total revenues for the first quarter of 2010 were adversely impacted by $56 million as a result of the U.S. healthcare legislation enacted in March 2010.

The significant impacts on revenues for the first quarter of 2010, compared to the same period in 2009, are as follows:
   
Three Months Ended
 
(millions of dollars)
 
April 4, 2010 vs.
Mar. 29, 2009
Increase/(decrease)
   
% Change
 
             
Enbrel (outside the U.S. and Canada)(a)
  $ 802       *  
Effexor(a)
    716       *  
Prevnar/Prevenar 7(a)
    520       *  
Prevnar/Prevenar 13(a)
    286       *  
Zosyn/Tazocin(a)
    264       *  
Premarin family(a)
    256       *  
Hemophilia family(a)
    244       *  
Sutent
    57       28  
Lyrica
    39       6  
Lipitor
    36       1  
Viagra
    25       5  
Geodon
    24       10  
Detrol/Detrol LA
    (28 )     (10 )
Camptosar(b)
    (71 )     (65 )
Norvasc(b)
    (113 )     (23 )
Alliance revenues(a)
    422       73  
Animal Health products(a)
    309       58  
Consumer Healthcare products(a)
    663       *  
Nutrition products(a)
    458       *  
(a)
First quarter 2010 reflects inclusion of revenues from legacy Wyeth products.
(b)
Camptosar lost exclusivity in Europe in July 2009. Norvasc lost exclusivity in Canada in July 2009.
*
Calculation not meaningful.
 
 
23

 
 
In the first quarter of 2010, U.S. revenues were $7.3 billion, an increase of 47% compared to the same period in 2009, primarily reflecting the inclusion of revenues from legacy Wyeth products, which was partially offset by lower revenues from certain legacy Pfizer products, increased rebates, partly as a result of the impact of the U.S. healthcare legislation enacted in March 2010, and increased pricing pressures. International revenues were $9.4 billion, an increase of 60% compared with the same period in 2009, which reflected 48% operational growth and a 12% favorable impact of foreign exchange. The increase in operational revenues primarily reflects the inclusion of operational revenues from legacy Wyeth products and higher operational revenues from legacy Pfizer products.

Income from continuing operations for the first quarter of 2010 was $2.0 billion, compared to $2.7 billion in the first quarter of 2009 reflecting:

·  
expenses associated with the legacy Wyeth operations;

·  
the impact of Wyeth purchase accounting adjustments on Cost of sales and Amortization of intangible assets;
 
·
higher restructuring charges and certain acquisition-related costs;

·  
higher net interest expense, mainly due to the issuance of debt in connection with the acquisition of Wyeth, as well as lower interest income; and

·  
an increase in the 2010 effective tax rate (see further discussion in the “Provision For Taxes On Income” section of this MD&A),

partially offset by:

·  
increased revenues, primarily reflecting the inclusion of revenues from legacy Wyeth products.

U.S. Healthcare Legislation

Principal Provisions Affecting Us
In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (together, the U.S. Healthcare Legislation), was enacted in the U.S. This legislation has both current and longer-term impacts on us, as discussed below.

The provisions of the U.S. Healthcare Legislation are effective on various dates over the next several years. The principal provisions affecting us provide for the following:

·  
an increase, from 15.1% to 23.1%, in the minimum rebate on branded prescription drugs sold to Medicaid beneficiaries (effective January 1, 2010);

·  
extension of Medicaid prescription drug rebates to drugs dispensed to enrollees in certain Medicaid managed care organizations (effective March 23, 2010);

·  
expansion of the types of institutions eligible for the “Section 340B discounts” for outpatient drugs provided to hospitals meeting the qualification criteria under Section 340B of the Public Health Service Act of 1944 (effective January 1, 2010);

·  
discounts on branded prescription drug sales to Medicare Part D participants who are in the Medicare “coverage gap”, known as the “doughnut hole” (effective January 1, 2011); and

·  
a non-deductible annual fee payable to the federal government based on a company’s prior-calendar-year share of branded prescription drug sales to specified government programs (effective January 1, 2011, with the total fee to be paid each year by the entire pharmaceutical industry increasing annually through 2018).

In addition, the U.S. Healthcare Legislation includes provisions that affect the cost of certain of our postretirement benefit plans. Companies currently are permitted to take a deduction for federal income tax purposes in an amount equal to the subsidy received from the federal government related to their provision of prescription drug coverage to Medicare-eligible retirees. Under the U.S. Healthcare Legislation, effective for tax years beginning after December 31, 2012, companies will no longer be able to take that deduction. While the loss of this deduction will not take effect for a few years, under U.S. generally accepted accounting principles, we are required to account for the impact in the first quarter of 2010, the period when the provision was enacted into law, through a write-off of the deferred tax asset associated with those previously expected future income tax deductions. Other provisions of the U.S. Healthcare Legislation relating to our postretirement benefit plans will affect the measurement of our obligations under those plans, but those impacts are not expected to be significant.

 
24

 
 
Current and Anticipated Financial Impacts
In the first quarter of 2010, our revenues were adversely impacted by $56 million compared to the same period last year as a result of the increase in the minimum rebate on branded prescription drugs sold to Medicaid beneficiaries and the extension of Medicaid prescription drug rebates to drugs dispensed to enrollees in certain Medicaid managed care organizations and, to a lesser extent, the expansion of the types of institutions eligible for the “340B discounts” for outpatient drugs. We expect that full-year 2010 revenues will be adversely impacted by approximately $300 million as a result of the U.S. Healthcare Legislation. Further, we expect that the foregoing provisions, together with discounts on branded prescription drug sales to Medicare Part D participants who are in the Medicare “doughnut hole” and the ann ual fee based on branded prescription drug sales to specified government programs, will adversely affect revenues by approximately $900 million in 2011 and $800 million in 2012. In view of these anticipated impacts, we have reduced our target revenue range for 2012 by $800 million. However, we have reaffirmed all of the other components of our 2012 financial targets, and we have reaffirmed all components of our 2010 financial guidance. (See the “Our Financial Guidance for 2010” and “Our Financial Targets for 2012” sections of this MD&A for additional information.)

In the first quarter of 2010, our income tax expense increased due to, among other things, the write-off of the deferred tax asset of approximately $270 million to account for the loss of the deduction, for tax years beginning after December 31, 2012, of an amount equal to the subsidy from the federal government related to our provision of prescription drug coverage to Medicare-eligible retirees. This write-off was recorded in Provision for taxes on income in our Condensed Consolidated Statement of Income. (For additional information on the impact of this write-off on our first-quarter 2010 effective tax rate, see the “Provision for Taxes on Income” section of this MD&A.)

The financial impact of U.S. healthcare reform may be affected by certain additional factors over the next few years, including pending implementation guidance relating to the U.S. Healthcare Legislation and certain healthcare reform proposals. In addition, the U.S. Healthcare Legislation requires that, except in certain circumstances, individuals obtain health insurance beginning in 2014, and it also provides for an expansion of Medicaid coverage in 2014. It is expected that, as a result of these provisions, there will be a substantial increase in the number of Americans with health insurance beginning in 2014, a significant portion of whom will be eligible for Medicaid. We anticipate that this will increase demand for pharmaceutical products overall. However, in view of the many uncertainties, we are unable at this time to determin e whether and to what extent sales of Pfizer prescription pharmaceutical products in the U.S. will be impacted.
 
Biotechnology Products
The U.S. Healthcare Legislation provides an abbreviated legal pathway to approve biosimilars (also referred to as “follow-on biologics”). Innovator biologics were granted 12 years data exclusivity, with a potential six-month pediatric extension. After the data exclusivity period expires, the FDA could approve biosimilar versions of innovator biologicals. The regulatory implementation of these provisions is ongoing and expected to take several years. If competitors are able to obtain marketing approval for biosimilars referencing our biotechnology products, our biotechnology products may become subject to competition from biosimilars, with the attendant competitive pressure.
 
Our Operating Environment

Industry-Specific Challenges
The majority of our revenues come from the manufacture and sale of Biopharmaceutical products. As explained more fully in Pfizer’s 2009 Annual Report on Form 10-K, the biopharmaceutical industry is highly competitive and requires us to address a number of industry-specific challenges, which can significantly impact the sales of our products.  These factors include among others: the loss or expiration of intellectual property rights, the regulatory environment and pipeline productivity, pricing and access pressures and increasing competition among branded products.

We expect that we will lose exclusivity for Lipitor in the U.S. in November 2011 and, as a result, will lose the substantial portion of our U.S. revenue from Lipitor shortly thereafter.  We have granted Watson Laboratories, Inc. (Watson) the exclusive right to sell the authorized generic version of Lipitor in the U.S. for a period of five years, which is expected to commence in November 2011. As Watson’s exclusive supplier, we will manufacture and sell to Watson the atorvastatin for use in this product. While the loss of exclusivity for Lipitor will occur at various times in developed markets outside the U.S., we expect to maintain a significant portion of the Lipitor revenue in those markets through 2011.  We do not expect that Lipitor revenue in emerging markets will be materially impacted by loss of exclusivit y over the next several years.  In 2009, revenue from Lipitor was approximately $5.7 billion in the U.S. and approximately $5.7 billion in markets outside the U.S. (of which approximately $900 million was attributable to emerging markets). We also expect to lose exclusivity for various other products over the next few years, including Effexor XR and Aricept in the U.S. later this year.

We will continue to aggressively defend our patent rights against increasing incidents of infringement whenever appropriate. For more detailed information about our significant products, see the discussion in the “Revenues – Biopharmaceutical – Selected Product Descriptions” section of this MD&A. See Part II – Other Information; Item 1. Legal Proceedings, of this Form 10-Q for a discussion of certain recent developments with respect to patent litigation.

The Overall Economic Environment
In addition to industry-specific factors, we, like other businesses, continue to face the effects of the weak economy. The impact of the weak economy on our Biopharmaceutical operations has been largely in the U.S. market, affecting the performance of products such as Lipitor, Celebrex and Lyrica. We believe that patients, experiencing the effects of the weak economy, including high unemployment levels, and increases in co-pays sometimes are switching to generics, delaying treatments, skipping doses or using less effective treatments to reduce their costs. The weak economy also has increased the number of patients in the Medicaid program, under which sales of pharmaceuticals are subject to substantial rebates and, in many states, to formulary restrictions limiting access to brand-name drugs, including ours.

 
25

 
 
Despite the challenging financial markets, Pfizer maintains a strong financial position. Due to our significant operating cash flows, financial assets, access to capital markets and available lines of credit and revolving credit agreements, we continue to believe that we have the ability to meet our liquidity needs for the foreseeable future. Our long-term debt is rated high quality and investment grade by both Standard & Poor’s and Moody’s Investors Service. As market conditions change, we continue to monitor our liquidity position. We have and will continue to take a conservative approach to our financial investments. Both short-term and long-term investments consist primarily of high-quality, highly liquid, well-diversified, investment-grade available-for-sale debt securities. For further discussion of our financial con dition, see the "Financial Condition, Liquidity and Capital Resources” section of this MD&A.

Foreign Exchange Risk
A significant portion of our revenues and earnings is exposed to changes in foreign exchange rates. We seek to manage our foreign exchange risk in part through operational means, including managing same-currency revenues in relation to same-currency costs and same-currency assets in relation to same-currency liabilities. Depending on market conditions, foreign exchange risk also is managed through the use of derivative financial instruments and foreign currency debt. As we operate in multiple foreign currencies including the euro, the U.K. pound, the Canadian dollar and approximately 100 other currencies, changes in those currencies relative to the U.S. dollar will impact our revenues and expenses. When the dollar weakens against a specific foreign currency our revenues will increase, or have a positive impact, and our expenses will incre ase, having a negative impact, on net income. Likewise, if the dollar strengthens against a specific currency, our revenues will decrease, or have a negative impact, and our expenses will decrease, having a positive impact, on net income. Therefore, significant shifts in currencies can impact our short-term results as well as our long-term forecasts or targets.

These and other industry-wide factors that may affect our businesses should be considered along with information presented in the “Forward-Looking Information and Factors That May Affect Future Results” section of this MD&A and in Part I, Item 1A, “Risk Factors”, of our 2009 Annual Report on Form 10-K.

Our Strategic Initiatives – Strategy and Recent Transactions

We are committed to capitalizing on growth opportunities by advancing our own pipeline and maximizing the value of our in-line products, as well as through various forms of business development, which can include alliances, licenses, joint ventures, dispositions and acquisitions. We view our business-development activity as an enabler of our strategies, and we seek to generate profitable revenue growth and enhance shareholder value by pursuing a disciplined, strategic and financial approach to evaluating business-development opportunities.  The 2012 target revenue range that we have announced (see the “Our Financial Targets For 2012” section of this MD&A) contemplates a modest level of business-development activity.  We are especially interested in opportunities in our Emerging Markets and Established P roducts units and our “invest to win” therapeutic areas––oncology, pain, inflammation, Alzheimer’s disease, psychoses, diabetes and vaccines.

In connection with our acquisition of Wyeth, we are required to divest certain animal health assets. Certain of these assets were sold in 2009.  In 2010, we completed the divestiture of legacy Fort Dodge Animal Health livestock business and related assets in Australia and entered into agreements for the divestiture of certain animal assets in China, the European Union, Switzerland and Mexico, completion of which is subject to regulatory approval and other closing conditions. It is possible that additional divestitures of animal health assets may be required based on ongoing regulatory reviews in other jurisdictions worldwide.

In the first quarter of 2009, we entered into a five-year agreement with Bausch & Lomb to co-promote prescription pharmaceuticals in the U.S. for the treatment of ophthalmic conditions. The agreement covers prescription ophthalmic pharmaceuticals, including our Xalatan product and Bausch & Lomb’s Alrex®, Lotemax® and Zylet® products, as well as Bausch & Lomb’s investigational anti-infective eye drop, besifloxacin ophthalmic suspension, 0.6%, which currently is under review by the U.S. Food and Drug Administration (FDA).

ACQUISITION OF WYETH
 
On October 15, 2009 (the acquisition date), we acquired all of the outstanding equity of Wyeth in a cash-and-stock transaction, valued at the acquisition date at approximately $68 billion. While Wyeth now is a wholly owned subsidiary of Pfizer, the merger of local Pfizer and Wyeth entities may be pending or delayed in various international jurisdictions and integration in these jurisdictions is subject to completion of various local legal and regulatory obligations.

 
26

 
 
In 2009, we recorded provisional amounts for the assets acquired and liabilities assumed, which were adjusted in the first quarter of 2010 (measurement period adjustments). Certain estimated values are not yet finalized (see below) and are subject to change, which could be significant. We will finalize the amounts recognized as we obtain the information necessary to complete the analyses, but no later than one year from the acquisition date. See Notes to Condensed Consolidated Financial Statements––Note 3. Acquisition of Wyeth.

Measurement Period Adjustments
The measurement period adjustments for Identifiable intangible assets reflect changes in the estimated fair value of certain acquired intangibles, principally in-process research and development assets, primarily to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date, such as long-term expectations as to patient population, general market potential, dosing regimens and pricing.  The fair value changes did not result from intervening events subsequent to the acquisition date.

The measurement period adjustments did not have a significant impact on our consolidated statements of income, balance sheets or cash flows in any period and, therefore, we have not retrospectively adjusted our financial statements. In addition, neither the measurement period adjustments nor the underlying scientific and market data leading to the changes impacted our financial guidance for 2010 (see the “Our Financial Guidance for 2010” section of this MD&A and in our 2009 Annual Report on Form 10-K) or our financial targets for 2012 (see the “Our Financial Targets for 2012” section in this MD&A and in our 2009 Annual Report on Form 10-K).

Provisional Amounts
The recorded amounts are provisional and subject to change. Specifically, the following items are subject to change:

·  
Amounts for intangibles and inventory, pending finalization of valuation efforts.

·  
Amounts for legal contingencies, pending the finalization of our examination and evaluation of the portfolio of filed cases.

·  
Amounts for income tax assets, receivables and liabilities pending the filing of Wyeth pre-acquisition tax returns, including all required disclosures and documentation, as well as the receipt of information from taxing authorities which may change certain estimates and assumptions used.

·  
The allocation of goodwill among reporting units.
 
REVENUES

Worldwide revenues by segment and geographic area for the first quarters of 2010 and 2009 follow:
     
% Change in Revenues
 
                     
World-
         
Inter-
 
   
Worldwide(a)
   
U.S.(a)
   
International(a)
   
wide
   
U.S.
   
national
 
   
April 4,
   
Mar. 29,
   
April 4,
   
Mar. 29,
   
April 4,
   
Mar. 29,
                   
(millions of dollars)
 
2010
   
2009
   
2010
   
2009
   
2010
   
2009
    10/09     10/09     10/09  
Three Months Ended:
                                                           
Biopharmaceutical
  $ 14,506     $ 10,102     $ 6,607     $ 4,709     $ 7,899     $ 5,393       44       40       46  
Diversified
    2,141       691       663       238       1,478       453       210       179       227  
Corporate/Other(b)
    103       74       44       22       59       52       39       100       13  
Total revenues
  $ 16,750     $ 10,867     $ 7,314     $ 4,969     $ 9,436     $ 5,898       54       47       60  
(a)
Reflects the inclusion of revenues from legacy Wyeth products for the three months ended April 4, 2010. Legacy Wyeth revenues are not included in the three months ended March 29, 2009. Prior-period amounts for Capsugel, which previously were classified as Corporate/Other, now are included in Diversified.
(b)
Includes Pfizer Centersource, which includes contract manufacturing and bulk pharmaceutical chemical sales.

 
27

 

Worldwide revenues by segment, and by business unit, for the first quarters of 2010 and 2009 follow:
   
Three Months Ended(a)
 
(millions of dollars)
 
April 4,
2010
   
Mar. 29,
2009
   
% Change
 
                   
Biopharmaceutical:
                 
Primary care
  $ 5,866     $ 5,322       10  
Specialty care
    3,521       1,463       141  
Established products(b)
    2,786       1,615       73  
Emerging markets(c)
    1,972       1,352       46  
Oncology(d)
    361       350       3  
Total Biopharmaceutical
    14,506       10,102       44  
Diversified:
                       
Animal Health products
    846       537       58  
Consumer Healthcare products
    663       ––       *  
Nutrition products
    458       ––       *  
Capsugel
    174       154       13  
Total Diversified
    2,141       691       210  
Corporate/Other(e)
    103       74       39  
Total revenues
  $ 16,750     $ 10,867          
(a) 
Reflects the inclusion of revenues from legacy Wyeth products for the three months ended April 4, 2010. Legacy Wyeth revenues are not included in the three months ended March 29, 2009. Prior-period amounts for Capsugel, which previously were classified as Corporate/Other, now are included in Diversified.
(b)
The legacy Pfizer Established Products unit was negatively impacted in the first quarter of 2010 by 5% due to the loss of exclusivity for Norvasc in Canada, offset by the favorable impact of the addition of Camptosar’s European revenues as well as the reclassification of revenues from South Korea.
(c)
Revenues from South Korea were included in the Emerging Markets unit in first-quarter 2009, but are included in the developed market units, as appropriate, beginning first-quarter 2010, which negatively impacted the legacy Pfizer Emerging Markets unit’s revenues by 5%.
(d)
Legacy Pfizer Oncology unit revenues in first-quarter 2010 no longer include Camptosar’s European revenues due to its loss of exclusivity in July 2009. The reclassification of those revenues to the Established Products unit negatively impacted the Oncology unit’s performance by 24% in first-quarter 2010 compared to the same period last year.
(e)
Includes Pfizer Centersource, which includes contract manufacturing and bulk pharmaceutical chemical sales.
*
Calculation not meaningful.

Biopharmaceutical Revenues
Worldwide Biopharmaceutical revenues for the first quarter of 2010 were $14.5 billion, an increase of 44% compared to the first quarter of 2009, primarily due to:

·  
the inclusion of revenues from legacy Wyeth products of approximately $4.1 billion, which favorably impacted Biopharmaceutical revenues by 41%;

·  
the weakening of the U.S. dollar relative to other currencies, primarily the euro, Australian dollar, Canadian dollar, and Brazilian real, which favorably impacted Biopharmaceutical revenues by approximately $617 million, or 6%, and

·  
solid operational performance from certain legacy Pfizer products, including Sutent, Lyrica, Viagra and Geodon, and higher legacy Pfizer alliance revenues,

partially offset by:

·  
a decrease in operational revenues, of approximately $260 million, from certain legacy Pfizer products, including Norvasc and Camptosar, as a result of loss of exclusivity, as well as from Lipitor and Detrol/Detrol LA.

Geographically,

·  
in the U.S., Biopharmaceutical revenues increased 40% in the first quarter of 2010 compared to the same period in 2009, primarily due to the inclusion of revenues from legacy Wyeth products of approximately $2.2 billion, which favorably impacted Biopharmaceutical revenues by 47%, which was partially offset by lower revenues from certain legacy Pfizer products of $322 million, or 4%, including Lipitor, Lyrica, Detrol and Celebrex, compared to the same period in 2009, as a result of continued generic pressures.  Revenues from legacy Pfizer products also were adversely affected by increased rebates partly as a result of the impact of the U.S. Healthcare Legislation, and increased pricing pressures. These factors were partially offset by the solid performance from Geodon and legacy Pfizer alliance revenues in the first quarter of 2010; and

 
28

 
 
·  
in our international markets, Biopharmaceutical revenues increased 46% in the first quarter of 2010, compared to the first quarter of 2009. The increase in revenues reflects the inclusion of operational revenues from legacy Wyeth products of $1.8 billion, which favorably impacted Biopharmaceutical revenues by 34%, higher operational revenues from legacy Pfizer products of $60 million, or 1%, and the favorable impact of foreign exchange on international Biopharmaceutical revenues of $617 billion, or 11%. The increase in operational revenues of legacy Pfizer products was due to operational growth from Lipitor, Lyrica, Sutent, Celebrex, Viagra and alliance products, partially offset by lower revenues from Norvasc and Camptosar, due to loss of exclusivity, among others.

During the first quarter of 2010, international Biopharmaceutical revenues represented 54% of total Biopharmaceutical revenues, compared to 53% in 2009.

Effective January 1, 2010, we increased the published prices for certain U.S. Biopharmaceutical products. These price increases had no material effect on wholesaler inventory levels in comparison to the prior year.

Diversified Revenues
 
Worldwide Diversified revenues in the first quarter of 2010 were $2.1 billion, an increase of 210% compared to the same period in 2009 due to:

·  
the inclusion of operational revenues from legacy Wyeth products of approximately $1.2 billion, which favorably impacted Diversified revenues by 179%, primarily from the addition of the legacy Wyeth Consumer Healthcare and Nutrition operations, the operational revenue increase in legacy Pfizer Diversified businesses of 15% and the favorable impact of foreign exchange of 16%.
 
Revenues from Animal Health products increased 58% in the first quarter of 2010 compared to the same period in 2009, reflecting the inclusion of operational revenues from legacy Wyeth Animal Health products of 31%, higher operational revenues from legacy Pfizer Animal Health products of 17% and the favorable impact of foreign exchange of 10%.

Rebates and Chargebacks
As is typical in the pharmaceutical industry, our gross product sales are subject to a variety of deductions, that are generally estimated and recorded in the same period that the revenues are recognized, and primarily represent rebates and discounts to government agencies, wholesalers, distributors and managed care organizations for our pharmaceutical products. These deductions represent estimates of the related obligations and, as such, judgment and knowledge of market conditions and practice are required when estimating the impact of these sales deductions on gross sales for a reporting period. Historically, our adjustments to actual results have not been material to our overall business. On a quarterly basis, our adjustments to actual results generally have been less than 1% of Biopharmaceutical net sales and can result in either a ne t increase or a net decrease in income. Product-specific rebate charges, however, can have a significant impact on year-over-year individual product growth trends.

Rebates and chargebacks reduced revenues as follows:
   
Three Months Ended
 
(millions of dollars)
 
April 4,
2010
   
Mar. 29,
2009
 
             
Medicaid and related state program rebates(a)
  $ 306     $ 150  
Medicare rebates(a)
    276       230  
Performance-based contract rebates(a), (b)
    649       605  
Chargebacks(c)
    814       486  
Total
  $ 2,045     $ 1,471  
(a)
Rebates are product-specific and, therefore, for any given year are impacted by the mix of products sold.
(b)
Performance-based contracts are with managed care customers, including health maintenance organizations and pharmacy benefit managers, which receive rebates based on the achievement of contracted performance terms for products.
(c)
Chargebacks primarily represent reimbursements to wholesalers for honoring contracted prices to third parties.

The above rebates and chargebacks for the first quarter of 2010 were higher than 2009, primarily as a result of:

·  
the inclusion of rebates and chargebacks related to legacy Wyeth products;

·  
the impact of increased Medicaid rebate rates due to the U.S. Healthcare Legislation in addition to higher rates for certain products that are subject to rebates; and

·  
the impact of increased chargebacks due to competitive pricing factors,
 
 
29

 
 
partially offset by:

·  
changes in product mix, among other factors.

Our accruals for Medicaid rebates, Medicare rebates, performance-based contract rebates and chargebacks totaled $2.5 billion as of April 4, 2010, an increase from $2.1 billion as of December 31, 2009 and primarily are included in Current deferred tax liabilities and other current liabilities in our Condensed Consolidated Balance Sheets.

Biopharmaceutical – Selected Product Revenues
Revenue information for several of our major Biopharmaceutical products follows:
     
Three Months Ended
 
           
% Change
 
(millions of dollars)
   
April 4,
   
From Mar. 29,
 
Product
Primary Indications
 
2010
   
2009
 
Lipitor
Reduction of LDL cholesterol
  $ 2,757       1  
Enbrel(a), (c)
Rheumatoid, juvenile rheumatoid and psoriatic arthritis,
     plaque psoriasis and ankylosing spondylitis
    802       *  
Lyrica
Epilepsy, post-herpetic neuralgia and diabetic
 peripheral neuropathy, fibromyalgia
    723       6  
Effexor(a)
Depression and certain anxiety disorders
    716       *  
Celebrex
Arthritis pain and inflammation, acute pain
    570       1  
Prevnar/Prevenar 7(a)
Vaccine for prevention of invasive pneumococcal disease
    520       *  
Viagra
Erectile dysfunction
    479       5  
Xalatan/Xalacom
Glaucoma and ocular hypertension
    422       4  
Norvasc
Hypertension
    368       (23 )
Zyvox
Bacterial infections
    292       3  
Prevnar/Prevenar 13(a)
Vaccine for prevention of invasive pneumococcal disease
    286       *  
Zosyn/Tazocin(a)
Antibiotic
    264       *  
Detrol/Detrol LA
Overactive bladder
    261       (10 )
Sutent
Advanced and/or metastatic renal cell carcinoma (mRCC)
and refractory gastrointestinal stromal tumors (GIST)
    259       28  
Premarin family(a)
Menopause
    256       *  
Geodon/Zeldox
Schizophrenia; acute manic or mixed episodes
 associated with bipolar disorder; maintenance
        treatment of bipolar mania
    254       10  
Genotropin
Replacement of human growth hormone
    206       4  
Chantix/Champix
An aid to smoking cessation
    189       7  
Vfend
Fungal infections
    188       5  
BeneFIX(a)
Hemophilia
    154       *  
Caduet
Reduction of LDL cholesterol and hypertension
    135       ––  
Aromasin
Breast cancer
    128       16  
Zoloft
Depression and certain anxiety disorders
    120       5  
Revatio
Pulmonary arterial hypertension
    114       ––  
Medrol
Inflammation
    109       (8 )
Cardura
Hypertension/Benign prostatic hyperplasia
    107       ––  
Aricept(b)
Alzheimer’s disease
    107       12  
Zithromax/Zmax
Bacterial infections
    103       (10 )
ReFacto/Xyntha(a)
Hemophilia
    90       *  
All other(d)
Various
    2,523       45  
Alliance revenues:
      1,004       73  
Enbrel (in the U.S. and Canada)(a),
       Aricept, Exforge, Rebif and Spiriva
Inflammation (Enbrel), Alzheimer’s disease (Aricept),
hypertension (Exforge), multiple sclerosis (Rebif)
        and chronic obstructive pulmonary disease (Spiriva)
               

(a)
Reflects the inclusion of revenues from legacy Wyeth products in the three months ended April 4, 2010.
 
Revenues from legacy Wyeth products are not included in the three months ended March 29, 2009.
(b)
Represents direct sales under license agreement with Eisai Co., Ltd.
(c)
Outside the U.S. and Canada.
(d)
Includes legacy Pfizer and legacy Wyeth products in the three months ended April 4, 2010 and includes only legacy Pfizer products in the first quarter of 2009.
Calculation not meaningful.
Certain amounts and percentages may reflect rounding adjustments.
 
 
30

 
 
Biopharmaceutical – Selected Product Descriptions:

·  
Lipitor, for the treatment of elevated LDL-cholesterol levels in the blood, is the most widely used branded prescription treatment for lowering cholesterol and the best-selling prescription pharmaceutical product of any kind in the world. Lipitor recorded worldwide revenues of $2.8 billion in the first quarter of 2010, reflecting 1% growth compared to the same period in 2009. These results, in part, reflect the favorable impact of foreign exchange, which increased revenues by $148 million, or 5%, in the first quarter of 2010, compared to the same period in 2009. In the U.S., revenues were $1.3 billion or a decrease of 10% in the first quarter of 2010 compared to the same period in 2009. Internationally, Lipitor revenues in the first quarter of 2010 were $1.4 billion, or an increase of 14%, comp ared to the same period in 2009, with 12% due to the favorable impact of foreign exchange.
 
 
Excluding the favorable impact of foreign exchange, the decrease in Lipitor worldwide operational revenues in the first quarter of 2010, compared to the first quarter of 2009, was driven by a combination of factors, including the following:
 
 
the continuing impact of an intensely competitive lipid-lowering market with competition from multi-source generics and branded products in the U.S.;
 
 
increased payer pressure in the U.S.; and
 
 
slower growth in the lipid-lowering market in the U.S. due, in part, to a slower rate of growth in the Medicare Part D population and, reflecting weak economic conditions, heightened overall patient cost-sensitivity in the U.S. and adoption of non-prescription treatment options,
 
 
partially offset by:
 
 
o
operational growth internationally.
 
 
See the “Our Operating Environment––Industry-Specific Challenges” section of this MD&A for a discussion concerning the expected loss of exclusivity for Lipitor in various markets.

·  
Enbrel, for the treatment of rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, plaque psoriasis and ankylosing spondylitis, a type of arthritis affecting the spine, recorded worldwide revenues, excluding the U.S. and Canada, of $802 million in the first quarter of 2010. Enbrel revenues from the U.S. and Canada are included in alliance revenues. The approval of competing products for the treatment of psoriasis is expected to increase competition with respect to Enbrel in 2010.

 
We have exclusive rights to Enbrel outside the U.S. and Canada and co-promote Enbrel with Amgen Inc. (Amgen) in the U.S. and Canada. Our co-promotion agreement with Amgen expires in October 2013, and we are entitled to a royalty stream for 36 months thereafter, which is significantly less than our current share of Enbrel profits from U.S. and Canadian sales. Our rights to Enbrel outside the U.S. and Canada will not be affected by the expiration of the co-promotion agreement.

·  
Lyrica, indicated for the management of post-herpetic neuralgia (PHN), diabetic peripheral neuropathy (DPN), fibromyalgia, and as adjunctive therapy for adult patients with partial onset seizures in the U.S., and for neuropathic pain, adjunctive treatment of epilepsy and general anxiety disorder (GAD) outside the U.S., recorded an increase in worldwide revenues of 6% in the first quarter of 2010 compared to the first quarter of 2009. Lyrica had a strong operational performance in international markets in the first quarter of 2010. In the U.S., revenues have been adversely affected by increased generic competition, as well as managed care pricing and formulary pressures.

 
See Part II––Other Information; Item 1. Legal Proceedings, of this Form 10-Q for a discussion of certain patent litigation relating to Lyrica.

·  
Effexor XR (extended release capsules), an antidepressant for treating adult patients with major depressive disorder, GAD, social anxiety disorder and panic disorder, recorded worldwide revenues of $716 million in the first quarter of 2010. Effexor XR faces generic competition outside the U.S. In the U.S., Effexor XR faces competition from a non-AB-rated (i.e., not therapeutically equivalent) generic product. Pursuant to a 2005 settlement agreement related to certain patent litigation with Wyeth, Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd. are permitted to launch generic versions of Effexor XR in the U.S. beginning July 1, 2010, subject to possible earlier launch based on specified market conditions or developments regarding the applicable patents rights, including t he outcome of other generic challenges to such patent rights.

 
31

 
 
·  
Celebrex, a treatment for the signs and symptoms of osteoarthritis and rheumatoid arthritis and acute pain in adults, experienced an increase in worldwide revenues of 1% in the first quarter of 2010 compared to the same period in 2009, primarily due to the favorable impact of foreign exchange partially offset by increased generic competition. Celebrex is supported by continued educational and promotional efforts highlighting its efficacy and safety profile for appropriate patients.

 
See Part II––Other Information; Item 1. Legal Proceedings, of this Form 10-Q for a discussion of certain product litigation relating to Celebrex.

·  
Prevnar/Prevenar 7, our 7-valent pneumococcal conjugate vaccine for preventing invasive pneumococcal disease in infants and young children, recorded worldwide revenues of $520 million in the first quarter of 2010.

·  
Viagra remains the leading treatment for erectile dysfunction and one of the world’s most recognized pharmaceutical brands after more than a decade. Viagra worldwide revenues in the first quarter of 2010 increased 5% compared to the same period in 2009. In the U.S., first quarter 2010 Viagra revenues decreased 2% compared to the same period in 2009 and, internationally, revenues increased 16% compared to the first quarter of 2009 due primarily to the favorable impact of foreign exchange.

 
See Part II––Other Information; Item 1. Legal Proceedings, of this Form 10-Q for a discussion of certain patent and product litigation relating to Viagra.

·  
Xalabrands consists of Xalatan, a prostaglandin, the world’s leading branded agent to reduce elevated eye pressure in patients with open-angle glaucoma or ocular hypertension and Xalacom, a fixed combination prostaglandin (Xalatan) and beta blocker (timolol) that is available outside the U.S. Xalatan/Xalacom worldwide revenues in the first quarter of 2010 increased 4% compared to the same period in 2009, primarily due to the favorable impact of foreign exchange.

·  
Norvasc, for treating hypertension, lost exclusivity in the U.S. in March 2007. Norvasc also has experienced patent expirations in other major markets, including Japan in July 2008 and most recently Canada in July 2009. Norvasc worldwide revenues in the first quarter of 2010 decreased 23% compared to the same period in 2009.

·  
Zyvox is the world’s best-selling branded agent for the treatment of certain serious Gram-positive pathogens, including Methicillin-Resistant Staphylococcus-Aureus (MRSA). Zyvox worldwide revenues in the first quarter of 2010 increased 3% compared to the same period in 2009, primarily due to growth in emerging markets and developed markets in Europe. Revenues have been adversely affected by a decrease in the number of patients treated for pneumonia and by increased generic competition in the U.S., as well as competition from recently launched agents in certain high-volume international markets such as the U.K.

 
See Part II––Other Information; Item 1. Legal Proceedings, of this Form 10-Q for a discussion of certain patent litigation relating to Zyvox.

·  
Prevnar/Prevenar 13, launched in Germany in late 2009 and in the U.S. in early 2010 with ongoing launches in other markets in the first quarter of 2010 and beyond, is our 13-valent pneumococcal conjugate vaccine for preventing invasive pneumococcal disease in infants and young children, recorded worldwide revenues of $286 million in the first quarter of 2010. To date, Prevnar/Prevenar 13 has been approved in over 40 countries.

·  
Zosyn/Tazocin, our broad-spectrum intravenous antibiotic, faces generic competition in the U.S. and certain other markets. It recorded worldwide revenues of $264 million in the first quarter of 2010. 

·  
Detrol/Detrol LA, a muscarinic receptor antagonist, is the most prescribed branded medicine worldwide for overactive bladder. Detrol LA is an extended-release formulation taken once a day. Detrol/Detrol LA worldwide revenues in the first quarter of 2010 declined 10%, compared to the same period in 2009, primarily due to increased competition from other branded medicines.

·  
Sutent is for the treatment of advanced renal cell carcinoma, including metastatic renal cell carcinoma (mRCC), and gastrointestinal stromal tumors (GIST) after disease progression on, or intolerance to, imatinib mesylate. Sutent worldwide revenues increased 28% in the first quarter of 2010, compared to the same period in 2009. We continue to drive total revenue and prescription growth, supported by cost-effectiveness data and efficacy data in first-line mRCC––including two-year survival data, which represent the first time that overall survival of two years has been seen in the treatment of advanced kidney cancer, as well as through access and healthcare coverage. As of April 4, 2010, Sutent was the best-selling medicine in the world for the treatment of first-line mRCC.
 
 
On April 7, 2010, the FDA requested that we revise the product labeling for Sutent to include information regarding the risk of hepatotoxicity as a boxed warning and convert the existing patient package insert to a Medication Guide for distribution to patients who are dispensed Sutent.  The FDA also requested a risk mitigation, assessment, and communication plan to ensure that the benefits of Sutent treatment continue to outweigh the risks.  Revised labeling for the product, which likely will include the addition of a boxed warning to prominently communicate this information, will be issued upon completion of discussions with the FDA.

 
Pfizer maintains a global safety database, monitoring all sponsored clinical trials and spontaneous adverse event reports. Hepatic failure has been uncommonly observed in clinical trials (0.3%) and post-marketing experience, consistent with the very low rate of hepatic failure observed in the clinical trials of Sutent used to support original registration in 2006. Over 80,000 patients worldwide have been treated with Sutent.

 
The risk-benefit profile of Sutent in both mRCC and second-line GIST has been well-established through large, randomized clinical trials evaluating its safety and efficacy.  Sutent remains an important treatment option for these two difficult-to-treat cancers.
 
 
See Part II––Other Information; Item 1. Legal Proceedings, of this Form 10-Q for a discussion of certain patent litigation relating to Sutent.

 
32

 
 
·  
Our Premarin family of products remains the leading therapy to help women address moderate to severe menopausal symptoms. It recorded worldwide revenues of $256 million in the first quarter of 2010.

·  
Geodon/Zeldox, an atypical antipsychotic, is indicated for the treatment of schizophrenia, as monotherapy for the acute treatment of bipolar manic or mixed episodes, and as an adjunct to lithium or valproate for the maintenance treatment of bipolar disorder.  Geodon recorded an increase in worldwide revenues of 10% in the first quarter of 2010 compared to the same period in 2009, due in part to continued growth in the U.S. antipsychotic market, recent U.S. approval for adjunctive bipolar maintenance therapy in adults, and the favorable impact of foreign exchange.

·  
Genotropin, the world’s leading human growth hormone, is used in children for the treatment of short stature with growth hormone deficiency, Prader-Willi Syndrome, Turner Syndrome, Small for Gestational Age Syndrome, Idiopathic Short Stature (in the U.S. only) and Chronic Renal Insufficiency (outside the U.S. only), as well as in adults with growth hormone deficiency. Genotropin is supported by a broad platform of innovative injection-delivery devices. Genotropin worldwide revenues increased 4% in the first quarter of 2010 compared to the same period in 2009, primarily due to the favorable impact of foreign exchange.

·  
Chantix/Champix, the first new prescription treatment to aid smoking cessation in nearly a decade, has been launched in all major markets. Chantix/Champix worldwide revenues in the first quarter of 2010 increased 7% compared to the same period in 2009 due to strong performance in developed markets in Europe partially offset by the impact of changes to the product’s label and other factors. We are continuing our educational and promotional efforts, which are focused on the Chantix benefit-risk proposition, the significant health consequences of smoking and the importance of the physician-patient dialogue in helping patients quit smoking.

·  
Vfend, as the only branded agent available in intravenous and oral forms, continues to build on its position as the best-selling systemic, antifungal agent worldwide. The overall global revenues of Vfend continue to be driven by its acceptance as an excellent broad-spectrum agent for treating yeast and molds. Vfend worldwide revenues increased 5% in the first quarter of 2010 compared to the same period in 2009, primarily due to the favorable impact of foreign exchange.

 
In October 2009, we settled a challenge by Mylan, Inc. (Mylan) and its subsidiary, Matrix Laboratories Limited (Matrix), to four of our patents relating to Vfend by entering into an agreement granting Matrix and another subsidiary of Mylan the right to market voriconazole (generic Vfend) tablets in the U.S. beginning in the first quarter of 2011.

·  
BeneFIX and ReFacto/Xyntha are our state-of-the-art hemophilia products that offer patients with this lifelong bleeding disorder the potential for a near-normal life. It recorded worldwide revenues of $244 million in the first quarter of 2010.

 
See Part II––Other Information; Item 1. Legal Proceedings, of this Form 10-Q for a discussion of certain patent litigation relating to ReFacto and Xyntha.

·  
Caduet, a single-pill therapy combining Norvasc and Lipitor, recorded virtually flat worldwide revenues in the first quarter of 2010 compared to the same period in 2009, primarily due to increased generic competition, as well as an overall decline in U.S. hypertension market volume.

·  
Revatio, for the treatment of pulmonary arterial hypertension, recorded virtually flat worldwide revenues in the first quarter of 2010 compared to the same period in 2009, primarily due to increased competition.

·  
Alliance revenues increased 73% in the first quarter of 2010 compared to the same period in 2009, due to the strong performance of Spiriva, Aricept and Rebif, as well as the inclusion of sales of Enbrel, a legacy Wyeth product, in the U.S. and Canada. We expect to lose exclusivity for Aricept in the U.S. later this year.

Product Developments – Biopharmaceutical

We continue to invest in R&D to provide potential future sources of revenues through the development of new products, as well as through additional uses for existing in-line and alliance products, and we have taken important steps to prioritize our R&D portfolio to maximize value. After a review in 2008 of all our therapeutic areas, we announced our decision to exit certain disease areas and give higher priority to the following disease areas: oncology, pain, inflammation, Alzheimer’s disease, psychoses and diabetes. With our acquisition of Wyeth, we also have added a focus on vaccines and biologics. While we continue to conduct research across a broad range of diseases, approximately 70% of our research projects and 75% of our late-stage portfolio currently are focused on our higher-priority areas.

In January 2010, we announced the combined company pipeline, comprised of assets from both legacy Pfizer and legacy Wyeth, which included 133 programs from Phase I through registration and showed growth and increased diversity in each of the areas where we invest in R&D.  We remain on track to achieve our previously announced goal of 15 to 20 regulatory submissions in the 2010 to 2012 period.

 
33

 
 
Notwithstanding our efforts, there are no assurances as to when, or if, we will receive regulatory approval for additional indications for existing products or any of our other products in development.

Below are significant regulatory actions by, and filings pending with, the FDA and regulatory authorities in the EU and Japan:
Recent FDA approvals:
 
PRODUCT
INDICATION
DATE APPROVED
Prevnar 13 Infant
Prevention of invasive pneumococcal disease in infants and young children
February 2010

Pending U.S. new drug applications (NDA) and supplemental filings:
 
PRODUCT
INDICATION
DATE SUBMITTED
Taliglucerase alfa
Treatment of Gaucher’s disease
December 2009
Sutent
Pancreatic neuroendocrine tumor
December 2009
Genotropin
Adult growth hormone deficiency (Mark VII multidose disposable device)
October 2009
Celebrex
Chronic pain
August 2009
Lyrica
Generalized anxiety disorder––monotherapy
June 2009
Geodon
Treatment of bipolar disorder––pediatric filing
October 2008
Spiriva
Respimat device for chronic obstructive pulmonary disease
November 2007
Zmax
Treatment of bacterial infections––sustained release––acute otitis media (AOM) and sinusitis––pediatric filing
November 2006
Viviant
Osteoporosis treatment and prevention
June 2006
Pristiq
Vasomotor symptoms of menopause
June 2006
Vfend
Treatment of fungal infections––pediatric filing
June 2005
Thelin
Treatment of pulmonary arterial hypertension (PAH)
May 2005

In December 2009, our co-promotion partner, Protalix BioTherapeutics, submitted an NDA with the FDA for taliglucerase alfa. Taliglucerase alfa was granted orphan drug designation and fast-track designation by the FDA. In November 2009, we entered into a license and supply agreement with Protalix BioTherapeutics, which provides us exclusive worldwide rights to develop and commercialize taliglucerase alfa for the treatment of Gaucher’s disease except in Israel.
 
In April 2010, we received a “complete response” letter from the FDA for Genotropin Mark VII multidose disposable device submission. We are working with the FDA to address the requests and recommendations included in the letter.
 
In June 2009, we resubmitted a data package to the FDA for Lyrica for the treatment of GAD monotherapy in response to a “not-approvable” letter issued by the FDA in August 2004. On December 23, 2009, we received a “complete response” letter from the FDA with respect to this NDA. We are working with the FDA to determine the next steps. On January 27, 2010, we announced the withdrawal of the NDA for the adjunctive treatment of GAD.
 
In June 2009, an FDA advisory committee concluded that Geodon is effective for the treatment of bipolar mania in children ages 10 to 17. On October 30, 2009, we received a “complete response” letter from the FDA with respect to this NDA. The FDA is seeking additional information and is requesting that we take certain actions with regard to the submission. On April 9, 2010, we received a “warning letter” from the FDA with respect to the clinical trial in support of this NDA. We are working with the FDA to address the requests and recommendations included in the “complete response” letter and the “warning” letter.

Boehringer Ingelheim (BI), our alliance partner, holds the NDA for Spiriva. In September 2008, BI received a “complete response” letter from the FDA for the Spiriva Respimat submission. The FDA is seeking additional data, and we are coordinating with BI, which is working with the FDA to provide the additional information. A full response will be submitted to the FDA upon the completion of planned and ongoing studies.

In September 2007, we received an “approvable” letter from the FDA for Zmax that sets forth requirements to obtain approval for the pediatric acute otitis media (AOM) indication based on pharmacokinetic data. A supplemental filing for pediatric AOM and sinusitis remains under review.

Two “approvable” letters were received by Wyeth in April and December 2007 from the FDA for Viviant (bazedoxifene) for the prevention of post-menopausal osteoporosis that set forth the additional requirements for approval. In May 2008, Wyeth received an “approvable” letter from the FDA for the treatment of post-menopausal osteoporosis. The FDA is seeking additional data, and we have been systematically working through these requirements and seeking to address the FDA’s concerns. In February 2008, the FDA advised Wyeth that it expects to convene an advisory committee to review the pending NDAs for both the treatment and prevention indications. In April 2009, Wyeth received approval in the EU for CONBRIZA (the EU trade name for Viviant) for the treatment of post-menopausal osteoporosis in women at increased ris k of fracture.

 
34

 
 
In July 2007, Wyeth received an “approvable” letter from the FDA for Pristiq for vasomotor symptoms of menopause that sets forth the additional requirements for approval. We have been systematically working through these requirements and seeking to address the FDA’s concerns, including initiation of an additional clinical trial, which is underway.

In December 2005, we received an “approvable” letter from the FDA for our Vfend pediatric filing that sets forth the additional requirements for approval. We have been systematically working through these requirements and seeking to address the FDA’s concerns, including initiation of an additional pharmacokinetics study in November 2008.

In June 2008, we completed the acquisition of Encysive Pharmaceuticals Inc. (Encysive), whose main asset is Thelin. In June 2007, Encysive received a third “approvable” letter from the FDA for Thelin for the treatment of pulmonary arterial hypertension (PAH). We began an additional Phase 3 clinical trial in patients with PAH during the fourth quarter of 2008 to address the concerns of the FDA regarding efficacy as reflected in that letter.

We are in the process of withdrawing the NDAs for Fablyn (lasofoxifene), for the prevention and treatment of osteoporosis in post-menopausal women and for the treatment of vulvar and vaginal atrophy. We are exploring strategic options for Fablyn, including out-licensing or sale.

Regulatory approvals and filings in the EU and Japan:
PRODUCT
DESCRIPTION OF EVENT
DATE APPROVED
DATE SUBMITTED
Lyrica
Approval in Japan for the treatment of pain associated with post-herpetic neuralgia
April 2010
Revatio
Application submitted in the EU for pediatric pulmonary arterial hypertension
February 2010
Apixaban
Application submitted in the EU for prevention of venous thromboembolism
February 2010
Xalacom
Approval in Japan for the treatment of glaucoma
January 2010
Prevenar 13 Infant
Application submitted in Japan for prevention of invasive pneumococcal disease in infants and young children
December 2009
Sutent
Application submitted in the EU for treatment of pancreatic neuroendocrine tumor
December 2009
Xiaflex
Application submitted in the EU for treatment of Dupuytren’s contracture
December 2009
atorvastatin calcium
Application submitted in the EU for type II variation for atorvastatin calcium (SORTIS and associated names) for pediatric hyperlipidemia/dyslipidemia
November 2009
Toviaz
Application submitted in Japan for overactive bladder
September 2009
Genotropin
Application submitted in the EU for adult growth hormone deficiency (Mark VII multidose disposable device)
September 2009
Lyrica
Application submitted in Japan for neuropathic pain
August 2009

In March 2010, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending that the European Commission approve a new chewable form, as well as the currently available tablet form, of atorvastatin calcium for the treatment of high levels of LDL cholesterol and triglycerides in children aged 10 or older.

Late-stage clinical trials for additional uses and dosage forms for in-line products:
PRODUCT
INDICATION
Eraxis/Vfend Combination
Aspergillosis fungal infections
Lyrica
Epilepsy monotherapy; post-operative pain; central neuropathic pain due to spinal cord injury; peripheral neuropathic pain
Macugen
Diabetic macular edema
Prevnar/Prevenar 13 Adult
Prevention of invasive pneumococcal disease in adults
Revatio
Pediatric pulmonary arterial hypertension
Sutent
Non-small cell lung cancer; prostate cancer; adjuvant renal cell carcinoma
Zithromax/chloroquine
Malaria
 
 
35

 
 
In March 2010, two Phase 3 trials of Sutent for first-line and second-line treatment of metastatic breast cancer completed and did not meet their primary endpoints.  In April 2010, we discontinued a Phase 3 trial for Sutent for advanced liver cancer based on a higher incidence of serious adverse events in the Sutent arm compared to the sorafenib arm and the fact that Sutent did not meet the criteria to demonstrate that it was either superior or non-inferior to sorafenib in the survival of patients with advanced hepatocellular cancer.

New drug candidates in late-stage development in the U.S.:
CANDIDATE
INDICATION
Apixaban
For acute coronary syndrome, the prevention and treatment of venous thromboembolism and prevention of stroke in patients with atrial fibrillation, which is being developed in collaboration with Bristol-Myers Squibb Company (BMS)
Aprela (Bazedoxifene-conjugated estrogens)
A tissue selective estrogen complex for the treatment of menopausal vasomotor symptoms
Axitinib
Oral and selective inhibitor of vascular endothelial growth factor (VEGF) receptor 1, 2, & 3 for the treatment of advanced renal cell carcinoma.
Bapineuzumab
A beta amyloid inhibitor for the treatment of Alzheimer’s disease being developed in collaboration with Janssen Alzheimer Immunotherapy Research & Development, LLC (Janssen AI), a subsidiary of Johnson & Johnson
Bosutinib
An src kinase inhibitor for the treatment of chronic myelogenous leukemia
Crizotinib (PF-02341066)
An oral ALK and c-Met inhibitor for the treatment of advanced non-small cell lung cancer
Dimebon (latrepirdine)
A novel mitochondrial protectant and enhancer being developed in collaboration with Medivation, Inc. for the treatment of Alzheimer’s disease and Huntington’s disease
Moxidectin
Treatment of onchocerciasis (river blindness)
Neratinib
A pan-HER inhibitor for the treatment of breast cancer
PF-0299804
A pan-HER tyrosine kinase inhibitor for the treatment of advanced non-small cell lung cancer
Tanezumab
An anti-nerve growth factor monoclonal antibody for the treatment of pain
Tasocitinib (CP-690,550)
A JAK-3 kinase inhibitor for the treatment of rheumatoid arthritis

The Phase 3 trial of apixaban for the prevention of stroke in patients with atrial fibrillation, is event driven. As such, it is not possible to predict with certainty when the results of this trial will be available.  BMS currently expects to have data from this trial in mid-2011 and to file for U.S. regulatory approval for this indication later in 2011 depending on the results of the trial.

Our collaboration with Janssen AI on bapineuzumab, a potential treatment for Alzheimer’s disease, continues with four Phase 3 studies continuing to enroll.  In April 2010, Johnson & Johnson announced that the Janssen AI North American studies would complete (last patient out) in mid-2012.  We announced in May 2010 that we expect that the last patient will have completed our 18-month trials, including associated biomarker studies, in 2014.
 
In March 2010, Pfizer and Medivation, Inc. announced that a Phase 3 trial of Dimebon (latrepiridine) did not meet its co-primary or secondary endpoints. Subsequently, we and Medivation, Inc. agreed to discontinue the CONSTELLATION and CONTACT Phase 3 trials in patients with moderate-to-severe Alzheimer’s disease. The 12-month Phase 3 CONCERT trial in patients with mild-to-moderate Alzheimer’s disease and the six-month Phase 3 Horizon trial in patients with Huntingdon’s disease continue. After completing our evaluation of the data from the trial that did not meet its endpoints, we will determine appropriate next steps regarding the Dimebon program.
 
In December 2009, we discontinued a Phase 3 trial of figitumumab in first-line treatment of advanced non-small cell lung cancer for futility. In March 2010, we discontinued a Phase 3 trial of figitumumab in second/third line treatment of advanced non-small cell lung cancer for futility.

Additional product-related programs are in various stages of discovery and development. Also, see the discussion in the “Our Strategic Initiatives––Strategy and Recent Transactions” section of this MD&A.

COSTS AND EXPENSES

Cost of Sales

Cost of sales increased 206% in the first quarter of 2010, compared to the first quarter of 2009, which reflects:

·  
purchase accounting charges of approximately $1.4 billion, primarily reflecting the fair value adjustments to inventory acquired from Wyeth in 2009 that was sold in the first quarter of 2010;

·  
the addition of Wyeth’s manufacturing operations; and

·  
the unfavorable impact of foreign exchange on cost of sales.

 
36

 

Cost of sales as a percentage of revenues in the first quarter of 2010 increased 12.7 percentage points to 25.7% compared to 13% in the same period in 2009, primarily reflecting the fair value adjustments to inventory acquired from Wyeth in 2009 that was sold in the first quarter of 2010, as well as the mix of products and businesses as a result of our acquisition of Wyeth, which was not reflected in our first-quarter 2009 results.

Selling, Informational and Administrative Expenses

Selling, informational and administrative (SI&A) expenses increased 54% in the first quarter of 2010, compared to the first quarter of 2009, which reflects:

·  
the addition of Wyeth’s operating costs; and

·  
the unfavorable impact of foreign exchange.

Research and Development Expenses

Research and development (R&D) expenses increased 31% in the first quarter of 2010, compared to the same period in 2009, which reflects:

·  
the addition of Wyeth operating costs;

·  
continued investment in the late-stage development portfolio; and

·  
the unfavorable impact of foreign exchange.

Acquisition-Related In-Process Research and Development Charges

In the first quarter of 2010, we resolved certain contingencies associated with our 2008 acquisition of CovX and recorded $74 million in Acquisition-related in-process research and development charges.

Cost-Reduction Initiatives and Acquisition-Related Costs

We have incurred significant costs in connection with our cost-reduction initiatives (several programs initiated since 2005) and our acquisition of Wyeth on October 15, 2009.
 
As described more fully in our 2009 Annual Report on Form 10-K, since the acquisition of Wyeth, our cost-reduction initiatives announced on January 26, 2009, but not completed as of  December 31, 2009, have been incorporated into a comprehensive plan to integrate Wyeth’s operations, generate cost savings and capture synergies across the combined company. In the aggregate, with the combination of these two initiatives into one comprehensive program, we expect to generate cost reductions, net of investments in the business, of approximately $4 billion to $5 billion, by the end of 2012, at 2008 average foreign exchange rates, in comparison with the 2008 pro-forma combined adjusted total costs of Pfizer and the legacy Wyeth operations. (For an understanding of adjusted total costs, see the “Adjusted Income” section of this MD&A). We remain on track to meet this target. We have incurred and will continue to incur costs associated with these cost-reduction activities and estimate that these costs could be in the range of approximately $11.5 billion to $13.5 billion through 2012, of which we have incurred approximately $6.3 billion in cost-reduction and acquisition-related costs (excluding transaction costs) through April 4, 2010.
 
At the end of the first quarter of 2010, the workforce totaled approximately 113,800, a decrease of 2,700 from December 31, 2009. Since the closing of the Wyeth acquisition on October 15, 2009, the workforce has declined by 6,900, primarily in the U.S. Primary Care field force, manufacturing and R&D operations.

 
37

 

We incurred the following costs in connection with all of our cost-reduction initiatives and the Wyeth acquisition:
   
Three Months Ended
 
(millions of dollars)
 
April 4,
2010
   
Mar. 29,
2009
 
             
Transaction costs(a)
  $ 9     $ 369  
Integration costs(b)
    208       28  
Restructuring charges(c)
    489       157  
Restructuring charges and certain acquisition-related costs
    706       554  
Additional depreciation––asset restructuring(d)
    93       90  
Implementation costs(e)
    ––       84  
Total
  $ 799     $ 728  
(a)
Transaction costs represent external costs directly related to effecting the acquisition of Wyeth and primarily include expenditures for banking, legal, accounting and other similar services. Substantially all of the costs incurred in the first quarter of 2009 were fees related to a $22.5 billion bridge term loan credit agreement entered into with certain financial institutions on March 12, 2009 to partially fund our acquisition of Wyeth. The bridge term loan credit agreement was terminated in June 2009 as a result of our issuance of approximately $24.0 billion of senior unsecured notes in the first half of 2009.
(b)
Integration costs represent external, incremental costs directly related to integrating Wyeth and primarily include expenditures for consulting and systems integration.

(c)
Restructuring charges include the following:
   
Costs Incurred
             
   
Three Months Ended
         
Activity
   
Accrual
 
(millions of dollars)
 
April 4,
2010
   
Mar. 29,
2009
      2005-2010    
Through
April 4,
2010(1)
   
As of
April 4,
2010(2)
 
                                 
Employee termination costs
  $ 458     $ 135     $ 8,179     $ 5,276     $ 2,903  
Asset impairments
    6       18       1,458       1,458       ––  
Other
    25       4       735       631       104  
Total restructuring charges
  $ 489     $ 157     $ 10,372     $ 7,365     $ 3,007  
 
(1)
Includes adjustments for foreign currency translation.
 
(2)
Included in Current deferred tax liabilities and other current liabilities ($2.0 billion) and Other noncurrent liabilities ($1.0 billion).

In the first quarter of 2010, the restructuring charges are related to the integration of Wyeth. From the beginning of our cost-reduction initiatives in 2005 through April 4, 2010, Employee termination costs represent the expected reduction of the workforce by approximately 45,400 employees, mainly in manufacturing, sales and research, of which approximately 28,100 employees have been terminated as of April 4, 2010. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination. Asset impairments prima rily include charges to write down property, plant and equipment to fair value. Other primarily includes costs to exit certain assets and activities.

(d)
Additional depreciation – asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions and are included in our condensed consolidated statements of income as follows:
   
Three Months Ended
 
(millions of dollars)
 
April 4,
2010
   
Mar. 29,
2009
 
             
Cost of sales
  $ 13     $ 63  
Selling, informational and administrative expenses
    60       6  
Research and development expenses
    20       21  
Total
  $ 93     $ 90  

(e)
Implementation costs in the first quarter of 2009 represent external, incremental costs directly related to implementing cost-reduction initiatives prior to our acquisition of Wyeth and primarily include expenditures related to system and process standardization and the expansion of shared services. For the three months ended March 29, 2009, implementation costs are included in Cost of sales ($13 million), Selling, informational and administrative expenses ($40 million), Research and development expenses ($20 million) and Other (income)/deductions  net ($11 million).

Other (Income)/Deductions––Net

Other (income)/deductions––net changed unfavorably by $471 million in the first quarter of 2010, compared to the same period in 2009, which primarily reflects:

 
38

 
 
·  
higher interest expense of $393 million in the first quarter of 2010, primarily associated with the $13.5 billion of senior unsecured notes that we issued in March 2009 and the approximately $10.5 billion of senior unsecured notes that we issued in June 2009, to partially finance the acquisition of Wyeth;

·  
lower interest income of $133 million in the first quarter of 2010, primarily due to lower interest rates coupled with lower average cash balances; and

·  
slightly higher charges for litigation-related matters,

partially offset by:

·  
higher royalty-related income.

PROVISION FOR TAXES ON INCOME

Our effective tax rate for continuing operations was 36.0% for the first quarter of 2010, compared to 28.2% for the first quarter of 2009. The higher tax rate for the first quarter of 2010 is primarily the result of:

·  
higher amortization charges, primarily related to intangible assets acquired in connection with the acquisition of Wyeth, and the mix of jurisdictions in which those charges were incurred;

·  
the write-off of the deferred tax asset of approximately $270 million related to the Medicare Part D subsidy for retiree prescription drug coverage, resulting from changes in the U.S. Healthcare Legislation enacted in March 2010 concerning the tax treatment of that subsidy effective for tax years beginning after December 31, 2012;

·  
the expiration of the U.S. research tax credit; and

·  
the increase in non-deductible in-process research and development charges.

These factors were partially offset by $410 million in tax benefits for the resolution of certain tax positions pertaining to prior years with various foreign tax authorities.

ADJUSTED INCOME

General Description of Adjusted Income Measure
Adjusted income is an alternative view of performance used by management, and we believe that investors’ understanding of our performance is enhanced by disclosing this performance measure. We report Adjusted income in order to portray the results of our major operations––the discovery, development, manufacture, marketing and sale of prescription medicines for humans and animals, consumer healthcare (over-the-counter) products, vaccines and nutritional products––prior to considering certain income statement elements. We have defined Adjusted income as Net income attributable to Pfizer Inc. before the impact of purchase accounting for acquisitions, acquisition-related costs, discontinued operations and certain significant items. The Adjusted income measure is not, and should not be viewed as, a substitute for U.S. GAAP net income. Adjusted total costs represent the total of Adjusted cost of sales, Adjusted SI&A expenses and Adjusted R&D expenses, which are income statement line items prepared on the same basis as and are components of the overall Adjusted income measure.
 
The Adjusted income measure is an important internal measurement for Pfizer. We measure the performance of the overall Company on this basis in conjunction with other performance metrics. The following are examples of how the Adjusted income measure is utilized:

·  
senior management receives a monthly analysis of our operating results that is prepared on an Adjusted income basis;

·  
our annual budgets are prepared on an Adjusted income basis; and

·  
senior management’s annual compensation is derived, in part, using this Adjusted income measure. Adjusted income is one of the performance metrics utilized in the determination of bonuses under the Pfizer Inc. Executive Annual Incentive Plan that is designed to limit the bonuses payable to the Executive Leadership Team (ELT) for purposes of Internal Revenue Code Section 162(m). Subject to the Section 162(m) limitation, the bonuses are funded from a pool based on the achievement of three financial metrics, including adjusted diluted earnings per share, which is derived from Adjusted income. Beginning in 2010, these metrics derived from Adjusted income account for (i) between 7% and 13% of the target bonus for ELT members and (ii) 33% of the bonus pool made available to ELT members and other members of senior management.
 
Despite the importance of this measure to management in goal setting and performance measurement, we stress that Adjusted income is a non-GAAP financial measure that has no standardized meaning prescribed by U.S. GAAP and, therefore, has limits in its usefulness to investors. Because of its non-standardized definition, Adjusted income (unlike U.S. GAAP net income) may not be comparable to the calculation of similar measures of other companies. Adjusted income is presented solely to permit investors to more fully understand how management assesses performance.

 
39

 
 
We also recognize that, as an internal measure of performance, the Adjusted income measure has limitations, and we do not restrict our performance-management process solely to this metric. A limitation of the Adjusted income measure is that it provides a view of our operations without including all events during a period, such as the effects of an acquisition or amortization of purchased intangibles, and does not provide a comparable view of our performance to other companies in the biopharmaceutical industry. We also use other specifically tailored tools designed to achieve the highest levels of performance. For example, our R&D organization has productivity targets, upon which its effectiveness is measured. In addition, the earn-out of Performance Share Award grants is determined based on a non-discretionary formula that measures ou r performance using relative total shareholder return.

Purchase Accounting Adjustments
Adjusted income is calculated prior to considering certain significant purchase accounting impacts, such as those related to business combinations and net asset acquisitions. These impacts can include the incremental charge to cost of sales from the sale of acquired inventory that was written up to fair value, amortization related to the increase in fair value of the acquired finite-lived intangible assets acquired from Pharmacia and Wyeth, depreciation related to the increase/decrease in fair value of the acquired fixed assets, amortization related to the increase in fair value of acquired debt and charges for purchased in-process R&D. Therefore, the Adjusted income measure includes the revenues earned upon the sale of the acquired products without considering the aforementioned significant charges.

Certain of the purchase accounting adjustments associated with a business combination, such as the amortization of intangibles acquired in connection with our acquisition of Wyeth in 2009 and Pharmacia in 2003, can occur through 20 or more years, but this presentation provides an alternative view of our performance that is used by management to internally assess business performance. We believe the elimination of amortization attributable to acquired intangible assets provides management and investors an alternative view of our business results by trying to provide a degree of parity to internally developed intangible assets for which research and development costs previously have been expensed.

However, a completely accurate comparison of internally developed intangible assets and acquired intangible assets cannot be achieved through Adjusted income. This component of Adjusted income is derived solely from the impacts of the items listed in the first paragraph of this section. We have not factored in the impacts of any other differences in experience that might have occurred if we had discovered and developed those intangible assets on our own, and this approach does not intend to be representative of the results that would have occurred in those circumstances. For example, our research and development costs in total, and in the periods presented, may have been different; our speed to commercialization and resulting sales, if any, may have been different; or our costs to manufacture may have been different. In addition, our mark eting efforts may have been received differently by our customers. As such, in total, there can be no assurance that our Adjusted income amounts would have been the same as presented had we discovered and developed the acquired intangible assets.

Acquisition-Related Costs
Adjusted income is calculated prior to considering transaction, integration, restructuring and additional depreciation costs associated with business combinations because these costs are unique to each transaction and represent costs that were incurred to restructure and integrate two businesses as a result of the acquisition decision. For additional clarity, only transaction costs, additional depreciation and restructuring and integration activities that are associated with a business combination or a net-asset acquisition are included in acquisition-related costs. We have made no adjustments for the resulting synergies.

We believe that viewing income prior to considering these charges provides investors with a useful additional perspective because the significant costs incurred in a business combination result primarily from the need to eliminate duplicate assets, activities or employees––a natural result of acquiring a fully integrated set of activities. For this reason, we believe that the costs incurred to convert disparate systems, to close duplicative facilities or to eliminate duplicate positions (for example, in the context of a business combination) can be viewed differently from those costs incurred in other, more normal, business contexts.

The integration and restructuring costs associated with a business combination may occur over several years, with the more significant impacts ending within three years of the transaction. Because of the need for certain external approvals for some actions, the span of time needed to achieve certain restructuring and integration activities can be lengthy. For example, due to the highly regulated nature of the pharmaceutical business, the closure of excess facilities can take several years, as all manufacturing changes are subject to extensive validation and testing and must be approved by the FDA and/or other global regulatory authorities.

 
40

 
 
Discontinued Operations
Adjusted income is calculated prior to considering the results of operations included in discontinued operations, as well as any related gains or losses on the sale of such operations. We believe that this presentation is meaningful to investors because, while we review our businesses and product lines periodically for strategic fit with our operations, we do not build or run our businesses with the intent to sell them.

Certain Significant Items
Adjusted income is calculated prior to considering certain significant items. Certain significant items represent substantive, unusual items that are evaluated on an individual basis. Such evaluation considers both the quantitative and the qualitative aspect of their unusual nature. Unusual, in this context, may represent items that are not part of our ongoing business; items that, either as a result of their nature or size, we would not expect to occur as part of our normal business on a regular basis; items that would be non-recurring; or items that relate to products we no longer sell. While not all-inclusive, examples of items that could be included as certain significant items would be a major non-acquisition-related restructuring charge and associated implementation costs for a program that is specific in nature with a defined term, such as those related to our non-acquisition-related cost-reduction initiatives; charges related to certain sales or disposals of products or facilities that do not qualify as discontinued operations as defined by U.S. GAAP; amounts associated with transition service agreements in support of discontinued operations after sale; certain intangible asset impairments; adjustments related to the resolution of certain tax positions; the impact of adopting certain significant, event-driven tax legislation; net interest expense incurred through the consummation date of the acquisition of Wyeth on acquisition-related borrowings made prior to that date; or possible charges related to legal matters, such as certain of those discussed in Legal Proceedings in our 2009 Annual Report on Form 10-K and in Part II. Other Information; Item 1. Legal Proceedings, in our Quarterly Reports on Form 10-Q filings. Normal , ongoing defense costs of the Company or settlements and accruals on legal matters made in the normal course of our business would not be considered certain significant items.

Reconciliation

A reconciliation between Net income attributable to Pfizer Inc., as reported under U.S. GAAP and Adjusted income follows:
   
Three Months Ended
 
(millions of dollars)
 
April 4,
2010
   
Mar. 29,
2009
   
% Incr./
(Decr.)
 
Reported net income attributable to Pfizer Inc.
  $ 2,026     $ 2,729       (26 )
Purchase accounting adjustments––net of tax
    2,129       354       *  
Acquisition-related costs––net of tax
    573       252       127  
Discontinued operations––net of tax
    (2 )     (1 )     35  
Certain significant items––net of tax
    156       333       (53 )
Adjusted income(a)
  $ 4,882     $ 3,667       33  
(a)
The effective tax rate on Adjusted income was 30.1% in the first quarter of 2010, relatively flat compared to 29.7% in the first quarter of 2009.
*
Calculation not meaningful.
Certain amounts and percentages may reflect rounding adjustments.

A reconciliation between Reported diluted EPS as reported under U.S. GAAP and Adjusted diluted EPS follows:
   
Three Months Ended
 
   
April 4,
2010
   
Mar. 29,
2009
   
% Incr./
(Decr.)
 
Reported net income attributable to Pfizer Inc. common shareholders(a)
  $ 0.25     $ 0.40       (38 )
Purchase accounting adjustments – net of tax
    0.26       0.05       *  
Acquisition-related costs––net of tax
    0.07       0.04       75  
Discontinued operations––net of tax
                   
Certain significant items––net of tax
    0.02       0.05       (60 )
Adjusted net income attributable to Pfizer Inc. common shareholders(a)
  $ 0.60     $ 0.54       11  
(a)
Reported and Adjusted diluted earnings per share in the first quarter of 2010 were impacted by the increased number of shares outstanding in comparison with the first quarter of 2009 resulting primarily from shares issued to partially fund the Wyeth acquisition.
*
Calculation not meaningful.
Certain amounts and percentages may reflect rounding adjustments.

 
41

 

Adjusted income as shown above excludes the following items:
   
Three Months Ended
 
(millions of dollars)
 
April 4,
2010
   
Mar. 29,
2009
 
Purchase accounting adjustments:
           
Amortization, depreciation and other(a)
  $ 1,417     $ 546  
Cost of sales primarily related to fair value adjustments of acquired inventory
    1,350        
In-process research and development charges(b)
    74        
Total purchase accounting adjustments, pre-tax
    2,841       546  
Income taxes
    (712 )     (192 )
Total purchase accounting adjustments––net of tax
    2,129       354  
Acquisition-related costs:
               
Transaction costs(c)
    9       369  
Integration costs(c)
    208       28  
Restructuring charges(c)
    489        
Additional depreciation––asset restructuring(d)
    93        
Total acquisition-related costs, pre-tax
    799       397  
Income taxes
    (226 )     (145 )
Total acquisition-related costs––net of tax
    573       252  
Total discontinued operations––net of tax
    (2 )     (1 )
Certain significant items:
               
Restructuring charges––cost-reduction initiatives(e)
          157  
Implementation costs––cost-reduction initiatives(f)
          174  
Certain legal matters(g)
    142       132  
Other
    40       10  
Total certain significant items, pre-tax
    182       473  
Income taxes
    (26 )     (140 )
Total certain significant items––net of tax
    156       333  
Total purchase accounting adjustments, acquisition-related costs,
discontinued operations and certain significant items––net of tax
  $ 2,856     $ 938  
(a)
Included primarily in Amortization of intangible assets.
(b)
Included in Acquisition-related in-process research and development charges.
(c)
Included in Restructuring charges and certain acquisition-related costs.
(d)
Amount relates to certain actions taken as a result of our acquisition of Wyeth. Prior to the acquisition of Wyeth on October 15, 2009, additional depreciation for asset restructuring related to our cost-reduction initiatives was classified as a certain significant item and included in implementation costs. For the first quarter of 2010, included in Cost of sales ($13 million), Selling, informational and administrative expenses ($60 million), and Research and development expenses ($20 million).
(e)
Represents restructuring charges incurred for our cost-reduction initiatives prior to the acquisition of Wyeth on October 15, 2009. Included in Restructuring charges and certain acquisition-related costs (see Notes to Condensed Consolidated Financial Statements—Note 4. Cost-Reduction Initiatives and Acquisition-Related Costs).
(f)
Represents implementation costs incurred for our cost-reduction initiatives prior to the acquisition of Wyeth on October 15, 2009. For the first quarter of 2009, included in Cost of sales ($76 million), Selling, informational and administrativeexpenses ($46 million), Research and development expenses ($41 million) and Other (income)/deductions––net ($11 million). Includes additional depreciation for asset restructuring of $90 million in the first quarter of 2009.
(g)
Included in Other (income)/deductions––net.

 
42

 

FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES

Net Financial Assets/(Liabilities), as shown below:
(millions of dollars)
 
April 4,
2010
   
Dec. 31,
2009
 
Financial assets:
           
Cash and cash equivalents
  $ 1,759     $ 1,978  
Short-term investments
    15,503       23,991  
Short-term loans
    919       1,195  
Long-term investments and loans
    12,081       13,122  
Total financial assets
  $ 30,262     $ 40,286  
Debt:
               
Short-term borrowings, including current portion of long-term debt
  $ 7,769     $ 5,469  
Long-term debt
    38,281       43,193  
Total debt
  $ 46,050     $ 48,662  
Net financial assets/(liabilities)
  $ (15,788 )   $ (8,376 )

We rely largely on operating cash flows, short-term investments, short-term commercial paper borrowings and long-term debt to provide for the working capital needs of our operations, including our R&D activities. We believe that we have the ability to obtain both short-term and long-term debt to meet our financing needs for the foreseeable future. We believe we have the flexibility to allocate our significant operating cash flows with a continued focus on seeking to provide the highest return for our shareholders, such as potential dividend increases, share repurchases, investments in our business, or by paying down outstanding debt. Short-term investments decreased due to the use of proceeds for tax payments made in the first quarter of 2010, associated with certain business decisions executed to finance the Wyeth acquisition.

Debt Capacity
We have available lines of credit and revolving-credit agreements with a group of banks and other financial intermediaries. We maintain cash and cash equivalent balances and short-term investments in excess of our commercial paper and other short-term borrowings. As of April 4, 2010, we had access to $8.4 billion of lines of credit, of which $6.2 billion expire within one year. Of these lines of credit, $8.3 billion are unused, of which our lenders have committed to loan us $7.1 billion at our request. Also, $7.0 billion of our unused lines of credit, of which $5.0 billion expire in late 2010 and $2.0 billion expire in 2013, may be used to support our commercial paper borrowings.

In March 2010, the shelf registration statement that we previously filed with the SEC, pursuant to the shelf registration process available to “well-known seasoned issuers,” expired.

SELECTED MEASURES OF LIQUIDITY AND CAPITAL RESOURCES

The following table sets forth certain relevant measures of our liquidity and capital resources:
(millions of dollars, except ratios and per common share data)
 
April 4,
2010
   
Dec. 31,
2009
 
             
Cash and cash equivalents and short-term investments and loans
  $ 18,181     $ 27,164  
                 
Working capital(a)
  $ 23,992     $ 24,445  
                 
Ratio of current assets to current liabilities
 
1.93:1
   
1.66:1
 
                 
Shareholders’ equity per common share(b)
  $ 11.12     $ 11.19  
(a)
Working capital includes assets held for sale of $490 million as of April 4, 2010, and $496 million as of December 31, 2009.
(b)
Represents total shareholders’ equity divided by the actual number of common shares outstanding (which excludes treasury shares and shares held by our employee benefit trusts).

The decrease in cash and cash equivalents and short-term investments and loans, as of April 4, 2010, compared to December 31, 2009, was primarily due to the use of proceeds of short-term investments for tax payments made in the first quarter of 2010, associated with certain business decisions executed to finance the Wyeth acquisition. The change in working capital and the ratio of current assets to current liabilities was due to the timing of accruals, cash receipts and payments in the ordinary course of business. We are monitoring developments regarding government receivables in several European country markets. No significant collectability issues have been identified.

 
43

 
 
Operating Activities

During the first quarter of 2010, net cash used in operating activities was $6.4 billion, compared to net cash provided of $3.1 billion in the same period of 2009. The change in operating cash flows was primarily attributable to:

·  
income tax payments of approximately $10.5 billion, associated with certain business decisions executed to finance the Wyeth acquisition; and

·  
the timing of receipts and payments in the ordinary course of business.
 
In 2010, the cash flow line item called Changes in assets and liabilities, net of acquisitions and divestitures reflects the $10.5 billion of tax payments described above.
 
Investing Activities

During the first quarter of 2010, net cash provided by investing activities was $9.4 billion, compared to net cash used of $13.6 billion in the same period in 2009. The change in investing cash flows was primarily attributable to:

·  
net proceeds from redemption and sales of investments of $9.5 billion in the first quarter of 2010, which were used for tax payments in the first quarter of 2010, compared to net purchases of investments of $13.6 billion in the first quarter of 2009 primarily reflecting the investment of proceeds from our issuance of $13.5 billion of senior unsecured notes in the first quarter of 2009.

Financing Activities

During the first quarter of 2010, net cash used in financing activities was $3.2 billion, compared to net cash provided of $9.6 billion in the same period in 2009. The change in financing cash flows was primarily attributable to:

·  
net repayments of borrowings of $1.8 billion in the first quarter of 2010 compared to net borrowings of $11.8 billion in the first quarter of 2009 primarily reflecting the proceeds from our issuance of $13.5 billion of senior unsecured notes in the first quarter of 2009,

partially offset by:

·  
lower dividend payments in the first quarter of 2010 compared to the first quarter of 2009.

On June 23, 2005, we announced that the Board of Directors authorized a $5 billion share-purchase plan (the “2005 Stock Purchase Plan”). On June 26, 2006, we announced that the Board of Directors increased the authorized amount of shares to be purchased under the 2005 Stock Purchase Plan from $5 billion to $18 billion. On January 23, 2008, we announced that the Board of Directors authorized a new $5 billion share-purchase plan, to be funded by operating cash flows that may be utilized from time to time. In total, under the 2005 Stock Purchase Plan, through April 4, 2010, we purchased approximately 710 million shares for approximately $18.0 billion. We did not purchase any shares of our common stock in the first quarter of 2010 or the first quarter of 2009. On May 4, 2010, we announced that we will purchase shares of our common stock as market conditions warrant.

Off-Balance Sheet Arrangements

In the ordinary course of business and in connection with the sale of assets and businesses, we often indemnify our counterparties against certain liabilities that may arise in connection with a transaction or that are related to activities prior to a transaction. These indemnifications typically pertain to environmental, tax, employee and/or product-related matters, and patent infringement claims. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we would be required to reimburse the loss. These indemnifications generally are subject to threshold amounts, specified claim periods and other restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of April 4, 2010, recorded amounts for the estimated fair value of these indemnification s are not significant.

Certain of our co-promotion or license agreements give our licensors or partners the rights to negotiate for, or in some cases to obtain under certain financial conditions, co-promotion or other rights in specified countries with respect to certain of our products.

Dividends on Common Stock

In April 2010, our Board of Directors declared a dividend of $0.18 per share, payable June 1, 2010 to shareholders of record at the close of business on May 7, 2010.
 
 
44

 
 
NEW ACCOUNTING STANDARDS

Recently Adopted Accounting Standards

See Notes to Condensed Consolidated Financial Statements––Note 2. Adoption of New Accounting Policies.

Recently Issued Accounting Standards, Not Adopted as of April 4, 2010

In October 2009, the Financial Accounting Standards Board (FASB) issued an accounting standard update that addresses the accounting for multiple-deliverable arrangements to enable companies to account for certain products or services separately rather than as a combined unit.  This update addresses how to separate deliverables and how to measure and allocate arrangement consideration to one or more units of accounting through the use of a selling price hierarchy to determine the selling price of a deliverable.  The provisions of the new standard will be adopted January 1, 2011, and we are in the process of evaluating the impact on our consolidated financial statements.

OUR FINANCIAL GUIDANCE FOR 2010

At average April 2010 exchange rates, we forecast 2010 revenues of $67.0 billion to $69.0 billion, Reported diluted earnings per common share (EPS) of $0.95 to $1.10 and Adjusted diluted EPS of $2.10 to $2.20. For an understanding of Adjusted income, see the “Adjusted Income” section of this MD&A.

A reconciliation of 2010 Adjusted income and Adjusted diluted EPS guidance to 2010 Reported Net income attributable to Pfizer Inc. and Reported diluted EPS attributable to Pfizer Inc. common shareholders guidance follows:
   
Full-Year 2010 Guidance
 
($ billions, except per share amounts)
 
Net Income(a)
   
Diluted EPS(a)
 
Adjusted income/diluted EPS(b) guidance
 
~$17.0-$17.8
   
~$2.10-$2.20
 
Purchase accounting impacts of transactions completed as of April 4, 2010
  (6.4)     (0.79)  
Acquisition-related costs
  (2.5-2.9)     (0.31-0.36)  
Reported Net income attributable to Pfizer Inc./diluted EPS guidance
 
~$7.7-$8.9
   
~$0.95-$1.10
 
(a)
Amounts do not assume the completion of any business-development transactions not completed as of April 4, 2010. Amounts exclude the potential effects of the resolution of litigation-related matters not substantially resolved as of April 4, 2010.
(b)
For an understanding of Adjusted income, see the “Adjusted Income” section of this MD&A.

Our 2010 financial guidance is subject to a number of factors and uncertainties—as described in the “U.S. Healthcare Legislation”, “Our Operating Environment” and “Forward-Looking Information and Factors That May Affect Future Results” sections of this MD&A; the “Our Operating Environment, Strategy and Responses to Key Opportunities and Challenges” section of our 2009 Financial Report, which is filed as Exhibit 13 to our 2009 Annual Report on Form 10-K; and Part I, Item 1A, “Risk Factors,” of our 2009 Annual Report on Form 10-K.

OUR FINANCIAL TARGETS FOR 2012

We have updated our target revenue range for 2012 to reflect the anticipated financial impact of the recently enacted U.S. Healthcare Legislation (see the “U.S. Healthcare Legislation” section of this MD&A). In comparison to the target revenue range provided on February 3, 2010, the updated target range has been reduced by $800 million. We are reaffirming all other elements of our 2012 targets. At average April 2010 exchange rates, we are targeting 2012 revenues of $65.2 billion to $67.7 billion, Reported diluted EPS between $1.58 and $1.73 and Adjusted diluted EPS between $2.25 and $2.35. For an understanding of Adjusted income, see the “Adjusted Income” section of this MD&A.

 
45

 
 
A reconciliation of 2012 Adjusted income and Adjusted diluted EPS targets to 2012 Reported Net income attributable to Pfizer Inc. and Reported diluted EPS attributable to Pfizer Inc. common shareholders targets follows:
   
Full-Year 2012 Targets
 
($ billions, except per share amounts)
 
Net Income (a)
   
Diluted EPS (a)
 
Adjusted income/diluted EPS(b) targets
 
~$18.3-$19.1
   
~$2.25-$2.35
 
Purchase accounting impacts of transactions completed as of April 4, 2010
  (3.8)     (0.47)  
Acquisition-related costs
  (1.2-1.6)     (0.15-0.20)  
Reported Net income attributable to Pfizer Inc./diluted EPS targets
 
~$12.9-$14.1
   
~$1.58-$1.73
 
(a)
Amounts exclude the potential effects of the resolution of litigation-related matters not substantially resolved as of April 4, 2010.  Given the longer-term nature of these targets, they are subject to greater variability as a result of potential material impacts related to foreign exchange fluctuations; macroeconomic activity, including inflation; and industry-specific challenges, including changes to government healthcare policy, among others.
(b)
For an understanding of Adjusted income, see the “Adjusted Income” section of this MD&A.

Our 2012 financial targets are subject to a number of factors and uncertainties—as described in the “U.S. Healthcare Legislation”, “Our Operating Environment” and “Forward-Looking Information and Factors That May Affect Future Results” sections of this MD&A; the “Our Operating Environment, Strategy and Responses to Key Opportunities and Challenges” section of our 2009 Financial Report, which is filed as Exhibit 13 to our 2009 Annual Report on Form 10-K; and Part I, Item 1A, “Risk Factors,” of our 2009 Annual Report on Form 10-K.

FORWARD-LOOKING INFORMATION AND FACTORS THAT MAY AFFECT FUTURE RESULTS
 
The SEC encourages companies to disclose forward-looking information so that investors can better understand a company’s future prospects and make informed investment decisions. This report and other written or oral statements that we make from time to time contain such forward-looking statements that set forth anticipated results based on management’s plans and assumptions. Such forward-looking statements involve substantial risks and uncertainties. We have tried, wherever possible, to identify such statements by using words such as “will,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “target,” “forecast,” and other words and terms of similar meaning in connection with any disc ussion of future operating or financial performance or business plans and prospects. In particular, these include statements relating to future actions, business plans and prospects, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, interest rates, foreign exchange rates, the outcome of contingencies, such as legal proceedings, and financial results, including, in particular, the financial guidance and targets and anticipated cost reductions set forth in the “Our Financial Guidance for 2010,” “Our Financial Targets for 2012” and “Costs and Expenses––Cost-Reduction Initiatives and Acquisition-Related Costs” sections of this MD&A.

Among the factors that could cause actual results to differ materially from past and projected future results are the following:

·  
Success of research and development activities;

·  
Decisions by regulatory authorities regarding whether and when to approve our drug applications, as well as their decisions regarding labeling, ingredients and other matters that could affect the availability or commercial potential of our products;

·  
Speed with which regulatory authorizations, pricing approvals and product launches may be achieved;

·  
Success of external business-development activities;

·  
Competitive developments, including the impact on our competitive position of new product entrants, in-line branded products, generic products, private label products and product candidates that treat diseases and conditions similar to those treated by our in-line products and product candidates;

·  
Ability to meet generic and branded competition after the loss of patent protection for our products and competitor products;

·  
Ability to successfully market both new and existing products domestically and internationally;

·  
Difficulties or delays in manufacturing;

·  
Trade buying patterns;

·  
Impact of existing and future legislation and regulatory provisions on product exclusivity;

·  
Trends toward managed care and healthcare cost containment;

·  
Impact of U.S. Healthcare Legislation enacted in 2010­­––the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act;

 
46

 
 
·  
U.S. legislation or regulatory action affecting, among other things, pharmaceutical product pricing, reimbursement or access, including under Medicaid, Medicare and other publicly funded or subsidized health programs; the importation of prescription drugs from outside the U.S. at prices that are regulated by governments of various foreign countries; direct-to-consumer advertising and interactions with healthcare professionals; and the use of comparative effectiveness methodologies that could be implemented in a manner that focuses primarily on the cost differences and minimizes the therapeutic differences among pharmaceutical products and restricts access to innovative medicines;

·  
Legislation or regulatory action in markets outside the U.S. affecting pharmaceutical product pricing, reimbursement or access;

·  
Contingencies related to actual or alleged environmental contamination;

·  
Claims and concerns that may arise regarding the safety or efficacy of in-line products and product candidates;

·  
Significant breakdown, infiltration or interruption of our information technology systems and infrastructure;

·  
Legal defense costs, insurance expenses, settlement costs and the risk of an adverse decision or settlement related to product liability, patent protection, governmental investigations, ongoing efforts to explore various means for resolving asbestos litigation, and other legal proceedings;

·  
Ability to protect our patents and other intellectual property both domestically and internationally;

·  
Interest rate and foreign currency exchange rate fluctuations;

·  
Governmental laws and regulations affecting domestic and foreign operations, including tax obligations and changes affecting the taxation by the U.S. of income earned outside the U.S. that may result from pending and possible future proposals;

·  
Changes in U.S. generally accepted accounting principles;

·  
Uncertainties related to general economic, political, business, industry, regulatory and market conditions, including, without limitation, uncertainties related to the impact on us, our lenders, our customers, our suppliers and counterparties to our foreign-exchange and interest-rate agreements of weak global economic conditions and recent and possible future changes in global financial markets;

·  
Any changes in business, political and economic conditions due to actual or threatened terrorist activity in the U.S. and other parts of the world and related U.S. military action overseas;

·  
Growth in costs and expenses;

·  
Changes in our product, segment and geographic mix; and

·  
Impact of acquisitions, divestitures, restructurings, product withdrawals and other unusual items, including our ability to realize the projected benefits of our acquisition of Wyeth and of our cost-reduction initiatives.
 
We cannot guarantee that any forward-looking statement will be realized, although we believe we have been prudent in our plans and assumptions. Achievement of anticipated results is subject to substantial risks, uncertainties and inaccurate assumptions. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors should bear this in mind as they consider forward-looking statements.
 
We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our Form 10-Q, 8-K and 10-K reports and our other filings with the SEC.

Our 2009 Annual Report on Form 10-K listed various important factors that could cause actual results to differ materially from projected and historic results. We note these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. Readers can find them in Part I, Item 1A, of that filing under the heading “Risk Factors.” We incorporate that section of that Form 10-K in this filing and investors should refer to it. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider any such list to be a complete set of all potential risks or uncertainties.
 
This report includes discussion of certain clinical studies relating to various in-line products and/or product candidates. These studies typically are part of a larger body of clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or effectiveness of a product candidate or a new indication for an in-line product, regulatory authorities may not share our views and may require additional data or may deny approval altogether.

 
47

 
 
Legal Proceedings and Contingencies

We and certain of our subsidiaries are involved in various patent, product liability, consumer, commercial, securities, environmental and tax litigations and claims; government investigations; and other legal proceedings that arise from time to time in the ordinary course of our business. We do not believe any of them will have a material adverse effect on our financial position.

We record accruals for income tax contingencies to the extent that we conclude that a tax position is not sustainable under a “more likely than not” standard and we record our estimate of the potential tax benefits in one tax jurisdiction that could result from the payment of income taxes in another tax jurisdiction when we conclude that the potential recovery is more likely than not. We record accruals for all other contingencies to the extent that we conclude their occurrence is probable and the related damages are estimable, and we record anticipated recoveries under existing insurance contracts when assured of recovery. If a range of liability is probable and estimable and some amount within the range appears to be a better estimate than any other amount within the range, we accrue that amount. If a range of liability is p robable and estimable and no amount within the range appears to be a better estimate than any other amount within the range, we accrue the minimum of such probable range. Many claims involve highly complex issues relating to causation, label warnings, scientific evidence, actual damages and other matters. Often these issues are subject to substantial uncertainties and, therefore, the probability of loss and an estimation of damages are difficult to ascertain. Consequently, we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for these contingencies. These assessments can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions. Our assessments are based on estimates and assumptions that have been deemed reasonable by management. Litigation is inherently unpredictable, and excessive verdicts do occur. Although we believe we have substantial defenses in these matters, we could in the future inc ur judgments or enter into settlements of claims that could have a material adverse effect on our results of operations in any particular period.

Patent claims include challenges to the coverage and/or validity of our patents on various products or processes. Although we believe we have substantial defenses to these challenges with respect to all our material patents, there can be no assurance as to the outcome of these matters, and a loss in any of these cases could result in a loss of patent protection for the drug at issue, which could lead to a significant loss of sales of that drug and could materially affect future results of operations.


Information required by this item is incorporated by reference from the discussion under the heading Financial Risk Management in our 2009 Financial Report, which is filed as exhibit 13 to our 2009 Annual Report on Form 10-K.


As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the Exchange Act)). Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures are effective in alerting them in a timely manner to material information required to be disclosed in our periodic reports filed with the SEC.

During our most recent fiscal quarter, there has not occurred any change in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. However, we do wish to highlight some changes which, taken together, are expected to have a favorable impact on our controls over a multi-year period. We continue to pursue a multi-year initiative to outsource some transaction-processing activities within certain accounting processes and are migrating to a consistent enterprise resource planning system across the organization. These are enhancements of ongoing activities to support the growth of our financial shared service capabilities and standardize our financial s ystems. None of these initiatives is in response to any identified deficiency or weakness in our internal control over financial reporting.



Certain legal proceedings in which we are involved are discussed in Note 19 to the consolidated financial statements included in our 2009 Financial Report, which is incorporated by reference in Part I, Item 3, of our Annual Report on Form 10-K for the year ended December 31, 2009. The following discussion is limited to certain recent developments concerning our legal proceedings and should be read in conjunction with our 2009 Financial Report. Unless otherwise indicated, all proceedings discussed in our 2009 Financial Report remain outstanding. Reference also is made to the Legal Proceedings and Contingencies section in Part I, Item 2, of this Form 10-Q.

 
48

 
 
Patent Matters

Lyrica (pregabalin)

In March 2010, Mylan Pharmaceuticals Inc. (Mylan), the U.S. agent for Alphapharm Pty. Ltd. (Alphapharm), notified us that it had filed an abbreviated new drug application with the FDA seeking approval for Alphapharm to market a generic version of Lyrica and asserting the invalidity and non-infringement of the Lyrica basic patent, which expires in 2018. In March 2010, we filed suit against Mylan and Alphapharm in the U.S. District Court for the District of Delaware asserting the validity and infringement of the basic patent.

Viagra (sildenafil)

In March 2010, we brought a patent-infringement action in the U.S. District Court for the Eastern District of Virginia against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd. (collectively, Teva), which had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Viagra. Teva asserts the invalidity and non-infringement of the Viagra use patent, which expires in 2019, but is not challenging the basic patent, which expires in 2012.

Protonix (pantoprazole sodium)

Wyeth has an exclusive license to market Protonix in the U.S. from Nycomed GmbH (Nycomed), which owns the patents relating to Protonix. The basic patent (including the six-month pediatric exclusivity period) for Protonix expires in January 2011.

As previously reported, Teva and Sun Pharmaceutical Advanced Research Centre Ltd. and Sun Pharmaceutical Industries Ltd. (collectively, Sun) launched generic versions of Protonix tablets at risk in December 2007 and January 2008, respectively. Wyeth and Nycomed then filed amended complaints in their pending patent-infringement action against Teva and Sun in the U.S. District Court for the District of New Jersey seeking compensation for damages resulting from the at-risk launches. In April 2010, the jury upheld the validity of the basic patent for Protonix. Judgment in the case will be entered after the judge rules on certain legal questions. If the judge’s opinion is consistent with the jury verdict, Wyeth intends to seek an injunction against the continuing sale by Teva and Sun of their generic versions of Protonix and also to seek compensation for damages from Teva and Sun resulting from their at-risk launches. Teva and Sun will have the right to appeal the decision of the District Court.

ReFacto and Xyntha

As previously reported, in February 2008, Novartis Vaccines and Diagnostics, Inc. (Novartis) filed suit against Wyeth and a subsidiary of Wyeth in the U.S. District Court for the Eastern District of Texas alleging that Wyeth’s ReFacto and Xyntha products infringe two Novartis patents.  In May 2008, a subsidiary of Wyeth filed suit against Novartis in the U.S. District Court for the District of Delaware seeking a declaration that those Novartis patents are invalid. In February 2010, the District of Delaware declined to invalidate the two Novartis patents. In March 2010, the Wyeth subsidiary appealed the decision to the U.S. Court of Appeals for the Federal Circuit.

Rapamune (sirolimus)

In March 2010, Watson Laboratories, Inc. (Watson) and Ranbaxy Laboratories Limited (Ranbaxy) notified us that they had filed abbreviated new drug applications with the FDA seeking approval to market generic versions of Rapamune. Watson and Ranbaxy assert the invalidity and non-infringement of a method-of-use patent which (including the six-month pediatric exclusivity period) expires in 2014 and a solid-dosage formulation patent which (including the six-month pediatric exclusivity period) expires in 2018. In April 2010, we filed actions against Watson and Ranbaxy in the U.S. District Court for the District of Delaware and against Watson in the U.S. District Court for the Southern District of Florida asserting the infringement of the method-of-use patent.

 
49

 

Sutent (sunitinib malate)

In May 2010, Mylan notified us that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Sutent and challenging on various grounds the Sutent basic patent, which expires in 2021, and two other patents, which expire in 2020 and 2021.

Product Litigation

Viagra

As previously reported, a number of lawsuits, including purported class actions, have been filed against us in various federal and state courts alleging that Viagra causes certain types of visual injuries. In January 2006, the federal cases were transferred for consolidated pre-trial proceedings to a Multi-District Litigation (In re Viagra Products Liability Litigation MDL-1724) in the U.S. District Court for the District of Minnesota (the MDL).

In March 2010, we and the representatives of the MDL Plaintiffs’ Steering Committee entered into a master settlement agreement providing for the settlement and dismissal of all pending cases, whether in the MDL or elsewhere, and all pending claims asserting visual injuries allegedly caused by Viagra. The master settlement agreement provides for the payment by us of an amount that is not material to Pfizer following our receipt by June 17, 2010 of a release and stipulation of dismissal from all of the claimants, with provision at our election for a specified reduction in the settlement amount in respect of any claimant who does not timely provide the release and stipulation.

Celebrex

As previously reported, in 2003, several class action complaints were filed in the U.S. District Court for the District of New Jersey against Pharmacia, Pfizer and certain former officers of Pharmacia. The complaints allege that the defendants violated federal securities laws by misrepresenting the data from a study concerning the gastrointestinal effects of Celebrex. These cases were consolidated for pre-trial proceedings in the District of New Jersey (Alaska Electrical Pension Fund et al. v. Pharmacia Corporation et al.).  In October 2007, the court granted defendants’ motion for summary judgment and dismissed the plaintiffs’ claims. In January 2009, the U.S. Court of Appeals for the Third Circuit vacated the District Court’s grant of summary judgment i n favor of defendants and remanded the case to the District Court for further proceedings. In June 2009, the District Court stayed proceedings in the case pending a determination by the U.S. Supreme Court with regard to defendants’ petition for certiorari seeking reversal of the Third Circuit’s decision. On May 3, 2010, the U.S. Supreme Court denied the defendants’ petition for certiorari, and the case will be remanded to the District Court for further proceedings.

Thimerosal

As previously reported, Wyeth is a defendant in a number of suits by or on behalf of vaccine recipients alleging that exposure through vaccines to cumulative doses of thimerosal, a preservative used in certain childhood vaccines formerly manufactured and distributed by Wyeth and other vaccine manufacturers, caused severe neurological damage and/or autism in children. The National Childhood Vaccine Injury Act (the Vaccine Act) requires that plaintiffs alleging injury from childhood vaccines first bring a claim under the Vaccine Act in the U.S. Court of Federal Claims.

In July 2002, the Office of Special Masters of the U.S. Court of Federal Claims established the Omnibus Autism Proceeding with jurisdiction over petitions in which vaccine recipients claim to suffer from autism or autism spectrum disorder as a result of receiving thimerosal-containing childhood vaccines and/or the measles, mumps and rubella (MMR) vaccine.  There currently are several thousand petitions pending in the Omnibus Autism Proceeding.  Special masters of the  court have heard six test cases on petitioners’ theories that either thimerosal-containing vaccines in combination with the MMR vaccine or thimerosal-containing vaccines alone can cause autism or autism spectrum disorder.
 
In February 2009,  special masters of the U.S. Court of Federal Claims rejected the three cases brought on the theory that a combination of MMR and thimerosal-containing vaccines caused petitioners’ conditions. After these rulings were affirmed by the U.S. Court of Federal Claims, two of them were appealed by petitioners to the U.S. Court of Appeals for the Federal Circuit. In May 2010, the Federal Circuit affirmed the decision of the special master in one of these cases.
 
In March 2010, special masters of the U.S. Court of Federal Claims rejected the three additional test cases brought on the theory that thimerosal-containing vaccines alone caused petitioners’ conditions. Petitioners did not seek review by the U.S. Court of Federal Claims of the decisions of the special masters in these latter three test cases, and judgments were entered dismissing the cases on April 14, 2010. Petitioners in each of these latter three test cases have filed an election to bring civil action.
 
Various Drugs

In May 2010, a purported class action was filed in the U.S. District Court for the Southern District of New York against Pfizer and several of our current and former officers. The complaint alleges that the defendants violated federal securities laws by failing to disclose that Pfizer was engaged in off-label marketing of certain drugs. Plaintiffs seek damages in an unspecified amount.
 
Commercial and Other Matters

Acquisition of Wyeth

As previously reported, in August 2009, a number of retail pharmacies in California brought an action against Pfizer and Wyeth in the U.S. District Court for the Northern District of California alleging, among other things, that our acquisition of Wyeth violates various federal antitrust laws by creating a monopoly in the manufacture, distribution and sale of prescription drugs in the U.S. In April 2010, the court granted our motion to dismiss the second amended complaint, and plaintiffs filed a notice of appeal to the U.S. Court of Appeals for the Ninth Circuit.

 
50

 

Tax Matters

The United States is one of our major tax jurisdictions. We currently are appealing two issues related to the Internal Revenue Service’s (IRS) audits of the Pfizer Inc. tax returns for the years 2002 through 2005. The 2006, 2007 and 2008 tax years currently are under audit. The 2009 and 2010 tax years are not yet under audit. All other tax years in the U.S. for Pfizer Inc. are closed under the statute of limitations. With respect to Pharmacia, the IRS currently is conducting an audit for the year 2003 through the date of merger with Pfizer (April 16, 2003). With respect to Wyeth, the years 2002 through 2005 currently are under IRS audit, and tax years 2006 through the Wyeth acquisition date (October 15, 2009) have not been audited yet. In addition to the open audit years in the U.S., we have open audit years in other major tax juris dictions, such as Canada (1998-2009), Japan (2006-2009), Europe (1997-2009, primarily reflecting Ireland, the United Kingdom, France, Italy, Spain and Germany) and Puerto Rico (2003-2009). Finalizing audits with the relevant taxing authorities can include formal administrative and legal proceedings, and, as a result, it is difficult to estimate the timing and range of possible changes to our uncertain tax positions. If our estimates and assumptions are not representative of actual outcomes, any change could have a significant impact.

We regularly reevaluate our tax positions based on the results of audits of federal, state and foreign income tax filings, statute of limitations expirations, and changes in tax law that would either increase or decrease the technical merits of a position relative to the ‘more-likely-than-not’ standard. We believe that our accruals for tax liabilities are adequate for all open years. Many factors are considered in making these evaluations, including past history, recent interpretations of tax law and the specifics of each matter. Because tax laws and regulations are subject to interpretation and tax litigation is inherently uncertain, these evaluations can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions. Our evaluations are based on estimates and assumptions that have been deemed reasonable by management. However, if our estimates and assumptions are not representative of actual outcomes, our results could be materially impacted.

In the first quarter of 2010, we recognized $410 million in tax benefits for the resolution of certain tax positions pertaining to prior years with various foreign tax authorities.


There have been no material changes from the risk factors disclosed in Part I, Item 1A, of our 2009 Annual Report on Form 10-K, except as discussed in the “U.S. Healthcare Legislation” section of Part I, Item 2, of this Form 10-Q, which section is incorporated by reference herein.


This table provides certain information with respect to our purchases of shares of Pfizer’s common stock during the fiscal first quarter of 2010:

Issuer’s Purchases of Equity Securities(a)
Period
 
Total Number of
Shares Purchased(b)
   
Average Price
Paid per Share(b)
   
Total Number of
Shares Purchased as
Part of Publicly
Announced Plan(a)
   
Approximate Dollar
Value of Shares That
May Yet Be Purchased
Under the Plan(a)
 
January 1, 2010, through January 31, 2010
    37,948     $ 19.02       ––     $ 5,033,723,295  
February 1, 2010, through February 28, 2010
    3,671,867     $ 18.28       ––     $ 5,033,723,295  
March 1, 2009, through April 4, 2010
    217,474     $ 17.86       ––     $ 5,033,723,295  
Total
    3,927,289     $ 18.26       ––          
(a)
On June 23, 2005, we announced that the Board of Directors authorized a $5 billion share-purchase plan (the “2005 Stock Purchase Plan”). On June 26, 2006, we announced that the Board of Directors increased the authorized amount of shares to be purchased under the 2005 Stock Purchase Plan from $5 billion to $18 billion. On January 23, 2008, we announced that the Board of Directors authorized a new $5 billion share-purchase plan to be utilized from time to time. In the first quarter of 2010, we did not purchase any shares of our common stock. On May 4, 2010, the Company announced that it will purchase its shares as market conditions warrant.
(b)
These columns reflect the following transactions during the fiscal first quarter of 2010: (i) the surrender to Pfizer of 3,817,679 shares of common stock to satisfy tax withholding obligations in connection with the vesting of restricted stock and restricted stock units issued to employees, (ii) the surrender to Pfizer of 63,759 shares of common stock to satisfy tax withholding obligations in connection with the vesting of performance-contingent share awards issued to employees, and (iii) the open-market purchase by the trustee of 45,851 shares of common stock in connection with the reinvestment of dividends paid on common stock held in trust for employees who were granted performance-contingent share awards and who deferred receipt of such awards.
 
 
51

 

None


None


1) Exhibit 3
-
Our By-laws, as amended April 22, 2010
2) Exhibit 10.1
-
Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors, as amended
3) Exhibit 12
-
Computation of Ratio of Earnings to Fixed Charges
4) Exhibit 15
-
Accountants’ Acknowledgement
5) Exhibit 31.1
-
Certification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
6) Exhibit 31.2
-
Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
7) Exhibit 32.1
-
Certification by the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
8) Exhibit 32.2
-
Certification by the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
9) Exhibit 101:
   
EX-101.INS
EX-101.SCH
EX-101.CAL
EX-101.LAB
EX-101.PRE
EX-101.DEF
 
XBRL Instance Document
XBRL Taxonomy Extension Schema
XBRL Taxonomy Extension Calculation Linkbase
XBRL Taxonomy Extension Label Linkbase
XBRL Taxonomy Extension Presentation Linkbase
XBRL Taxonomy Extension Definition Document

 
 
52

 
 

Under the requirements of the Securities Exchange Act of 1934, this report was signed on behalf of the Registrant by the authorized person named below.

 
Pfizer Inc.
 
(Registrant)
   
   
Dated:  May 13, 2010
/s/ Loretta V. Cangialosi
   
 
Loretta V. Cangialosi, Senior Vice President and
Controller
(Principal Accounting Officer and
Duly Authorized Officer)
 
 
 
 
53

EX-3 2 a6285704ex3.htm EXHIBIT 3 a6285704ex3.htm
EXHIBIT 3
 

 

 

 
PFIZER INC.
 
By-laws
 
 
As Amended April 22, 2010
 
 
 
 
 
 
 
 

 
 
TABLE OF CONTENTS
 
    Page
   
Article I Stockholders' Meeting 1
     
1.
Place of Meeting
1
     
2.
Annual Meeting
1
     
3.
Quorum
1
     
4.
Adjournments; Postponement
1
     
5.
Voting; Proxies
2
     
6.
Notice
2
     
7.
Inspectors of Election
3
     
8.
Stock List
3
     
9.
Special Meetings
3
     
10.
Organization
4
     
11.
Conduct of Meetings
4
     
12.
Fixing Date for Determination of Stockholders of Record
5
     
13.
Notice of Stockholder Proposal
5
     
14.
Compliance with Procedures
7
     
Article II Directors 7
     
1.
Number; Election; Term
7
     
2.
Place of Meetings, Records
7
     
3.
Vacancies
7
     
4.
Organizational Meeting
8
     
5.
Regular Meetings
8
     
6.
Special Meetings
8
     
7.
Quorum
8
 
 
i

 

 
8.
Executive Committee
8
     
9.
Additional Committees
9
     
10.
Presence at Meeting
9
     
11.
Action Without Meetings
9
     
12.
Eligibility to Make Nominations
9
     
13.
Procedure for Nominations by Stockholders
9
     
14.
Compliance with Procedures
11
     
15.
Submission of Questionnaire; Representation and Agreement
11
   
Article III Officers. 12
     
1.
Election; Term of Office; Appointments
12
     
2.
Removal and Resignation
12
     
3.
Chair of the Board
12
     
4.
President
12
     
5.
Vice Presidents
13
     
6.
Secretary
13
     
7.
Treasurer
13
     
8.
Controller
13
     
Article IV Stock 13
     
1.
Stock
13
     
2.
Lost Certificates
14
     
3.
Transfers of Stock
14
     
4.
Holder of Record
14
     
Article V Indemnification and Severance 14
     
1.
Right to Indemnification
14
     
2.
Prepayment of Expenses
15
 
 
ii

 
 
3.
Claims
15
     
4.
Nonexclusivity of Rights
15
     
5.
Other Indemnification
15
     
6.
Amendment or Repeal
15
     
7.
Severance
15
     
Article VI Miscellaneous 16
     
1.
Delaware Office
16
     
2.
Other Offices
16
     
3.
Seal
16
     
4.
Notice
16
     
5.
Amendments
16
     
6.
Form of Records
16
     
7.
Checks
17
     
8.
Fiscal Year
17
 
 
iii

 
 
BY-LAWS OF PFIZER INC
 
AS AMENDED APRIL 22, 2010
 
Article I
 
Stockholders' Meeting.
 
1.  Place of Meeting.  Meetings of the stockholders shall be held at the registered office of the Corporation in Delaware, or at such other place within or without the State of Delaware as may be designated by the Board of Directors or the stockholders.
 
2.  Annual Meeting.  The annual meeting of the stockholders shall be held on such date and at such time and place as the Board of Directors may designate.  The date, place and time of the annual meeting shall be stated in the notice of such meeting delivered to or mailed to stockholders.  At such annual meeting the stockholders shall elect directors, in accordance with the requirements of the Certificate of Incorporation, and transact such other business as may properly be brought before the meeting.
 
3.  Quorum.  The holders of stock representing a majority of the voting power of all shares of stock issued and outstanding and entitled to vote, present in person or represented by proxy, shall be requisite for and shall constitute a quorum of all meetings of the stockholders, except as otherwise provided by law, by the Certificate of Incorporation or by these By-laws.  If a quorum shall not be present or represented at any meeting of the stockholders, the me eting may be adjourned from time to time by the vote of holders of stock representing a majority of the voting power of all shares present or represented at the meeting or by the chairman of the meeting, in the manner provided in paragraph 4 of Article I of these By-laws, until a quorum shall be present or represented.
 
4.  Adjournments; Postponement.  In the absence of a quorum, holders of stock representing a majority of the voting power of all shares present in person or represented by proxy at the meeting, or the chairman of the meeting, may adjourn any meeting of stockholders, annual or special, from time to time, to reconvene at the same or some other place, and notice need not be given of any such adjourned meeting if the time and place thereof are announced at the meeting at wh ich the adjournment is taken.  Furthermore, after the meeting has been duly organized, the chairman of the meeting may adjourn any meeting of stockholders, annual or special, from time to time, to reconvene at the same or some other place, and notice need not be given of any such adjourned meeting if the time and place thereof are announced at the meeting at which the adjournment is taken.  At the adjourned meeting the Corporation may transact any business which might have been transacted at the original meeting.  If the adjournment is for more than thirty days, or if after the adjournment a new record date is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting.  Any previously scheduled meeting of stockholders may be postponed by the Board of Directors prior to the date previously scheduled for such meeting and the Corporation shall publicly announce such postponement.
 
 
 

 
 
5.  Voting; Proxies.  At each meeting of the stockholders of the Corporation, every stockholder having the right to vote may authorize another person to act for him or her by proxy. Such authorization must be in writing and executed by the stockholder or his or her authorized officer, director, employee, or agent.  To the extent permitted by law, a stockholder may authorize another person or persons to act for him or her as proxy by transmitting or authorizing the transmission of a telegram, cablegram or other means of electronic transmission to the person who will be the holder of the proxy or to a proxy solicitation firm, proxy support service organization or like agent duly authorized by the person who will be the holder of the proxy to receive such transmission provided that the telegram, cablegram or electronic transmission either sets forth or is submitted with information from which it can be determined that the telegram, cablegram or other electronic transmission was authorized by the stockholder.  A copy, facsimile transmission or other reliable reproduction of a writing or transmission authorized by this paragraph 5 of Article I may be substituted for or used in lieu of the original writing or electronic transmission for any and all purposes for which the original writing or transmission could be used, provided that such copy, facsimile transmission or other reproduction shall be a complete reproduction of the entire original writing or transmission.  No proxy authorized hereby shall be voted or acted upon more than three years from its date, unless the proxy provides for a longer period.  No ballot, proxies or votes, nor any revocations thereof or changes thereto shall be accepted after the time set for the closing of the polls pursuant to paragraph 11 of Article I of these By-laws unless the Court of Chancery upon application of a stockholder shall determine otherwise.  Each proxy shall be delivered to the inspectors of election prior to or at the meeting.  A duly executed proxy shall be irrevocable if it states that it is irrevocable and if, and only as long as, it is coupled with an interest sufficient in law to support an irrevocable power.  A stockholder may revoke any proxy which is not irrevocable by attending the meeting and voting in person or by filing an instrument in writing revoking the proxy or by filing a subsequent duly executed proxy with the Secretary of the Corporation.  The vote for directors shall be by ballot. Unless a greater number of affirmative votes is required by the Certificate of Incorporation, these By-laws, the rules or regulations of any stock exchange applicable to the Corporation, or as otherwise required by law or pursuant to any regulation applicable to the Corporation, if a quorum exists at any meeting of stockholders, stockholders shall have approved any matter, other than the election of directors, if the votes cast by stockholders present in person or represented by proxy at the meeting and entitled to vote on the matter in favor of such matter exceed the votes cast by such stockholders against such matter.  A nominee for director shall be elected to the Board of Directors if the votes cast for such nominee's election exceed the votes cast against such nominee's election; provided, however, that directors shall be elected by a plurality of the votes cast at any meeting of stockholders for which the Secretary of the Corp oration determines that the number of nominees exceeds the number of directors to be elected as of the record date for such meeting.  If directors are to be elected by a plurality of the votes cast, stockholders shall not be permitted to vote against a nominee.
 
6.  Notice.  Written notice of an annual or special meeting shall be given to each stockholder entitled to vote thereat, not less than ten nor more than sixty days prior to the meeting.  If mailed, such notice shall be deemed to be given when deposited in the mail, postage pre paid, directed to the stockholder at his or her address as it appears on the records of the Corporation.
 
 
2

 
 
7.  Inspectors of Election.  The Corporation shall, in advance of any meeting of stockholders, appoint one or more inspectors of election to act at the meeting and make a written report thereof.  The Corporation may designate one or more persons as alternate inspectors to replace any inspector who fails to act. In the event that no inspector so appointed or designated is able to act at a meeting of stockholders, the person presiding at the meeting shall appoin t one or more inspectors to act at the meeting.  Each inspector, before entering upon the discharge of his or her duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of his or her ability.  The inspector or inspectors so appointed or designated shall (i) ascertain the number of shares of capital stock of the Corporation outstanding and the voting power of each such share, (ii) determine the shares of capital stock of the Corporation present or represented at the meeting and the validity of proxies and ballots, (iii) count all votes and ballots, (iv) determine and retain for a reasonable period a record of the disposition of any challenges made to any determination by the inspectors, and (v) certify their determination of the number of shares of capital stock of the Corporation present or represented at the meeting and such inspectors' count of all votes and ballots.  Such ce rtification shall specify such other information as may be required by law.  In determining the validity and counting of proxies and ballots cast at any meeting of stockholders of the Corporation, the inspectors may consider such information as is permitted by applicable law.  No person who is a candidate for an office at an election may serve as an inspector at such election.
 
8.  Stock List.  At least ten days before every meeting of the stockholders a complete list of the stockholders entitled to vote at said meeting, arranged in alphabetical order, with the post office address of each, and the number of shares held by each, shall be prepared by the Secretary.  Such list shall be open to the examination of any stockholder for any purpose germane to the meeting, during ordinary business hours at a place within the city where t he meeting is to be held, which place shall be specified in the notice of the meeting, or, if not so specified, at the place where the meeting is to be held for said ten days, and shall be produced and kept at the time and place of meeting during the whole time thereof and subject to the inspection of any stockholder who may be present.  The original or duplicate stock ledger shall be provided at the time and place of each meeting and shall be the only evidence as to who are the stockholders entitled to examine the list of stockholders or to vote in person or by proxy at such meeting.
 
9.  Special Meetings.  Special meetings of the stockholders for any purpose or purposes may be called by the Chair of the Board, and shall be called by the Chair of the Board or the Secretary at the request in writing of a majority of the Board of Directors or one or more record holders of shares of stock of the Corporation representing in the aggregate not less than twenty percent (20%) of the total number of shares of stock entitled to vote on the matter or matters to be brought before the proposed special meeting.  A stockholder re quest for a special meeting shall be directed to the Secretary and shall be signed by each stockholder, or a duly authorized agent of such stockholder, requesting the special meeting and shall be accompanied by a notice setting forth the information required by paragraph 13 of this Article or paragraph 13 of Article II of these By-laws, as applicable, as to any nominations proposed to be presented and any other business proposed to be conducted at such special meeting and as to the stockholder(s) requesting the special meeting, as well as the written questionnaire and written representation and agreement required by paragraph 15 of Article II of these By-laws from any nominee for election as a director of the Corporation.  A special meeting requested by stockholders shall be
 
 
3

 
 
held at such date, time and place within or without the state of Delaware as may be designated by the Board of Directors; provided, however, that the date of any such special meeting shall be not more than ninety (90) days after the request to call the special  meeting by one or  more stockholders who satisfy the requirements of this paragraph 9 of Article I is received by the Secretary.  Notwithstanding the foregoing, a special meeting requested by stockholders shall not be held if:  (i) the stated business to be brought before the special meeting is not a proper subject for stockholder action under applicable law, or (ii) the Board of Directors has called or calls for an annual meeting of stockholders to be held within ninety (90) days after the Secretary receives the request for the special meeting and the Board of Directors determines in good faith that the business of such annual meeting includes (among any other matters properly brought before the annual meeting) the business specified in the stockholder's request.  A stockholder may revoke a request for a special meeting at any time by written revocation delivered to the Secretary, and if, following such revocation, there are un-revoked requests from stockholders holding in the aggregate less than the requisite number of shares entitling the stockholders to request the calling of a special meeting, the Board of Directors, in its discretion, may cancel the special meeting.  If none of the stockholders who submitted the request for a special meeting appears or sends a qualified representative to present the nominations proposed to be presented or other business proposed to be conducted at the special meeting, the Corporation need not present such nominations or other business for a vote at such meeting.  Business transacted at all special meetings shall be confined to the matters stated in the notice of special meeting.  Business transacted at a special meeting requested by stockholders shall be limited to the matters described in the special meeting request; provided, however, that nothing herein shall prohibit the Board of Directors from submitting matters to the stockholders at any special meeting requested by stockholders.  The Chair of a special meeting shall determine all matters relating to the conduct of the meeting, including, but not limited to, determining whether any nomination or other item of business has been properly brought before the meeting in accordance with these By-laws, and if the Chair should so determine and declare that any nomination or other item of business has not been properly brought before the special meeting, then such business shall not be transacted at such meeting.
 
10.  Organization.  Meetings of stockholders shall be presided over by the Chair of the Board, if any, or in his or her absence by a Chair designated by the Board of Directors, or in the absence of such designation by a Chair chosen at the meeting.  The Secretary shall act as secretary of the meeting, but in his or her absence the Chair of the meeting may appoint any person to act as secretary of the meeting.
 
11.  Conduct of Meetings.  The date and time of the opening and the closing of the polls for each matter upon which the stockholders will vote at a meeting shall be announced at such meeting by the person presiding over the meeting.  The Board of Directors of the Corporation may adopt by resolution such rules or regulations for the conduct of meetings of stockholders as it shall deem appropriate.  Except to the extent inconsistent with such rules and regulations as adopted by the Board of Directors, the chair of any meeting of stockholders shall have the right and authority to prescribe such rules, regulations and procedures and to do all such acts as, in the judgment of such chair, are appropriate for the proper conduct of the meeting.  Such rules, regulations or procedures, whether adopted by the Board of Directors or prescribed by the chair of the meeting, may include, without limitation, the following:  (1) the establishment of an agenda or order of business for the meeting; (2) rules and procedures for maintaining order
 
 
4

 
 
at the meeting and the safety of those present; (3) limitations on attendance at or participation in the meeting, to stockholders of record of the Corporation, their duly authorized and constituted proxies or such other persons as the chair shall permit; (4) restrictions on entry to the meeting after the time fixed for the commencement thereof, and (5) limitations on the time allotted to questions or comments by participants.  Unless, and to the extent determined by the Board of Directors or the chair of the meeting, meetings of stockholders shall not be required to be held in accordance with rules of parliamentary procedure.
 
12.  Fixing Date for Determination of Stockholders of Record.  In order that the Corporation may determine the stockholders entitled to notice of or to vote at any meeting of the stockholders or any adjournment thereof, or entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action, the Board of Dire ctors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors and which record date:  (1) in the case of determination of stockholders entitled to vote at any meeting of stockholders or adjournment thereof, shall, unless otherwise required by law, not be more than sixty nor less than ten days before the date of such meeting; and (2) in the case of any other action, shall not be more than sixty days prior to such other action.  If no record date is fixed:  (1)(a) the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the date next preceding the day on which the meeting is held; and (1)(b) the record date for determining stockholders for any other purpose shall be at the clo se of business on the day on which the of Board of Directors adopts the resolution relating, thereto.  A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the Board of Directors may fix a new record date for the adjourned meeting.
 
13.  Notice of Stockholder Proposal.  At an annual meeting of the stockholders, only such business shall be conducted as shall have been properly brought before the meeting.  To be properly brought before an annual meeting business must be:  (a) specified in the notice of meeting (or any supplement thereto) given by or at the direction of the Board of Directors, (b) otherwise properly brought before the meeting by or at the direction of the Board of Directors, or (c) otherwise properly brought before the meeting by a stockholder.  For business to be properly brought before an annual meeting by a stockholder (other than the nomination of a person for election as a director, which is governed by paragraphs 13, 14 and 15 of Article II of these By-laws), the stockholder intending to propose the business (the "Proponent") must have given timely notice thereof in proper written form to the Secretary of the Corporation.  To be timely, a Proponent's notice must be delivered to or mailed and received by the Secretary at the principal executive offices of the Corporation not less than 90 days nor more than 120 days in advance of the anniversary of the previous year's annual meeting; provided, however, that in the event the annual meeting is called for a date that is not within 25 days before or after such anniversary date, notice by the stockholder in order to be timely must be so received no later than the close of business on the 10th day fo llowing the date on which such notice of the date of the annual meeting was mailed or the public disclosure of the date of the annual meeting was made, whichever first occurs.  In no event shall the adjournment or postponement of the annual meeting, or the public announcement of such an adjournment or postponement, commence a new
 
 
5

 
 
time period (or extend any time period) for the giving of a stockholder's notice as described above.  (For  purposes of these By-laws, public disclosure shall be deemed to include a disclosure made in a press release reported by the Dow Jones News Services, Associated Press or a comparable national news service or in a document filed by the Corporation with the Securities and Exchange Commission pursuant to Section 13, 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")).  To be in proper written form, a Proponent's notice to the Secretary must set forth:  (a) as to each matter the Proponent proposes to bring before the annual meeting, a brief description of the business desired to be brought before the annual meeting and the reasons for conducting such business at the annual meeting, and (b) as to the Proponent and the beneficia l owner, if any, on whose behalf the proposal is being made, (i) the name and address of each such person, and of any holder of record of the Proponent's shares as they appear on the Corporation's books, (ii) the class and number of all shares of capital stock of the Corporation that are owned by each such person (beneficially and of record) and owned by any holder of record of each such person's shares, as of the date of the Proponent's notice, and a representation that the Proponent will notify the Corporation in writing of the class and number of such shares owned of record and beneficially by each such person as of the record date for the meeting not later than five business days following the later of the record date or the date notice of the record date is first publicly disclosed, (iii) any material interest of each such person, or any affiliates or associates of each such person, in such business, (iv) a description of any agreement, arrangement or understanding with respect to such business between or among each such person and any of its affiliates or associates, and any others (including their names) acting in concert with any of the foregoing, and a representation that the Proponent will notify the Corporation in writing of any such agreement, arrangement or understanding in effect as of the record date for the meeting not later than five business days following the later of the record date or the date notice of the record date is first publicly disclosed, (v) a description of any agreement, arrangement or understanding (including any derivative instruments, swaps, warrants, short positions, profit interests, options, hedging transactions, borrowed or loaned shares or other transactions) that has been entered into as of the date of the Proponent's notice by, or on behalf of, each such person or any of its affiliates or associates, the effect or intent of which is to mitigate loss to, manage risk or benefit of share price changes for, or increase or decrease the voting power of each such person or an y of its affiliates or associates with respect to shares of stock of the Corporation, and a representation that the Proponent will notify the Corporation in writing of any such agreement, arrangement or understanding in effect as of the record date for the meeting not later than five business days following the later of the record date or the date notice of the record date is first publicly disclosed, (vi) a representation that the Proponent is a holder of record or beneficial owner of shares of the Corporation entitled to vote at the annual meeting and intends to appear in person or by proxy at the meeting to propose such business, (vii) a representation whether the Proponent intends to deliver a proxy statement and/or form of proxy to holders of at least the percentage of the Corporation's outstanding shares required to approve the proposal and/or otherwise to solicit proxies from stockholders in support of the proposal, and (viii) any other information relating to each such person that would be required t o be disclosed in a proxy statement or other filing required to be made in connection with the solicitation of proxies by each such person with respect to the proposed business to be brought by each such person before the annual meeting pursuant to Section 14 of the Exchange Act, and the rules and regulations promulgated thereunder.
 
 
6

 
 
14.  Compliance with Procedures.  Notwithstanding anything in these By-laws to the contrary:  (a) no business shall be conducted at any annual meeting except in accordance with the procedures set forth in paragraph 13 of this Article I, and (b) unless otherwise required by law, if a Proponent intending to propose business at an annual meeting pursuant to paragraph 13 of this Article I does not provide the information required under paragraph 13 to the Corporat ion (including providing the updated information required by clauses (b)(ii), (b)(iv) and (b)(v) of paragraph 13 by the deadlines specified therein), or the Proponent (or a qualified representative of the Proponent) does not appear at the meeting to present the proposed business, such business shall not be transacted, notwithstanding that proxies in respect of such business may have been received by the Corporation.  The chair of the annual meeting shall, if the facts warrant, determine and declare to the meeting that business was not properly brought before the meeting in accordance with the provisions of paragraph 13 of this Article I, and if he or she should so determine, he or she shall so declare to the meeting and any such business not properly brought before the meeting shall not be transacted.  Nothing contained in paragraphs 13 and 14 of this Article I shall be deemed to affect any rights of stockholders to request inclusion of proposals in the Corporation's proxy statement pursu ant to Rule 14a-8 under the Exchange Act (or any successor provision of law).
 
Article II
 
Directors.
 
1.  Number; Election; Term.  The number of directors which shall constitute the whole Board shall not be less than ten, nor more than twenty-four, the exact number within said limits to be fixed from time to time solely by resolution of the Board, acting by the vote of not less than a majority of the directors then in office.  A majority of the directors shall consist of persons who are not employees of the Corporation or of any subsidiary of the Corporation.& #160; Should the death, resignation or other removal of any non employee director result in the failure of the requirement set forth in the preceding sentence to be met, such requirement shall not apply during the time of the vacancy caused by the death, resignation or removal of any such non employee director.  The remaining directors of the Corporation shall cause any such vacancy to be filled in accordance with these By-laws within a reasonable period of time.  At the annual meeting or a special meeting at which directors are to be elected in accordance with the Corporation's notice of meeting,directors shall be elected in accordance with the requirements of these By-laws and the Certificate of Incorporation.
 
2.  Place of Meetings, Records.  The directors may hold their meetings and keep the books of the Corporation outside of the State of Delaware at such places as they may from time to time determine.
 
3.  Vacancies.  Subject to the rights of the holders of any one or more series of Preferred Stock then outstanding, if the office of any director becomes vacant for any reason or any new directorship is created by any increase in the authorized number of directors, a majority of the directors then in office, although less than a quorum, may choose a successor or successors or fill the newly created directorship.  Any director so chosen shall hold office until the next election of the class for which such director shall have been chosen and until his successor shall be elected and qualified.
 
 
7

 
 
4.  Organizational Meeting.  The Board of Directors shall meet for the purpose of organization, the election of officers and the transaction of other business, after each annual election of directors on the day and at the place of the next regular meeting of the Board.  Notice of such meeting need not be given.  Such meeting may be held at any other time or place which shall be specified in a notice given as hereinafter provided for special meetings of the Board of Directors or in a consent and waiver of notice thereof signed by all of the directors.
 
5.  Regular Meetings.  Regular meetings of the Board may be held without notice at such time and place either within or without the State of Delaware as shall from time to time be determined by the Board.
 
6.  Special Meetings.  Special meetings of the Board may be called by the Chair of the Board a Vice Chair of the Board or the President by the mailing of notice to each director at least 48 hours before the meeting or by notifying each director of the meeting at least 24 hours prior thereto either personally, by telephone or by electronic transmission; special meetings shall be called on like notice by the Chair of the Board, a Vice Chair of the Board, the President or, on the written request of any two directors, by the Secretary.
 
7.  Quorum.  At all meetings of the Board the presence of one third of the total number of directors determined by resolution pursuant to paragraph 1 of this Article II to constitute the Board of Directors shall be necessary and sufficient to constitute a quorum for the transaction of business, and the act of a majority of the directors present at any meeting at which there is a quorum shall be the act of the Board of Directors, except as may be otherwise specifically p rovided by law, by the Certificate of Incorporation or by these By-laws.
 
8.  Executive Committee.  There shall be an Executive Committee of three or more directors elected by a majority of the Board.  The Committee shall be composed of the Chief Executive Officer, the President, and such other directors as the Board shall elect.  The Board, by resolution, may designate one or more directors as alternate members of the Committee, who may replace any absent or disqualified member at any meeting of the Committee.   In the absence or disqualification of a member of the Committee, the member or members present at any meeting of the Committee and not disqualified from voting, whether or not he, she or they constitute a quorum, may unanimously appoint another member of the Board to act at the meeting in the place of any such absent or disqualified member.  The ratio of inside directors to outside directors serving on the Committee shall, to the extent feasible, be as near as possible to the ratio of inside directors to outside directors serving on the full Board.  A quorum shall be a majority of the members of the Committee.  Regular meetings of the Committee shall be held without notice at such time and place as shall from time to time be determined by the Committee; special meetings of the Committee may be called pursuant to the rules determined by the Committee.  The Committee shall generally perform such duties and exercise such powers as may be directed or delegated by the Board of Directors from time to time. Except as otherwise provided by law, the Committee shall have authority to exercise all the powers of the Board while the Board is not in session. The act of a majority of the Committee members present at any meeting at which there is a quorum shall be the act of the Committee except as may be otherwise specifically provided by law, by the Certificate of Incorporation or by these By-laws.  The Committee shall keep regular minutes of its proceedings and report the same to the Board at its next regular meeting.
 
 
8

 
 
9.  Additional Committees.  The Board of Directors may, by resolution passed by a majority of the whole Board, designate one or more additional committees, each committee to consist of one or more of the directors of the Corporation.  In the event that the Board shall designate a committee that shall have the power to recommend changes in the compensation of senior management of the Corporation and/or a committee that shall have the power to recommend nominees for election as directors of the Corporation, the membership of such committees shall consist solely of directors who are not employees of the Corporation or of any subsidiary of the Corporation.  The Board may designate one or more directors as alternate members of any such additional committee, who may replace any absent or disqualified member at any meeting of the committee. Any such committee shall have such powers as are granted to it by the resolution of the Board or by subsequent resolutions passed by a majority of the whole Board.  Nothing herein shall limit the authority of the Board of Directors to appoint other committees consisting in whole or in part of persons who are not directors of the Corporation to carry out such functions as the Board may designate.  Unless otherwise provided for in any resolution of the Board of Directors designating a committee pursuant to this paragraph 9 of Article II:  (i) a quorum for the transaction of busines s of such committee shall be fifty percent or more of the authorized number of members of such committee; and (ii) the act of a majority of the members of such committee present at any meeting of such committee at which there is a quorum shall be the act of the committee (except as otherwise specifically provided by law, the Certificate of Incorporation or by these By-laws).
 
10.  Presence at Meeting.  Members of the Board of Directors or any committee designated by such Board may participate in the meeting of said Board or committee by means of conference telephone or similar communications equipment by means of which all persons in the meeting can hear each other and participate.  The ability to participate in a meeting in the above manner shall constitute presence at said meeting for purposes of a quorum and any action thereat.< /font>
 
11.  Action Without Meetings.  Any action required or permitted to be taken at any meeting of the Board of Directors or any committee designated by such Board may be taken without a meeting, if all members of the Board or committee consent thereto in writing and the writing or writings are filed with the minutes of the proceedings of the Board or committee.
 
12.  Eligibility to Make NominationsNominations of candidates for election as directors at an annual meeting of stockholders or a special meeting of stockholders at which directors are to be elected pursuant to the Corporation's notice of meeting (an "Election Meeting") may be made (1) by any stockholder entitled to vote at such Election Meeting only in accordance with the procedures established by paragraph 13 of this Article II, or (2) by the Board of Directors; provide d, however, that nothing in these By-laws shall be deemed to limit any class voting rights upon the occurrence of dividend arrearages provided to holders of Preferred Stock.  In order to be eligible for election as a director, any director nominee must first be nominated in accordance with the provisions of these By-laws.
 
13.  Procedure for Nominations by Stockholders.  Any stockholder entitled to vote for the election of a director at an Election Meeting may nominate one or more persons for such election only if written notice of such stockholder's intent to make such nomination is delivered to or mailed and received by the Secretary of the Corporation at the principal executive offices of
 
 
9

 
 
the Corporation.  In addition to any other applicable requirements,  for a nomination to be made by a stockholder,  such stockholder  must  have  given  timely  notice thereof in proper written form to the Secretary of the Corporation.  To be timely, such notice must be received by the Secretary (1) with respect to an annual meeting of stockholders, not less than 90 days nor more than 120 days in advance of the anniversary of the previous year's annual meeting; provided, however, that in the event the annual meeting is called for a date that is not within 25 days before or after such anniversary date, notice by the stockholder in order to be timely must be so received no later than the close of business on the 10th day following the date on which such notice of the date of the annual meeting was mailed or the public disclosure of the date of the annual meeting was made, whichever first occurs; and (2) with respect to a special meeting of stockholders at which directors are to be elected pursuant to the Corporation's notice of meeting, by the close of business on the 10th day following the date on which such notice of the date of the special meeting was mailed or the public disclosure of the date of the special meeting was made, whichever first occurs.  In no event shall the adjournment or postponement of the annual meeting or a special meeting called for the purpose of electing directors, or the public announcement of such an adjournment or postponement, commence a new time period (or extend any time period) for the giving of a stockholder's notice as described above.  To be in proper written form, the notice of the stockholder intending to make the nomination (the "Proponent") shall set forth:  (a) as to each person whom the stockholder proposes to nominate for election as director (i) the name, age, business address a nd residence address of such person, (ii) the principal occupation or employment of such person, (iii) the class and number of all shares of capital stock of the Corporation that are owned of record and beneficially by such person, (iv) a statement whether each such nominee, if elected, intends to tender, promptly following such person's failure to receive the required vote for election or reelection at the next meeting at which such person would face election or reelection, an irrevocable resignation effective upon acceptance of such resignation by the Board of Directors, in accordance with the Corporation's Corporate Governance Principles, (v) as an appendix, a completed and signed questionnaire, representation and agreement required by paragraph 15 of this Article II, and (vi) any other information relating to such nominee that would be required to be disclosed in a proxy statement or other filing required to be made in connection with the solicitation of proxies for election as directors pursuant to Sect ion 14 of the Exchange Act, and the rules and regulations promulgated thereunder, and (b) as to the Proponent and the beneficial owner, if any, on whose behalf the nomination is being made:  (i) the name and address of each such person, and of any holder of record of the Proponent's shares as they appear on the Corporation's books, (ii) the class and number of all shares of capital stock of the Corporation that are owned by each such person (beneficially and of record) and owned by any holder of record of each such person's shares, as of the date of the Proponent's notice, and a representation that the Proponent will notify the Corporation in writing of the class and number of such shares owned of record and beneficially by each such person as of the record date for the meeting not later than five business days following the later of the record date or the date notice of the record date is first publicly disclosed, (iii) a description of any agreement, arrangement or understanding with respect to s uch nomination between or among each such person and any of its affiliates or associates, and any others (including their names) acting in concert with any of the foregoing, and a representation that the Proponent will notify the Corporation in writing of any such agreement, arrangement or understanding in effect as of the record date for the meeting not later than five business days following the later of the record date or the date notice of the record date is first
 
 
10

 
 
publicly disclosed,  (iv)  a description of any agreement, arrangement or understanding (including any derivative instruments, swaps, warrants, short positions, profit interests, options, hedging transactions, borrowed or loaned shares or other transactions) that has been entered into as of the date of the Proponent's notice by, or on behalf of, each such person or any of its affiliates or associates, the effect or intent of which is to mitigate loss to, manage risk or benefit of share price changes for, or increase or decrease the voting power of each such person or any of its affiliates or associates with respect to shares of stock of the Corporation, and a representation that the Proponent will notify the Corporation in writing of any such agreement, arrangement or understanding in effect as of the r ecord date for the meeting not later than five business days following the later of the record date or the date notice of the record date is first publicly disclosed, (v) a representation that the Proponent is a holder of record or beneficial owner of shares of the Corporation entitled to vote at the meeting and intends to appear in person or by proxy at the meeting to nominate the person or persons specified in the notice, (vi) a representation whether the Proponent intends to deliver a proxy statement and/or form of proxy to holders of at least the percentage of the Corporation's outstanding capital stock required to elect the nominee and/or otherwise to solicit proxies from stockholders in support of the nomination, and (vii) any other information relating to each such person that would be required to be disclosed in a proxy statement or other filing required to be made in connection with the solicitation of proxies for election as directors pursuant to Section 14 of the Exchange Act, and the rules and re gulations promulgated thereunder.  Such notice must be accompanied by a written consent of each proposed nominee to being named as a nominee and to serve as a director if elected.  The Corporation may require any proposed nominee to furnish such other information as it may reasonably require to determine the eligibility of such proposed nominee to serve as an independent director of the Corporation or that could be material to a reasonable stockholder's understanding of the independence, or lack thereof, of such nominee.
 
14.  Compliance with Procedures.  If the Chair of the Election Meeting determines that a nomination of any candidate for election as a director was not made in accordance with the applicable provisions of these By-laws, such nomination shall be void.  Notwithstanding anything in these By-laws to the contrary, unless otherwise required by law, if a Proponent intending to make a nomination at an annual or special meeting pursuant to paragraph 13 of this Article II does not provide the information required under paragraph 13 to the Corporation (including providing the updated information required by clauses (b)(ii), (b)(iii) and (b)(iv) of paragraph 13 by the deadlines specified therein), or the Proponent (or a qualified representative of the Proponent) does not appear at the meeting to present the nomination, such nomination shall be disregarded, notwithstanding that proxies in respect of such nomination may have been received by the Corporation.
 
15.  Submission of Questionnaire; Representation and Agreement.  To be eligible to be a nominee for election or reelection as a director of the Corporation, a person must deliver (in accordance with the time periods prescribed for delivery of notice under paragraph 13 of this Article II of these By-laws) to the Secretary of the Corporation at the principal executive offices of the Corporation a written questionnaire with respect to the background and qualification of such person and the background of any other person or entity on whose behalf t he nomination is being made (which questionnaire shall be provided by the Secretary upon written request) and a written representation and agreement (in the form provided by the Secretary upon written request) that such person (i) is not and will not become a party to (A) any agreement,
 
 
11

 
 
arrangement or understanding with, and has not given any commitment or assurance to, any person or entity as to how such person, if elected as a director of the Corporation, will act or vote on any issue or question (a "Voting Commitment") that has not been disclosed to the Corporation or (B) any Voting Commitment that could limit or interfere with such person's ability to comply, if elected as a director of the Corporation, with such person's fiduciary duties under applicable law, (ii) is not and will not become a party to any agreement, arrangement or understanding with any person or entity other than the Corporation with respect to any direct or indirect compensation, reimbursement or indemnification in connection with service or action as a director that has not been disclosed therein, and (iii) in such person's individual capacity and on behalf of any person or entity on whose behalf the nominat ion is being made, would be in compliance, if elected as a director of the Corporation, and will comply with, applicable law and all applicable publicly disclosed corporate governance, conflict of interest, corporate opportunities, confidentiality and stock ownership and trading policies and guidelines of the Corporation.
 
Article III
 
Officers.
 
1.  Election; Term of Office; Appointments.  The Board of Directors, at its first meeting after each annual meeting, of stockholders, shall elect at least the following officers: a Chair of the Board and/or a President, one or more Vice Presidents, a Controller, a Treasurer and a Secretary.  The Board may also elect, appoint, or provide for the appointment of such other officers and agents as may from time to time appear necessary or advisable in the conduct of the affairs of the Corporation.  Such additional officers may include one or more Vice Chairmen, who shall not be Directors unless otherwise prescribed by the Board of Directors, and whose duties shall be to assist the Chief Executive Officer of the Corporation in establishing and implementing overall corporate policy. Officers of the Corporation shall hold office until their successors are chosen and qualify in their stead or until their earlier death, resignation or removal, and shall perform such duties as from time to time shall be prescribed by these By-laws and by the Board and, to the extent not so provided, as generally pertain to their respective offices.  The Board of Directors may fill any vacancy occurring in any office of the Corporation at any regular or special meeting.  Two or more offices may be held by the same person.
 
2.  Removal and Resignation.  Any officer elected or appointed by the Board of Directors or the Executive Committee may be removed at any time by the affirmative vote of a majority of the whole Board of Directors.  If the office of any officer elected or appointed by the Board becomes vacant for any reason, the vacancy may be filled by the Board.  Any officer may resign at any time upon written notice to the Corporation.
 
3.  Chair of the Board.  The Chair of the Board shall preside at all meetings of the stockholders and of the full Board of Directors.  He or she shall perform such other duties, and exercise such powers, as from time to time shall be prescribed by these By-laws or by the Board of Directors.
 
4.  President.  The President, in the absence of the Chair of the Board or the Vice Chair, if any, shall preside at meetings of the Directors.  He or she shall have such authority and
 
 
12

 
 
perform such duties in the management of the Corporation as from time to time shall be prescribed by the Board of Directors and, to the extent not so prescribed, he or she shall have such authority and perform such duties in the management of the Corporation, subject to the control of the Board, as generally pertain to the office of President.
 
5.  Vice Presidents.  Vice Presidents shall perform such duties as from time to time shall be prescribed by these By-laws, by the Chair of the Board, by the President or by the Board of Directors, and except as otherwise prescribed by the Board of Directors, they shall have such powers and duties as generally pertain to the office of Vice President.
 
6.  Secretary.  The Secretary or person appointed as secretary at all meetings of the Board and of the stockholders shall record all votes and the minutes of all proceedings in a book to be kept for that purpose, and he or she shall perform like duties for the Executive Committee when required.  He or she shall give, or cause to be given, notice of all meetings of the stockholders, and of the Board of Directors if required.  He or she shall perform such other duties as may be prescribed by these By-laws or as may be assigned to him or her by the Chair of the Board, the President or the Board of Directors, and, except as otherwise prescribed by the Board of Directors, he or she shall have such powers and duties as generally pertain to the office of Secretary.
 
7.  Treasurer.  The Treasurer shall have custody of the Corporation's funds and securities.  He or she shall perform such other duties as may be prescribed by these By-laws or as may be assigned to him or her by the Chair of the Board, the President or the Board of Directors, and, except as otherwise prescribed by the Board of Directors, he or she shall have such powers and duties as generally pertain to the office of Treasurer.
 
8.  Controller.  The Controller shall have charge of the Corporation's books of account, and shall be responsible for the maintenance of adequate records of all assets, liabilities and financial transactions of the Corporation.  The Controller shall prepare and render such balance sheets, profit and loss statements and other financial reports as the Board of Directors, the Chair of the Board or the President may require.  He or she shall perform such other duties as may be prescribed by these By-laws or as may be assigned to him or her by the Chair of the Board, the President or the Board of Directors, and, except as otherwise prescribed by the Board of Directors, he or she shall have such powers and duties as generally pertain to the office of Controller.
 
Article IV
 
Stock.
 
1.  Stock.  The shares of the Corporation shall be represented by certificates or shall be uncertificated. Each registered holder of shares, upon request to the Corporation, shall be provided with a certificate of stock representing the number of shares owned by such holder.  The certificates of stock of the Corporation shall be in the form or forms from time to time approved by the Board of Directors.  Such certificates shall be numbered and re gistered, shall exhibit the holder's name and the number of shares, and shall be signed in the name of the Corporation by the following officers of the Corporation: the Chair of the Board of Directors, or
 
 
13

 
 
the President or a Senior Vice President or Vice President; and by the Treasurer or an Assistant Treasurer, or the Secretary or an Assistant Secretary.  If any certificate is manually signed (1) by a transfer agent other than the Corporation or its employee, or (2) by a registrar other than the Corporation or its employee, any other signature on the certificate, including those of the aforesaid officers of the Corporation, may be a facsimile.  In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if he or she were such officer, transfer agent or registrar at the date of issue.
 
2.  Lost Certificates.  The Board of Directors or any officer of the Corporation to whom the Board of Directors has delegated authority may authorize any transfer agent of the Corporation to issue, and any registrar of the Corporation to register, at any time and from time to time unless otherwise directed, a new certificate or certificates of stock in the place of a certificate or certificates theretofore issued by the Corporation, alleged to have been lost or destroye d, upon receipt by the transfer agent of evidence of such loss or destruction, which may be the affidavit of the applicant; a bond indemnifying the Corporation and any transfer agent and registrar of the class of stock involved against claims that may be made against it or them on account of the lost or destroyed certificate or the issuance of a new certificate, of such kind and in such amount as the Board of Directors shall have authorized the transfer agent to accept generally or as the Board of Directors or an authorized officer shall approve in particular cases; and any other documents or instruments that the Board of Directors or an authorized officer may require from time to time to protect adequately the interest of the Corporation.  A new certificate may be issued without requiring any bond when, in the judgment of the directors, it is proper to do so.
 
3.  Transfers of Stock.  Transfers of stock shall be made upon the books of the Corporation:  (1) upon presentation of the certificates by the registered holder in person or by duly authorized attorney, or upon presentation of proper evidence of succession, assignment or authority to transfer the stock, and upon surrender of the appropriate certificate(s), or (2) in the case of uncertificated shares, upon receipt of proper transfer instructions from the registered owner of such uncertificated shares, or from a duly authorized attorney or from an individual presenting proper evidence of succession, assignment or authority to transfer the stock.
 
4.  Holder of Record.  The Corporation shall be entitled to treat the holder of record of any share or shares of stock as the holder in fact thereof and accordingly shall not be bound to recognize any equitable or other claim to or interest in such share on the part of any other person whether or not it shall have express or other notice thereof, save as expressly provided by the laws of the State of Delaware.
 
Article V
 
Indemnification and Severance.
 
1.  Right to Indemnification.  The Corporation shall indemnify and hold harmless, to the fullest extent permitted by applicable law as it presently exists or may hereafter be amended, any person who was or is made or is threatened to be made a party or is otherwise
 
 
14

 
 
involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative (a "proceeding") by reason of the fact that he or she, or a person for whom he or she is the legal representative, is or was a director, officer, employee or agent of the Corporation or is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust, nonprofit entity, or other enterprise, including service with respect to employee benefit plans, against all liability and loss suffered and expenses (including attorneys' fees) reasonably incurred by such person.  The Corporation shall be required to indemnify a person in connection with a proceeding (or part thereof) initiated by such person only if the proceeding (or part thereof) was authorized by the Board of Directors of the Corporation.
 
2.  Prepayment of Expenses.  The Corporation shall pay the expenses (including attorneys' fees) incurred by an officer or director of the Corporation in defending any proceeding in advance of its final disposition, provided, however, that the payment of such expenses shall be made only upon receipt of an undertaking by the director or officer to repay all amounts advanced if it shall ultimately be determined that the director or officer is not entitled to be indemnified .  Payment of such expenses incurred by other employees and agents of the Corporation may be made by the Board of Directors in its discretion upon such terms and conditions, if any, as it deems appropriate.
 
3.  Claims.  If a claim for indemnification or payment of expenses (including attorneys' fees) under this Article is not paid in full within sixty days after a written claim therefor has been received by the Corporation the claimant may file suit to recover the unpaid amount of such claim and, if successful in whole or in part, shall be entitled to be paid the expense of prosecuting such claim.  In any such action the Corporation shall have the burden of provi ng that the claimant was not entitled to the requested indemnification or payment of expenses under applicable law.
 
4.  Nonexclusivity of Rights.  The right conferred on any person by this Article V shall not be exclusive of any other rights which such person may have or hereafter acquire under any statute, provision of the Certificate of Incorporation, these By-laws, agreement, vote of stockholders or disinterested directors or otherwise.
 
5.  Other Indemnification.  The corporation's obligation, if any, to indemnify any person who was or is serving at its request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust, enterprise or non profit entity shall be reduced by any amount such person may collect as indemnification from such other corporation, partnership, joint venture, trust, non profit entity, or other enterprise.
 
6.  Amendment or Repeal.  Any repeal or modification of the foregoing provisions of this Article V shall not adversely affect any right or protection hereunder of any person in respect of any act or omission occurring prior to the time of such repeal or modification.
 
7.  Severance.  Any written agreement or any amendment of an existing written agreement that provides for payments to a director, officer or other employee of the Corporation or any subsidiary of the Corporation upon (i) a "change in control" of the Corporation or (ii) the termination or constructive termination of the employment of such director, officer, or other
 
 
15

 
 
employee following a "change in control" of the Corporation, must be approved by (a) the unanimous vote of the members of the committee of the Board of Directors which has the power to recommend changes in the compensation of the senior management of the Corporation, if any, and (b) a majority of the directors who are not employees of the Corporation or any subsidiary of the Corporation.  For the purposes hereof, a "change of control" of the Corporation shall mean through (i) the accumulation by a person or group of related persons of 20% or more of the Company's outstanding, capital stock and/or (ii) a change in the composition of a majority of the Corporation's Board of Directors without the approval of the incumbent Board.
 
Article VI
 
Miscellaneous.
 
1.  Delaware Office.  The address of the registered office of the Corporation in the State of Delaware shall be at Corporation Trust Center, 1209 Orange Street, Wilmington, County of New Castle, Delaware 19801 and the name of its registered agent at such address is Corporation Trust Company.
 
2.  Other Offices.  The Corporation may also have an office in the City and State of New York, and such other offices at such places as the Board of Directors from time to time may appoint or the business of the Corporation may require.
 
3.  Seal.  The corporate seal shall be in the form adopted by the Board of Directors.  Said seal may be used by causing it or a facsimile thereof to be impressed or affixed or reproduced or otherwise.  The seal may be affixed by any officer of the Corporation to any instrument executed by authority of the Corporation, and the seal when so affixed may be attested by the signature of any officer of the Corporation.
 
4.  Notice.  Whenever notice is required to be given by law, the Certificate of Incorporation or these By-laws, a written waiver signed by the person entitled to notice, whether before or after the time stated therein, shall be deemed equivalent to notice.  Attendance of a person at a meeting shall constitute a waiver of notice of such meeting except when the person attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting, is not lawfully called or convened.
 
5.  Amendments.  The Board of Directors shall have the power to adopt, amend or repeal the Bylaws of the Corporation by the affirmative action of a majority of its members.  The By-laws may be adopted, amended or repealed by the affirmative vote of a majority of the stock issued and outstanding and entitled to vote at any regular meeting of the stockholders or at any special meeting of the stockholders if notice of such proposed adoption, amendment or repeal b e contained in the notice of such special meeting.
 
6.  Form of Records.  Any records maintained by the Corporation in the regular course of its business, including its stock ledger, books of account, and minutes books, may be kept on, or be in the form of, punch cards, magnetic tape, photographs, microphotographs, or any other information storage device, provided that the records so kept can be converted into clearly
 
 
16

 
 
legible form within a reasonable time. The Corporation shall so convert any records so kept upon the request of any person entitled to inspect the same.
 
7.  Checks.  All checks, drafts, notes and other orders for the payment of money shall be signed by such officer or officers or agents as from time to time may be designated by the Board of Directors or by such officers of the Corporation as may be designated by the Board to make such designation.
 
8.  Fiscal Year.  The fiscal year shall begin the first day of January in each year.
 
 
 
17
EX-10.1 3 a6285704ex10_1.htm EXHIBIT 10.1 a6285704ex10_1.htm
EXHIBIT 10.1


PFIZER INC. NONFUNDED DEFERRED
COMPENSATION AND UNIT AWARD PLAN FOR
NON-EMPLOYEE DIRECTORS
(Effective June 23, 1994)
(Amended September 26, 1996)
(Further Amended Effective March 1, 2006)
(Further Amended Effective January 1, 2008)
(Further Amended Effective January 1, 2009)
(Further Amended Effective March 25, 2010)

1.           Deferral Election for Cash Compensation.  Each director who is not an employee of Pfizer Inc. (the “Company”) or any of its subsidiaries may elect on or before the last day of any calendar year to have payment of all or a specified part of all fees payable to him or her for services as a director during the following calendar year and thereafter deferred until he or she Separates from Service (as defined in Paragraph 8) with the Company.  Any such election shall be made by written notice directed to the Secretary of the Company. A director’s election to defer fees shall continue until a director Separates from Service unless he or she earlier terminates such election with respect to future fees by timely written notice delivered to the Secretary of the Company.  Any such notice shall become effective on the first day of the calendar year immediately following written notice directed to the Secretary of the Company.  Amounts credited to the account of a director prior to the effective date of such notice shall not be affected thereby and shall be paid to him or her in accordance with paragraph 5 (or paragraph 6 in the event of his or her death) below.

2.           Investment of Deferred Cash Compensation.  All deferred cash fees (“Deferred Cash Compensation”) shall be held in the general funds of the Company and shall be credited to the director’s account, and, at the director’s election, the account shall be credited either with a) interest at a rate equal to the rate of return for an intermediate treasury index as selected by the Plan Assets Committee, compounded monthly, or b) a number of units, calculated to the nearest thousandth of a unit, produced by dividing the amount of fees deferred by the closing market price of the Company’s common stock as reported on the Consolidated Tape of the New York Stock Exchange on the last business day of the fiscal quarter in which the fees are earned.  A director may elect to switch the investment form of deferral of previously deferred Deferred Cash Compensation effective on the first day of any calendar quarter by giving prior written notice directed to the Secretary of the Company; provided, however, that a switch into, or out of, the unit account shall be permitted only if the director has not elected to switch out of, or into, the unit account within this Plan, the Pfizer Company Stock Fund within the Pfizer Savings Plan or the unit account within the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan during the prior six months.  The Awarded Units, as described in paragraph 3, shall not be affected by any such election.

3.           Awards of Units.

(A)           An award consisting of 5,500 units shall be made to each director who is elected for the first time, and thereafter each year that he or she continues

 
 

 
 
as a director effective as of the date of the annual meeting of shareholders.   All such units shall be referred to as the “Awarded Units.” In the event of any change in the number or kind of outstanding shares of common stock of the Company, including a stock split or splits, or a stock dividend, an appropriate adjustment shall be made in the number of Awarded Units. The director’s account shall be credited with the number of Units so awarded and such Units shall remain credited until distribution as described in paragraph 5 below (or paragraph 6 in the case of the director’s death).
 
(B)           Notwithstanding anything in this Plan to the contrary, the following provisions shall apply if any director notifies the Company that he or she is subject to any policy or provision imposed by his or her employer that limits or restricts the amount and/or type of compensation that may be received by such director from the Company (any such policy or provision being referred to as a “Limitation”):

(i)            
If the Limitation restricts the amount of compensation that may be received by the director, the dollar value of the Awarded Units (based on the closing price of the Company’s common stock on the date of the annual meeting of shareholders) shall be reduced to comply with the Limitation; provided, however, that the director may elect, before the first day of any calendar year, in a manner that complies with section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), and regulations thereunder (“Section 409A”), to comply with the Limitation as to amount by reducing the cash compensation payable to such director for such year rather t han reducing the dollar value of the 5,500 units to be credited to the director’s account.

(ii)            
If the Limitation prohibits the director from receiving any compensation in the form of Awarded Units, the award specified in paragraph 3(A) (reduced as provided in subparagraph (i) above to comply with the Limitation as to amount), shall not be made.  Instead, the dollar value of such Awarded Units (based on the closing price of the Company’s common stock on the date of the annual meeting of shareholders) shall be credited to the director’s account.

(iii)           
Any dollar amounts credited to the director’s account in accordance with subparagraph (ii) above shall be credited with interest at a rate equal to the rate of return for an intermediate treasury index as selected by the Plan Assets Committee, compounded monthly.

(iv)           
If, as permitted by the proviso to subparagraph (i) above, the director elects to reduce his or her cash compensation, such reduced cash compensation will be payable on a quarterly basis.

(v)            
A director subject to the Limitation described in subparagraph (ii) above may not elect to switch the form of investment of any
 
 
2

 
 
        
amounts deferred pursuant to subparagraph (ii) above, and no dividends shall be declared with respect thereto, and any election under Section 4(C) is inapplicable to any such amounts.
 
(vi)           
The dollar value, if any, in excess of the amounts that the director is permitted to receive pursuant to the Limitation may be contributed to one or more charities selected by the Corporate Governance Committee of the Company’s Board of Directors, on the terms approved by such Committee, acting in its sole discretion; provided, that such Committee may consider the director’s recommendation as to the recipient or recipients of such contribution.
 
4.           Dividends.
 
(A)           Whenever a dividend is declared, the number of units in the director’s account (both with respect to Deferred Cash Compensation invested in the unit account and Awarded Units, and including any increase in units due to deferred dividends pursuant to this Paragraph 4(A)) shall be increased by the result of the following calculations: 1) the number of units in the director’s account multiplied by any cash dividend declared by the Company on a share of its common stock, divided by the closing market price of such common stock on the related dividend record date; and/or 2) the number of units in the director’s account multiplied by any stock dividend declared by the Company on a share of its common stock. In the event of any change in the number or kin d of outstanding shares of common stock of the Company including a stock split or splits, other than a stock dividend as provided above, an appropriate adjustment shall be made in the number of units credited to the director’s account.
 
(B)           Solely as to the Awarded Units granted, earned and vested prior to January 1, 2005 (within the meaning of Section 409A), a director may elect to receive directly in cash without deferral the value of any cash dividend, declared by the Company on a share of its common stock, in lieu of having his or her account credited as specified above in Paragraph 4(A). Any such election shall be made, and may also be terminated, by written notice directed to the Secretary of the Company prior to the calendar year of the payment of the dividend.
 
(C)           Solely as to the Awarded Units granted, earned or vested after December 31, 2004 (within the meaning of Section 409A), a director may elect to receive directly in cash without deferral the value of any cash dividend, declared by the Company on a share of its common stock, in lieu of having his or her account credited as specified above in Paragraph 4(A), if such election is made within 30 days of the director’s first becoming eligible to participate in this Plan or another account balance plan required to be aggregated with this Plan under Section 409A, provided that such election shall apply only with respect to dividends declared subsequent to the date of receipt of the election by the Compan y.  Otherwise such dividends on any such Awarded Units will be deferred to the director’s unit account as described above in Paragraph 4(A). Such election is permanent and may not be changed thereafter.  For individuals who were, are, or will be eligible directors at any time between December 31, 2004 and

 
3

 
 
December 31, 2008, and with respect to the cash dividends received on Awarded Units granted, earned or vested after December 31, 2004 (within the meaning of Section 409A) and granted, earned, and vested prior to December 31, 2008, such directors shall make their elections as to the receipt of such cash dividends prior to the year of payment of the applicable dividend and such elections shall not apply to the dividends payable on any Awarded Units previously granted in a year prior to such election.  The last such election shall apply to all future cash dividends made subsequent to December 31, 2008 with respect to Awarded Units granted, earned or vested after December 31, 2004 (within the meaning of Section 409A).  Such election is permanent and may not be changed thereafter.
 
5.           Distributions.

(A)           Deferred Cash Compensation and Awarded Units deferred prior to January 1, 2005.   With respect to Deferred Cash Compensation and Awarded Units granted, earned and vested prior to January 1, 2005 (within the meaning of Section 409A), and including related earnings thereon, at least one year before he or she ceases to be a director of the Company, a director may elect, or may modify an election that he or she had previously made, to receive payment (payable in either cash or shares of common stock at the election of the director) of his or her combined Deferred Cash Compensation and Awarded Units accounts in a lump sum or in annual installments from two to fifteen, and he or she may elect to have such lump sum payment or first annual installment made either (1) on the last business day of the month following termination, or (2) in January of the year following his or her termination as a director.  In the absence of an election, such payment will begin with the first month of the year following the director’s termination and will be made in five annual installments.

(B)           Deferred Cash Compensation and Awarded Units deferred after December 31, 2004.  With respect to Deferred Cash Compensation and Awarded Units granted, earned or vested after December 31, 2004 (within the meaning of Section 409A), and including related earnings thereon, within 30 days of first becoming eligible to participate in this Plan or another account balance plan required to be aggregated with this Plan under Section 409A, a director must elect the timing and form of his or her distribution (payable in either cash or shares of common stock at the election of the director) of his or her deferred compensation account (containing both Deferred Cash Compensation and Awarded Units and related earnings thereon); except that for individuals who were, are, or will be eligible directors prior to or as of December 31, 2008, such directors shall make their elections as to the form and timing of distribution on or before December 31, 2008 in accordance with the transition rule contained in IRS Notice 2007-86.  Such elections are permanent and may not be changed thereafter. The director must elect as to:
 
(i)            
Timing:
 
i.       
to receive the lump sum distribution or first annual installment on the last business day of the month following his or her Separation from Service; or
 
 
4

 
 
ii.      
to receive the lump sum distribution or first annual installment in the first month of the year following the director’s Separation from Service; and
 
(ii)           
Form:
 
i.       
to receive the distribution in a lump sum; or
ii.      
to receive the distribution in installments from two to fifteen.
 
(iii)           
In the absence of an election, such payments will begin with the first month of the year following the director’s Separation from Service and will be made in five annual installments.
 
(C)           (i)           With respect to all units in the director’s account (containing both Deferred Cash Compensation and Awarded Units and related earnings thereon), the amount payable to the director in each instance shall be determined by multiplying the number of units by the closing market price of the Company’s common stock on the day prior to the date for payment or the last business day prior to that date, if the day prior to the date for payment is not a business day.

(ii)           Where the director receives the balance of his or her account in annual installments, each installment shall be a fraction of the value of the balance of the deferred compensation credited to the director’s account either by way of interest or units calculated under Paragraph 2 hereof, as the case may be, on the date of such payment, the numerator of which is one (1) and the denominator of which is the total number of installments remaining to be paid at that time.

(D)           Notwithstanding the foregoing, with respect to Deferred Cash Compensation and Awarded Units granted, earned or vested after December 31, 2004 (within the meaning of Section 409A), and including related earnings thereon, distributions may not be made to a Key Employee (as defined in Paragraph 8) upon a Separation from Service before the date which is six months after the date of the Key Employee’s Separation from Service (or, if earlier, the date of death of the Key Employee).  Any payments that would otherwise be made during this period of delay shall be accumulated and paid on the first day of the seventh month following the director’s Separation from Service (or, if earlier, the first day of the month after the director’s death).

(E)           Notwithstanding the foregoing, with respect to Deferred Cash Compensation and Awarded Units granted, earned or vested after December 31, 2004 (within the meaning of Section 409A), and granted, earned and vested as of December 31, 2008, including related earnings thereon (the “2009 Distribution Amounts”), such 2009 Distribution Amounts shall be paid in a lump sum to the director on July 1, 2009, provided the director files an election to do so with the Company by December 31, 2008.  Such elections are permanent and may not be changed after December 31, 2008, and will have no subsequent effect after July 1, 2009.

 
5

 
 
6.           Death.
 
(A)           A director may designate one or more beneficiaries (which may be an entity other than a natural person) to receive any payments to be made upon the director’s death.  At any time, and from time to time, the identity of such beneficiary designation may be changed or canceled by the director without the consent of any beneficiary.  Any such beneficiary designation, change or cancellation must be by written notice filed with the Secretary of the Company and shall not be effective until received by the Secretary.  If a director designates more than one beneficiary, any payments to such beneficiaries shall be made in equal shares unless the director has designated otherwise.  If no beneficiary has been named by the director, or the designated beneficiaries have predeceased him or her, the director’s beneficiary shall be the executor or administrator of the director’s estate.
 
(B)           With respect to Deferred Cash Compensation and Awarded Units granted, earned and vested prior to January 1, 2005 (within the meaning of Section 409A), and including related earnings thereon, if a director should die before full payment of all amounts credited to his or her account, such amounts shall be paid to his or her designated beneficiary or beneficiaries or to his or her estate in a single sum payment to be made as soon as practicable after his or her death.
 
(C)           With respect to Deferred Cash Compensation and Awarded Units granted, earned or vested after December 31, 2004 (within the meaning of Section 409A), and including related earnings thereon, within 30 days of first becoming eligible to participate in this Plan or another account balance plan required to be aggregated with this Plan under Section 409A, a director may elect for his or her designated beneficiary or beneficiaries to receive the account in a lump sum payment or installments from two to fifteen, provided the elections (including the election hereunder) are made in accordance with paragraph 5(B).  For individuals who were, are, or will be eligible directors prior to or as of December 31, 2008, such directors shall make their election as to the form of distribution for their beneficiary or beneficiaries on or before December 31, 2008 in accordance with the transition rule contained in IRS Notice 2007-86. Such elections are permanent and may not be changed thereafter.

7.           The right of a director to any Deferred Cash Compensation or Awarded Units credited to his or her account and including related earnings thereon shall not be subject to assignment by him or her.  If a director does assign his or her right to any Deferred Cash Compensation or Awarded Units credited to his or her account, the Company may disregard such assignment and discharge its obligation hereunder by making payment as though no such assignment had been made.

8.           For purposes of this Plan:

(A)           “Key Employee” means an individual who is treated as a “specified employee” as of his Separation from Service under Code section 409A(a)(2)(B)(i), i.e., a key employee (as defined in Code section 416(i) without regard to paragraph (5) thereof) of the Company or its affiliates if the Company’s
 
 
6

 
 
stock is publicly traded on an established securities market or otherwise.  Key Employees shall be determined in accordance with Code section 409A using a January 1 identification date.  A listing of Key Employees as of an identification date shall be effective for the 12-month period following the identification date; and
 
(B)           “Separation from Service” or “Separate(s) from Service” means a “separation from service” within the meaning of Section 409A.
 

 
7
EX-12 4 a6285704ex12.htm EXHIBIT 12 a6285704ex12.htm
Exhibit 12

PFIZER INC. AND SUBSIDIARY COMPANIES
COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES

   
Three
Months
Ended
April 4,
   
Year Ended December 31,
 
(in millions, except ratios)
 
2010
   
2009
   
2008
   
2007
   
2006
   
2005
 
                                     
Determination of earnings:
                                   
Income from continuing operations
                                   
before provision for taxes on income,
noncontrolling interests and
cumulative effect of a change in
accounting principles
  $ 3,179     $ 10,827     $ 9,694     $ 9,278     $ 13,028     $ 10,800  
Less:
                                               
Noncontrolling interests
    9       9       23       42       12       12  
Income attributable to Pfizer Inc.
    3,170       10,818       9,671       9,236       13,016       10,788  
Add:
                                               
Fixed charges
    553       1,361       647       541       642       622  
Total earnings as defined
  $ 3,723     $ 12,179     $ 10,318     $ 9,777     $ 13,658     $ 11,410  
                                                 
Fixed charges:
                                               
Interest expense(a)
  $ 522     $ 1,233     $  516     $ 397     $ 488     $ 471  
Preferred stock dividend(b)
    1       7       8       11       14       14  
Rents(c)
    30       121       123       133       140       137  
Fixed charges
    553       1,361       647       541       642       622  
Capitalized interest
    9       34       46       43       29       17  
                                                 
Total fixed charges
  $ 562     $ 1,395     $  693     $ 584     $ 671     $ 639  
                                                 
Ratio of earnings to fixed charges
    6.6       8.7       14.9       16.7       20.4       17.9  

All financial information reflects the following as discontinued operations for 2006 and 2005: the Company’s former consumer healthcare business, and certain European generics business.

(a)
Interest expense includes amortization of debt premium, discount and expenses. Interest expense does not include interest related to uncertain tax positions of $92 million for the first three months of 2010; $337 million for 2009; $333 million for 2008; $331 million for 2007; $200 million for 2006; and $203 million for 2005.
(b)
Preferred stock dividends are from our Series A convertible perpetual preferred stock held by an Employee Stock Ownership Plan assumed in connection with our acquisition of Pharmacia in 2003.
(c)
Rents included in the computation consist of one-third of rental expense, which we believe to be a conservative estimate of an interest factor in our leases, which are not material.
 
 
EX-15 5 a6285704ex15.htm EXHIBIT 15 a6285704ex15.htm
Exhibit 15

ACCOUNTANTS’ ACKNOWLEDGEMENT

To the Shareholders and Board of Directors of Pfizer Inc.:

We hereby acknowledge our awareness of the use therein of our report dated May 13, 2010, included within the Quarterly Report on Form 10-Q of Pfizer Inc. for the quarter ended April 4, 2010, in the following Registration Statements:

- Form S-8 dated October 27, 1983 (File No. 2-87473),
- Form S-8 dated March 22, 1990 (File No. 33-34139),
- Form S-8 dated January 24, 1991 (File No. 33-38708),
- Form S-8 dated November 18, 1991 (File No. 33-44053),
- Form S-8 dated May 27, 1993 (File No. 33-49631),
- Form S-8 dated May 19, 1994 (File No. 33-53713),
- Form S-8 dated October 5, 1994 (File No. 33-55771),
- Form S-8 dated December 20, 1994 (File No. 33-56979),
- Form S-8 dated March 29, 1996 (File No. 33-02061),
- Form S-8 dated September 25, 1997 (File No. 333-36371),
- Form S-8 dated April 24, 1998 (File No. 333-50899),
- Form S-8 dated April 22, 1999 (File No. 333-76839),
- Form S-8 dated June 19, 2000 (File No. 333-90975),
- Form S-8 dated June 19, 2000 (File No. 333-39606),
- Form S-8 dated April 27, 2001 (File No. 333-59660),
- Form S-8 dated April 27, 2001 (File No. 333-59654),
- Form S-8 dated April 16, 2003 (File No. 333-104581),
- Form S-8 dated April 16, 2003 (File No. 333-104582),
- Form S-8 dated November 18, 2003 (File No. 333-110571),
- Form S-8 dated December 18, 2003 (File No. 333-111333),
- Form S-8 dated April 26, 2004 (File No. 333-114852),
- Form S-8 dated March 1, 2007 (File No. 333-140987),
- Form S-3 dated March 1, 2007 (File No. 333-140989),
- Form S-4 dated March 27, 2009 (File No. 333-158237),
- Form S-8 dated October 16, 2009 (File No. 333-162519),
- Form S-8 dated October 16, 2009 (File No. 333-162520),
- Form S-8 dated October 16, 2009 (File No. 333-162521) and
- Form S-8 dated March 1, 2010 (File No. 333-165121)

Pursuant to Rule 436 under the Securities Act of 1933 (the Act), such report is not considered a part of a registration statement prepared or certified by an independent registered public accounting firm, or a report prepared or certified by an independent registered public accounting firm within the meaning of Sections 7 and 11 of the Act.

KPMG LLP

New York, New York
May 13, 2010
 
 
EX-31.1 6 a6285704ex31-1.htm EXHIBIT 31.1 a6285704ex31-1.htm
Exhibit 31.1

CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Jeffrey B. Kindler, certify that:

1.
I have reviewed this report on Form 10-Q of Pfizer Inc.;
   
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
     
 
a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
 
b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
 
c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
 
d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
   
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
   
 
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
   
 
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
     
 
Date:  May 13, 2010
 
         
/s/ Jeffrey B. Kindler
   
 
 
Jeffrey B. Kindler
   
 
 
Chairman of the Board and Chief Executive Officer
   
 
 

 
EX-31.2 7 a6285704ex31-2.htm EXHIBIT 31.2 a6285704ex31-2.htm
Exhibit 31.2

CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Frank A. D’Amelio, certify that:

1.
I have reviewed this report on Form 10-Q of Pfizer Inc.;
   
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
     
 
a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
 
b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
 
c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
 
d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
   
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
   
 
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
   
 
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
     

Date:  May 13, 2010

         
/s/ Frank A. D’Amelio
   
 
 
Frank A. D’Amelio
   
 
 
Senior Vice President and Chief Financial Officer
   
 
 
 
 
EX-32.1 8 a6285704ex32-1.htm EXHIBIT 32.1 a6285704ex32-1.htm
Exhibit 32.1


Certification by the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002


Pursuant to 18 U.S.C. Section 1350, I, Jeffrey B. Kindler, hereby certify that, to the best of my knowledge, the Quarterly Report on Form 10-Q of Pfizer Inc. for the quarter ended April 4, 2010 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, and that the information contained in that Report fairly presents, in all material respects, the financial condition and results of operations of Pfizer Inc.


         
/s/ Jeffrey B. Kindler
   
 
 
Jeffrey B. Kindler
   
 
 
Chairman of the Board and Chief Executive Officer
   
 
 
May 13, 2010

This certification accompanies this Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.
 
 
EX-32.2 9 a6285704ex32-2.htm EXHIBIT 32.2 a6285704ex32-2.htm
Exhibit 32.2


Certification by the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002


Pursuant to 18 U.S.C. Section 1350, I, Frank A. D’Amelio, hereby certify that, to the best of my knowledge, the Quarterly Report on Form 10-Q of Pfizer Inc. for the quarter ended April 4, 2010 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, and that the information contained in that Report fairly presents, in all material respects, the financial condition and results of operations of Pfizer Inc.

         
/s/ Frank A. D’Amelio
   
 
 
Frank A. D’Amelio
   
 
 
Senior Vice President and Chief Financial Officer
   
 
 
May 13, 2010

This certification accompanies this Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.
 
 
EX-101.INS 10 pfe-20100404.xml XBRL INSTANCE DOCUMENT 0000078003 2010-04-04 0000078003 2009-12-31 0000078003 2010-01-01 2010-04-04 0000078003 2009-01-01 2009-03-29 0000078003 2008-12-31 0000078003 2009-03-29 0000078003 2010-05-10 0000078003 2009-06-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares 61000000 443000000 70497000000 -333000000 21632000000 40426000000 552000000 90014000000 432000000 90446000000 212949000000 5469000000 4370000000 1454000000 10107000000 2242000000 37225000000 43193000000 6392000000 3243000000 17839000000 9000000000 5611000000 122503000000 1978000000 23991000000 14645000000 1195000000 12403000000 496000000 61670000000 13122000000 22780000000 42376000000 68015000000 212949000000 10-Q false 2010-04-04 PFIZER INC 0000078003 --12-31 Yes No Yes Large Accelerated Filer 2122000000 1247000000 8066133809 16750000000 4306000000 4436000000 2226000000 1409000000 74000000 706000000 414000000 3179000000 1146000000 2033000000 2000000 2035000000 9000000 2026000000 0.25 10867000000 1408000000 2876000000 1705000000 578000000 554000000 -57000000 3803000000 1074000000 2729000000 1000000 2730000000 1000000 2729000000 0.41 0 0.25 0.25 0 0.25 8061000000 8101000000 0.18 0 0.41 0.40 0 0.40 6723000000 6753000000 0.32 1759000000 15503000000 13611000000 919000000 10132000000 490000000 49916000000 12081000000 21651000000 42648000000 64480000000 195113000000 7769000000 3028000000 765000000 2060000000 25924000000 6119000000 3239000000 17460000000 8338000000 5670000000 105031000000 443000000 70456000000 -89000000 21697000000 42429000000 -1941000000 89659000000 423000000 90082000000 195113000000 2051000000 138000000 840000000 319000000 11817000000 -6360000000 305000000 2178000000 858000000 1127000000 -220000000 9394000000 1008000000 71000000 533000000 -296000000 899000000 3147000000 253000000 17724000000 3442000000 889000000 -185000000 -13634000000 1892000000 3663000000 9000000 1441000000 8000000 -3211000000 -42000000 10774000000 12100000000 13392000000 303000000 2133000000 5000000 9635000000 -23000000 -875000000 -219000000 10547000000 792000000 454000000 84000000 102000000000 2010 Q1 7502000000 4337000000 12301000000 38281000000 58000000 6962000000 4986000000 13583000000 6711000000 11388000000 1000000 <div class="BWxbrlnote2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <div> <div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><a style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline" id="xbrlnote2" name="xbrlnote2">Note 2. Adoption of New Accounting Policies</a></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">&#160;</div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">The provisions of the following new accounting standards were adopted as of January 1, 2010 and did not have a significant impact on our consolidated financial statements:</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 9pt; TEXT-ALIGN: left" width="1%" valign="top"> <div style="DISPLAY: inline; FONT-FAMILY: symbol, serif; FONT-SIZE: 10pt; FONT-WEIGHT: normal; TEXT-ALIGN: left">&#183;</div></td> <td width="99%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">An amendment to the recognition and measurement guidance for the transfers of financial assets.</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 9pt; TEXT-ALIGN: left" width="1%" valign="top"> <div style="DISPLAY: inline; FONT-FAMILY: symbol; FONT-SIZE: 10pt; FONT-WEIGHT: normal; TEXT-ALIGN: left">&#183;</div></td> <td width="99%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">An amendment to the guidelines for determining the primary beneficiary in a variable interest entity.</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div></div></div></div></div> <div class="BWxbrlnote9"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <div> <div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><a style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline" id="xbrlnote9" name="xbrlnote9">Note 9. Pension and Postretirement Benefit Plans</a></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">The components of net periodic benefit costs of the U.S. and international pension plans and the postretirement plans, which provide medical and life insurance benefits to retirees and their eligible dependents, follow:</div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="28%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid" width="52%" valign="bottom" colspan="22"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">Pension Plans</div></td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="16%" valign="bottom" colspan="6">&#160;</td> <td style="BORDER-TOP: medium none; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="28%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid" width="16%" valign="bottom" colspan="6"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">U.S.</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">Qualified</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid" width="16%" valign="bottom" colspan="6"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">U.S.</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">Supplemental</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">(Non-Qualified)</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid" width="16%" valign="bottom" colspan="6"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: center">International</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid" width="16%" valign="bottom" colspan="6"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">Postretirement</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">Plans</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 2px solid" width="28%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-VARIANT: small-caps; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">(millions of dollars)</div></td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="1%" valign="bottom">&#160;</td> <td style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="7%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">April 4,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2010</div></td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="7%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Mar. 29,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2009</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" width="1%" valign="bottom">&#160;</td> <td style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="7%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">April 4,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2010</div></td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="7%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Mar. 29,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2009</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" width="1%" valign="bottom">&#160;</td> <td style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="7%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">April 4,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2010</div></td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="1%" valign="bottom">&#160;</td> <td style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="7%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Mar. 29,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2009</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" width="1%" valign="bottom">&#160;</td> <td style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="7%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">April 4,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2010</div></td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="7%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Mar. 29,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2009</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="28%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-DECORATION: underline; TEXT-INDENT: 0pt; text-align: left">Three Months Ended:</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="7%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="7%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="7%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="7%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="7%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="7%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="7%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="7%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="28%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Service cost</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">94</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">59</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">8</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">5</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">60</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">45</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">22</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">8</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="28%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Interest cost</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">191</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">119</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">19</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">13</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">111</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">78</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">54</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">30</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="28%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Expected return on plan assets</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">(202</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">(118</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">(112</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">(86</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">(8</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">(6</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td></tr> <tr> <td align="left" width="28%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Amortization of:</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="28%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Actuarial losses</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">38</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">57</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">7</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">8</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">17</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">6</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">4</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="28%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Prior service costs/(credits)</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">1</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">(1</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">(1</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">(1</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">(1</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">(4</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">(1</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td></tr> <tr> <td align="left" width="28%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left">Curtailments and settlements--net</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">(33</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">24</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">(1</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">7</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">1</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">2</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">5</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="28%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Special termination benefits</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">14</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">13</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">90</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">1</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">1</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">6</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">12</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 4px double" width="28%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Net periodic benefit costs</div></td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">102</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">155</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">122</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">32</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">77</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">45</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">70</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">52</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">The decrease in net periodic benefit costs in the first three months of 2010 compared to the first three months of 2009 for our U.S. qualified plans was primarily driven by curtailment gains and lower settlement charges associated with Wyeth-related restructuring initiatives.&#160;&#160;The acquisition of Wyeth contributed to the increase in certain components of net periodic benefit costs, such as service cost and interest cost, offset by related expected return on plan assets.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">The increase in net periodic benefit costs in the first three months of 2010, compared to the first three months of 2009 for our U.S. supplemental (non-qualified) pension plans was primarily driven by special termination benefits recognized for certain executives as part of Wyeth-related restructuring initiatives.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">For the first quarter of 2010, we contributed from our general assets $87 million to our international pension plans, $61 million to our U.S. supplemental (non-qualified) pension plans and $60 million to our postretirement plans. Contributions to our U.S. qualified pension plans in the first quarter of 2010 were not significant.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">During 2010, we expect to contribute from our general assets, a total of $439 million to our international pension plans, $257 million to our postretirement plans, $205 million to our U.S. supplemental (non-qualified) pension plans and $7 million to our U.S. qualified pension plans. Contributions expected to be made for 2010 are inclusive of amounts contributed during the first quarter of 2010. The international pension plan, postretirement plan and U.S. supplemental (non-qualified) pension plan contributions from our general assets include direct employer benefit payments.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div></div></div></div></div> <div class="BWxbrlnote8"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <div> <div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><a style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline" id="xbrlnote8" name="xbrlnote8">Note 8. Goodwill and Other Intangible Assets</a></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-DECORATION: underline; TEXT-INDENT: 0pt">A. Goodwill</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt">The changes in the carrying amount of goodwill for the three months ended April 4, 2010, follow:</div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr> <td align="left" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid" width="44%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-VARIANT: small-caps; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">(millions of dollars)</div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="12%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Biopharmaceutical</div></td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="12%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Diversified</div></td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="12%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Other</div></td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="12%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Total</div></td> <td style="BORDER-TOP: medium none; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="44%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="12%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="12%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="12%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="12%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="44%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Balance, December 31, 2009<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="11%" valign="bottom">22,165</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="11%" valign="bottom">173</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="11%" valign="bottom">20,038</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="11%" valign="bottom">42,376</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="44%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Additions</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="11%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="11%" valign="bottom">18</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="11%" valign="bottom">985</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left; VERTICAL-ALIGN: text-top; font-size: 70%" width="1%" valign="bottom">&#160;(b)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="11%" valign="bottom">1,003</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="44%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Other<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(c)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="11%" valign="bottom">(570</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="11%" valign="bottom">(3</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="11%" valign="bottom">(158</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="11%" valign="bottom">(731</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">)</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 4px double" width="44%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Balance, April 4, 2010</div></td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="11%" valign="bottom">21,595</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="11%" valign="bottom">188</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="11%" valign="bottom">20,865</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="11%" valign="bottom">42,648</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(a)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;The <font style="DISPLAY: inline; FONT-STYLE: italic">Other</font> goodwill relates to our acquisition of Wyeth and is subject to change until we complete the recording of the assets acquired and liabilities assumed from Wyeth (see <font style="DISPLAY: inline; FONT-STYLE: italic">Note 3. Acquisition of Wyeth</font>). The allocation of Wyeth goodwill among the Biopharmaceutical and Diversified segments has not yet been completed, but will be completed within one year of the acquisition date.</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 14.4pt" width="2%"> <div style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(b)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Reflects the impact of measurement period adjustments (see <font style="DISPLAY: inline; FONT-STYLE: italic">Note 3. Acquisition of Wyeth</font>).</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 14.4pt" width="2%"> <div style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(c)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Primarily reflects the impact of foreign exchange.</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-DECORATION: underline; TEXT-INDENT: 0pt">B. Other Intangible Assets</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt">The components of identifiable intangible assets, primarily included in our Biopharmaceutical segment, follow:</div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="10"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">April 4, 2010</div></td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="10"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">December 31, 2009</div></td> <td style="BORDER-TOP: medium none; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 2px solid" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-VARIANT: small-caps; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">(millions of dollars)</div></td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Gross</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Carrying</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Amount</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Accumulated</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Amortization</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Identifiable</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Intangible</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Assets, less</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Accumulated</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Amortization</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Gross</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Carrying</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Amount</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Accumulated</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Amortization</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Identifiable</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Intangible</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Assets, less Accumulated</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Amortization</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom">&#160;</td></tr> <tr> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td></tr> <tr> <td align="left" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left">Finite-lived intangible assets:</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="22%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left">Developed technology rights</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">68,416</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(22,417</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">45,999</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">68,870</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(21,223</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">47,647</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="22%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Brands</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,627</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(563</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,064</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,637</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(535</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,102</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="22%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">License agreements</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">620</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(148</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">472</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">622</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(119</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">503</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="22%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Trademarks</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">107</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(69</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">38</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">113</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(73</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">40</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="22%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Other</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">425</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(228</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">197</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">488</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(231</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">257</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="22%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left">Total amortized finite-lived</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="22%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> &#160; intangible assets</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">71,195</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(23,425</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">47,770</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">71,730</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(22,181</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">49,549</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="22%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left">Indefinite-lived intangible assets:</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="22%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Brands</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">12,462</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">12,462</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">12,562</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">12,562</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="22%" valign="bottom"> <div style="DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">In-process research and</font> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">development <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">4,178</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">4,178</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">5,834</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">5,834</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="22%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Trademarks</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">70</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">70</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">70</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">70</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="22%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -18pt; text-align: left"><font>&#160;</font> Total indefinite-lived</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="22%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> intangible assets</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">16,710</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">16,710</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">18,466</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">18,466</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 4px double" width="22%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -18pt; text-align: left">Total identifiable intangible assets<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(b)</font></div></td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">87,905</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(23,425</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">64,480</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">90,196</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(22,181</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">68,015</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(a)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Decrease is primarily related to the impact of measurement period adjustments (see <font style="DISPLAY: inline; FONT-STYLE: italic">Note 3. Acquisition of Wyeth</font>).</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(b)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Decrease is primarily related to amortization of finite-lived intangible assets, the impact of measurement period adjustments (see <font style="DISPLAY: inline; FONT-STYLE: italic">Note 3. Acquisition of Wyeth</font>) and the impact of foreign exchange.</div></td></tr></table></div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">&#160;</div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">&#160;</div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Amortization expense related to acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in <font style="DISPLAY: inline; FONT-STYLE: italic">Amortization of intangible assets</font> as it benefits multiple business functions. Amortization expense related to acquired intangible assets that are associated with a single function is included in <font style="DISPLAY: inline; FONT-STYLE: italic">Cost of sales, Selling, informational and administrative expenses</font> and <font style="DISPLAY: inline; FONT-STYLE: italic">Research and development expenses</font>, as appropriate. Total amortization expense for finite-lived intangible assets was $1.4 billion for the first quarter of 2010, and $610 million for the first quarter of 2009.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div></div></div></div></div> <div class="BWxbrlnote10"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <div> <div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><a style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline" id="xbrlnote10" name="xbrlnote10">Note 10. Earnings Per Share Attributable to Common Shareholders</a></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Basic and diluted earnings per share (EPS) were computed using the following data:</div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="74%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid" width="24%" valign="bottom" colspan="6"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">Three Months Ended</div></td> <td style="BORDER-TOP: medium none; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 2px solid" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-VARIANT: small-caps; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">(millions)</div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="11%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">April 4,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2010</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="11%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Mar. 29,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2009</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="74%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">EPS Numerator--Basic:</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Income from continuing operations attributable to Pfizer Inc.</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,024</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,728</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Less: Preferred stock dividends--net of tax</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -18pt; text-align: left"><font>&#160;</font> Income from continuing operations attributable to Pfizer Inc. common shareholders</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,023</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,728</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Discontinued operations--net of tax</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 4px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Net income attributable to Pfizer Inc. common shareholders</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,025</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,729</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="74%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">EPS Denominator--Basic:</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 4px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Weighted-average number of common shares outstanding</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">8,061</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">6,723</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="74%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">EPS Numerator--Diluted:</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -18pt; text-align: left"><font>&#160;</font> Income from continuing operations attributable to Pfizer Inc. common shareholders</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,024</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,728</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Discontinued operations--net of tax</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 4px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Net income attributable to Pfizer Inc. common shareholders</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,026</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,729</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="74%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">EPS Denominator--Diluted:</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Weighted-average number of common shares outstanding</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">8,061</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">6,723</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -18pt; text-align: left"><font>&#160;</font> Common-share equivalents: stock options, stock issuable under employee compensation</div> <div style="DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -18pt; text-align: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160; plans&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">and convertible preferred stock</font></div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">40</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">30</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 4px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -18pt; text-align: left"><font>&#160;</font> Weighted-average number of common shares outstanding and common-share equivalents</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">8,101</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">6,753</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="74%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 4px double" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -18pt; text-align: left"><font>&#160;</font> Stock options that had exercise prices greater than the average market price of our common</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -18pt; text-align: left">&#160;&#160;&#160;&#160;&#160;&#160;&#160; stock issuable under employee compensation plans<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">366</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">475</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(a)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;These common stock equivalents were outstanding during the first quarters of 2010 and 2009, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div></div></div></div></div> <div class="BWxbrlnote4"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <div> <div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><a style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline" id="xbrlnote4" name="xbrlnote4">Note 4. Cost-Reduction Initiatives and Acquisition-Related Costs</a></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">We have incurred significant costs in connection with our cost-reduction initiatives (several programs initiated since 2005) and our acquisition of Wyeth on October 15, 2009.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Since the acquisition of Wyeth, our cost-reduction initiatives that were announced on January 26, 2009, but not completed as of December 31, 2009, have been incorporated into a comprehensive plan to integrate Wyeth's operations, generate cost savings and capture synergies across the combined company. We are focusing our efforts on achieving an appropriate cost structure for the combined company.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-INDENT: 0pt">We incurred the following costs in connection with all of our cost-reduction initiatives and the acquisition of Wyeth:</div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="6"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">Three Months Ended</div></td> <td style="BORDER-TOP: medium none; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 2px solid" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-VARIANT: small-caps; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">(millions of dollars)</div></td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">April 4,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2010</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Mar. 29,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2009</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom">&#160;</td></tr> <tr> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Transaction costs<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">9</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">369</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Integration costs<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(b)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">208</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">28</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Restructuring charges<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(c)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">489</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">157</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-STYLE: italic; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Restructuring charges and certain acquisition-related costs</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">706</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">554</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Additional depreciation--asset restructuring<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(d)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">93</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">90</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Implementation costs<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(e)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">84</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 4px double" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Total</div></td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">799</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">728</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 18pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(a)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Transaction costs represent external costs directly related to effecting the acquisition of Wyeth and primarily include expenditures for banking, legal, accounting and other similar services. Substantially all of the costs incurred in the first quarter of 2009 were fees related to a $22.5 billion bridge term loan credit agreement entered into with certain financial institutions on March 12, 2009 to partially fund our acquisition of Wyeth. The bridge term loan credit agreement was terminated in June 2009 as a result of our issuance of approximately $24.0 billion of senior unsecured notes in the first half of 2009.</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 18pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(b)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Integration costs represent external, incremental costs directly related to integrating Wyeth and primarily include expenditures for consulting and systems integration.</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt; TEXT-ALIGN: left" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt">(c)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Restructuring charges include the following:</div></td></tr></table></div> <div style="text-align: right"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="98%" cellpadding="0"> <tr> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="35%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid" width="37%" valign="bottom" colspan="10"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">Costs Incurred</div></td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="BORDER-TOP: medium none; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="35%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid" width="24%" valign="bottom" colspan="6"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">Three Months Ended</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid" width="11%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">Activity</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="right" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" width="11%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center; TEXT-INDENT: 0pt">Accrual</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 2px solid" width="35%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-VARIANT: small-caps; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">(millions of dollars)</div></td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="1%" valign="bottom">&#160;</td> <td style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="11%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">April 4,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2010</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" width="1%" valign="bottom">&#160;</td> <td style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="11%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Mar. 29,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2009</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2005-2010</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" width="1%" valign="bottom">&#160;</td> <td style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="11%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Through</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">April 4,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2010<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(1)</font></div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" width="1%" valign="bottom">&#160;</td> <td style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="11%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">As of</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">April 4,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2010<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(2)</font></div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="35%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="35%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Employee termination costs</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">458</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">135</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">8,179</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">5,276</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,903</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="35%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Asset impairments</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">6</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">18</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,458</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,458</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="35%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Other</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">25</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">4</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">735</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">631</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">104</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 4px double" width="35%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Total restructuring charges</div></td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">489</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">157</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">10,372</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">7,365</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">3,007</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr></table></div> <div style="DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt; text-align: right"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="98%" cellpadding="0"> <tr valign="top"> <td align="right" style="WIDTH: 9pt" width="2%"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt">(1)&#160;</div></td> <td align="left" width="98%"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt">Includes adjustments for foreign currency translation.</div></td></tr></table></div> <div style="DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt; text-align: right"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="98%" cellpadding="0"> <tr valign="top"> <td align="right" style="WIDTH: 9pt" width="2%"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt">(2)&#160;</div></td> <td align="left" width="98%"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Included in</font> <font style="DISPLAY: inline; FONT-STYLE: italic">Current</font> <font style="DISPLAY: inline; FONT-STYLE: italic">deferred tax liabilities and other current liabilities</font> ($2.0 billion) and <font style="DISPLAY: inline; FONT-STYLE: italic">Other noncurrent liabilities</font><font>&#160;</font>($1.0 billion).</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">In the first quarter of 2010, the restructuring charges are related to the integration of Wyeth.&#160;&#160;From the beginning of our cost-reduction initiatives in 2005 through April 4, 2010, <font style="DISPLAY: inline; FONT-STYLE: italic">Employee termination costs</font> represent the expected reduction of the workforce by approximately 45,400 employees, mainly in manufacturing, sales and research, of which approximately 28,100 employees have been terminated as of April 4, 2010. <font style="DISPLAY: inline; FONT-STYLE: italic">Employee termination costs</font> are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination. <font style="DISPLAY: inline; FONT-STYLE: italic"> Asset impairments</font> primarily include charges to write down property, plant and equipment to fair value. <font style="DISPLAY: inline; FONT-STYLE: italic">Other</font> primarily includes costs to exit certain assets and activities.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 18pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(d)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Additional depreciation - asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions and are included in our condensed consolidated statements of income as follows:</div></td></tr></table></div> <div style="text-align: right"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="98%" cellpadding="0"> <tr> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="74%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid" width="24%" valign="bottom" colspan="6"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">Three Months Ended</div></td> <td style="BORDER-TOP: medium none; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 2px solid" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-VARIANT: small-caps; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">(millions of dollars)</div></td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="11%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">April 4,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2010</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="11%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Mar. 29,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2009</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="74%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-STYLE: italic; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Cost of sales</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">13</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">63</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-STYLE: italic; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Selling, informational and administrative expenses</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">60</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">6</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-STYLE: italic; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Research and development expenses</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">20</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">21</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 4px double" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Total</div></td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">93</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">90</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr></table></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">&#160;</div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 18pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(e)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Implementation costs in the first quarter of 2009 represent external, incremental costs directly related to implementing cost-reduction initiatives prior to our acquisition of Wyeth, and primarily include expenditures related to system and process standardization and the expansion of shared services. For the three months ended March 29, 2009, implementation costs are included in <font style="DISPLAY: inline; FONT-STYLE: italic">Cost of sales</font> ($13 million), <font style="DISPLAY: inline; FONT-STYLE: italic">Selling, informational and administrative expenses</font> ($40 million), <font style="DISPLAY: inline; FONT-STYLE: italic">Research and development expenses</font> ($20 million) and <font style="DISPLAY: inline; FONT-STYLE: italic">Other (income)/deductions</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">--</font><font style= "DISPLAY: inline; FONT-STYLE: italic">net</font> ($11 million).</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div></div></div></div></div> <div class="BWxbrlnote7"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <div> <div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><a style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline" id="xbrlnote7" name="xbrlnote7">Note 7. Inventories</a></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">The components of inventories follow:</div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr> <td align="left" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-VARIANT: small-caps; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">&#160;(millions of dollars)</div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">April 4,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2010</div></td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td align="left" style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Dec. 31,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2009</div></td> <td style="BORDER-TOP: medium none; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom">&#160;</td></tr> <tr> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Finished goods</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">4,535</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">5,249</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Work-in-process</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">4,233</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">5,776</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Raw materials and supplies</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,364</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,378</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 4px double" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Total inventories<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">10,132</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">12,403</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 9pt" width="2%"> <div style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(a)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;The decrease in total inventories is primarily due to the inventory sold during the first quarter of 2010 that was acquired from Wyeth and had been recorded at fair value, as well as operational reductions and the impact of foreign exchange. Certain amounts of inventories are in excess of one year's supply.&#160;&#160;These excess amounts are primarily attributable to biologics inventory acquired from Wyeth and recorded at fair value and the quantities are generally consistent with the normal operating cycle of such inventory. There are no recoverability issues associated with these quantities.</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div></div></div></div></div> <div class="BWxbrlnote12"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <div> <div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><a style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline" id="xbrlnote12" name="xbrlnote12">Note 12. Taxes on Income</a></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Our effective tax rate for continuing operations was 36.0% for the first quarter of 2010, compared to 28.2% for the first quarter of 2009. The higher tax rate for the first quarter of 2010 is primarily the result of:</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr valign="top"> <td align="right" style="WIDTH: 9pt" width="1%"> <div style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;&#160;&#160;</div></td> <td width="99%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">higher amortization charges, primarily related to intangible assets acquired in connection with the acquisition of Wyeth, and the mix of jurisdictions in which those charges were incurred;</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr valign="top"> <td align="right" style="WIDTH: 9pt" width="1%"> <div style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;&#160;&#160;</div></td> <td style="TEXT-ALIGN: left" width="99%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt">the write-off of the deferred tax asset of approximately $270 million related to the Medicare Part D subsidy for retiree prescription drug coverage, resulting from changes in the U.S. healthcare legislation enacted in March 2010 concerning the tax treatment of that subsidy effective for tax years beginning after December 31, 2012;</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr valign="top"> <td align="right" style="WIDTH: 9pt" width="1%"> <div style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;&#160;&#160;</div></td> <td width="99%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">the expiration of the U.S. research tax credit; and</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr valign="top"> <td align="right" style="WIDTH: 9pt" width="1%"> <div style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;&#160;&#160;</div></td> <td width="99%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">the increase in non-deductible in-process research and development charges.</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt">These factors were partially offset by $410 million in tax benefits for the resolution of certain tax positions pertaining to prior years with various foreign tax authorities.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div></div></div></div></div> <div class="BWxbrlnote1"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <div> <div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><a style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline" id="xbrlnote1" name="xbrlnote1">Note 1. Basis of Presentation</a></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">We prepared the condensed consolidated financial statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (U.S. GAAP) can be condensed or omitted. Balance sheet amounts and operating results for subsidiaries operating outside the U.S. are as of and for the three-month periods ended February 28, 2010, and February 22, 2009.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">On October 15, 2009, we completed our acquisition of Wyeth and, commencing from the acquisition date, our financial statements include the assets, liabilities, operating results and cash flows of Wyeth. As a result, legacy Wyeth operations are reflected in our results of operations and cash flows for the first quarter of 2010, but not for the first quarter of 2009.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">We are responsible for the unaudited financial statements included in this document.&#160;&#160;The financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our financial position and operating results.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended</font> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">December 31, 2009.</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div></div></div></div></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline"><a name="xbrlnote3">Note 3. Acquisition of Wyeth</a></font></font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On October 15, 2009 (the acquisition date), we acquired all of the outstanding equity of Wyeth in a cash-and-stock transaction, valued at the acquisition date at approximately $68 billion. While Wyeth now is a wholly-owned subsidiary of Pfizer, the merger of local Pfizer and Wyeth entities may be pending or delayed in various international jurisdictions and integration in these jurisdictions is subject to completion of various local legal and regulatory obligations.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Recording of Assets Acquired and Liabilities Assumed</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table summarizes the provisional amounts recognized for assets acquired and liabilities assumed as of the acquisition date as well as adjustments made in the first quarter of 2010 to the amounts initially recorded in 2009 (measurement period adjustments). The measurement period adjustments did not have a significant impact on our consolidated statements of income, balance sheets or cash flows in any period and, therefore, we have not retrospectively adjusted our financial statements. Certain estimated values are not yet finalized (see below) and are subject to change, which could be significant. We will finalize the amounts recognized as we obtain the information necessary to complete the analyses, but no later than one year from the acquisition date.</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div align="left"> <table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td align="left" valign="bottom" width="50%" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid"> <div align="left" style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">(millions of dollars)</font></div></td> <td align="right" valign="bottom" width="1%" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td colspan="2" valign="bottom" width="16%" style="BORDER-TOP: black 1.5pt solid; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Amounts Recognized</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">as of Acquisition Date</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(as previously reported)</font></div></td> <td valign="bottom" nowrap="nowrap" width="1%" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td align="right" valign="bottom" width="1%" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td colspan="2" valign="bottom" width="14%" style="BORDER-TOP: black 1.5pt solid; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Measurement </font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Period </font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Adjustments</font></div></td> <td valign="bottom" nowrap="nowrap" width="1%" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td align="right" valign="bottom" width="1%" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td colspan="2" valign="bottom" width="14%" style="BORDER-TOP: black 1.5pt solid; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Amounts Recognized</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">as of Acquisition Date</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(as adjusted)</font></div></td> <td valign="bottom" nowrap="nowrap" width="1%" style="BORDER-TOP: medium none; PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td></tr> <tr> <td valign="bottom" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td colspan="2" valign="bottom" width="16%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td colspan="2" valign="bottom" width="14%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td colspan="2" valign="bottom" width="14%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td></tr> <tr> <td align="left" valign="bottom" width="50%"> <div align="left" style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Working capital, excluding inventories</font></div></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td> <td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">16,342</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8211;&#8211;</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">16,342</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td></tr> <tr> <td align="left" valign="bottom" width="50%"> <div align="left" style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Inventories</font></div></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,388</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(167</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,221</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td></tr> <tr> <td align="left" valign="bottom" width="50%"> <div align="left" style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Property, plant and equipment</font></div></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10,054</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(171</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9,883</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td></tr> <tr> <td align="left" valign="bottom" width="50%"> <div align="left" style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Identifiable intangible assets, excluding</font></div> <div align="left" style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font id="TAB1a" style="MARGIN-LEFT: 9pt"/>in-process research and development <font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></font></font></div></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">37,595</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(452</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">37,143</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td></tr> <tr> <td align="left" valign="bottom" width="50%"> <div align="left" style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">In-process research and development <font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></font></font></div></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">14,918</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(956</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">13,962</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td></tr> <tr> <td align="left" valign="bottom" width="50%"> <div align="left" style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Other noncurrent assets</font></div></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,394</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8211;&#8211;</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,394</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td></tr> <tr> <td align="left" valign="bottom" width="50%"> <div align="left" style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Long-term debt</font></div></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(11,187</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8211;&#8211;</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(11,187</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td></tr> <tr> <td align="left" valign="bottom" width="50%"> <div align="left" style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Benefit obligations</font></div></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(3,211</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8211;&#8211;</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(3,211</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td></tr> <tr> <td align="left" valign="bottom" width="50%"> <div align="left" style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net tax accounts</font></div></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(24,773</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">761</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(24,012</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td></tr> <tr> <td align="left" valign="bottom" width="50%" style="PADDING-BOTTOM: 2px"> <div align="left" style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Other noncurrent liabilities</font></div></td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,908</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8211;&#8211;</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,908</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td></tr> <tr> <td align="left" valign="bottom" width="50%"> <div align="left" style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total identifiable net assets</font></div></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">48,612</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(985</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">47,627</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td></tr> <tr> <td align="left" valign="bottom" width="50%" style="PADDING-BOTTOM: 2px"> <div align="left" style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Goodwill</font></div></td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">19,954</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">985</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">20,939</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td></tr> <tr> <td align="left" valign="bottom" width="50%"> <div align="left" style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net assets acquired</font></div></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">68,566</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8211;&#8211;</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">68,566</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td></tr> <tr> <td align="left" valign="bottom" width="50%" style="PADDING-BOTTOM: 2px"> <div align="left" style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Less: Amounts attributable to</font></div> <div align="left" style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font id="TAB1b" style="MARGIN-LEFT: 10pt"/>noncontrolling interests</font></div></td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(330</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8211;&#8211;</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(330</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td></tr> <tr> <td align="left" valign="bottom" width="50%" style="BORDER-BOTTOM: black 4px double"> <div align="left" style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total consideration transferred</font></div></td> <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td> <td valign="bottom" width="15%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">68,236</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td> <td valign="bottom" width="13%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8211;&#8211;</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td> <td valign="bottom" width="13%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">68,236</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td></tr></table></div> <div align="left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellpadding="0" width="100%" cellspacing="0" border="0" id="hangingindent"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(a)</font></div></td> <td style="TEXT-ALIGN: left" width="98%"> <div style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;The measurement period adjustments for <font style="DISPLAY: inline; FONT-STYLE: italic">Identifiable intangible assets</font> reflect changes in the estimated fair value of certain acquired intangibles, principally in-process research and development assets, primarily to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date.&#160;&#160;The measurement period adjustments did not result from intervening events subsequent to the acquisition date.</font></div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The recorded amounts are provisional and subject to change. Specifically, the following items are subject to change:</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div align="left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellpadding="0" width="100%" cellspacing="0" id="list1"> <tr valign="top"> <td style="WIDTH: 9pt" width="1%" align="right"> <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;&#160;&#160;</font></div></td> <td width="99%"> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Amounts for intangibles and inventory, pending finalization of valuation efforts.</font></div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div align="left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellpadding="0" width="100%" cellspacing="0" id="list2"> <tr valign="top"> <td style="WIDTH: 9pt" width="1%" align="right"> <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;&#160;&#160;</font></div></td> <td style="TEXT-ALIGN: left" width="99%"> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Amounts for legal contingencies, pending the finalization of our examination and evaluation of the portfolio of filed cases.</font></div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div align="left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellpadding="0" width="100%" cellspacing="0" id="list3"> <tr valign="top"> <td style="WIDTH: 9pt" width="1%" align="right"> <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;&#160;&#160;</font></div></td> <td style="TEXT-ALIGN: left" width="99%"> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Amounts for income tax assets, receivables and liabilities pending the filing of Wyeth pre-acquisition tax returns, including all required disclosures and documentation, as well as the receipt of information from taxing authorities which may change certain estimates and assumptions used.</font></div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div align="left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellpadding="0" width="100%" cellspacing="0" id="list4"> <tr valign="top"> <td style="WIDTH: 9pt" width="1%" align="right"> <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;&#160;&#160;</font></div></td> <td width="99%"> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The allocation of goodwill among reporting units.</font></div></td></tr></table></div> <div class="BWxbrlnote6"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <div> <div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><a style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline" id="xbrlnote6" name="xbrlnote6">Note 6. Comprehensive Income/(Loss)</a></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">The components of comprehensive income/(loss) follow:</div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="6"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">Three Months Ended</div></td> <td style="BORDER-TOP: medium none; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 2px solid" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-VARIANT: small-caps; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">(millions of dollars)</div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">April 4,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">&#160;2010</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Mar. 29,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2009</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom">&#160;</td></tr> <tr> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Net income before allocation to noncontrolling interests</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,035</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,730</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Other comprehensive income/(loss):</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -27pt; text-align: left"><font>&#160;</font> Currency translation adjustment and other</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(2,747</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(384</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -27pt; text-align: left"><font>&#160;</font> Net unrealized gains/(losses) on derivative financial instruments</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">134</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(23</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -27pt; text-align: left"><font>&#160;</font> Net unrealized gains/(losses) on available-for-sale securities</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(15</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">145</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -27pt; text-align: left"><font>&#160;</font> Benefit plan adjustments</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">117</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">159</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Total other comprehensive loss</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(2,511</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(103</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">)</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Total comprehensive (loss)/income before allocation to noncontrolling interests</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(476</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,627</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Less: Comprehensive (loss)/income attributable to noncontrolling interests</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(9)</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 4px double" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Comprehensive (loss)/income attributable to Pfizer Inc.</div></td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(467</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,625</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr></table></div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">&#160;</div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">&#160;</div></div></div></div></div> <div class="BWxbrlnote11"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <div> <div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><a style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline" id="xbrlnote11" name="xbrlnote11">Note 11. Segment Information</a></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">We operate in the following two distinct commercial organizations, which constitute our two business segments:</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr valign="top"> <td align="right" style="WIDTH: 9pt" width="1%"> <div style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;&#160;&#160;</div></td> <td style="TEXT-ALIGN: left" width="99%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Biopharmaceutical</font> consists of the Primary Care, Specialty Care, Oncology, Established Products and Emerging Markets customer-focused units and includes products that prevent and treat cardiovascular and metabolic diseases, central nervous system disorders, arthritis and pain, infectious and respiratory diseases, urogenital conditions, cancer, eye diseases and endocrine disorders, among others. Biopharmaceutical's segment profit includes costs related to research and development, manufacturing, and sales and marketing activities that are associated with the products in our Biopharmaceutical segment.</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr valign="top"> <td align="right" style="WIDTH: 9pt" width="1%"> <div style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;&#160;&#160;</div></td> <td style="TEXT-ALIGN: left" width="99%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Diversified</font> includes Animal Health products that prevent and treat diseases in livestock and companion animals, including vaccines, parasiticides and anti-infectives; Consumer Healthcare products that include over-the-counter healthcare products such as pain management therapies (analgesics and heat wraps), cough/cold/allergy remedies, dietary supplements, hemorrhoidal care and personal care items; Nutrition products such as infant and toddler nutritional products; and Capsugel, which represents our capsule products and services business. Diversified's segment profit includes costs related to research and development, manufacturing, and sales and marketing activities that are associated with the products in our Diversified segment.</div></td></tr></table></div> ; <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Segment profit/(loss) is measured based on income from continuing operations before provision for taxes on income and income attributable to noncontrolling interests. Certain costs, such as significant impacts of purchase accounting for acquisitions, restructuring and acquisition-related costs and costs related to our cost-reduction initiatives are included in <font style="DISPLAY: inline; FONT-STYLE: italic">Corporate/Other</font> only. This methodology is utilized by management to evaluate our businesses. Each segment is managed separately and offers different products requiring different marketing and distribution strategies.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Revenues and profit/(loss) by segment for the first quarters of 2010 and 2009 follow:</div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="74%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid" width="24%" valign="bottom" colspan="6"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">Three Months Ended<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td style="BORDER-TOP: medium none; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 2px solid" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-VARIANT: small-caps; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">(millions of dollars)</div></td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt" width="1%" valign="bottom">&#160;</td> <td style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="11%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">April 4,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2010</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; TEXT-INDENT: 0pt" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; TEXT-INDENT: 0pt" width="1%" valign="bottom">&#160;</td> <td style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="11%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Mar. 29,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2009</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; TEXT-INDENT: 0pt" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Revenues</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Biopharmaceutical</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">14,506</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">10,102</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Diversified</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,141</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">691</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Corporate/Other<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(b)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">103</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">74</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 4px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Total revenues</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">16,750</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">10,867</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="74%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Segment profit/(loss)<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(c)</font></div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Biopharmaceutical</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">7,912</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">5,407</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Diversified</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">510</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">163</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Corporate/Other<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(b), (d)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(5,243</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(1,767</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">)</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 4px double" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Total profit/(loss)</div></td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">3,179</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">3,803</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(a)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Includes revenues and profit/(loss) from legacy Wyeth products and operations for the three months ended April 4, 2010. Revenues and profit/(loss) from legacy Wyeth products and operations are not included in the three months ended March 29, 2009. Prior-period amounts for Capsugel, which were previously classified in <font style="DISPLAY: inline; FONT-STYLE: italic">Corporate/Other</font>, are now classified in <font style="DISPLAY: inline; FONT-STYLE: italic">Diversified.</font></div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(b)&#160;</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left"><font style="DISPLAY: inline; FONT-STYLE: italic">Corporate/Other</font> includes Pfizer Centersource, which includes contract manufacturing and bulk pharmaceutical chemical sales. <font style="DISPLAY: inline; FONT-STYLE: italic">Corporate/Other</font> under <font style="DISPLAY: inline; FONT-STYLE: italic">Segment profit/(loss)</font> also includes interest income/(expense), corporate expenses (e.g., corporate administration costs), other income/(expense) (e.g., realized gains and losses attributable to our investments in debt and equity securities), certain performance-based and all share-based compensation expenses, significant impacts of purchase accounting for acquisitions, acquisition-related costs, intangible asset impairments and costs related to our cost-reduction initiatives.</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(c)&#160;</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left"><font style="DISPLAY: inline; FONT-STYLE: italic">Segment profit/(loss)</font> equals <font style="DISPLAY: inline; FONT-STYLE: italic">Income from continuing operations before provision for taxes on income.</font> Certain costs, such as significant impacts of purchase accounting for acquisitions, acquisition-related costs and costs related to our cost-reduction initiatives are included in <font style="DISPLAY: inline; FONT-STYLE: italic">Corporate/Other</font> only. This methodology is utilized by management to evaluate our businesses.</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(d)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;For the first quarter of 2010, <font style="DISPLAY: inline; FONT-STYLE: italic">Corporate/Other</font> includes: (i) significant impacts of purchase accounting for acquisitions of $2.8 billion, including intangible asset amortization related to our acquisitions of Wyeth in 2009 and Pharmacia in 2003 and charges related to fair value adjustments of inventory acquired from Wyeth and sold during the period; (ii) restructuring and acquisition-related costs of $799 million, primarily related to our acquisition of Wyeth; (iii) all share-based compensation expense; and (iv) net interest expense of $410 million. For the first quarter of 2009, <font style="DISPLAY: inline; FONT-STYLE: italic">Corporate/Other</font> includes: (i) significant impacts of purchase accounting for acquisitions of $546 million, including intangible asset amortization and other charges, primarily related to o ur acquisition of Pharmacia in 2003; (ii) acquisition-related costs of $397 million, primarily related to our acquisition of Wyeth; (iii) restructuring charges and implementation costs associated with our cost-reduction initiatives of $331 million; (iv) all share-based compensation expense; and (v) net interest income of $116.</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-INDENT: 0pt">Significant product revenues are as follows:</div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="6"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">Three Months Ended</div></td> <td style="BORDER-TOP: medium none; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 2px solid" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-VARIANT: small-caps; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">(millions of dollars)</div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" valign="bottom">&#160;</td> <td style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">April 4,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2010</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Mar. 29,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2009</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom">&#160;</td></tr> <tr> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td></tr> <tr> <td align="left" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Biopharmaceutical products:</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Lipitor</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,757</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,721</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Enbrel<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font>, <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(c)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">802</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Lyrica</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">723</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">684</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Effexor<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">716</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Celebrex</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">570</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">564</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Prevnar/Prevenar 7<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">520</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Viagra</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">479</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">454</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Xalatan/Xalacom</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">422</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">407</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Norvasc</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">368</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">481</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Zyvox</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">292</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">283</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Prevnar/Prevenar 13<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">286</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Zosyn/Tazocin<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">264</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Detrol/Detrol LA</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">261</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">289</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Sutent</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">259</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">202</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Premarin family<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">256</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Geodon/Zeldox</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">254</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">230</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Genotropin</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">206</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">197</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Chantix/Champix</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">189</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">177</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Vfend</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">188</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">179</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> BeneFIX<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">154</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Caduet</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">135</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">134</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Aromasin</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">128</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">110</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Zoloft</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">120</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">115</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Revatio</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">114</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">113</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Medrol</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">109</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">118</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Cardura</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">107</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">107</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Aricept<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(b)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">107</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">95</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Zithromax/Zmax</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">103</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">114</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> ReFacto/Xyntha<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">90</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> All other<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(d)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,523</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,746</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Alliance revenues (Enbrel (in the U.S. and Canada)<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font>, Aricept, Exforge, Rebif and Spiriva)</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,004</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">582</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 18pt; text-align: left">Total Biopharmaceutical products</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">14,506</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">10,102</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Diversified products:</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Animal Health products<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(d)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">846</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">537</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Consumer Healthcare products<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">663</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Nutrition products<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">458</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Capsugel<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(e)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">174</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">154</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Total Diversified products</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,141</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">691</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Corporate/Other</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">103</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">74</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 4px double" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Total revenues</div></td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">16,750</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">10,867</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(a)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Represents legacy Wyeth products for the three months ended April 4, 2010. Legacy Wyeth products are not included in the three months ended March 29, 2009.</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(b)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Represents direct sales under license agreement with Eisai. Co. Ltd.</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(c)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Outside the U.S. and Canada.</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(d)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Includes legacy Pfizer and legacy Wyeth products for the three months ended April 4, 2010 and includes only legacy Pfizer products in the three months ended March 29, 2009.</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(e)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Prior-period amounts for Capsugel, which were previously classified in <font style="DISPLAY: inline; FONT-STYLE: italic">Corporate/Other,</font> are now classified in <font style="DISPLAY: inline; FONT-STYLE: italic">Diversified.</font></div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-INDENT: 0pt">Revenues by geographic area follow:</div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="61%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid" width="37%" valign="bottom" colspan="10"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">Three Months Ended<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td style="BORDER-TOP: medium none; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 2px solid" width="61%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-VARIANT: small-caps; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">(millions of dollars)</div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="11%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">April 4,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2010</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" width="1%" valign="bottom">&#160;</td> <td style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="11%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Mar. 29,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2009</div></td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="1%" valign="bottom">&#160;</td> <td style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="11%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">% Change</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="61%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="61%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Revenues</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="61%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> United States</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">7,314</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">4,969</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">47</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="61%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Europe</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">4,785</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">3,005</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">59</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="61%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Japan/Other Asia</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,659</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,738</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">53</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="61%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Canada/Latin America/Africa/Middle East</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,992</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,155</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" width="10%" valign="bottom">72</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 4px double" width="61%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Total Revenues</div></td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">16,750</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">10,867</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">54</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(a)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Includes revenues from legacy Wyeth products for the three months ended April 4, 2010. Revenues from legacy Wyeth products are not included in the three months ended March 29, 2009.</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div></div></div></div></div> <div class="BWxbrlnote5"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <div> <div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><a style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline" id="xbrlnote5" name="xbrlnote5">Note 5. Financial Instruments</a></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-DECORATION: underline; TEXT-INDENT: 0pt; text-align: left">A. Selected Financial Assets and Liabilities</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Information about certain of our financial assets and liabilities follows:</div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr> <td align="left" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-VARIANT: small-caps; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">(millions of dollars)</div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">April 4,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2010</div></td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td align="left" style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Dec. 31,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2009</div></td> <td style="BORDER-TOP: medium none; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom">&#160;</td></tr> <tr> <td valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">Selected financial assets measured at fair value on a recurring basis <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font> :</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td></tr> <tr> <td width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify"><font>&#160;</font> Trading securities <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(b)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">168</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">184</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify"><font>&#160;</font> Available-for-sale debt securities<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(c)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">23,787</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">32,338</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -27pt; text-align: left"><font>&#160;</font> Available-for-sale money market funds<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(d)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,484</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,569</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Available-for-sale equity securities, excluding money market funds<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(c)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">243</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">281</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify"><font>&#160;</font> Derivative financial instruments in receivable positions<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(e)</font>:</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify"><font>&#160;</font> Foreign currency swaps</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">400</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">798</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify"><font>&#160;</font> Interest rate swaps</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">315</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">276</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 2px solid" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify"><font>&#160;</font> Foreign currency forward-exchange contracts</div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">284</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">502</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 2px solid" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify"><font>&#160;</font> Total</div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">26,681</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">36,948</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Other selected financial assets<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(f)</font>:</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Short-term loans, carried at cost <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(g)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">919</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,195</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Held-to-maturity debt securities, carried at amortized cost<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(c)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">642</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">812</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Private equity securities, carried at cost or equity method <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(h)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">858</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">811</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 2px solid" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Long-term loans, carried at cost<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(g)</font></div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">782</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">784</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 2px solid" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify"><font>&#160;</font> Total</div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">3,201</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">3,602</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 4px double" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Total selected financial assets</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(i)</font></div></td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">29,882</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">40,550</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">Financial liabilities measured at fair value on a recurring basis<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font>:</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify"><font>&#160;</font> Derivative financial instruments in a liability position<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(j)</font>:</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify"><font>&#160;</font> Foreign currency forward-exchange contracts</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">351</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">237</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">Foreign currency swaps</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">221</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">528</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 2px solid" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify"><font>&#160;</font> Interest rate swaps</div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">73</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">25</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 2px solid" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify"><font>&#160;</font> Total</div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">645</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">790</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Other financial liabilities <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(k)</font>:</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Short-term borrowings, carried at historical proceeds, as adjusted<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(f), (l)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">7,769</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">5,469</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 2px solid" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Long-term debt, carried at historical proceeds, as adjusted<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(m), (n)</font></div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">38,281</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">43,193</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 2px solid" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Total</div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">46,050</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">48,662</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 4px double" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -18pt; text-align: left">Total selected financial liabilities</div></td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">46,695</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">49,452</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(a)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Fair values are determined based on valuation techniques categorized as follows: Level 1 means the use of quoted prices for identical instruments in active markets; Level 2 means the use of quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active or are directly or indirectly observable; Level 3 means the use of unobservable inputs. Virtually all of our financial assets and liabilities measured at fair value on a recurring basis use Level 2 inputs in the calculation of fair value, except that included in available-for-sale equity securities, excluding money market funds, are $93 million as of April 4, 2010 and $77 million as of December 31, 2009 of investments that use Level 1 inputs in the calculation of fair value. None of our financial assets and liabilities measured at fair value on a recurring basis are valued us ing Level 3 inputs as of April 4, 2010 or December 31, 2009.</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(b)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Trading securities are held in trust for legacy Pharmacia severance benefits.</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(c)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Gross unrealized gains and losses are not significant.</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(d)</div></td> <td style="TEXT-ALIGN: left" width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left">&#160;Includes approximately $1.2 billion of money market funds held in escrow to secure certain of Wyeth's payment obligations under its 1999 Nationwide Class Action Settlement Agreement, which relates to litigation against Wyeth concerning its former weight-loss products, Redux and Pondimin (see <font style="DISPLAY: inline; FONT-STYLE: italic">Note 5G. Financial Instruments: Guarantee).</font></div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(e)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Designated as hedging instruments, except for certain foreign currency contracts used as offsets; namely, foreign currency forward-exchange contracts with fair values of $150 million and foreign currency swaps with fair values of $36 million as of April 4, 2010; and foreign currency swaps with fair values of $106 million and foreign currency forward-exchange contracts with fair values of $100 million at <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">December 31, 2009.</font></div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 18pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(f)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;The differences between the estimated fair values and carrying values of our financial assets and liabilities not measured at fair value on a recurring basis were not significant as of April 4, 2010 or December 31, 2009.</div></td></tr></table></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td align="right" style="WIDTH: 9pt" width="2%"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">(g)</div></td> <td align="left" width="98%"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">&#160;Our short-term and long-term loans are due from companies with highly rated securities (Standard &amp; Poor's (S&amp;P) ratings of mostly AA or better).</div></td></tr></table></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td align="right" style="WIDTH: 9pt" width="2%"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">(h)</div></td> <td align="left" width="98%"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">&#160;Our private equity securities represent investments in the life sciences sector.</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 18pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(i)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;The decrease in selected financial assets is primarily due to the use of proceeds of short-term investments for tax payments made in the first quarter of 2010, associated with certain business decisions executed to finance the Wyeth acquisition.</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 14.4pt" width="2%"> <div style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(j)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Designated as hedging instruments, except for certain foreign currency contracts used as offsets; namely, foreign currency forward exchange contracts with fair values of $157 million and foreign currency swaps with fair values of $72 million as of April 4, 2010; and foreign currency forward-exchange contracts with fair values of $122 million and foreign currency swaps with fair values of $3 million as of December 31, 2009.</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(k)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;The carrying amounts may include adjustments for discount or premium amortization or for the effect of interest rate swaps designated as hedges.</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 18pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(l)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Includes foreign currency borrowings with fair values of $2.3 billion at April 4, 2010 and $1.1 billion as of December 31, 2009, which are used as hedging instruments.</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(m)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Includes foreign currency debt with fair value of $754 million as of April 4, 2010 and $2.1 billion as of December 31, 2009, which is used as a hedging instrument.</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(n)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;The fair value of our long-term debt is $41.7 billion as of April 4, 2010 and $46.2 billion as of December 31, 2009.</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt">We use a market approach to determine the fair value of our financial assets and liabilities and apply the following methods and assumptions:</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">&#160;</div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr valign="top"> <td align="right" style="WIDTH: 9pt" width="1%"> <div style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;&#160;&#160;</div></td> <td width="99%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">Trading equity securities--quoted market prices.</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr valign="top"> <td align="right" style="WIDTH: 9pt" width="1%"> <div style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;&#160;&#160;</div></td> <td width="99%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">Trading debt securities--observable market interest rates.</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr valign="top"> <td align="right" style="WIDTH: 9pt" width="1%"> <div style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;&#160;&#160;</div></td> <td style="TEXT-ALIGN: left" width="99%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt">Available-for-sale debt securities--third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and credit-adjusted interest rate curves.</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr valign="top"> <td align="right" style="WIDTH: 9pt" width="1%"> <div style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;&#160;&#160;</div></td> <td width="99%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">Available-for-sale money market funds--observable prices.</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr valign="top"> <td align="right" style="WIDTH: 9pt" width="1%"> <div style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;&#160;&#160;</div></td> <td style="TEXT-ALIGN: left" width="99%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt">Available-for-sale equity securities, excluding money market funds--third-party pricing services that principally use a composite of observable prices.</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 18pt; TEXT-ALIGN: left" width="1%"> <div style="DISPLAY: inline; FONT-FAMILY: symbol, serif; FONT-SIZE: 10pt; TEXT-ALIGN: left">&#183;&#160;&#160;</div></td> <td style="TEXT-ALIGN: left" width="99%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt">Derivative financial instruments (assets and liabilities)-- third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data.&#160;&#160;Where applicable, these models discount future cash flow amounts using market-based observable inputs including interest rate curves, foreign exchange rates, and forward and spot prices for currencies.&#160;&#160;The credit risk impact to our derivative financial instruments was not significant.</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr valign="top"> <td align="right" style="WIDTH: 9pt" width="1%"> <div style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;&#160;&#160;</div></td> <td style="TEXT-ALIGN: left" width="99%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt">Held-to-maturity debt securities-- third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and credit-adjusted interest rate curves.</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr valign="top"> <td align="right" style="WIDTH: 9pt" width="1%"> <div style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;&#160;&#160;</div></td> <td style="TEXT-ALIGN: left" width="99%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt">Short-term and long-term loans--<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>third-party model that discounts future cash flows using current interest rates at which similar loans would be made to borrowers with similar credit ratings and for the same remaining maturities.</div></td></tr></table></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">&#160;</div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr valign="top"> <td align="right" style="WIDTH: 9pt" width="1%"> <div style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;&#160;&#160;</div></td> <td style="TEXT-ALIGN: left" width="99%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt">Private equity securities--application of the implied volatility associated with an observable biotech index to the carrying amount of our portfolio and, to a lesser extent, performance multiples of comparable securities adjusted for company-specific information.</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr valign="top"> <td align="right" style="WIDTH: 9pt" width="1%"> <div style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;&#160;&#160;</div></td> <td style="TEXT-ALIGN: left" width="99%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt">Short-term borrowings and long-term debt-- third-party matrix-pricing model that uses significant inputs derived from or collaborated by observable market data and our own credit rating.</div></td></tr></table></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">&#160;</div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">In addition, we have long-term receivables where the determination of fair value uses discounted future cash flows, using current interest rates at which similar loans would be made to borrowers with similar credit ratings and for the same remaining maturities.</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">&#160;</div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">These selected financial assets and liabilities are presented in the condensed consolidated balance sheets as follows:</div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr> <td align="left" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-VARIANT: small-caps; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">(millions of dollars)</div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="11%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">April 4,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2010</div></td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="11%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Dec. 31,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2009</div></td> <td style="BORDER-TOP: medium none; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">Assets</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-STYLE: italic; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">Cash and cash equivalents</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">380</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">666</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-STYLE: italic; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify"><font>&#160;</font> Short-term investments</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">15,503</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">23,991</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-STYLE: italic; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify"><font>&#160;</font> Short-term loans</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">919</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,195</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-STYLE: italic; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify"><font>&#160;</font> Long-term investments and loans</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">12,081</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">13,122</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> <font style="DISPLAY: inline; FONT-STYLE: italic">Current deferred tax assets and other current assets</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">313</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">526</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 2px solid" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify"><font>&#160;</font> <font style="DISPLAY: inline; FONT-STYLE: italic">Noncurrent deferred tax assets and other noncurrent assets</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(b)</font></div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">686</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,050</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 2px solid" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">Total</div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">29,882</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">40,550</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">Liabilities</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-STYLE: italic; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">Short-term borrowings, including current portion of long-term debt</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">7,769</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">5,469</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify"><font style="DISPLAY: inline; FONT-STYLE: italic">Current deferred tax liabilities and other current liabilities</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(c)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">414</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">369</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-STYLE: italic; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">Long-term debt</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">38,281</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">43,193</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 2px solid" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify"><font style="DISPLAY: inline; FONT-STYLE: italic">Other noncurrent liabilities</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(d)</font></div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">231</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">421</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 4px double" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">Total</div></td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">46,695</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">49,452</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(a)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;As of April 4, 2010, derivative instruments at fair value include foreign currency forward-exchange contracts ($284 million) and foreign currency swaps ($29 million) and as of December 31, 2009, include foreign currency forward-exchange contracts ($503 million) and foreign currency swaps ($23 million).</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(b)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;As of April 4, 2010, derivative instruments at fair value include foreign currency swaps ($371 million) and interest rate swaps ($315 million) and as of December 31, 2009, include foreign currency swaps ($774 million) and interest rate swaps ($276 million).</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(c)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;As of April 4, 2010, derivative instruments at fair value include foreign currency forward-exchange contracts ($351 million) and foreign currency swaps ($63 million) and as of December 31, 2009, include foreign currency forward-exchange contracts ($237 million) and foreign currency swaps ($132 million).</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(d)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;As of April 4, 2010, derivative instruments at fair value include foreign currency swaps ($158 million) and interest rate swaps ($73 million) and as of December 31, 2009, include foreign currency swaps ($396 million) and interest rate swaps ($25 million).</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">We regularly evaluate all of our financial assets for impairment. For investments in debt and equity securities, when a decline in fair value, if any, is determined to be other-than-temporary, an impairment charge is recorded, and a new cost basis in the investment is established. For loans, an impairment charge is recorded if it is probable that we will not be able to collect all amounts due according to the loan agreement. There were no significant impairments recognized in the first quarter of 2010 or the year ended December 31, 2009.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-DECORATION: underline; TEXT-INDENT: 0pt; text-align: left">B. Investments in Debt and Equity Securities</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">The contractual maturities of the available-for-sale and held-to-maturity debt securities as of April 4, 2010, follow:</div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="6"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">Years</div></td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" valign="bottom" colspan="2">&#160;</td> <td style="BORDER-TOP: medium none; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 2px solid" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-VARIANT: small-caps; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">(millions of dollars)</div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Within 1</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Over 1</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">to 5</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Total as of</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">April 4,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2010</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom">&#160;</td></tr> <tr> <td align="left" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -27pt; text-align: left">Available-for-sale debt securities:</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="61%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Western<font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#160;</font>European and other government debt</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">9,157</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,576</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">11,733</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="61%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Western European and other government agency debt</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,678</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">266</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,944</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="61%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Corporate debt<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">996</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,885</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,881</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="61%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -18pt; text-align: left"><font>&#160;</font> Federal Home Loan Mortgage Corporation and Federal National Mortgage</div> <div style="DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -18pt; text-align: left">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Association asset-backed securities</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">102</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,531</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,633</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="61%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Reverse repurchase agreements<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(b)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,263</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,263</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="61%" valign="bottom"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font>&#160;</font> U.S. government Federal Deposit Insurance Corporation&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">guaranteed debt</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,101</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,101</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="61%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Supranational debt</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">636</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">386</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,022</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="61%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Other asset-backed securities</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">33</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">125</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">158</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="61%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Certificates of deposit</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">52</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">52</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="61%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -27pt; text-align: left">Held-to-maturity debt securities:</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="61%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Certificates of deposit and other</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">636</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">6</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">642</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="61%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -27pt; text-align: left">Total debt securities</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">15,553</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">8,876</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">24,429</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="61%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -27pt; text-align: left">Trading securities</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">168</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="61%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -27pt; text-align: left">Available-for-sale money market funds<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(c)</font></div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,484</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="61%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left">Available-for-sale equity securities, excluding money market funds</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">243</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 4px double" width="61%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -27pt; text-align: left">Total</div></td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">26,324</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(a)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Largely issued by above-investment-grade institutions in the financial services sector.</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 9.35pt" width="2%"> <div style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(b)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Very short-term agreements involving U.S. government securities.</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(c)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Consisting of securities issued by the U.S. government and its agencies or instrumentalities and reverse repurchase agreements involving the same investments held.</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-DECORATION: underline; TEXT-INDENT: 0pt; text-align: left">C. Short-Term Borrowings</div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Short-term borrowings include amounts for commercial paper of $3.1 billion as of April 4, 2010 and $3.9 billion as of December 31, 2009.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-DECORATION: underline; TEXT-INDENT: 0pt; text-align: left">D. Long-Term Debt</div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">In March 2007, we filed a securities registration statement with the SEC. The registration statement was filed under the automatic shelf registration process available to "well-known seasoned issuers" and expired in March 2010. On March 24, 2009, in order to partially finance our acquisition of Wyeth, we issued $13.5 billion of senior unsecured notes under this registration statement. On June 3, 2009, also in order to partially finance our acquisition of Wyeth, we issued approximately $10.5 billion of senior unsecured notes in a private placement pursuant to Regulation S under the Securities Act of 1933, as amended (Securities Act of 1933). The notes have not been and will not be registered under the Securities Act of 1933 and, subject to certain exceptions, may not be sold, offered or delivered within the U.S. to, or for, the account or benefit of U.S. per sons.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-DECORATION: underline; TEXT-INDENT: 0pt; text-align: left">E. Derivative Financial Instruments and Hedging Activities</div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Foreign Exchange Risk</font>-A significant portion of our revenues, earnings and net investments in foreign affiliates is exposed to changes in foreign exchange rates. We seek to manage our foreign exchange risk, in part, through operational means, including managing expected same-currency revenues in relation to same-currency costs and same-currency assets in relation to same-currency liabilities. Depending on market conditions, foreign exchange risk also is managed through the use of derivative financial instruments and foreign currency debt. These financial instruments serve to protect net income and net investments against the impact of the translation into U.S. dollars of certain foreign exchange-denominated transactions. The aggregate notional amount of foreign exchange derivative financial instruments hedging or offsetting foreign currency exposures is $44.8 billion. The derivative financial instruments primarily hedge or offset exposures in euro, Japanese yen and U.K. pound. The maximum length of time over which we are hedging future foreign exchange cash flows relates to our $2.4 billion U.K. pound debt maturing in 2038.</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">&#160;</div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Interest Rate Risk-</font>Our interest-bearing investments, loans and borrowings are subject to interest rate risk. We seek to invest and loan primarily on a short-term or variable-rate basis; however, in light of current market conditions, we currently borrow primarily on a long-term, fixed-rate basis. From time to time, depending on market conditions, we will change the profile of our outstanding debt by entering into derivative financial instruments like interest rate swaps.</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">&#160;</div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">We entered into derivative financial instruments to hedge or offset the fixed interest rates on the hedged item, matching the amount and timing of the hedged item. The aggregate notional amount of interest rate derivative financial instruments is $9.2 billion. The derivative financial instruments hedge U.S. dollar and euro fixed-rate debt.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Information about gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk is as follows:</div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="74%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid" width="24%" valign="bottom" colspan="6"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">Gains/(Losses)</div></td> <td style="BORDER-TOP: medium none; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="74%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid" width="24%" valign="bottom" colspan="6"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">Three Months Ended</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 2px solid" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-VARIANT: small-caps; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">(millions of dollars)</div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="11%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">April 4, 2010</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="11%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Mar. 29, 2009</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Derivative Financial Instruments in Fair Value Hedge Relationships</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Interest rate swaps</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Recognized in OID<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(284</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Foreign currency swaps</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 2px solid" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Recognized in OID<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(1</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">)</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Derivative Financial Instruments in Cash Flow Hedge Relationships</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> U.S. Treasury interest rate locks</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Recognized in OID<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(11</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Recognized in OCI<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">,</font> <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(b)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(15</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Reclassified from OCI to OID<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a), (b)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Foreign currency swaps</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Recognized in OID<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Recognized in OCI<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a), (b)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(438</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(19</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Reclassified from OCI to OID<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a), (b)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(628</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Foreign currency forward exchange contracts</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Recognized in OID<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Recognized in OCI<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a), (b)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 2px solid" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Reclassified from OCI to OID<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a), (b)</font></div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">10</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Derivative Financial Instruments in Net Investment Hedge Relationships</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Foreign currency swaps</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Recognized in OID<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(2</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 2px solid" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Recognized in OCI<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">,</font> <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(b)</font></div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">11</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">53</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Derivative Financial Instruments Not Designated as Hedges</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Foreign currency swaps</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Recognized in OID<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">4</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(5</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Foreign currency forward-exchange contracts</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 2px solid" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Recognized in OID<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(890</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(255</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">)</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Non-Derivative Financial Instruments in Net Investment Hedge Relationships</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Foreign currency short-term borrowings</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Recognized in OID<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Recognized in OCI<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">,</font> <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(b)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">31</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">110</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Foreign currency long-term debt</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Recognized in OID<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 4px double" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Recognized in OCI<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a), (b)</font></div></td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">16</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">158</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(a)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;OID = <font style="DISPLAY: inline; FONT-STYLE: italic">Other (income)/deductions--net.</font> OCI = <font style="DISPLAY: inline; FONT-STYLE: italic">Other comprehensive income/(expense),</font> a balance sheet account.</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(b)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Amounts presented represent the effective portion of the gain or loss. For derivative financial instruments in cash flow hedge relationships, the effective portion is included in <font style="DISPLAY: inline; FONT-STYLE: italic">Other comprehensive income/(expense) - Net unrealized gains/(losses) on derivative financial instruments</font>. For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the effective portion is included in <font style="DISPLAY: inline; FONT-STYLE: italic">Other comprehensive income/(expense)--Currency translation adjustment.</font></div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">For information about the fair value of our derivative financial instruments, and the impact on our Condensed Consolidated Balance Sheets, see <font style="DISPLAY: inline; FONT-STYLE: italic">Note 5A. Financial Instruments: Selected Financial Assets and Liabilities.</font> Certain of our derivative instruments are covered by associated credit-support agreements that have credit-risk-related contingent features designed to reduce our counterparties' exposure to our risk of defaulting on amounts owed. The aggregate fair value of these derivative instruments that are in a liability position is $353 million, for which we have posted collateral of $188 million in the normal course of business. These features include the requirement to pay additional collateral in the event of a downgrade in our debt ratings. If there had been a downgrade to below an A rating by S&amp;P or the equivalent rating by Moody's Investors Service, on April 4, 2010, we would have been required to post an additional $171 million of collateral to our counterparties. The collateral advanced receivables are reported in <font style="DISPLAY: inline; FONT-STYLE: italic">Short-term loans.</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-DECORATION: underline; TEXT-INDENT: 0pt; text-align: left">F. Credit Risk</div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">On an ongoing basis, we review the creditworthiness of counterparties to our foreign exchange and interest rate agreements and do not expect to incur a significant loss from failure of any counterparties to perform under the agreements. There are no significant concentrations of credit risk related to our financial instruments with any individual counterparty. As of April 4, 2010, we had $2.1 billion due from a well-diversified, highly rated group (S&amp;P ratings of primarily A+ or better) of bank counterparties around the world.&#160;&#160;See <font style="DISPLAY: inline; FONT-STYLE: italic">Note 5B.&#160;&#160;Financial Instruments: Investment in Debt and Equity Securities</font> for a distribution of our investments.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">In general, there is no requirement for collateral from customers. However, derivative financial instruments are executed under master netting agreements with financial institutions. These agreements contain provisions that provide for the ability for collateral payments, depending on levels of exposure, our credit rating and the credit rating of the counterparty. As of April 4, 2010, we received cash collateral of $518 million against various counterparties. The collateral primarily supports the approximate fair value of our derivative contracts. The collateral received obligations are reported in <font style="DISPLAY: inline; FONT-STYLE: italic">Short-term borrowings, including current portion of long-term debt.</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-DECORATION: underline; TEXT-INDENT: 0pt; text-align: left">G. Guarantee</div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">In April 2010, Wyeth LLC (Wyeth), a wholly owned subsidiary of Pfizer Inc. (Pfizer), entered into the Tenth Amendment (Tenth Amendment) to the 1999 Diet Drug Nationwide Settlement Agreement (Settlement Agreement) related to the litigation against Wyeth concerning its former weight-loss products, Redux and Pondimin. Pursuant to the Tenth Amendment, Pfizer entered into an agreement to guarantee Wyeth's obligation to make certain payments under the Settlement Agreement up to a maximum amount of $1.5 billion (Guarantee). The Guarantee will remain in effect until the termination of Wyeth's long-term obligation to make such payments. The Tenth Amendment and the Guarantee are subject to the approval of the United States District Court for the Eastern District of Pennsylvania and will become effective following such approval.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div></div></div></div></div> 2000000 Exclusive of amortization of intangible assets, except as disclosed in Note 8B. Goodwill and Other Intangible Assets: Other Intangible Assets. Unaudited. Condensed from audited financial statements. EX-101.SCH 11 pfe-20100404.xsd XBRL TAXONOMY EXTENSION SCHEMA 000030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) link:calculationLink link:definitionLink link:presentationLink 000010 - Document - Document Information link:calculationLink link:definitionLink link:presentationLink 000020 - Document - Entity Information link:calculationLink link:definitionLink link:presentationLink 000040 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) link:calculationLink link:definitionLink link:presentationLink 000050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) link:calculationLink link:definitionLink link:presentationLink 000100 - Disclosure - Basis of Presentation link:calculationLink link:definitionLink link:presentationLink 000110 - Disclosure - Adoption of New Accounting Policies link:calculationLink link:definitionLink link:presentationLink 000120 - Disclosure - Acquisition of Wyeth link:calculationLink link:definitionLink link:presentationLink 000130 - Disclosure - Collaborative Arrangements link:calculationLink link:definitionLink link:presentationLink 000140 - Disclosure - Cost-Reduction Initiatives and Acquisition-Related Costs link:calculationLink link:definitionLink link:presentationLink 000150 - Disclosure - Acquisition-Related Costs link:calculationLink link:definitionLink link:presentationLink 000160 - Disclosure - Comprehensive Income (Loss) link:calculationLink link:definitionLink link:presentationLink 000155 - Disclosure - Financial Instruments link:calculationLink link:definitionLink link:presentationLink 000180 - Disclosure - Inventories link:calculationLink link:definitionLink link:presentationLink 000190 - Disclosure - Goodwill and Other Intangible Assets link:calculationLink link:definitionLink link:presentationLink 000200 - Disclosure - Pension and Postretirement Benefit Plans link:calculationLink link:definitionLink link:presentationLink 000210 - Disclosure - Earnings Per Share Attributable to Common Shareholders link:calculationLink link:definitionLink link:presentationLink 000220 - Disclosure - Segment Information link:calculationLink link:definitionLink link:presentationLink 000230 - Disclosure - Subsequent Events link:calculationLink link:definitionLink link:presentationLink 000240 - Disclosure - Taxes on Income link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 12 pfe-20100404_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.LAB 13 pfe-20100404_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document Information [Line Items] Document type Amendment flag Document period end date Amendment description Entity common stock shares outstanding Entity Listings [Line Items] Entity Listings, Instrument [Axis] Instrument [Domain] Entity Listings [Table] Entity [Text Block] Entities [Table] Entity Information [Line Items] Entity registrant name Entity central index key Current fiscal year end date Entity well known seasoned issuer Entity voluntary filers Entity current reporting status Entity filer category Entity public float Income Statement [Abstract] Statement [Table] Statement Scenario [Axis] Statement [Line Items] Statement of Financial Position [Abstract] Statement of Cash Flows [Abstract] Basis of Presentation [Abstract] Adoption of New Accounting Policies [Abstract] Financial Instruments [Abstract] Inventories [Abstract] Goodwill and Other Intangible Assets [Abstract] Earnings Per Share Attributable to Common Shareholders [Abstract] Segment Information [Abstract] Net Income (Loss), Including Portion Attributable to Noncontrolling Interest [Abstract] Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest [Abstract] Costs and expenses: Revenues [Abstract] Cost of sales [1] Restructuring charges and acquisition related costs Other Income Expense Net Selling, informational and administrative expenses [1] Research and development expenses [1] Amortization of intangible assets Acquisition-related in-process research and development charges Less: Net income attributable to noncontrolling interests Net income attributable to Pfizer Inc. Net income before allocation to noncontrolling interests Discontinued operations - net of tax, total Income from continuing operations Provision for taxes on income Earnings Per Share [Abstract] Earnings per common share - diluted: Earnings per common share - basic: Earnings Per Share Other Disclosures [Abstract] Diluted Basic Cash dividends paid per common share Income from continuing operations attributable to Pfizer Inc. common shareholders Discontinued operations - net of tax Net income attributable to Pfizer Inc. common shareholders Net income attributable to Pfizer Inc. common shareholders [Diluted] Discontinued operations - net of tax [Diluted] Income from continuing operations attributable to Pfizer Inc. common shareholders Basis of Presentation [Text Block] Adoption of New Accounting Policies [Text Block] Comprehensive Income (Expense) [Text Block] Inventories [Text Block] Goodwill and Other Intangible Assets [Text Block] Pension and Postretirement Benefit Plans [Text Block] Earnings Per Share Attributable to Common Shareholders [Text Block] Segment Information [Text Block] Assets Liabilities and Shareholders' Equity Total liabilities and shareholders' equity Liabilities [Abstract] Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Total assets Total liabilities Inventories Short-term loans Accounts receivable, less allowance for doubtful accounts Short-term investments Cash and cash equivalents Total current assets Long-term investments and loans Property, plant and equipment, less accumulated depreciation Goodwill Identifiable intangible assets, less accumulated amortization Short-term borrowings, including current portion of long-term debt Accounts payable Dividends payable Income taxes payable Accrued compensation and related items Total current liabilities Long-term debt Pension benefit obligations Postretirement benefit obligations Noncurrent deferred tax liabilities Other noncurrent liabilities Total Pfizer Inc shareholders' equity Common stock Additional paid-in capital Employee benefit trust, at fair value Treasury stock Retained earnings Accumulated other comprehensive income/(loss) Preferred stock Equity attributable to noncontrolling interests Total shareholders' equity Cash and Cash Equivalents, Period Increase (Decrease) [Abstract] Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Revenues This element represents (i) the total amount of other operating income, not previously categorized, from items that are associated with the entity's normal revenue producing operation; and (ii) recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales, as well as excludes research and development expenses and selling, informational and administrative expenses. Income from continuing operations before provision for taxes on income Assets held for sale Acquisition of Wyeth [Text Block] Financial Instruments Disclosure [Text Block] Income taxes Interest Supplemental Cash Flow Information: Net decrease in cash and cash equivalents Operating Activities: Investing Activities: Financing Activities: Adjustments To Reconcile Net Income Loss Before Allocation To Noncontrolling Interests To Net Cash Provided By Used In Operating Activities Abstract Share-based compensation expense Depreciation and amortization Deferred taxes from continuing operations Other non-cash adjustments Net cash provided by operating activities Purchases of property, plant and equipment Purchases of short-term investments Purchases of long-term investments Other investing activities Net cash used in investing activities Proceeds From Issuances Of Short Term Debt Net Of Proceeds From Repayments Of Short Term Debt Maturing In Three Months Or Less The cash inflow from a borrowing having initial term of repayment of more than three months but less than one year or one operating cycle (if the normal cycle is more than one year) and may include the cash inflow from a borrowing having initial term of repayment within three months net of the cash outflow from repayment of a borrowing having initial term of repayment within three months. Proceeds from issuances of long-term debt Principal payments on long-term debt Cash dividends paid Net cash (used in)/provided by financing activities Effect of exchange-rate changes on cash and cash equivalents Income from continuing operations attributable to Pfizer Inc. common shareholders [Dilluted] Discontinued operations - net of tax Net income attributable to Pfizer Inc. common shareholders Treasury stock Accumulated other comprehensive expense Purchases of property, plant and equipment Purchases of short-term investments Purchases of long-term investments Other investing activities Increase in short-term borrowings, net Principal payments on long-term debt Cash dividends paid Other taxes payable Repayments Of Short Term Debt Maturing In More Than Three Months Net Of Repayments Of Short Term Debt Maturing In Three Months Or Less Principal payments on short-term borrowings Changes in assets and liabilities, net of acquisitions and divestitures The cash outflow from a repayment of a borrowing having initial term of repayment of more than three months but less than one year or one operating cycle (if the normal cycle is more than one year) and may include the cash outflow from a repayment of a borrowing having initial term of repayment within three months net of the cash inflow of a borrowing having initial term of repayment within three months. Proceeds From Sale And Maturity Of Long Term Marketable Securities Discontinued operations - net of tax The cash inflow associated with the aggregate amount received by the entity through sale or maturity of short term marketable securities (trading, held-to-maturity, or available-for-sale) during the period. The cash inflow associated with the aggregate amount received by the entity through sale or maturity of long-term marketable securities (trading, held-to-maturity, or available-for-sale) during the period. This element represents the complete disclosure related to financial instruments, which may include i) selected financial assets and liabilities; ii) investments in debt and equity securities; iii) short-term borrowings; iv) long-term debt; v) derivative financial instruments and hedging activities; vi) credit risk; and vii) other disclosures related to financial instruments. This element represents (i) restructuring charges, which are amounts charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a program that is planned and controlled by management, and materially changes either the scope of a business undertaken by an entity, or the manner in which that business is conducted; and (ii) acquisition-related costs, which are costs incurred to effect a business combination which costs have been expensed during the period. Such costs can include transaction costs such as banking, legal, accounting and other costs directly related to effect a business combination as well as external, incremental costs of integration planning that are directly related to a business combination, in cluding costs associated with preparing for systems and other integration activities. Income from continuing operations before provision for taxes on income Income from continuing operations Net income before allocation to noncontrolling interests Net income attributable to Pfizer Inc. Net income attributable to Pfizer Inc. common shareholders Total current assets Total assets Total current liabilities Total liabilities Total Pfizer Inc. shareholders' equity Total shareholders' equity Total liabilities and shareholders' equity Net cash (used in)/provided by operating activities Net cash provided by/(used in) investing activities Net cash (used in)/provided by financing activities Employee benefit trusts Other financing activities Changes in assets and liabilities, net of acquisitions and divestitures Document fiscal year focus Document fiscal period focus Document Information [Table] Legal Entity [Axis] Entity [Domain] Parent Company [Member] Restructuring charges and certain acquisition-related costs Current Deferred Tax Assets And Other Assets Current This element represents (i) carrying amount as of the balance sheet date of payments made in advance for income and other taxes, which will be charged against earnings within one year or the normal operating cycle, if longer as well as the current portion of the aggregate tax effects as of the balance sheet date of all future tax deductions arising from temporary differences between tax basis and generally accepted accounting principles basis recognition of assets, liabilities, revenues and expenses, which can only be deducted for tax purposes when permitted under enacted tax laws; after deducting the allocated valuation allowance, if any, to reduce such amount to net realizable value; and (ii) aggregate carrying amount, as of the balance sheet date, of current assets not separately presented elsewhere in the ba lance sheet. Current deferred tax assets and other current assets Non Current Deferred Tax Assets And Other Assets Noncurrent This element represents (i)the noncurrent portion as of the balance sheet date of the aggregate carrying amount of all future tax deductions arising from temporary differences between tax basis and generally accepted accounting principles basis recognition of assets, liabilities, revenues and expenses, which can only be deducted for tax purposes when permitted under enacted tax laws; after the valuation allowance, if any, to reduce such amount to net realizable value. Deferred tax liabilities and assets shall be classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, shall be classi fied according to the expected reversal date of the temporary difference; and (ii) the aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet due to materiality considerations. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer). Noncurrent deferred tax assets and other noncurrent assets Proceeds From Sale And Maturity Of Short Term Marketable Securities Proceeds from sales and redemptions of short-term investments Proceeds from redemptions and sales of short-term investments Proceeds from redemptions and sales of long-term investments Current deferred tax liabilities and other current liabilities This element represents (i) the current portion of deferred tax liabilities, which result from applying the applicable tax rate to net taxable temporary differences pertaining to each jurisdiction to which the entity is obligated to pay income tax. A current taxable temporary difference is a difference between the tax basis and the carrying amount of a current asset or liability in the financial statements prepared in accordance with generally accepted accounting principles. In a classified statement of financial position, an enterprise shall separate deferred tax liabilities and assets into a current amount and a noncurrent amount. Deferred tax liabilities and assets shall be classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A de ferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, shall be classified according to the expected reversal date of the temporary difference; and (ii) the aggregate carrying amount, as of the balance sheet date, of current obligations not separately disclosed in the balance sheet due to materiality considerations. Current liabilities are expected to be paid within one year (or the normal operating cycle, if longer). Acquisition of Wyeth [Abstract] Cost Reduction Initiatives and Acquisition Related Costs [Abstract] Cost Reduction Initiatives And Acquisition Related Costs Disclosure [Text Block] Cost-Reduction Initiatives and Acquistion-Related Costs [Text Block] Pension and Postretirement Benefit Plans [Abstract] Adjustments to reconcile net income before allocation to noncontrolling interests to net cash (used in)/provided by operating activities: Weighted-average shares used to calculate earnings per common share: Financial Instruments [Text Block] Other (income)/deductions - net Increase in short-term borrowings Supplemental Cash Flow Information Cash Paid During Period For [Abstract] Supplemental Cash Flow Information - Cash paid during the period for: Comprehensive Income/(Loss) [Text Block] Taxes on Income [Abstract] Taxes on Income [Text Block] Net decrease in cash and cash equivalents Description of cost-reduction initiatives associated with a comprehensive plan to integrate acquired operations, generate cost savings and capture synergies across the company; as well as costs incurred in connection with an acquisition. These costs include (i) restructuring activities, including exit and disposal activities, the major types of costs associated with the plan activities and the accrual balance at the end of the period; (ii) integration costs, which represent external, incremental costs directly related to integrating acquired businesses; (iii) implementation costs, which represent external, incremental costs directly related to implementing cost-reduction initiatives prior to the Wyeth acquisition and primarily include expenditures related to system and process standardi zation and the expansion of shared services; (iv) additional depreciation-asset restructuring, which represents the impact of changes in the estimated useful lives of assets involved in restructuring actions; and (v) transaction costs, representing external costs incurred in connection with an acquisition. Comprehensive Income (Loss) [Abstract] EX-101.PRE 14 pfe-20100404_pre.xml XBRL TAXONOMY EXTENSION PRESENATION LINKBASE EX-101.DEF 15 pfe-20100404_def.xml XBRL TAXONOMY EXTENSION DEFINITION DOCUMENT XML 16 R11.xml IDEA: Comprehensive Income (Loss) 2.0.0.10 false Comprehensive Income (Loss) 000160 - Disclosure - Comprehensive Income (Loss) true false false false 1 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDperShare Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 pfe_ComprehensiveIncomeLossAbstract pfe false na duration string No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false No definition available. false 3 1 us-gaap_ComprehensiveIncomeNoteTextBlock us-gaap true na duration string No definition available. false false false false false false false false false false false verboselabel false 1 false false false false 0 0 <div class="BWxbrlnote6"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <div> <div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><a style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline" id="xbrlnote6" name="xbrlnote6">Note 6. Comprehensive Income/(Loss)</a></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">The components of comprehensive income/(loss) follow:</div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="6"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">Three Months Ended</div></td> <td style="BORDER-TOP: medium none; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 2px solid" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-VARIANT: small-caps; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">(millions of dollars)</div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">April 4,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">&#160;2010</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Mar. 29,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2009</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom">&#160;</td></tr> <tr> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Net income before allocation to noncontrolling interests</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,035</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,730</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Other comprehensive income/(loss):</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -27pt; text-align: left"><font>&#160;</font> Currency translation adjustment and other</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(2,747</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(384</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -27pt; text-align: left"><font>&#160;</font> Net unrealized gains/(losses) on derivative financial instruments</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">134</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(23</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -27pt; text-align: left"><font>&#160;</font> Net unrealized gains/(losses) on available-for-sale securities</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(15</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">145</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -27pt; text-align: left"><font>&#160;</font> Benefit plan adjustments</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">117</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">159</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Total other comprehensive loss</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(2,511</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(103</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">)</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Total comprehensive (loss)/income before allocation to noncontrolling interests</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(476</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,627</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Less: Comprehensive (loss)/income attributable to noncontrolling interests</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(9)</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 4px double" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Comprehensive (loss)/income attributable to Pfizer Inc.</div></td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(467</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,625</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr></table></div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">&#160;</div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">&#160;</div></div></div></div></div> Note 6. Comprehensive Income/(Loss) The components of comprehensive income/(loss) follow: &#160; &#160; Three Months Ended &#160; (millions of false false false This label may include the following: 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income. Components of comprehensive income include: (1) foreign currency translation adjustments; (2) gains and losses on foreign currency transactions that are designated as, and are effective as, economic hedges of a net investment in a foreign entity; (3) gains and losses on intercompany foreign currency transactions that are of a long-term-investment nature, when the entities to the transaction are consolidated, combined, or accounted for by the equity method in the reporting enterprise's financial statements; (4) change in the market value of a futures contract that qualifies as a hedge of an asset reported at fair value; (5) unrealize d holding gains and losses on available-for-sale securities and that resulting from transfers of debt securities from the held-to-maturity category to the available-for-sale category; (6) a net loss recognized as an additional pension liability not yet recognized as net periodic pension cost; and (7) the net gain or loss and net prior service cost or credit for pension plans and other postretirement benefit plans. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 130 -Paragraph 14-26 false false 1 2 false UnKnown UnKnown UnKnown false true XML 17 R10.xml IDEA: Financial Instruments 2.0.0.10 false Financial Instruments 000155 - Disclosure - Financial Instruments true false false false 1 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDperShare Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 pfe_FinancialInstrumentsAbstract pfe false na duration string No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false No definition available. false 3 1 pfe_FinancialInstrumentsDisclosureTextBlock pfe false na duration string This element represents the complete disclosure related to financial instruments, which may include i) selected financial... false false false false false false false false false false false terselabel false 1 false false false false 0 0 <div class="BWxbrlnote5"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <div> <div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><a style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline" id="xbrlnote5" name="xbrlnote5">Note 5. Financial Instruments</a></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-DECORATION: underline; TEXT-INDENT: 0pt; text-align: left">A. Selected Financial Assets and Liabilities</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Information about certain of our financial assets and liabilities follows:</div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr> <td align="left" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-VARIANT: small-caps; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">(millions of dollars)</div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">April 4,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2010</div></td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td align="left" style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Dec. 31,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2009</div></td> <td style="BORDER-TOP: medium none; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom">&#160;</td></tr> <tr> <td valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">Selected financial assets measured at fair value on a recurring basis <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font> :</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td></tr> <tr> <td width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify"><font>&#160;</font> Trading securities <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(b)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">168</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">184</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify"><font>&#160;</font> Available-for-sale debt securities<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(c)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">23,787</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">32,338</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -27pt; text-align: left"><font>&#160;</font> Available-for-sale money market funds<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(d)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,484</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,569</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Available-for-sale equity securities, excluding money market funds<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(c)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">243</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">281</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify"><font>&#160;</font> Derivative financial instruments in receivable positions<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(e)</font>:</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify"><font>&#160;</font> Foreign currency swaps</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">400</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">798</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify"><font>&#160;</font> Interest rate swaps</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">315</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">276</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 2px solid" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify"><font>&#160;</font> Foreign currency forward-exchange contracts</div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">284</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">502</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 2px solid" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify"><font>&#160;</font> Total</div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">26,681</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">36,948</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Other selected financial assets<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(f)</font>:</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Short-term loans, carried at cost <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(g)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">919</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,195</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Held-to-maturity debt securities, carried at amortized cost<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(c)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">642</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">812</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Private equity securities, carried at cost or equity method <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(h)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">858</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">811</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 2px solid" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Long-term loans, carried at cost<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(g)</font></div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">782</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">784</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 2px solid" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify"><font>&#160;</font> Total</div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">3,201</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">3,602</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 4px double" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Total selected financial assets</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(i)</font></div></td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">29,882</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">40,550</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">Financial liabilities measured at fair value on a recurring basis<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font>:</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify"><font>&#160;</font> Derivative financial instruments in a liability position<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(j)</font>:</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify"><font>&#160;</font> Foreign currency forward-exchange contracts</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">351</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">237</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">Foreign currency swaps</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">221</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">528</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 2px solid" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify"><font>&#160;</font> Interest rate swaps</div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">73</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">25</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 2px solid" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify"><font>&#160;</font> Total</div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">645</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">790</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Other financial liabilities <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(k)</font>:</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Short-term borrowings, carried at historical proceeds, as adjusted<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(f), (l)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">7,769</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">5,469</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 2px solid" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Long-term debt, carried at historical proceeds, as adjusted<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(m), (n)</font></div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">38,281</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">43,193</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 2px solid" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Total</div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">46,050</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">48,662</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 4px double" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -18pt; text-align: left">Total selected financial liabilities</div></td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">46,695</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">49,452</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(a)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Fair values are determined based on valuation techniques categorized as follows: Level 1 means the use of quoted prices for identical instruments in active markets; Level 2 means the use of quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active or are directly or indirectly observable; Level 3 means the use of unobservable inputs. Virtually all of our financial assets and liabilities measured at fair value on a recurring basis use Level 2 inputs in the calculation of fair value, except that included in available-for-sale equity securities, excluding money market funds, are $93 million as of April 4, 2010 and $77 million as of December 31, 2009 of investments that use Level 1 inputs in the calculation of fair value. None of our financial assets and liabilities measured at fair value on a recurring basis are valued us ing Level 3 inputs as of April 4, 2010 or December 31, 2009.</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(b)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Trading securities are held in trust for legacy Pharmacia severance benefits.</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(c)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Gross unrealized gains and losses are not significant.</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(d)</div></td> <td style="TEXT-ALIGN: left" width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left">&#160;Includes approximately $1.2 billion of money market funds held in escrow to secure certain of Wyeth's payment obligations under its 1999 Nationwide Class Action Settlement Agreement, which relates to litigation against Wyeth concerning its former weight-loss products, Redux and Pondimin (see <font style="DISPLAY: inline; FONT-STYLE: italic">Note 5G. Financial Instruments: Guarantee).</font></div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(e)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Designated as hedging instruments, except for certain foreign currency contracts used as offsets; namely, foreign currency forward-exchange contracts with fair values of $150 million and foreign currency swaps with fair values of $36 million as of April 4, 2010; and foreign currency swaps with fair values of $106 million and foreign currency forward-exchange contracts with fair values of $100 million at <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">December 31, 2009.</font></div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 18pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(f)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;The differences between the estimated fair values and carrying values of our financial assets and liabilities not measured at fair value on a recurring basis were not significant as of April 4, 2010 or December 31, 2009.</div></td></tr></table></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td align="right" style="WIDTH: 9pt" width="2%"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">(g)</div></td> <td align="left" width="98%"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">&#160;Our short-term and long-term loans are due from companies with highly rated securities (Standard &amp; Poor's (S&amp;P) ratings of mostly AA or better).</div></td></tr></table></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td align="right" style="WIDTH: 9pt" width="2%"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">(h)</div></td> <td align="left" width="98%"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">&#160;Our private equity securities represent investments in the life sciences sector.</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 18pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(i)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;The decrease in selected financial assets is primarily due to the use of proceeds of short-term investments for tax payments made in the first quarter of 2010, associated with certain business decisions executed to finance the Wyeth acquisition.</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 14.4pt" width="2%"> <div style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(j)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Designated as hedging instruments, except for certain foreign currency contracts used as offsets; namely, foreign currency forward exchange contracts with fair values of $157 million and foreign currency swaps with fair values of $72 million as of April 4, 2010; and foreign currency forward-exchange contracts with fair values of $122 million and foreign currency swaps with fair values of $3 million as of December 31, 2009.</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(k)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;The carrying amounts may include adjustments for discount or premium amortization or for the effect of interest rate swaps designated as hedges.</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 18pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(l)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Includes foreign currency borrowings with fair values of $2.3 billion at April 4, 2010 and $1.1 billion as of December 31, 2009, which are used as hedging instruments.</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(m)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Includes foreign currency debt with fair value of $754 million as of April 4, 2010 and $2.1 billion as of December 31, 2009, which is used as a hedging instrument.</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(n)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;The fair value of our long-term debt is $41.7 billion as of April 4, 2010 and $46.2 billion as of December 31, 2009.</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt">We use a market approach to determine the fair value of our financial assets and liabilities and apply the following methods and assumptions:</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">&#160;</div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr valign="top"> <td align="right" style="WIDTH: 9pt" width="1%"> <div style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;&#160;&#160;</div></td> <td width="99%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">Trading equity securities--quoted market prices.</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr valign="top"> <td align="right" style="WIDTH: 9pt" width="1%"> <div style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;&#160;&#160;</div></td> <td width="99%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">Trading debt securities--observable market interest rates.</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr valign="top"> <td align="right" style="WIDTH: 9pt" width="1%"> <div style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;&#160;&#160;</div></td> <td style="TEXT-ALIGN: left" width="99%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt">Available-for-sale debt securities--third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and credit-adjusted interest rate curves.</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr valign="top"> <td align="right" style="WIDTH: 9pt" width="1%"> <div style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;&#160;&#160;</div></td> <td width="99%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">Available-for-sale money market funds--observable prices.</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr valign="top"> <td align="right" style="WIDTH: 9pt" width="1%"> <div style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;&#160;&#160;</div></td> <td style="TEXT-ALIGN: left" width="99%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt">Available-for-sale equity securities, excluding money market funds--third-party pricing services that principally use a composite of observable prices.</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 18pt; TEXT-ALIGN: left" width="1%"> <div style="DISPLAY: inline; FONT-FAMILY: symbol, serif; FONT-SIZE: 10pt; TEXT-ALIGN: left">&#183;&#160;&#160;</div></td> <td style="TEXT-ALIGN: left" width="99%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt">Derivative financial instruments (assets and liabilities)-- third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data.&#160;&#160;Where applicable, these models discount future cash flow amounts using market-based observable inputs including interest rate curves, foreign exchange rates, and forward and spot prices for currencies.&#160;&#160;The credit risk impact to our derivative financial instruments was not significant.</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr valign="top"> <td align="right" style="WIDTH: 9pt" width="1%"> <div style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;&#160;&#160;</div></td> <td style="TEXT-ALIGN: left" width="99%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt">Held-to-maturity debt securities-- third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and credit-adjusted interest rate curves.</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr valign="top"> <td align="right" style="WIDTH: 9pt" width="1%"> <div style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;&#160;&#160;</div></td> <td style="TEXT-ALIGN: left" width="99%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt">Short-term and long-term loans--<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font>third-party model that discounts future cash flows using current interest rates at which similar loans would be made to borrowers with similar credit ratings and for the same remaining maturities.</div></td></tr></table></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">&#160;</div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr valign="top"> <td align="right" style="WIDTH: 9pt" width="1%"> <div style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;&#160;&#160;</div></td> <td style="TEXT-ALIGN: left" width="99%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt">Private equity securities--application of the implied volatility associated with an observable biotech index to the carrying amount of our portfolio and, to a lesser extent, performance multiples of comparable securities adjusted for company-specific information.</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr valign="top"> <td align="right" style="WIDTH: 9pt" width="1%"> <div style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;&#160;&#160;</div></td> <td style="TEXT-ALIGN: left" width="99%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt">Short-term borrowings and long-term debt-- third-party matrix-pricing model that uses significant inputs derived from or collaborated by observable market data and our own credit rating.</div></td></tr></table></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">&#160;</div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">In addition, we have long-term receivables where the determination of fair value uses discounted future cash flows, using current interest rates at which similar loans would be made to borrowers with similar credit ratings and for the same remaining maturities.</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">&#160;</div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">These selected financial assets and liabilities are presented in the condensed consolidated balance sheets as follows:</div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr> <td align="left" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-VARIANT: small-caps; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">(millions of dollars)</div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="11%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">April 4,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2010</div></td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="11%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Dec. 31,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2009</div></td> <td style="BORDER-TOP: medium none; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">Assets</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-STYLE: italic; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">Cash and cash equivalents</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">380</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">666</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-STYLE: italic; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify"><font>&#160;</font> Short-term investments</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">15,503</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">23,991</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-STYLE: italic; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify"><font>&#160;</font> Short-term loans</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">919</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,195</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-STYLE: italic; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify"><font>&#160;</font> Long-term investments and loans</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">12,081</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">13,122</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> <font style="DISPLAY: inline; FONT-STYLE: italic">Current deferred tax assets and other current assets</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">313</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">526</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 2px solid" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify"><font>&#160;</font> <font style="DISPLAY: inline; FONT-STYLE: italic">Noncurrent deferred tax assets and other noncurrent assets</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(b)</font></div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">686</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,050</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 2px solid" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">Total</div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">29,882</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">40,550</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">Liabilities</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-STYLE: italic; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">Short-term borrowings, including current portion of long-term debt</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">7,769</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">5,469</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify"><font style="DISPLAY: inline; FONT-STYLE: italic">Current deferred tax liabilities and other current liabilities</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(c)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">414</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">369</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-STYLE: italic; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">Long-term debt</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">38,281</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">43,193</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 2px solid" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify"><font style="DISPLAY: inline; FONT-STYLE: italic">Other noncurrent liabilities</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(d)</font></div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">231</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">421</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 4px double" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">Total</div></td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">46,695</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">49,452</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(a)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;As of April 4, 2010, derivative instruments at fair value include foreign currency forward-exchange contracts ($284 million) and foreign currency swaps ($29 million) and as of December 31, 2009, include foreign currency forward-exchange contracts ($503 million) and foreign currency swaps ($23 million).</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(b)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;As of April 4, 2010, derivative instruments at fair value include foreign currency swaps ($371 million) and interest rate swaps ($315 million) and as of December 31, 2009, include foreign currency swaps ($774 million) and interest rate swaps ($276 million).</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(c)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;As of April 4, 2010, derivative instruments at fair value include foreign currency forward-exchange contracts ($351 million) and foreign currency swaps ($63 million) and as of December 31, 2009, include foreign currency forward-exchange contracts ($237 million) and foreign currency swaps ($132 million).</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(d)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;As of April 4, 2010, derivative instruments at fair value include foreign currency swaps ($158 million) and interest rate swaps ($73 million) and as of December 31, 2009, include foreign currency swaps ($396 million) and interest rate swaps ($25 million).</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">We regularly evaluate all of our financial assets for impairment. For investments in debt and equity securities, when a decline in fair value, if any, is determined to be other-than-temporary, an impairment charge is recorded, and a new cost basis in the investment is established. For loans, an impairment charge is recorded if it is probable that we will not be able to collect all amounts due according to the loan agreement. There were no significant impairments recognized in the first quarter of 2010 or the year ended December 31, 2009.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-DECORATION: underline; TEXT-INDENT: 0pt; text-align: left">B. Investments in Debt and Equity Securities</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">The contractual maturities of the available-for-sale and held-to-maturity debt securities as of April 4, 2010, follow:</div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="6"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">Years</div></td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" valign="bottom" colspan="2">&#160;</td> <td style="BORDER-TOP: medium none; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 2px solid" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-VARIANT: small-caps; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">(millions of dollars)</div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Within 1</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Over 1</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">to 5</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Total as of</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">April 4,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2010</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom">&#160;</td></tr> <tr> <td align="left" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -27pt; text-align: left">Available-for-sale debt securities:</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="61%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Western<font style="DISPLAY: inline; FONT-FAMILY: times new roman">&#160;</font>European and other government debt</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">9,157</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,576</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">11,733</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="61%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Western European and other government agency debt</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,678</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">266</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,944</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="61%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Corporate debt<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">996</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,885</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,881</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="61%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -18pt; text-align: left"><font>&#160;</font> Federal Home Loan Mortgage Corporation and Federal National Mortgage</div> <div style="DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -18pt; text-align: left">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Association asset-backed securities</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">102</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,531</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,633</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="61%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Reverse repurchase agreements<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(b)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,263</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,263</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="61%" valign="bottom"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font>&#160;</font> U.S. government Federal Deposit Insurance Corporation&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">guaranteed debt</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,101</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,101</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="61%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Supranational debt</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">636</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">386</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,022</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="61%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Other asset-backed securities</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">33</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">125</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">158</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="61%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Certificates of deposit</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">52</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">52</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="61%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -27pt; text-align: left">Held-to-maturity debt securities:</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="61%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Certificates of deposit and other</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">636</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">6</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">642</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="61%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -27pt; text-align: left">Total debt securities</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">15,553</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">8,876</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">24,429</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="61%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -27pt; text-align: left">Trading securities</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">168</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="61%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -27pt; text-align: left">Available-for-sale money market funds<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(c)</font></div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,484</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="61%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left">Available-for-sale equity securities, excluding money market funds</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">243</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 4px double" width="61%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -27pt; text-align: left">Total</div></td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">26,324</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(a)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Largely issued by above-investment-grade institutions in the financial services sector.</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 9.35pt" width="2%"> <div style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(b)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Very short-term agreements involving U.S. government securities.</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(c)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Consisting of securities issued by the U.S. government and its agencies or instrumentalities and reverse repurchase agreements involving the same investments held.</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-DECORATION: underline; TEXT-INDENT: 0pt; text-align: left">C. Short-Term Borrowings</div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Short-term borrowings include amounts for commercial paper of $3.1 billion as of April 4, 2010 and $3.9 billion as of December 31, 2009.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-DECORATION: underline; TEXT-INDENT: 0pt; text-align: left">D. Long-Term Debt</div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">In March 2007, we filed a securities registration statement with the SEC. The registration statement was filed under the automatic shelf registration process available to "well-known seasoned issuers" and expired in March 2010. On March 24, 2009, in order to partially finance our acquisition of Wyeth, we issued $13.5 billion of senior unsecured notes under this registration statement. On June 3, 2009, also in order to partially finance our acquisition of Wyeth, we issued approximately $10.5 billion of senior unsecured notes in a private placement pursuant to Regulation S under the Securities Act of 1933, as amended (Securities Act of 1933). The notes have not been and will not be registered under the Securities Act of 1933 and, subject to certain exceptions, may not be sold, offered or delivered within the U.S. to, or for, the account or benefit of U.S. per sons.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-DECORATION: underline; TEXT-INDENT: 0pt; text-align: left">E. Derivative Financial Instruments and Hedging Activities</div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Foreign Exchange Risk</font>-A significant portion of our revenues, earnings and net investments in foreign affiliates is exposed to changes in foreign exchange rates. We seek to manage our foreign exchange risk, in part, through operational means, including managing expected same-currency revenues in relation to same-currency costs and same-currency assets in relation to same-currency liabilities. Depending on market conditions, foreign exchange risk also is managed through the use of derivative financial instruments and foreign currency debt. These financial instruments serve to protect net income and net investments against the impact of the translation into U.S. dollars of certain foreign exchange-denominated transactions. The aggregate notional amount of foreign exchange derivative financial instruments hedging or offsetting foreign currency exposures is $44.8 billion. The derivative financial instruments primarily hedge or offset exposures in euro, Japanese yen and U.K. pound. The maximum length of time over which we are hedging future foreign exchange cash flows relates to our $2.4 billion U.K. pound debt maturing in 2038.</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">&#160;</div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Interest Rate Risk-</font>Our interest-bearing investments, loans and borrowings are subject to interest rate risk. We seek to invest and loan primarily on a short-term or variable-rate basis; however, in light of current market conditions, we currently borrow primarily on a long-term, fixed-rate basis. From time to time, depending on market conditions, we will change the profile of our outstanding debt by entering into derivative financial instruments like interest rate swaps.</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">&#160;</div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">We entered into derivative financial instruments to hedge or offset the fixed interest rates on the hedged item, matching the amount and timing of the hedged item. The aggregate notional amount of interest rate derivative financial instruments is $9.2 billion. The derivative financial instruments hedge U.S. dollar and euro fixed-rate debt.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Information about gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk is as follows:</div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="74%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid" width="24%" valign="bottom" colspan="6"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">Gains/(Losses)</div></td> <td style="BORDER-TOP: medium none; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="74%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid" width="24%" valign="bottom" colspan="6"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">Three Months Ended</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 2px solid" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-VARIANT: small-caps; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">(millions of dollars)</div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="11%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">April 4, 2010</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="11%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Mar. 29, 2009</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Derivative Financial Instruments in Fair Value Hedge Relationships</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Interest rate swaps</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Recognized in OID<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(284</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Foreign currency swaps</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 2px solid" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Recognized in OID<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(1</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">)</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Derivative Financial Instruments in Cash Flow Hedge Relationships</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> U.S. Treasury interest rate locks</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Recognized in OID<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(11</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Recognized in OCI<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">,</font> <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(b)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(15</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Reclassified from OCI to OID<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a), (b)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Foreign currency swaps</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Recognized in OID<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Recognized in OCI<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a), (b)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(438</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(19</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Reclassified from OCI to OID<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a), (b)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(628</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Foreign currency forward exchange contracts</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Recognized in OID<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Recognized in OCI<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a), (b)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 2px solid" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Reclassified from OCI to OID<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a), (b)</font></div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">10</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Derivative Financial Instruments in Net Investment Hedge Relationships</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Foreign currency swaps</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Recognized in OID<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(2</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 2px solid" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Recognized in OCI<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">,</font> <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(b)</font></div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">11</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">53</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Derivative Financial Instruments Not Designated as Hedges</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Foreign currency swaps</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Recognized in OID<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">4</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(5</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Foreign currency forward-exchange contracts</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 2px solid" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Recognized in OID<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(890</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(255</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">)</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Non-Derivative Financial Instruments in Net Investment Hedge Relationships</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Foreign currency short-term borrowings</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Recognized in OID<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Recognized in OCI<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">,</font> <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(b)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">31</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">110</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Foreign currency long-term debt</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Recognized in OID<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 4px double" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Recognized in OCI<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a), (b)</font></div></td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">16</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">158</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(a)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;OID = <font style="DISPLAY: inline; FONT-STYLE: italic">Other (income)/deductions--net.</font> OCI = <font style="DISPLAY: inline; FONT-STYLE: italic">Other comprehensive income/(expense),</font> a balance sheet account.</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(b)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Amounts presented represent the effective portion of the gain or loss. For derivative financial instruments in cash flow hedge relationships, the effective portion is included in <font style="DISPLAY: inline; FONT-STYLE: italic">Other comprehensive income/(expense) - Net unrealized gains/(losses) on derivative financial instruments</font>. For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the effective portion is included in <font style="DISPLAY: inline; FONT-STYLE: italic">Other comprehensive income/(expense)--Currency translation adjustment.</font></div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">For information about the fair value of our derivative financial instruments, and the impact on our Condensed Consolidated Balance Sheets, see <font style="DISPLAY: inline; FONT-STYLE: italic">Note 5A. Financial Instruments: Selected Financial Assets and Liabilities.</font> Certain of our derivative instruments are covered by associated credit-support agreements that have credit-risk-related contingent features designed to reduce our counterparties' exposure to our risk of defaulting on amounts owed. The aggregate fair value of these derivative instruments that are in a liability position is $353 million, for which we have posted collateral of $188 million in the normal course of business. These features include the requirement to pay additional collateral in the event of a downgrade in our debt ratings. If there had been a downgrade to below an A rating by S&amp;P or the equivalent rating by Moody's Investors Service, on April 4, 2010, we would have been required to post an additional $171 million of collateral to our counterparties. The collateral advanced receivables are reported in <font style="DISPLAY: inline; FONT-STYLE: italic">Short-term loans.</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-DECORATION: underline; TEXT-INDENT: 0pt; text-align: left">F. Credit Risk</div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">On an ongoing basis, we review the creditworthiness of counterparties to our foreign exchange and interest rate agreements and do not expect to incur a significant loss from failure of any counterparties to perform under the agreements. There are no significant concentrations of credit risk related to our financial instruments with any individual counterparty. As of April 4, 2010, we had $2.1 billion due from a well-diversified, highly rated group (S&amp;P ratings of primarily A+ or better) of bank counterparties around the world.&#160;&#160;See <font style="DISPLAY: inline; FONT-STYLE: italic">Note 5B.&#160;&#160;Financial Instruments: Investment in Debt and Equity Securities</font> for a distribution of our investments.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">In general, there is no requirement for collateral from customers. However, derivative financial instruments are executed under master netting agreements with financial institutions. These agreements contain provisions that provide for the ability for collateral payments, depending on levels of exposure, our credit rating and the credit rating of the counterparty. As of April 4, 2010, we received cash collateral of $518 million against various counterparties. The collateral primarily supports the approximate fair value of our derivative contracts. The collateral received obligations are reported in <font style="DISPLAY: inline; FONT-STYLE: italic">Short-term borrowings, including current portion of long-term debt.</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-DECORATION: underline; TEXT-INDENT: 0pt; text-align: left">G. Guarantee</div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">In April 2010, Wyeth LLC (Wyeth), a wholly owned subsidiary of Pfizer Inc. (Pfizer), entered into the Tenth Amendment (Tenth Amendment) to the 1999 Diet Drug Nationwide Settlement Agreement (Settlement Agreement) related to the litigation against Wyeth concerning its former weight-loss products, Redux and Pondimin. Pursuant to the Tenth Amendment, Pfizer entered into an agreement to guarantee Wyeth's obligation to make certain payments under the Settlement Agreement up to a maximum amount of $1.5 billion (Guarantee). The Guarantee will remain in effect until the termination of Wyeth's long-term obligation to make such payments. The Tenth Amendment and the Guarantee are subject to the approval of the United States District Court for the Eastern District of Pennsylvania and will become effective following such approval.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div></div></div></div></div> Note 5. Financial Instruments A. Selected Financial Assets and Liabilities Information about certain of our financial assets and liabilities false false false This element represents the complete disclosure related to financial instruments, which may include i) selected financial assets and liabilities; ii) investments in debt and equity securities; iii) short-term borrowings; iv) long-term debt; v) derivative financial instruments and hedging activities; vi) credit risk; and vii) other disclosures related to financial instruments. No authoritative reference available. false false 1 2 false UnKnown UnKnown UnKnown false true XML 18 R8.xml IDEA: Acquisition of Wyeth 2.0.0.10 false Acquisition of Wyeth 000120 - Disclosure - Acquisition of Wyeth true false false false 1 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDperShare Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 pfe_AcquisitionOfWyethAbstract pfe false na duration string No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false No definition available. false 3 1 us-gaap_BusinessCombinationDisclosureTextBlock us-gaap true na duration string No definition available. false false false false false false false false false false false false 1 false false false false 0 0 <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline"><a name="xbrlnote3">Note 3. Acquisition of Wyeth</a></font></font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On October 15, 2009 (the acquisition date), we acquired all of the outstanding equity of Wyeth in a cash-and-stock transaction, valued at the acquisition date at approximately $68 billion. While Wyeth now is a wholly-owned subsidiary of Pfizer, the merger of local Pfizer and Wyeth entities may be pending or delayed in various international jurisdictions and integration in these jurisdictions is subject to completion of various local legal and regulatory obligations.</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Recording of Assets Acquired and Liabilities Assumed</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table summarizes the provisional amounts recognized for assets acquired and liabilities assumed as of the acquisition date as well as adjustments made in the first quarter of 2010 to the amounts initially recorded in 2009 (measurement period adjustments). The measurement period adjustments did not have a significant impact on our consolidated statements of income, balance sheets or cash flows in any period and, therefore, we have not retrospectively adjusted our financial statements. Certain estimated values are not yet finalized (see below) and are subject to change, which could be significant. We will finalize the amounts recognized as we obtain the information necessary to complete the analyses, but no later than one year from the acquisition date.</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div align="left"> <table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td align="left" valign="bottom" width="50%" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid"> <div align="left" style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-VARIANT: small-caps">(millions of dollars)</font></div></td> <td align="right" valign="bottom" width="1%" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td colspan="2" valign="bottom" width="16%" style="BORDER-TOP: black 1.5pt solid; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Amounts Recognized</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">as of Acquisition Date</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(as previously reported)</font></div></td> <td valign="bottom" nowrap="nowrap" width="1%" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td align="right" valign="bottom" width="1%" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td colspan="2" valign="bottom" width="14%" style="BORDER-TOP: black 1.5pt solid; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Measurement </font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Period </font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Adjustments</font></div></td> <td valign="bottom" nowrap="nowrap" width="1%" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td align="right" valign="bottom" width="1%" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td colspan="2" valign="bottom" width="14%" style="BORDER-TOP: black 1.5pt solid; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Amounts Recognized</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">as of Acquisition Date</font></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(as adjusted)</font></div></td> <td valign="bottom" nowrap="nowrap" width="1%" style="BORDER-TOP: medium none; PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td></tr> <tr> <td valign="bottom" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td colspan="2" valign="bottom" width="16%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td colspan="2" valign="bottom" width="14%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td colspan="2" valign="bottom" width="14%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td></tr> <tr> <td align="left" valign="bottom" width="50%"> <div align="left" style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Working capital, excluding inventories</font></div></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td> <td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">16,342</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8211;&#8211;</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">16,342</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td></tr> <tr> <td align="left" valign="bottom" width="50%"> <div align="left" style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Inventories</font></div></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,388</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(167</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,221</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td></tr> <tr> <td align="left" valign="bottom" width="50%"> <div align="left" style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Property, plant and equipment</font></div></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10,054</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(171</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9,883</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td></tr> <tr> <td align="left" valign="bottom" width="50%"> <div align="left" style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Identifiable intangible assets, excluding</font></div> <div align="left" style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font id="TAB1a" style="MARGIN-LEFT: 9pt"/>in-process research and development <font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></font></font></div></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">37,595</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(452</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">37,143</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td></tr> <tr> <td align="left" valign="bottom" width="50%"> <div align="left" style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">In-process research and development <font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></font></font></div></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">14,918</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(956</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">13,962</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td></tr> <tr> <td align="left" valign="bottom" width="50%"> <div align="left" style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Other noncurrent assets</font></div></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,394</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8211;&#8211;</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,394</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td></tr> <tr> <td align="left" valign="bottom" width="50%"> <div align="left" style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Long-term debt</font></div></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(11,187</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8211;&#8211;</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(11,187</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td></tr> <tr> <td align="left" valign="bottom" width="50%"> <div align="left" style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Benefit obligations</font></div></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(3,211</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8211;&#8211;</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(3,211</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td></tr> <tr> <td align="left" valign="bottom" width="50%"> <div align="left" style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net tax accounts</font></div></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(24,773</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">761</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(24,012</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td></tr> <tr> <td align="left" valign="bottom" width="50%" style="PADDING-BOTTOM: 2px"> <div align="left" style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Other noncurrent liabilities</font></div></td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,908</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8211;&#8211;</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,908</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td></tr> <tr> <td align="left" valign="bottom" width="50%"> <div align="left" style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total identifiable net assets</font></div></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">48,612</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(985</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">47,627</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td></tr> <tr> <td align="left" valign="bottom" width="50%" style="PADDING-BOTTOM: 2px"> <div align="left" style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Goodwill</font></div></td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">19,954</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">985</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">20,939</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td></tr> <tr> <td align="left" valign="bottom" width="50%"> <div align="left" style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net assets acquired</font></div></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="15%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">68,566</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8211;&#8211;</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">68,566</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td></tr> <tr> <td align="left" valign="bottom" width="50%" style="PADDING-BOTTOM: 2px"> <div align="left" style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Less: Amounts attributable to</font></div> <div align="left" style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font id="TAB1b" style="MARGIN-LEFT: 10pt"/>noncontrolling interests</font></div></td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(330</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8211;&#8211;</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(330</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td></tr> <tr> <td align="left" valign="bottom" width="50%" style="BORDER-BOTTOM: black 4px double"> <div align="left" style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total consideration transferred</font></div></td> <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td> <td valign="bottom" width="15%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">68,236</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td> <td valign="bottom" width="13%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#8211;&#8211;</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td> <td valign="bottom" width="13%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">68,236</font></td> <td valign="bottom" nowrap="nowrap" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td></tr></table></div> <div align="left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellpadding="0" width="100%" cellspacing="0" border="0" id="hangingindent"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(a)</font></div></td> <td style="TEXT-ALIGN: left" width="98%"> <div style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;The measurement period adjustments for <font style="DISPLAY: inline; FONT-STYLE: italic">Identifiable intangible assets</font> reflect changes in the estimated fair value of certain acquired intangibles, principally in-process research and development assets, primarily to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date.&#160;&#160;The measurement period adjustments did not result from intervening events subsequent to the acquisition date.</font></div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The recorded amounts are provisional and subject to change. Specifically, the following items are subject to change:</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div align="left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellpadding="0" width="100%" cellspacing="0" id="list1"> <tr valign="top"> <td style="WIDTH: 9pt" width="1%" align="right"> <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;&#160;&#160;</font></div></td> <td width="99%"> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Amounts for intangibles and inventory, pending finalization of valuation efforts.</font></div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div align="left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellpadding="0" width="100%" cellspacing="0" id="list2"> <tr valign="top"> <td style="WIDTH: 9pt" width="1%" align="right"> <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;&#160;&#160;</font></div></td> <td style="TEXT-ALIGN: left" width="99%"> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Amounts for legal contingencies, pending the finalization of our examination and evaluation of the portfolio of filed cases.</font></div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div align="left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellpadding="0" width="100%" cellspacing="0" id="list3"> <tr valign="top"> <td style="WIDTH: 9pt" width="1%" align="right"> <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;&#160;&#160;</font></div></td> <td style="TEXT-ALIGN: left" width="99%"> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Amounts for income tax assets, receivables and liabilities pending the filing of Wyeth pre-acquisition tax returns, including all required disclosures and documentation, as well as the receipt of information from taxing authorities which may change certain estimates and assumptions used.</font></div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div align="left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellpadding="0" width="100%" cellspacing="0" id="list4"> <tr valign="top"> <td style="WIDTH: 9pt" width="1%" align="right"> <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;&#160;&#160;</font></div></td> <td width="99%"> <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The allocation of goodwill among reporting units.</font></div></td></tr></table></div> Note 3. Acquisition of Wyeth &#160; On October 15, 2009 (the acquisition date), we acquired all of the outstanding equity of Wyeth in a cash-and-stock false false false Description of a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. This element may be used as a single block of text to encapsulate the entire disclosure (including data and tables) regarding business combinations, including leverage buyout transactions (as applicable). Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141 -Paragraph 51, 52 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 88-16 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141R -Paragraph 67-73 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141R -Paragraph F4 -Subparagraph e -Appendix F false false 1 2 false UnKnown UnKnown UnKnown false true XML 19 R12.xml IDEA: Inventories 2.0.0.10 false Inventories 000180 - Disclosure - Inventories true false false false 1 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDperShare Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 pfe_InventoriesAbstract pfe false na duration string No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false No definition available. false 3 1 us-gaap_InventoryDisclosureTextBlock us-gaap true na duration string No definition available. false false false false false false false false false false false false 1 false false false false 0 0 <div class="BWxbrlnote7"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <div> <div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><a style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline" id="xbrlnote7" name="xbrlnote7">Note 7. Inventories</a></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">The components of inventories follow:</div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr> <td align="left" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-VARIANT: small-caps; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">&#160;(millions of dollars)</div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">April 4,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2010</div></td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td align="left" style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Dec. 31,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2009</div></td> <td style="BORDER-TOP: medium none; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom">&#160;</td></tr> <tr> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Finished goods</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">4,535</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">5,249</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Work-in-process</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">4,233</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">5,776</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Raw materials and supplies</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,364</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,378</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 4px double" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Total inventories<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">10,132</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">12,403</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 9pt" width="2%"> <div style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(a)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;The decrease in total inventories is primarily due to the inventory sold during the first quarter of 2010 that was acquired from Wyeth and had been recorded at fair value, as well as operational reductions and the impact of foreign exchange. Certain amounts of inventories are in excess of one year's supply.&#160;&#160;These excess amounts are primarily attributable to biologics inventory acquired from Wyeth and recorded at fair value and the quantities are generally consistent with the normal operating cycle of such inventory. There are no recoverability issues associated with these quantities.</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div></div></div></div></div> Note 7. Inventories The components of inventories follow: &#160;(millions of dollars) &#160; April 4, 2010 &#160; &#160; Dec. false false false This element represents the complete disclosure related to inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 43 -Chapter 3 -Section A -Paragraph 9 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 6 -Subparagraph a, b, c -Article 5 false false 1 2 false UnKnown UnKnown UnKnown false true XML 20 R3.xml IDEA: CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) 2.0.0.10 false CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) (USD $) 000030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) true false In Millions, except Per Share data false false 1 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDperShare Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 false 2 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDperShare Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 5 3 us-gaap_SalesRevenueNet us-gaap true credit duration monetary No definition available. false false false false false false false false false false false false 1 true true false false 16750000000 16750 false false false 2 true true false false 10867000000 10867 false false false Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 false 6 3 us-gaap_CostsAndExpensesAbstract us-gaap true na duration string No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false No definition available. false 7 4 us-gaap_CostOfGoodsAndServicesSold us-gaap true debit duration monetary No definition available. false false false false false false false false false false false false 1 false true false false 4306000000 4306 [1] false false false 2 false true false false 1408000000 1408 [1] false false false The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 2 -Article 5 false 8 4 us-gaap_SellingGeneralAndAdministrativeExpense us-gaap true debit duration monetary No definition available. false false false false false false false false false false false false 1 false true false false 4436000000 4436 [1] false false false 2 false true false false 2876000000 2876 [1] false false false The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 4 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 43 -Chapter 4 -Paragraph 5A false 9 4 us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost us-gaap true debit duration monetary No definition available. false false false false false false false false false false false false 1 false true false false 2226000000 2226 [1] false false false 2 false true false false 1705000000 1705 [1] false false false The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 86 -Paragraph 11 -Subparagraph b Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 86 -Paragraph 3 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 2 -Paragraph 8, 12, 13 false 10 4 us-gaap_AmortizationOfIntangibleAssets us-gaap true debit duration monetary No definition available. false false false false false false false false false false false false 1 false true false false 1409000000 1409 false false false 2 false true false false 578000000 578 false false false The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by (used in) operations using the indirect method. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 142 -Paragraph 45 -Subparagraph a(2) false 11 4 us-gaap_ResearchAndDevelopmentInProcess us-gaap true debit duration monetary No definition available. false false false false false false false false false false false false 1 false true false false 74000000 74 false false false 2 false false false false 0 0 false false false The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141 -Paragraph 51 -Subparagraph g Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Interpretation (FIN) -Number 4 -Paragraph 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 2 -Paragraph 13 false 12 4 pfe_RestructuringChargesAndAcquisitionRelatedCosts pfe false debit duration monetary This element represents (i) restructuring charges, which are amounts charged against earnings in the period for incurred and... false false false false false false false false false false false terselabel false 1 false true false false 706000000 706 false false false 2 false true false false 554000000 554 false false false This element represents (i) restructuring charges, which are amounts charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a program that is planned and controlled by management, and materially changes either the scope of a business undertaken by an entity, or the manner in which that business is conducted; and (ii) acquisition-related costs, which are costs incurred to effect a business combination which costs have been expensed during the period. Such costs can include transaction costs such as banking, legal, accounting and other costs directly related to effect a business combination as well as external, incremental costs of integration planning that are directly related to a business combination, including costs associated with preparing for systems and other integration activities. No authoritative reference available. false 13 4 pfe_OtherIncomeExpenseNet pfe false debit duration monetary This element represents (i) the total amount of other operating income, not previously categorized, from items that are... false false false false false false false false false false false verboselabel false 1 false true false false 414000000 414 false false false 2 false true false false -57000000 -57 false false false This element represents (i) the total amount of other operating income, not previously categorized, from items that are associated with the entity's normal revenue producing operation; and (ii) recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales, as well as excludes research and development expenses and selling, informational and administrative expenses. No authoritative reference available. false 14 3 us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments us-gaap true credit duration monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false 3179000000 3179 false false false 2 false true false false 3803000000 3803 false false false Sum of operating profit and nonoperating income (expense) before income (loss) from equity method investments, income taxes, extraordinary items, cumulative effects of changes in accounting principles, and noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph h -Subparagraph 1(i) -Article 4 true 15 3 us-gaap_IncomeTaxExpenseBenefit us-gaap true debit duration monetary No definition available. false false false false false false false false false false false false 1 false true false false 1146000000 1146 false false false 2 false true false false 1074000000 1074 false false false The sum of the current income tax expense (benefit) and the deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph h -Article 4 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 109 -Paragraph 45 -Subparagraph a, b false 16 3 us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest us-gaap true credit duration monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false 2033000000 2033 false false false 2 false true false false 2729000000 2729 false false false This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items, cumulative effects of changes in accounting principles, and noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 29 true 17 3 us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax us-gaap true credit duration monetary No definition available. false false false false false false false false false false false terselabel false 1 false true false false 2000000 2 false false false 2 false true false false 1000000 1 false false false This element represents the overall income (loss) from a disposal group that is classified as a component of the entity, net of income tax, reported as a separate component of income before extraordinary items and the cumulative effect of accounting changes before deduction or consideration of the amount which may be allocable to noncontrolling interests, if any. Includes the following (net of tax): income (loss) from operations during the phase-out period, gain (loss) on disposal, provision (or any reversals of earlier provisions) for loss on disposal, and adjustments of a prior period gain (loss) on disposal. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 13 -Article 7 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 15 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 29 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 144 -Paragraph 43 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 144 -Paragraph 47 -Subparagraph c false 18 3 us-gaap_ProfitLoss us-gaap true credit duration monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false 2035000000 2035 false false false 2 false true false false 2730000000 2730 false false false The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A1, A4, A5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 5 -Subparagraph b Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 29 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph a Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph c(1) true 19 3 us-gaap_NetIncomeLossAttributableToNoncontrollingInterest us-gaap true debit duration monetary No definition available. false false false false false false false false false false false false 1 false true false false 9000000 9 false false false 2 false true false false 1000000 1 false false false The portion of net income (loss) attributable to the noncontrolling interest (if any) deducted in order to derive the portion attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph a Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph c(1) Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A1, A4, A5 false 20 3 us-gaap_NetIncomeLoss us-gaap true credit duration monetary No definition available. false false false false false false false false false false false totallabel false 1 true true false false 2026000000 2026 false false false 2 true true false false 2729000000 2729 false false false The portion of consolidated profit or loss for the period, net of income taxes, which is attributable to the parent. If the entity does not present consolidated financial statements, the amount of profit or loss for the period, net of income taxes. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph d Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A7 -Appendix A Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph a Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 130 -Paragraph 10, 15 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 87-21 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28, 29, 30 true 21 3 us-gaap_EarningsPerShareBasicAbstract us-gaap true na duration string No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false No definition available. false 22 4 us-gaap_IncomeLossFromContinuingOperationsPerBasicShare us-gaap true na duration decimal No definition available. false false false false false false false false false false false true 1 true true false false 0.25 0.25 false false false 2 true true false false 0.41 0.41 false false false The amount of income (loss) from continuing operations per each share of common stock outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 21 -Article 9 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 36, 37, 38 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 20 -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 18 -Article 7 false 23 4 us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare us-gaap true na duration decimal No definition available. false false false false false false false false false false false true 1 true true false false 0 0 false false false 2 true true false false 0 0 false false false The amount of income (loss) from disposition of discontinued operations, net of related tax effect, per each share of common stock outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 8, 9, 10, 36, 37, 38 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 20 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 18 -Article 7 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 21 -Article 9 false 24 4 us-gaap_EarningsPerShareBasic us-gaap true na duration decimal No definition available. false false false false false false false false false false false totallabel true 1 true true false false 0.25 0.25 false false false 2 true true false false 0.41 0.41 false false false The amount of net income or loss for the period per each share of common stock outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 21 -Article 9 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 36, 37, 38 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 20 -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 18 -Article 7 true 25 3 us-gaap_EarningsPerShareDilutedAbstract us-gaap true na duration string No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false No definition available. false 26 4 us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare us-gaap true na duration decimal No definition available. false false false false false false false false false false false terselabel true 1 true true false false 0.25 0.25 false false false 2 true true false false 0.40 0.40 false false false The amount of income (loss) from continuing operations available to each share of common stock outstanding during the reporting period and each share that would have been outstanding assuming the issuance of common shares for all dilutive potential common shares outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 21 -Article 9 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 11, 12, 36, 37, 38 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 40 -Subparagraph a Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 20 -Article 5 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 18 -Article 7 false 27 4 us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare us-gaap true na duration decimal No definition available. false false false false false false false false false false false terselabel true 1 true true false false 0 0 false false false 2 true true false false 0 0 false false false The amount of income (loss) from discontinued operations, net of related tax effect, per each diluted share of common stock outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 5 -Section E -Paragraph Question 3 false 28 4 us-gaap_EarningsPerShareDiluted us-gaap true na duration decimal No definition available. false false false false false false false false false false false totallabel true 1 true true false false 0.25 0.25 false false false 2 true true false false 0.40 0.40 false false false The amount of net income or loss for the period per each share of common stock and dilutive common stock equivalents outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 11, 12, 36 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 20 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 18 -Article 7 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 21 -Article 9 true 29 3 pfe_EarningsPerShareOtherDisclosuresAbstract pfe false na duration string No definition available. false false false false false true false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false No definition available. false 30 4 us-gaap_WeightedAverageNumberOfSharesOutstandingBasic us-gaap true na duration shares No definition available. false false false false false false false false false false false false 1 false true false false 8061000000 8061 false false false 2 false true false false 6723000000 6723 false false false Number of [basic] shares, after adjustment for contingently issuable shares and other shares not deemed outstanding, determined by relating the portion of time within a reporting period that common shares have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 171 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 40 -Subparagraph a Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 8 false 31 4 us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding us-gaap true na duration shares No definition available. false false false false false false false false false false false false 1 false true false false 8101000000 8101 false false false 2 false true false false 6753000000 6753 false false false The average number of shares issued and outstanding that are used in calculating diluted EPS, determined based on the timing of issuance of shares in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 40 -Subparagraph a Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 8 false 32 3 us-gaap_CommonStockDividendsPerShareCashPaid us-gaap true na duration decimal No definition available. false false false false false false false false false false false true 1 true true false false 0.18 0.18 false false false 2 true true false false 0.32 0.32 false false false Aggregate dividends paid during the period for each share of common stock outstanding. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 false 1 Exclusive of amortization of intangible assets, except as disclosed in Note 8B. Goodwill and Other Intangible Assets: Other Intangible Assets. false 2 28 false Millions Millions Hundreds false true XML 21 R14.xml IDEA: Pension and Postretirement Benefit Plans 2.0.0.10 false Pension and Postretirement Benefit Plans 000200 - Disclosure - Pension and Postretirement Benefit Plans true false false false 1 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDperShare Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 pfe_PensionAndPostretirementBenefitPlansAbstract pfe false na duration string No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false No definition available. false 3 1 us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock us-gaap true na duration string No definition available. false false false false false false false false false false false false 1 false false false false 0 0 <div class="BWxbrlnote9"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <div> <div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><a style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline" id="xbrlnote9" name="xbrlnote9">Note 9. Pension and Postretirement Benefit Plans</a></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">The components of net periodic benefit costs of the U.S. and international pension plans and the postretirement plans, which provide medical and life insurance benefits to retirees and their eligible dependents, follow:</div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="28%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid" width="52%" valign="bottom" colspan="22"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">Pension Plans</div></td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="16%" valign="bottom" colspan="6">&#160;</td> <td style="BORDER-TOP: medium none; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="28%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid" width="16%" valign="bottom" colspan="6"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">U.S.</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">Qualified</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid" width="16%" valign="bottom" colspan="6"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">U.S.</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">Supplemental</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">(Non-Qualified)</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid" width="16%" valign="bottom" colspan="6"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: center">International</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid" width="16%" valign="bottom" colspan="6"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">Postretirement</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">Plans</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 2px solid" width="28%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-VARIANT: small-caps; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">(millions of dollars)</div></td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="1%" valign="bottom">&#160;</td> <td style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="7%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">April 4,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2010</div></td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="7%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Mar. 29,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2009</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" width="1%" valign="bottom">&#160;</td> <td style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="7%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">April 4,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2010</div></td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="7%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Mar. 29,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2009</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" width="1%" valign="bottom">&#160;</td> <td style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="7%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">April 4,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2010</div></td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="1%" valign="bottom">&#160;</td> <td style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="7%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Mar. 29,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2009</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" width="1%" valign="bottom">&#160;</td> <td style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="7%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">April 4,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2010</div></td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="7%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Mar. 29,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2009</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="28%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-DECORATION: underline; TEXT-INDENT: 0pt; text-align: left">Three Months Ended:</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="7%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="7%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="7%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="7%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="7%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="7%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="7%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="7%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="28%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Service cost</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">94</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">59</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">8</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">5</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">60</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">45</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">22</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">8</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="28%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Interest cost</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">191</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">119</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">19</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">13</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">111</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">78</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">54</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">30</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="28%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Expected return on plan assets</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">(202</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">(118</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">(112</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">(86</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">(8</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">(6</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td></tr> <tr> <td align="left" width="28%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Amortization of:</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="28%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Actuarial losses</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">38</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">57</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">7</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">8</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">17</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">6</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">4</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="28%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Prior service costs/(credits)</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">1</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">(1</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">(1</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">(1</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">(1</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">(4</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">(1</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td></tr> <tr> <td align="left" width="28%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left">Curtailments and settlements--net</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">(33</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">24</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">(1</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">7</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">1</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">2</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">5</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="28%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Special termination benefits</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">14</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">13</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">90</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">1</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">1</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">6</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">12</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 4px double" width="28%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Net periodic benefit costs</div></td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">102</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">155</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">122</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">32</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">77</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">45</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">70</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="6%" valign="bottom">52</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">The decrease in net periodic benefit costs in the first three months of 2010 compared to the first three months of 2009 for our U.S. qualified plans was primarily driven by curtailment gains and lower settlement charges associated with Wyeth-related restructuring initiatives.&#160;&#160;The acquisition of Wyeth contributed to the increase in certain components of net periodic benefit costs, such as service cost and interest cost, offset by related expected return on plan assets.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">The increase in net periodic benefit costs in the first three months of 2010, compared to the first three months of 2009 for our U.S. supplemental (non-qualified) pension plans was primarily driven by special termination benefits recognized for certain executives as part of Wyeth-related restructuring initiatives.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">For the first quarter of 2010, we contributed from our general assets $87 million to our international pension plans, $61 million to our U.S. supplemental (non-qualified) pension plans and $60 million to our postretirement plans. Contributions to our U.S. qualified pension plans in the first quarter of 2010 were not significant.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">During 2010, we expect to contribute from our general assets, a total of $439 million to our international pension plans, $257 million to our postretirement plans, $205 million to our U.S. supplemental (non-qualified) pension plans and $7 million to our U.S. qualified pension plans. Contributions expected to be made for 2010 are inclusive of amounts contributed during the first quarter of 2010. The international pension plan, postretirement plan and U.S. supplemental (non-qualified) pension plan contributions from our general assets include direct employer benefit payments.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div></div></div></div></div> Note 9. Pension and Postretirement Benefit Plans The components of net periodic benefit costs of the U.S. and international pension plans and the false false false Description containing the entire pension and other postretirement benefits disclosure as a single block of text. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Staff Position (FSP) -Number FAS106-2 -Paragraph 20, 21, 22 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 132R -Paragraph 5, 6, 7, 8 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 87 -Paragraph 264 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Implementation Guide (Q and A) -Number FAS88 -Paragraph 63 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 158 -Paragraph 7, 21, 22 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 132R -Paragraph 5 -Subparagraph b Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 30 -Paragraph 26 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 106 -Paragraph 518 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 03-2 -Paragraph 8 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 132R -Paragraph 8 -Subparagraph m Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 132R -Paragraph 5 -Subparagraph h Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 132R -Paragraph 5 -Subparagraph a Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 132R -Paragraph 5 -Subparagraph q false false 1 2 false UnKnown UnKnown UnKnown false true XML 22 R15.xml IDEA: Earnings Per Share Attributable to Common Shareholders 2.0.0.10 false Earnings Per Share Attributable to Common Shareholders 000210 - Disclosure - Earnings Per Share Attributable to Common Shareholders true false false false 1 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDperShare Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 pfe_EarningsPerShareAttributableToCommonShareholdersAbstract pfe false na duration string No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false No definition available. false 3 1 us-gaap_EarningsPerShareTextBlock us-gaap true na duration string No definition available. false false false false false false false false false false false false 1 false false false false 0 0 <div class="BWxbrlnote10"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <div> <div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><a style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline" id="xbrlnote10" name="xbrlnote10">Note 10. Earnings Per Share Attributable to Common Shareholders</a></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Basic and diluted earnings per share (EPS) were computed using the following data:</div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="74%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid" width="24%" valign="bottom" colspan="6"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">Three Months Ended</div></td> <td style="BORDER-TOP: medium none; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 2px solid" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-VARIANT: small-caps; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">(millions)</div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="11%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">April 4,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2010</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="11%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Mar. 29,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2009</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="74%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">EPS Numerator--Basic:</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Income from continuing operations attributable to Pfizer Inc.</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,024</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,728</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Less: Preferred stock dividends--net of tax</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -18pt; text-align: left"><font>&#160;</font> Income from continuing operations attributable to Pfizer Inc. common shareholders</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,023</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,728</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Discontinued operations--net of tax</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 4px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Net income attributable to Pfizer Inc. common shareholders</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,025</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,729</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="74%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">EPS Denominator--Basic:</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 4px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Weighted-average number of common shares outstanding</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">8,061</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">6,723</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="74%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">EPS Numerator--Diluted:</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -18pt; text-align: left"><font>&#160;</font> Income from continuing operations attributable to Pfizer Inc. common shareholders</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,024</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,728</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Discontinued operations--net of tax</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 4px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Net income attributable to Pfizer Inc. common shareholders</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,026</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,729</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="74%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">EPS Denominator--Diluted:</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Weighted-average number of common shares outstanding</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">8,061</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">6,723</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -18pt; text-align: left"><font>&#160;</font> Common-share equivalents: stock options, stock issuable under employee compensation</div> <div style="DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -18pt; text-align: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160; plans&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">and convertible preferred stock</font></div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">40</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">30</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 4px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -18pt; text-align: left"><font>&#160;</font> Weighted-average number of common shares outstanding and common-share equivalents</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">8,101</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">6,753</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="74%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 4px double" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -18pt; text-align: left"><font>&#160;</font> Stock options that had exercise prices greater than the average market price of our common</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -18pt; text-align: left">&#160;&#160;&#160;&#160;&#160;&#160;&#160; stock issuable under employee compensation plans<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">366</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">475</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(a)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;These common stock equivalents were outstanding during the first quarters of 2010 and 2009, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div></div></div></div></div> Note 10. Earnings Per Share Attributable to Common Shareholders Basic and diluted earnings per share (EPS) were computed using the following false false false This element may be used to capture the complete disclosure pertaining to an entity's earnings per share. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 40 false false 1 2 false UnKnown UnKnown UnKnown false true XML 23 R4.xml IDEA: CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) 2.0.0.10 false CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (USD $) 000040 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) true false In Millions false false 1 usd $ false false USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 false 2 usd $ false false USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 5 3 us-gaap_AssetsAbstract us-gaap true na duration string No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false No definition available. false 6 4 us-gaap_CashAndCashEquivalentsAtCarryingValue us-gaap true debit instant monetary No definition available. false false false false false false false false false false false false 1 true true false false 1759000000 1759 [1] false false false 2 true true false false 1978000000 1978 [2] false false false Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased th ree years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits should not be reported as cash and cash equivalents. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7, 26 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 8, 9 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7 -Footnote 1 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 false 7 4 us-gaap_ShortTermInvestments us-gaap true debit instant monetary No definition available. false false false false false false false false false false false false 1 false true false false 15503000000 15503 [1] false false false 2 false true false false 23991000000 23991 [2] false false false Investments which are intended to be sold in the short term (usually less than one year or the normal operating cycle, whichever is longer) including trading securities, available-for-sale securities, held-to-maturity securities, and other short-term investments not otherwise listed in the existing taxonomy. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Subparagraph g -Article 7 false 8 4 us-gaap_AccountsReceivableNetCurrent us-gaap true debit instant monetary No definition available. false false false false false false false false false false false false 1 false true false false 13611000000 13611 [1] false false false 2 false true false false 14645000000 14645 [2] false false false Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 3 -Subparagraph a(1) -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 4 -Article 5 false 9 4 us-gaap_NotesAndLoansReceivableGrossCurrent us-gaap true debit instant monetary No definition available. false false false false false false false false false false false false 1 false true false false 919000000 919 [1] false false false 2 false true false false 1195000000 1195 [2] false false false An amount representing an agreement for an unconditional promise by the maker to pay the Entity (holder) a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer. Such amount may include accrued interest receivable in accordance with the terms of the debt. The debt also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 3 -Subparagraph a -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 43 -Chapter 3 -Section A -Paragraph 4 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 3 -Subparagraph b -Article 5 false 10 4 us-gaap_InventoryNet us-gaap true debit instant monetary No definition available. false false false false false false false false false false false false 1 false true false false 10132000000 10132 [1] false false false 2 false true false false 12403000000 12403 [2] false false false Carrying amount (lower of cost or market) as of the balance sheet date of inventories less all valuation and other allowances. Excludes noncurrent inventory balances (expected to remain on hand past one year or one operating cycle, if longer). No authoritative reference available. false 11 4 pfe_CurrentDeferredTaxAssetsAndOtherAssetsCurrent pfe false debit instant monetary This element represents (i) carrying amount as of the balance sheet date of payments made in advance for income and other... false false false false false false false false false false false verboselabel false 1 false true false false 7502000000 7502 [1] false false false 2 false true false false 6962000000 6962 [2] false false false This element represents (i) carrying amount as of the balance sheet date of payments made in advance for income and other taxes, which will be charged against earnings within one year or the normal operating cycle, if longer as well as the current portion of the aggregate tax effects as of the balance sheet date of all future tax deductions arising from temporary differences between tax basis and generally accepted accounting principles basis recognition of assets, liabilities, revenues and expenses, which can only be deducted for tax purposes when permitted under enacted tax laws; after deducting the allocated valuation allowance, if any, to reduce such amount to net realizable value; and (ii) aggregate carrying amount, as of the balance sheet date, of current assets not separately presented elsewhere in the balance sheet. No authoritative reference available. false 12 4 us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation us-gaap true debit instant monetary No definition available. false false false false false false false false false false false false 1 false true false false 490000000 490 [1] false false false 2 false true false false 496000000 496 [2] false false false The aggregate value (measured at the lower of net carrying value or fair value less cost of disposal) for assets of a disposal group, including a component of the entity (discontinued operation), to be sold or that has been disposed of through sale, as of the financial statement date. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 144 -Paragraph 46 false 13 4 us-gaap_AssetsCurrent us-gaap true debit instant monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false 49916000000 49916 [1] false false false 2 false true false false 61670000000 61670 [2] false false false Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 9 -Article 5 true 14 4 us-gaap_LongTermInvestmentsAndReceivablesNet us-gaap true debit instant monetary No definition available. false false false false false false false false false false false false 1 false true false false 12081000000 12081 [1] false false false 2 false true false false 13122000000 13122 [2] false false false The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle) and amount due to the Entity from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such investments and receivables to an amount that approximates their net realizable value. No authoritative reference available. false 15 4 us-gaap_PropertyPlantAndEquipmentNet us-gaap true debit instant monetary No definition available. false false false false false false false false false false false false 1 false true false false 21651000000 21651 [1] false false false 2 false true false false 22780000000 22780 [2] false false false Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, and production equipment. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 13 -Subparagraph a -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 12 -Paragraph 5 -Subparagraph b, c Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 8 -Article 7 false 16 4 us-gaap_Goodwill us-gaap true debit instant monetary No definition available. false false false false false false false false false false false false 1 false true false false 42648000000 42648 [1] false false false 2 false true false false 42376000000 42376 [2] false false false Carrying amount as of the balance sheet date, which is the cumulative amount paid, adjusted for any amortization recognized prior to adoption of FAS 142 and for any impairment charges, in excess of the fair value of net assets acquired in one or more business combination transactions. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 142 -Paragraph 43 false 17 4 us-gaap_IntangibleAssetsNetExcludingGoodwill us-gaap true debit instant monetary No definition available. false false false false false false false false false false false false 1 false true false false 64480000000 64480 [1] false false false 2 false true false false 68015000000 68015 [2] false false false Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 142 -Paragraph 42, 45 false 18 4 pfe_NonCurrentDeferredTaxAssetsAndOtherAssetsNoncurrent pfe false debit instant monetary This element represents (i)the noncurrent portion as of the balance sheet date of the aggregate carrying amount of all future... false false false false false false false false false false false terselabel false 1 false true false false 4337000000 4337 [1] false false false 2 false true false false 4986000000 4986 [2] false false false This element represents (i)the noncurrent portion as of the balance sheet date of the aggregate carrying amount of all future tax deductions arising from temporary differences between tax basis and generally accepted accounting principles basis recognition of assets, liabilities, revenues and expenses, which can only be deducted for tax purposes when permitted under enacted tax laws; after the valuation allowance, if any, to reduce such amount to net realizable value. Deferred tax liabilities and assets shall be classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, shall be classified according to the expected reversal date of the temporary difference; and (ii) the aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately di sclosed in the balance sheet due to materiality considerations. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer). No authoritative reference available. false 19 4 us-gaap_Assets us-gaap true debit instant monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false 195113000000 195113 [1] false false false 2 false true false false 212949000000 212949 [2] false false false Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Concepts (CON) -Number 6 -Paragraph 25 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 18 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 12 -Article 7 true 20 3 us-gaap_LiabilitiesAndStockholdersEquityAbstract us-gaap true na duration string No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false No definition available. false 21 4 us-gaap_DebtCurrent us-gaap true credit instant monetary No definition available. false false false false false false false false false false false false 1 false true false false 7769000000 7769 [1] false false false 2 false true false false 5469000000 5469 [2] false false false Carrying value as of the balance sheet date of the sum of short-term debt and current maturities of long-term debt and capital lease obligations, which are due within one year (or one business cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19 -Article 5 false 22 4 us-gaap_AccountsPayableCurrent us-gaap true credit instant monetary No definition available. false false false false false false false false false false false false 1 false true false false 3028000000 3028 [1] false false false 2 false true false false 4370000000 4370 [2] false false false Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19 -Subparagraph a -Article 5 false 23 4 us-gaap_DividendsPayableCurrentAndNoncurrent us-gaap true credit instant monetary No definition available. false false false false false false false false false false false false 1 false true false false 1000000 1 [1] false false false 2 false true false false 1454000000 1454 [2] false false false Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 15 -Subparagraph 5 -Article 9 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 15 -Subparagraph a -Article 7 false 24 4 us-gaap_TaxesPayableCurrent us-gaap true credit instant monetary No definition available. false false false false false false false false false false false false 1 false true false false 765000000 765 [1] false false false 2 false true false false 10107000000 10107 [2] false false false Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19, 20 -Article 5 false 25 4 us-gaap_EmployeeRelatedLiabilitiesCurrent us-gaap true credit instant monetary No definition available. false false false false false false false false false false false false 1 false true false false 2060000000 2060 [1] false false false 2 false true false false 2242000000 2242 [2] false false false Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 20 -Article 5 false 26 4 pfe_CurrentDeferredTaxLiabilitiesAndOtherCurrentLiabilities pfe false credit instant monetary This element represents (i) the current portion of deferred tax liabilities, which result from applying the applicable tax... false false false false false false false false false false false false 1 false true false false 12301000000 12301 [1] false false false 2 false true false false 13583000000 13583 [2] false false false This element represents (i) the current portion of deferred tax liabilities, which result from applying the applicable tax rate to net taxable temporary differences pertaining to each jurisdiction to which the entity is obligated to pay income tax. A current taxable temporary difference is a difference between the tax basis and the carrying amount of a current asset or liability in the financial statements prepared in accordance with generally accepted accounting principles. In a classified statement of financial position, an enterprise shall separate deferred tax liabilities and assets into a current amount and a noncurrent amount. Deferred tax liabilities and assets shall be classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, shall be classified according to the expected reversal date of the temporary difference; and (ii) the aggregate carrying amount, as of the balance sheet date, of current obligations not separately disclosed in the balance sheet due to materiality considerations. Current liabilities are expected to be paid within one year (or the normal operating cycle, if longer). No authoritative reference available. false 27 4 us-gaap_LiabilitiesCurrent us-gaap true credit instant monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false 25924000000 25924 [1] false false false 2 false true false false 37225000000 37225 [2] false false false Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 21 -Article 5 true 28 4 us-gaap_LongTermDebtNoncurrent us-gaap true credit instant monetary No definition available. false false false false false false false false false false false false 1 false true false false 38281000000 38281 [1] false false false 2 false true false false 43193000000 43193 [2] false false false Sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year from the balance sheet date or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year (current maturities) or the normal operating cycle, if longer, and after deducting unamortized discount or premiums, if any. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 22 -Article 5 false 29 4 us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent us-gaap true credit instant monetary No definition available. false false false false false false false false false false false false 1 false true false false 6119000000 6119 [1] false false false 2 false true false false 6392000000 6392 [2] false false false This represents the noncurrent liability recognized in the balance sheet that is associated with the defined benefit pension plans. (The current liability will be separate, but it will normally be small, if there is even any at all.) Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 132R -Paragraph 5 -Subparagraph c Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 132R -Paragraph 6 false 30 4 us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent us-gaap true credit instant monetary No definition available. false false false false false false false false false false false false 1 false true false false 3239000000 3239 [1] false false false 2 false true false false 3243000000 3243 [2] false false false This represents the noncurrent liability recognized in the balance sheet that is associated with other postretirement defined benefit plans (excluding pension plans). (The current liability will be separate, but it will normally be small, if there is even any at all.) Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 132R -Paragraph 5 -Subparagraph c Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 132R -Paragraph 6 false 31 4 us-gaap_DeferredTaxLiabilitiesNoncurrent us-gaap true credit instant monetary No definition available. false false false false false false false false false false false false 1 false true false false 17460000000 17460 [1] false false false 2 false true false false 17839000000 17839 [2] false false false Represents the noncurrent portion of deferred tax liabilities, which result from applying the applicable tax rate to net taxable temporary differences pertaining to each jurisdiction to which the entity is obligated to pay income tax. A noncurrent taxable temporary difference is a difference between the tax basis and the carrying amount of a noncurrent asset or liability in the financial statements prepared in accordance with generally accepted accounting principles. In a classified statement of financial position, an enterprise shall separate deferred tax liabilities and assets into a current amount and a noncurrent amount. Deferred tax liabilities and assets shall be classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, shall be classified according to the expected reversal date of the temporary difference. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 109 -Paragraph 41, 42 false 32 4 us-gaap_AccruedIncomeTaxesNoncurrent us-gaap true credit instant monetary No definition available. false false false false false false false false false false false false 1 false true false false 8338000000 8338 [1] false false false 2 false true false false 9000000000 9000 [2] false false false Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 15 -Article 9 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 24 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Interpretation (FIN) -Number 48 -Paragraph 15, 21 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 15 -Subparagraph b(1) -Article 7 false 33 4 us-gaap_OtherLiabilitiesNoncurrent us-gaap true credit instant monetary No definition available. false false false false false false false false false false false false 1 false true false false 5670000000 5670 [1] false false false 2 false true false false 5611000000 5611 [2] false false false Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet due to materiality considerations. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer). Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 24 -Article 5 false 34 4 us-gaap_Liabilities us-gaap true credit instant monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false 105031000000 105031 [1] false false false 2 false true false false 122503000000 122503 [2] false false false Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. No authoritative reference available. true 35 4 us-gaap_PreferredStockValue us-gaap true credit instant monetary No definition available. false false false false false false false false false false false false 1 false true false false 58000000 58 [1] false false false 2 false true false false 61000000 61 [2] false false false Dollar value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) whether issued at par value, no par or stated value. This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 129 -Paragraph 2, 3, 4, 5, 6, 7, 8 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 false 36 4 us-gaap_CommonStockValue us-gaap true credit instant monetary No definition available. false false false false false false false false false false false false 1 false true false false 443000000 443 [1] false false false 2 false true false false 443000000 443 [2] false false false Dollar value of issued common stock whether issued at par value, no par or stated value. This item includes treasury stock repurchased by the entity. Note: elements for number of common shares, par value and other disclosure concepts are in another section within stockholders' equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false 37 4 us-gaap_AdditionalPaidInCapital us-gaap true credit instant monetary No definition available. false false false false false false false false false false false false 1 false true false false 70456000000 70456 [1] false false false 2 false true false false 70497000000 70497 [2] false false false Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of APIC associated with common AND preferred stock. For APIC associated with only common stock, use the element Additional Paid In Capital, Common Stock. For APIC associated with only preferred stock, use the element Additional Paid In Capital, Preferred Stock. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 false 38 4 us-gaap_CompensationAndBenefitsTrust us-gaap true credit instant monetary No definition available. false false false false false false false false false false false negativelabel false 1 false true false false -89000000 -89 [1] false false false 2 false true false false -333000000 -333 [2] false false false A trust established to hold the stock of an employee compensation and benefits plan. No authoritative reference available. false 39 4 us-gaap_TreasuryStockValue us-gaap true debit instant monetary No definition available. false false false false false false false false false false true negated false 1 false true false false -21697000000 -21697 [1] false false false 2 false true false false -21632000000 -21632 [2] false false false Value of common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury. Treasury stock is issued but is not outstanding. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Note: number of treasury shares concept is in another section within stockholders' equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Technical Bulletin (FTB) -Number 85-6 -Paragraph 3 false 40 4 us-gaap_RetainedEarningsAccumulatedDeficit us-gaap true credit instant monetary No definition available. false false false false false false false false false false false false 1 false true false false 42429000000 42429 [1] false false false 2 false true false false 40426000000 40426 [2] false false false The cumulative amount of the reporting entity's undistributed earnings or deficit. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 false 41 4 us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax us-gaap true credit instant monetary No definition available. false false false false false false false false false false false false 1 false true false false -1941000000 -1941 [1] false false false 2 false true false false 552000000 552 [2] false false false Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at fiscal year-end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, and unrealized gains and losses on certain investments in debt and equity securities as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 130 -Paragraph 14, 17, 26 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 false 42 4 us-gaap_StockholdersEquity us-gaap true credit instant monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false 89659000000 89659 [1] false false false 2 false true false false 90014000000 90014 [2] false false false Total of all Stockholders' Equity (deficit) items, net of receivables from officers, directors owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A3 -Appendix A Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 true 43 4 us-gaap_MinorityInterest us-gaap true credit instant monetary No definition available. false false false false false false false false false false false false 1 false true false false 423000000 423 [1] false false false 2 false true false false 432000000 432 [2] false false false Total of all Stockholders' Equity (deficit) items, net of receivables from officers, directors owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 27 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 20 -Article 7 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 26 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A3 -Appendix A false 44 4 us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest us-gaap true credit instant monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false 90082000000 90082 [1] false false false 2 false true false false 90446000000 90446 [2] false false false Total of Stockholders' Equity (deficit) items, net of receivables from officers, directors owners, and affiliates of the entity including portions attributable to both the parent and noncontrolling interests (previously referred to as minority interest), if any. The entity including portions attributable to the parent and noncontrolling interests is sometimes referred to as the economic entity. This excludes temporary equity and is sometimes called permanent equity. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 25 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 26 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A3 -Appendix A true 45 4 us-gaap_LiabilitiesAndStockholdersEquity us-gaap true credit instant monetary No definition available. false false false false false false false false false false false totallabel false 1 true true false false 195113000000 195113 [1] false false false 2 true true false false 212949000000 212949 [2] false false false Total of all Liabilities and Stockholders' Equity items. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 32 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 25 -Article 7 true 1 Unaudited. 2 Condensed from audited financial statements. false 2 41 false Millions UnKnown UnKnown false true XML 24 R16.xml IDEA: Segment Information 2.0.0.10 false Segment Information 000220 - Disclosure - Segment Information true false false false 1 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDperShare Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 pfe_SegmentInformationAbstract pfe false na duration string No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false No definition available. false 3 1 us-gaap_SegmentReportingDisclosureTextBlock us-gaap true na duration string No definition available. false false false false false false false false false false false false 1 false false false false 0 0 <div class="BWxbrlnote11"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <div> <div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><a style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline" id="xbrlnote11" name="xbrlnote11">Note 11. Segment Information</a></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">We operate in the following two distinct commercial organizations, which constitute our two business segments:</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr valign="top"> <td align="right" style="WIDTH: 9pt" width="1%"> <div style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;&#160;&#160;</div></td> <td style="TEXT-ALIGN: left" width="99%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Biopharmaceutical</font> consists of the Primary Care, Specialty Care, Oncology, Established Products and Emerging Markets customer-focused units and includes products that prevent and treat cardiovascular and metabolic diseases, central nervous system disorders, arthritis and pain, infectious and respiratory diseases, urogenital conditions, cancer, eye diseases and endocrine disorders, among others. Biopharmaceutical's segment profit includes costs related to research and development, manufacturing, and sales and marketing activities that are associated with the products in our Biopharmaceutical segment.</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr valign="top"> <td align="right" style="WIDTH: 9pt" width="1%"> <div style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;&#160;&#160;</div></td> <td style="TEXT-ALIGN: left" width="99%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Diversified</font> includes Animal Health products that prevent and treat diseases in livestock and companion animals, including vaccines, parasiticides and anti-infectives; Consumer Healthcare products that include over-the-counter healthcare products such as pain management therapies (analgesics and heat wraps), cough/cold/allergy remedies, dietary supplements, hemorrhoidal care and personal care items; Nutrition products such as infant and toddler nutritional products; and Capsugel, which represents our capsule products and services business. Diversified's segment profit includes costs related to research and development, manufacturing, and sales and marketing activities that are associated with the products in our Diversified segment.</div></td></tr></table></div> ; <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Segment profit/(loss) is measured based on income from continuing operations before provision for taxes on income and income attributable to noncontrolling interests. Certain costs, such as significant impacts of purchase accounting for acquisitions, restructuring and acquisition-related costs and costs related to our cost-reduction initiatives are included in <font style="DISPLAY: inline; FONT-STYLE: italic">Corporate/Other</font> only. This methodology is utilized by management to evaluate our businesses. Each segment is managed separately and offers different products requiring different marketing and distribution strategies.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Revenues and profit/(loss) by segment for the first quarters of 2010 and 2009 follow:</div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="74%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid" width="24%" valign="bottom" colspan="6"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">Three Months Ended<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td style="BORDER-TOP: medium none; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 2px solid" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-VARIANT: small-caps; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">(millions of dollars)</div></td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt" width="1%" valign="bottom">&#160;</td> <td style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="11%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">April 4,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2010</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; TEXT-INDENT: 0pt" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; TEXT-INDENT: 0pt" width="1%" valign="bottom">&#160;</td> <td style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="11%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Mar. 29,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2009</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; TEXT-INDENT: 0pt" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Revenues</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Biopharmaceutical</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">14,506</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">10,102</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Diversified</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,141</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">691</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Corporate/Other<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(b)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">103</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">74</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 4px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Total revenues</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">16,750</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">10,867</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="74%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Segment profit/(loss)<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(c)</font></div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Biopharmaceutical</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">7,912</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">5,407</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Diversified</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">510</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">163</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Corporate/Other<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(b), (d)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(5,243</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(1,767</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">)</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 4px double" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Total profit/(loss)</div></td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">3,179</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">3,803</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(a)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Includes revenues and profit/(loss) from legacy Wyeth products and operations for the three months ended April 4, 2010. Revenues and profit/(loss) from legacy Wyeth products and operations are not included in the three months ended March 29, 2009. Prior-period amounts for Capsugel, which were previously classified in <font style="DISPLAY: inline; FONT-STYLE: italic">Corporate/Other</font>, are now classified in <font style="DISPLAY: inline; FONT-STYLE: italic">Diversified.</font></div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(b)&#160;</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left"><font style="DISPLAY: inline; FONT-STYLE: italic">Corporate/Other</font> includes Pfizer Centersource, which includes contract manufacturing and bulk pharmaceutical chemical sales. <font style="DISPLAY: inline; FONT-STYLE: italic">Corporate/Other</font> under <font style="DISPLAY: inline; FONT-STYLE: italic">Segment profit/(loss)</font> also includes interest income/(expense), corporate expenses (e.g., corporate administration costs), other income/(expense) (e.g., realized gains and losses attributable to our investments in debt and equity securities), certain performance-based and all share-based compensation expenses, significant impacts of purchase accounting for acquisitions, acquisition-related costs, intangible asset impairments and costs related to our cost-reduction initiatives.</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(c)&#160;</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left"><font style="DISPLAY: inline; FONT-STYLE: italic">Segment profit/(loss)</font> equals <font style="DISPLAY: inline; FONT-STYLE: italic">Income from continuing operations before provision for taxes on income.</font> Certain costs, such as significant impacts of purchase accounting for acquisitions, acquisition-related costs and costs related to our cost-reduction initiatives are included in <font style="DISPLAY: inline; FONT-STYLE: italic">Corporate/Other</font> only. This methodology is utilized by management to evaluate our businesses.</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(d)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;For the first quarter of 2010, <font style="DISPLAY: inline; FONT-STYLE: italic">Corporate/Other</font> includes: (i) significant impacts of purchase accounting for acquisitions of $2.8 billion, including intangible asset amortization related to our acquisitions of Wyeth in 2009 and Pharmacia in 2003 and charges related to fair value adjustments of inventory acquired from Wyeth and sold during the period; (ii) restructuring and acquisition-related costs of $799 million, primarily related to our acquisition of Wyeth; (iii) all share-based compensation expense; and (iv) net interest expense of $410 million. For the first quarter of 2009, <font style="DISPLAY: inline; FONT-STYLE: italic">Corporate/Other</font> includes: (i) significant impacts of purchase accounting for acquisitions of $546 million, including intangible asset amortization and other charges, primarily related to o ur acquisition of Pharmacia in 2003; (ii) acquisition-related costs of $397 million, primarily related to our acquisition of Wyeth; (iii) restructuring charges and implementation costs associated with our cost-reduction initiatives of $331 million; (iv) all share-based compensation expense; and (v) net interest income of $116.</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-INDENT: 0pt">Significant product revenues are as follows:</div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="6"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">Three Months Ended</div></td> <td style="BORDER-TOP: medium none; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 2px solid" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-VARIANT: small-caps; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">(millions of dollars)</div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" valign="bottom">&#160;</td> <td style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">April 4,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2010</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Mar. 29,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2009</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom">&#160;</td></tr> <tr> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td></tr> <tr> <td align="left" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Biopharmaceutical products:</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Lipitor</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,757</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,721</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Enbrel<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font>, <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(c)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">802</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Lyrica</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">723</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">684</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Effexor<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">716</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Celebrex</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">570</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">564</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Prevnar/Prevenar 7<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">520</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Viagra</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">479</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">454</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Xalatan/Xalacom</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">422</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">407</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Norvasc</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">368</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">481</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Zyvox</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">292</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">283</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Prevnar/Prevenar 13<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">286</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Zosyn/Tazocin<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">264</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Detrol/Detrol LA</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">261</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">289</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Sutent</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">259</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">202</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Premarin family<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">256</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Geodon/Zeldox</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">254</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">230</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Genotropin</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">206</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">197</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Chantix/Champix</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">189</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">177</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Vfend</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">188</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">179</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> BeneFIX<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">154</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Caduet</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">135</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">134</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Aromasin</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">128</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">110</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Zoloft</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">120</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">115</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Revatio</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">114</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">113</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Medrol</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">109</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">118</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Cardura</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">107</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">107</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Aricept<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(b)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">107</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">95</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Zithromax/Zmax</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">103</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">114</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> ReFacto/Xyntha<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">90</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> All other<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(d)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,523</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,746</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font>&#160;</font> Alliance revenues (Enbrel (in the U.S. and Canada)<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font>, Aricept, Exforge, Rebif and Spiriva)</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,004</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">582</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 18pt; text-align: left">Total Biopharmaceutical products</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">14,506</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">10,102</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Diversified products:</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Animal Health products<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(d)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">846</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">537</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Consumer Healthcare products<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">663</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Nutrition products<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">458</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Capsugel<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(e)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">174</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">154</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Total Diversified products</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,141</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">691</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Corporate/Other</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">103</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">74</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 4px double" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Total revenues</div></td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">16,750</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">10,867</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(a)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Represents legacy Wyeth products for the three months ended April 4, 2010. Legacy Wyeth products are not included in the three months ended March 29, 2009.</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(b)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Represents direct sales under license agreement with Eisai. Co. Ltd.</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(c)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Outside the U.S. and Canada.</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(d)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Includes legacy Pfizer and legacy Wyeth products for the three months ended April 4, 2010 and includes only legacy Pfizer products in the three months ended March 29, 2009.</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(e)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Prior-period amounts for Capsugel, which were previously classified in <font style="DISPLAY: inline; FONT-STYLE: italic">Corporate/Other,</font> are now classified in <font style="DISPLAY: inline; FONT-STYLE: italic">Diversified.</font></div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-INDENT: 0pt">Revenues by geographic area follow:</div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="61%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid" width="37%" valign="bottom" colspan="10"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">Three Months Ended<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td style="BORDER-TOP: medium none; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 2px solid" width="61%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-VARIANT: small-caps; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">(millions of dollars)</div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="11%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">April 4,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2010</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" width="1%" valign="bottom">&#160;</td> <td style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="11%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Mar. 29,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2009</div></td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="1%" valign="bottom">&#160;</td> <td style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="11%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">% Change</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="61%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="61%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Revenues</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="61%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> United States</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">7,314</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">4,969</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">47</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="61%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Europe</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">4,785</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">3,005</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">59</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="61%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Japan/Other Asia</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,659</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,738</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">53</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="61%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Canada/Latin America/Africa/Middle East</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,992</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,155</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" width="10%" valign="bottom">72</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 4px double" width="61%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Total Revenues</div></td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">16,750</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">10,867</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">54</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(a)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Includes revenues from legacy Wyeth products for the three months ended April 4, 2010. Revenues from legacy Wyeth products are not included in the three months ended March 29, 2009.</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div></div></div></div></div> Note 11. Segment Information We operate in the following two distinct commercial organizations, which constitute our two business false false false This element may be used to capture the complete disclosure of reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10% or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 131 false false 1 2 false UnKnown UnKnown UnKnown false true XML 25 R9.xml IDEA: Cost-Reduction Initiatives and Acquisition-Related Costs 2.0.0.10 false Cost-Reduction Initiatives and Acquisition-Related Costs 000140 - Disclosure - Cost-Reduction Initiatives and Acquisition-Related Costs true false false false 1 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDperShare Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 pfe_CostReductionInitiativesAndAcquisitionRelatedCostsAbstract pfe false na duration string No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false No definition available. false 3 1 pfe_CostReductionInitiativesAndAcquisitionRelatedCostsDisclosureTextBlock pfe false na duration string Description of cost-reduction initiatives associated with a comprehensive plan to integrate acquired operations, generate... false false false false false false false false false false false verboselabel false 1 false false false false 0 0 <div class="BWxbrlnote4"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <div> <div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><a style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline" id="xbrlnote4" name="xbrlnote4">Note 4. Cost-Reduction Initiatives and Acquisition-Related Costs</a></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">We have incurred significant costs in connection with our cost-reduction initiatives (several programs initiated since 2005) and our acquisition of Wyeth on October 15, 2009.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Since the acquisition of Wyeth, our cost-reduction initiatives that were announced on January 26, 2009, but not completed as of December 31, 2009, have been incorporated into a comprehensive plan to integrate Wyeth's operations, generate cost savings and capture synergies across the combined company. We are focusing our efforts on achieving an appropriate cost structure for the combined company.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; TEXT-INDENT: 0pt">We incurred the following costs in connection with all of our cost-reduction initiatives and the acquisition of Wyeth:</div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="6"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">Three Months Ended</div></td> <td style="BORDER-TOP: medium none; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 2px solid" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-VARIANT: small-caps; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">(millions of dollars)</div></td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">April 4,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2010</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Mar. 29,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2009</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom">&#160;</td></tr> <tr> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Transaction costs<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">9</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">369</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Integration costs<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(b)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">208</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">28</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Restructuring charges<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(c)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">489</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">157</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-STYLE: italic; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> Restructuring charges and certain acquisition-related costs</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">706</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">554</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Additional depreciation--asset restructuring<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(d)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">93</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">90</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Implementation costs<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(e)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">84</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 4px double" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Total</div></td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">799</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">728</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 18pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(a)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Transaction costs represent external costs directly related to effecting the acquisition of Wyeth and primarily include expenditures for banking, legal, accounting and other similar services. Substantially all of the costs incurred in the first quarter of 2009 were fees related to a $22.5 billion bridge term loan credit agreement entered into with certain financial institutions on March 12, 2009 to partially fund our acquisition of Wyeth. The bridge term loan credit agreement was terminated in June 2009 as a result of our issuance of approximately $24.0 billion of senior unsecured notes in the first half of 2009.</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 18pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(b)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Integration costs represent external, incremental costs directly related to integrating Wyeth and primarily include expenditures for consulting and systems integration.</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt; TEXT-ALIGN: left" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt">(c)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Restructuring charges include the following:</div></td></tr></table></div> <div style="text-align: right"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="98%" cellpadding="0"> <tr> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="35%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid" width="37%" valign="bottom" colspan="10"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">Costs Incurred</div></td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="BORDER-TOP: medium none; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="35%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid" width="24%" valign="bottom" colspan="6"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">Three Months Ended</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid" width="11%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">Activity</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="right" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" width="11%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center; TEXT-INDENT: 0pt">Accrual</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 2px solid" width="35%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-VARIANT: small-caps; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">(millions of dollars)</div></td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="1%" valign="bottom">&#160;</td> <td style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="11%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">April 4,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2010</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" width="1%" valign="bottom">&#160;</td> <td style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="11%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Mar. 29,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2009</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2005-2010</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" width="1%" valign="bottom">&#160;</td> <td style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="11%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Through</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">April 4,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2010<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(1)</font></div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" width="1%" valign="bottom">&#160;</td> <td style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="11%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">As of</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">April 4,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2010<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(2)</font></div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="35%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="35%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Employee termination costs</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">458</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">135</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">8,179</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">5,276</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">2,903</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="35%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Asset impairments</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">6</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">18</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,458</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,458</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="35%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Other</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">25</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">4</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">735</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">631</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">104</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 4px double" width="35%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Total restructuring charges</div></td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">489</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">157</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">10,372</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">7,365</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">3,007</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr></table></div> <div style="DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt; text-align: right"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="98%" cellpadding="0"> <tr valign="top"> <td align="right" style="WIDTH: 9pt" width="2%"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt">(1)&#160;</div></td> <td align="left" width="98%"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt">Includes adjustments for foreign currency translation.</div></td></tr></table></div> <div style="DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt; text-align: right"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="98%" cellpadding="0"> <tr valign="top"> <td align="right" style="WIDTH: 9pt" width="2%"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt">(2)&#160;</div></td> <td align="left" width="98%"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Included in</font> <font style="DISPLAY: inline; FONT-STYLE: italic">Current</font> <font style="DISPLAY: inline; FONT-STYLE: italic">deferred tax liabilities and other current liabilities</font> ($2.0 billion) and <font style="DISPLAY: inline; FONT-STYLE: italic">Other noncurrent liabilities</font><font>&#160;</font>($1.0 billion).</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">In the first quarter of 2010, the restructuring charges are related to the integration of Wyeth.&#160;&#160;From the beginning of our cost-reduction initiatives in 2005 through April 4, 2010, <font style="DISPLAY: inline; FONT-STYLE: italic">Employee termination costs</font> represent the expected reduction of the workforce by approximately 45,400 employees, mainly in manufacturing, sales and research, of which approximately 28,100 employees have been terminated as of April 4, 2010. <font style="DISPLAY: inline; FONT-STYLE: italic">Employee termination costs</font> are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination. <font style="DISPLAY: inline; FONT-STYLE: italic"> Asset impairments</font> primarily include charges to write down property, plant and equipment to fair value. <font style="DISPLAY: inline; FONT-STYLE: italic">Other</font> primarily includes costs to exit certain assets and activities.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 18pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(d)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Additional depreciation - asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions and are included in our condensed consolidated statements of income as follows:</div></td></tr></table></div> <div style="text-align: right"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="98%" cellpadding="0"> <tr> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="74%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid" width="24%" valign="bottom" colspan="6"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">Three Months Ended</div></td> <td style="BORDER-TOP: medium none; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 2px solid" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-VARIANT: small-caps; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">(millions of dollars)</div></td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="11%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">April 4,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2010</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="11%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Mar. 29,</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">2009</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="74%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="11%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-STYLE: italic; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Cost of sales</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">13</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">63</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-STYLE: italic; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Selling, informational and administrative expenses</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">60</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">6</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-STYLE: italic; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Research and development expenses</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">20</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">21</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 4px double" width="74%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Total</div></td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">93</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">90</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr></table></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">&#160;</div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 18pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(e)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Implementation costs in the first quarter of 2009 represent external, incremental costs directly related to implementing cost-reduction initiatives prior to our acquisition of Wyeth, and primarily include expenditures related to system and process standardization and the expansion of shared services. For the three months ended March 29, 2009, implementation costs are included in <font style="DISPLAY: inline; FONT-STYLE: italic">Cost of sales</font> ($13 million), <font style="DISPLAY: inline; FONT-STYLE: italic">Selling, informational and administrative expenses</font> ($40 million), <font style="DISPLAY: inline; FONT-STYLE: italic">Research and development expenses</font> ($20 million) and <font style="DISPLAY: inline; FONT-STYLE: italic">Other (income)/deductions</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">--</font><font style= "DISPLAY: inline; FONT-STYLE: italic">net</font> ($11 million).</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div></div></div></div></div> Note 4. Cost-Reduction Initiatives and Acquisition-Related Costs We have incurred significant costs in connection with our cost-reduction initiatives false false false Description of cost-reduction initiatives associated with a comprehensive plan to integrate acquired operations, generate cost savings and capture synergies across the company; as well as costs incurred in connection with an acquisition. These costs include (i) restructuring activities, including exit and disposal activities, the major types of costs associated with the plan activities and the accrual balance at the end of the period; (ii) integration costs, which represent external, incremental costs directly related to integrating acquired businesses; (iii) implementation costs, which represent external, incremental costs directly related to implementing cost-reduction initiatives prior to the Wyeth acquisition and primarily include expenditures related to system and process standardization and the expansion of shared services; (iv) additional depreciation-asset restructuring, which represents the impact of changes in the estimated useful lives of assets involved in restructuring actions; and (v) transaction costs, representing external costs incurred in connection with an acquisition. No authoritative reference available. false false 1 2 false UnKnown UnKnown UnKnown false true XML 26 R6.xml IDEA: Basis of Presentation 2.0.0.10 false Basis of Presentation 000100 - Disclosure - Basis of Presentation true false false false 1 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDperShare Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 pfe_BasisOfPresentationAbstract pfe false na duration string No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false No definition available. false 3 1 us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock us-gaap true na duration string No definition available. false false false false false false false false false false false false 1 false false false false 0 0 <div class="BWxbrlnote1"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <div> <div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><a style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline" id="xbrlnote1" name="xbrlnote1">Note 1. Basis of Presentation</a></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">We prepared the condensed consolidated financial statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (U.S. GAAP) can be condensed or omitted. Balance sheet amounts and operating results for subsidiaries operating outside the U.S. are as of and for the three-month periods ended February 28, 2010, and February 22, 2009.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">On October 15, 2009, we completed our acquisition of Wyeth and, commencing from the acquisition date, our financial statements include the assets, liabilities, operating results and cash flows of Wyeth. As a result, legacy Wyeth operations are reflected in our results of operations and cash flows for the first quarter of 2010, but not for the first quarter of 2009.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">We are responsible for the unaudited financial statements included in this document.&#160;&#160;The financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our financial position and operating results.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended</font> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">December 31, 2009.</font></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div></div></div></div></div> Note 1. Basis of Presentation We prepared the condensed consolidated financial statements following the requirements of the Securities and Exchange false false false Description containing the entire organization, consolidation and basis of presentation of financial statements disclosure. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Staff Position (FSP) -Number FAS140-4 and FIN46(R)-8 -Paragraph 8, C1, C7 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 2-6 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Statement of Position (SOP) -Number 94-6 -Paragraph 10 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Interpretation (FIN) -Number 46R -Paragraph 4, 14, 15 false false 1 2 false UnKnown UnKnown UnKnown false true XML 27 R5.xml IDEA: CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) 2.0.0.10 false CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $) 000050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) true false In Millions false false 1 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDperShare Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 false 2 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDperShare Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 6 4 us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract us-gaap true na duration string No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities include all transactions and events that are not defined as investing or financing activities. Operating activities generally involve producing and delivering goods and providing services. Cash flows from operating activities are generally the cash effects of transactions and other events that enter into the determination of net income. false 7 5 us-gaap_ProfitLoss us-gaap true credit duration monetary No definition available. false false false false false false false false false false false false 1 true true false false 2035000000 2035 false false false 2 true true false false 2730000000 2730 false false false The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A1, A4, A5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 5 -Subparagraph b Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 29 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph a Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph c(1) false 8 5 pfe_AdjustmentsToReconcileNetIncomeLossBeforeAllocationToNoncontrollingInterestsToNetCashProvidedByUsedInOperatingActivitiesAbstract pfe false na duration string No definition available. false false false false false true false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false No definition available. false 9 6 us-gaap_DepreciationDepletionAndAmortization us-gaap true debit duration monetary No definition available. false false false false false false false false false false false false 1 false true false false 2051000000 2051 false false false 2 false true false false 1008000000 1008 false false false The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. No authoritative reference available. false 10 6 us-gaap_ShareBasedCompensation us-gaap true debit duration monetary No definition available. false false false false false false false false false false false false 1 false true false false 138000000 138 false false false 2 false true false false 71000000 71 false false false The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock options, amortization of restricted stock, and adjustment for officers compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 false 11 6 us-gaap_ResearchAndDevelopmentInProcess us-gaap true debit duration monetary No definition available. false false false false false false false false false false false false 1 false true false false 74000000 74 false false false 2 false false false false 0 0 false false false The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141 -Paragraph 51 -Subparagraph g Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Interpretation (FIN) -Number 4 -Paragraph 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 2 -Paragraph 13 false 12 6 us-gaap_DeferredIncomeTaxExpenseBenefit us-gaap true debit duration monetary No definition available. false false false false false false false false false false false false 1 false true false false 840000000 840 false false false 2 false true false false 533000000 533 false false false The component of income tax expense for the period representing the net change in the entity's deferred tax assets and liabilities pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 6 -Section I -Subsection 7 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 109 -Paragraph 45 -Subparagraph b Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 109 -Paragraph 289 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph h -Article 4 false 13 6 us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesOther us-gaap true debit duration monetary No definition available. false false false false false false false false false false false false 1 false true false false 319000000 319 false false false 2 false true false false -296000000 -296 false false false Transactions that do not result in cash inflows or outflows in the period in which they occur, but affect net income and thus are removed when calculating net cash flow from operating activities using the indirect cash flow method. This element is used when there is not a more specific and appropriate element. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 false 14 6 us-gaap_IncreaseDecreaseInOperatingCapital us-gaap true credit duration monetary No definition available. false false false false false false false false false false true negated false 1 false true false false -11817000000 -11817 false false false 2 false true false false -899000000 -899 false false false The net change during the reporting period of all current assets and liabilities used in operating activities. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 false 15 5 us-gaap_NetCashProvidedByUsedInOperatingActivities us-gaap true na duration monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false -6360000000 -6360 false false false 2 false true false false 3147000000 3147 false false false The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 26 true 16 4 us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract us-gaap true na duration string No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false No definition available. false 17 5 us-gaap_PaymentsToAcquirePropertyPlantAndEquipment us-gaap true credit duration monetary No definition available. false false false false false false false false false false true negated false 1 false true false false -305000000 -305 false false false 2 false true false false -253000000 -253 false false false The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 15 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 17 -Subparagraph c false 18 5 us-gaap_PaymentsToAcquireShortTermInvestments us-gaap true credit duration monetary No definition available. false false false false false false false false false false true negated false 1 false true false false -2178000000 -2178 false false false 2 false true false false -17724000000 -17724 false false false The cash outflow for securities or other assets acquired with excess cash, having ready marketability, which qualify for treatment as an investing activity based on management's intention and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 15, 17 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 159 -Section Appendix C -Paragraph 5 -Subparagraph c false 19 5 pfe_ProceedsFromSaleAndMaturityOfShortTermMarketableSecurities pfe false debit duration monetary The cash inflow associated with the aggregate amount received by the entity through sale or maturity of short term marketable... false false false false false false false false false false false terselabel false 1 false true false false 11388000000 11388 false false false 2 false true false false 6711000000 6711 false false false The cash inflow associated with the aggregate amount received by the entity through sale or maturity of short term marketable securities (trading, held-to-maturity, or available-for-sale) during the period. No authoritative reference available. false 20 5 us-gaap_PaymentsToAcquireMarketableSecurities us-gaap true credit duration monetary No definition available. false false false false false false false false false false true negated false 1 false true false false -858000000 -858 false false false 2 false true false false -3442000000 -3442 false false false The cash outflow from purchases of trading, available-for-sale securities and held-to-maturity securities. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 15 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 17 -Subparagraph a Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 17 -Subparagraph b false 21 5 pfe_ProceedsFromSaleAndMaturityOfLongTermMarketableSecurities pfe false debit duration monetary The cash inflow associated with the aggregate amount received by the entity through sale or maturity of long-term marketable... false false false false false false false false false false false terselabel false 1 false true false false 1127000000 1127 false false false 2 false true false false 889000000 889 false false false The cash inflow associated with the aggregate amount received by the entity through sale or maturity of long-term marketable securities (trading, held-to-maturity, or available-for-sale) during the period. No authoritative reference available. false 22 5 us-gaap_PaymentsForProceedsFromOtherInvestingActivities us-gaap true credit duration monetary No definition available. false false false false false false false false false false true negated false 1 false true false false 220000000 220 false false false 2 false true false false 185000000 185 false false false The net cash outflow (inflow) from other investing activities. This element is used when there is not a more specific and appropriate element in the taxonomy. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 15 false 23 5 us-gaap_NetCashProvidedByUsedInInvestingActivities us-gaap true debit duration monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false 9394000000 9394 false false false 2 false true false false -13634000000 -13634 false false false The net cash inflow (outflow) from investing activity. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 26 true 24 4 us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract us-gaap true na duration string No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false No definition available. false 25 5 pfe_ProceedsFromIssuancesOfShortTermDebtNetOfProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess pfe false debit duration monetary The cash inflow from a borrowing having initial term of repayment of more than three months but less than one year or one... false false false false false false false false false false false terselabel false 1 false true false false 1892000000 1892 false false false 2 false true false false 10774000000 10774 false false false The cash inflow from a borrowing having initial term of repayment of more than three months but less than one year or one operating cycle (if the normal cycle is more than one year) and may include the cash inflow from a borrowing having initial term of repayment within three months net of the cash outflow from repayment of a borrowing having initial term of repayment within three months. No authoritative reference available. false 26 5 pfe_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonthsNetOfRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess pfe false credit duration monetary The cash outflow from a repayment of a borrowing having initial term of repayment of more than three months but less than one... false false false false false false false false false false true negated false 1 false true false false -3663000000 -3663 false false false 2 false true false false -12100000000 -12100 false false false The cash outflow from a repayment of a borrowing having initial term of repayment of more than three months but less than one year or one operating cycle (if the normal cycle is more than one year) and may include the cash outflow from a repayment of a borrowing having initial term of repayment within three months net of the cash inflow of a borrowing having initial term of repayment within three months. No authoritative reference available. false 27 5 us-gaap_ProceedsFromIssuanceOfLongTermDebt us-gaap true debit duration monetary No definition available. false false false false false false false false false false false false 1 false true false false 2000000 2 false false false 2 false true false false 13392000000 13392 false false false The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 18 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 19 -Subparagraph b false 28 5 us-gaap_RepaymentsOfLongTermDebt us-gaap true credit duration monetary No definition available. false false false false false false false false false false true negated false 1 false true false false -9000000 -9 false false false 2 false true false false -303000000 -303 false false false The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 18 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 20 -Subparagraph b false 29 5 us-gaap_PaymentsOfOrdinaryDividends us-gaap true credit duration monetary No definition available. false false false false false false false false false false true negated false 1 false true false false -1441000000 -1441 false false false 2 false true false false -2133000000 -2133 false false false The cash outflow from distribution of an entity's earnings to common and preferred stockholders, including minority shareholders. This element excludes special dividends, which are included in a separate element for capital distributions. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 18 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 20 -Subparagraph a false 30 5 us-gaap_ProceedsFromPaymentsForOtherFinancingActivities us-gaap true debit duration monetary No definition available. false false false false false false false false false false false false 1 false true false false 8000000 8 false false false 2 false true false false 5000000 5 false false false The net cash inflow (outflow) from other financing activities. This element is used when there is not a more specific and appropriate element in the taxonomy. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 18, 19, 20 false 31 5 us-gaap_NetCashProvidedByUsedInFinancingActivities us-gaap true debit duration monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false -3211000000 -3211 false false false 2 false true false false 9635000000 9635 false false false The net cash inflow (outflow) from financing activity for the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 26 true 32 4 us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents us-gaap true debit duration monetary No definition available. false false false false false false false false false false false label false 1 false true false false -42000000 -42 false false false 2 false true false false -23000000 -23 false false false The effect of exchange rate changes on cash balances held in foreign currencies. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 25 false 33 4 us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease us-gaap true na duration monetary No definition available. false false false false false false false false false false false totallabel false 1 false true false false -219000000 -219 false false false 2 false true false false -875000000 -875 false false false The net change between the beginning and ending balance of cash and cash equivalents. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 26 true 34 3 us-gaap_CashAndCashEquivalentsAtCarryingValue us-gaap true debit instant monetary No definition available. false false false false false false false false true false false periodstartlabel false 1 false true false false 1978000000 1978 [1] false false false 2 false true false false 2122000000 2122 false false false Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased th ree years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits should not be reported as cash and cash equivalents. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7, 26 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 8, 9 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7 -Footnote 1 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 false 35 3 us-gaap_CashAndCashEquivalentsAtCarryingValue us-gaap true debit instant monetary No definition available. false false false false false false false false false true false periodendlabel false 1 false true false false 1759000000 1759 [2] false false false 2 false true false false 1247000000 1247 false false false Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased th ree years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits should not be reported as cash and cash equivalents. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7, 26 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 8, 9 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7 -Footnote 1 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 false 37 4 pfe_SupplementalCashFlowInformationCashPaidDuringPeriodForAbstract pfe false na duration string No definition available. false false false false false true false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false No definition available. false 38 5 us-gaap_IncomeTaxesPaidNet us-gaap true credit duration monetary No definition available. false false false false false false false false false false false false 1 false true false false 10547000000 10547 false false false 2 false true false false 454000000 454 false false false The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 29 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 27 -Subparagraph f false 39 5 us-gaap_InterestPaid us-gaap true credit duration monetary No definition available. false false false false false false false false false false false false 1 true true false false 792000000 792 false false false 2 true true false false 84000000 84 false false false The amount of cash paid during the current period for interest owed on money borrowed; includes amount of interest capitalized Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 29 false 1 Condensed from audited financial statements. 2 Unaudited. false 2 33 false Millions UnKnown UnKnown false true XML 28 defnref.xml IDEA: XBRL DOCUMENT No authoritative reference available. No authoritative reference available. The cash inflow from a borrowing having initial term of repayment of more than three months but less than one year or one operating cycle (if the normal cycle is more than one year) and may include the cash inflow from a borrowing having initial term of repayment within three months net of the cash outflow from repayment of a borrowing having initial term of repayment within three months. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The cash inflow associated with the aggregate amount received by the entity through sale or maturity of long-term marketable securities (trading, held-to-maturity, or available-for-sale) during the period. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. This element represents (i) carrying amount as of the balance sheet date of payments made in advance for income and other taxes, which will be charged against earnings within one year or the normal operating cycle, if longer as well as the current portion of the aggregate tax effects as of the balance sheet date of all future tax deductions arising from temporary differences between tax basis and generally accepted accounting principles basis recognition of assets, liabilities, revenues and expenses, which can only be deducted for tax purposes when permitted under enacted tax laws; after deducting the allocated valuation allowance, if any, to reduce such amount to net realizable value; and (ii) aggregate carrying amount, as of the balance sheet date, of current assets not separately presented elsewhere in the balance sheet. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The cash inflow associated with the aggregate amount received by the entity through sale or maturity of short term marketable securities (trading, held-to-maturity, or available-for-sale) during the period. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. Description of cost-reduction initiatives associated with a comprehensive plan to integrate acquired operations, generate cost savings and capture synergies across the company; as well as costs incurred in connection with an acquisition. These costs include (i) restructuring activities, including exit and disposal activities, the major types of costs associated with the plan activities and the accrual balance at the end of the period; (ii) integration costs, which represent external, incremental costs directly related to integrating acquired businesses; (iii) implementation costs, which represent external, incremental costs directly related to implementing cost-reduction initiatives prior to the Wyeth acquisition and primarily include expenditures related to system and process standardization and the expansion of shared services; (iv) additional depreciation-asset restructuring, which represents the impact of changes in the estimated useful lives of assets involved in restructuring actions; and (v) transaction costs, representing external costs incurred in connection with an acquisition. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. The cash outflow from a repayment of a borrowing having initial term of repayment of more than three months but less than one year or one operating cycle (if the normal cycle is more than one year) and may include the cash outflow from a repayment of a borrowing having initial term of repayment within three months net of the cash inflow of a borrowing having initial term of repayment within three months. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. This element represents (i) the total amount of other operating income, not previously categorized, from items that are associated with the entity's normal revenue producing operation; and (ii) recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales, as well as excludes research and development expenses and selling, informational and administrative expenses. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. This element represents (i)the noncurrent portion as of the balance sheet date of the aggregate carrying amount of all future tax deductions arising from temporary differences between tax basis and generally accepted accounting principles basis recognition of assets, liabilities, revenues and expenses, which can only be deducted for tax purposes when permitted under enacted tax laws; after the valuation allowance, if any, to reduce such amount to net realizable value. Deferred tax liabilities and assets shall be classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, shall be classified according to the expected reversal date of the temporary difference; and (ii) the aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed i n the balance sheet due to materiality considerations. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer). No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. This element represents the complete disclosure related to financial instruments, which may include i) selected financial assets and liabilities; ii) investments in debt and equity securities; iii) short-term borrowings; iv) long-term debt; v) derivative financial instruments and hedging activities; vi) credit risk; and vii) other disclosures related to financial instruments. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. This element represents (i) restructuring charges, which are amounts charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a program that is planned and controlled by management, and materially changes either the scope of a business undertaken by an entity, or the manner in which that business is conducted; and (ii) acquisition-related costs, which are costs incurred to effect a business combination which costs have been expensed during the period. Such costs can include transaction costs such as banking, legal, accounting and other costs directly related to effect a business combination as well as external, incremental costs of integration planning that are directly related to a business combination, including costs associated with preparing for systems and other integration activities. No authoritative reference available. This element represents (i) the current portion of deferred tax liabilities, which result from applying the applicable tax rate to net taxable temporary differences pertaining to each jurisdiction to which the entity is obligated to pay income tax. A current taxable temporary difference is a difference between the tax basis and the carrying amount of a current asset or liability in the financial statements prepared in accordance with generally accepted accounting principles. In a classified statement of financial position, an enterprise shall separate deferred tax liabilities and assets into a current amount and a noncurrent amount. Deferred tax liabilities and assets shall be classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, shall be classified according to the e xpected reversal date of the temporary difference; and (ii) the aggregate carrying amount, as of the balance sheet date, of current obligations not separately disclosed in the balance sheet due to materiality considerations. Current liabilities are expected to be paid within one year (or the normal operating cycle, if longer). No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. No authoritative reference available. XML 29 R13.xml IDEA: Goodwill and Other Intangible Assets 2.0.0.10 false Goodwill and Other Intangible Assets 000190 - Disclosure - Goodwill and Other Intangible Assets true false false false 1 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDperShare Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 pfe_GoodwillAndOtherIntangibleAssetsAbstract pfe false na duration string No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false No definition available. false 3 1 us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock us-gaap true na duration string No definition available. false false false false false false false false false false false false 1 false false false false 0 0 <div class="BWxbrlnote8"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <div> <div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><a style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline" id="xbrlnote8" name="xbrlnote8">Note 8. Goodwill and Other Intangible Assets</a></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-DECORATION: underline; TEXT-INDENT: 0pt">A. Goodwill</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt">The changes in the carrying amount of goodwill for the three months ended April 4, 2010, follow:</div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr> <td align="left" style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid" width="44%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-VARIANT: small-caps; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">(millions of dollars)</div></td> <td align="left" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="12%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Biopharmaceutical</div></td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="12%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Diversified</div></td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="12%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Other</div></td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" width="12%" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Total</div></td> <td style="BORDER-TOP: medium none; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="44%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="12%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="12%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="12%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="12%" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="44%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Balance, December 31, 2009<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="11%" valign="bottom">22,165</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="11%" valign="bottom">173</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="11%" valign="bottom">20,038</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="11%" valign="bottom">42,376</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="44%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Additions</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="11%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="11%" valign="bottom">18</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="11%" valign="bottom">985</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left; VERTICAL-ALIGN: text-top; font-size: 70%" width="1%" valign="bottom">&#160;(b)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="11%" valign="bottom">1,003</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="44%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Other<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(c)</font></div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="11%" valign="bottom">(570</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="11%" valign="bottom">(3</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="11%" valign="bottom">(158</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="11%" valign="bottom">(731</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">)</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 4px double" width="44%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Balance, April 4, 2010</div></td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="11%" valign="bottom">21,595</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="11%" valign="bottom">188</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="11%" valign="bottom">20,865</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="11%" valign="bottom">42,648</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(a)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;The <font style="DISPLAY: inline; FONT-STYLE: italic">Other</font> goodwill relates to our acquisition of Wyeth and is subject to change until we complete the recording of the assets acquired and liabilities assumed from Wyeth (see <font style="DISPLAY: inline; FONT-STYLE: italic">Note 3. Acquisition of Wyeth</font>). The allocation of Wyeth goodwill among the Biopharmaceutical and Diversified segments has not yet been completed, but will be completed within one year of the acquisition date.</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 14.4pt" width="2%"> <div style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(b)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Reflects the impact of measurement period adjustments (see <font style="DISPLAY: inline; FONT-STYLE: italic">Note 3. Acquisition of Wyeth</font>).</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 14.4pt" width="2%"> <div style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(c)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Primarily reflects the impact of foreign exchange.</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-DECORATION: underline; TEXT-INDENT: 0pt">B. Other Intangible Assets</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt">The components of identifiable intangible assets, primarily included in our Biopharmaceutical segment, follow:</div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="10"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">April 4, 2010</div></td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td> <td style="BORDER-TOP: black 1.5pt solid; BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="10"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: center">December 31, 2009</div></td> <td style="BORDER-TOP: medium none; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 2px solid" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-VARIANT: small-caps; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">(millions of dollars)</div></td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Gross</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Carrying</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Amount</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Accumulated</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Amortization</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Identifiable</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Intangible</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Assets, less</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Accumulated</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Amortization</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Gross</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Carrying</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Amount</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Accumulated</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Amortization</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: right" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" colspan="2"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Identifiable</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Intangible</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Assets, less Accumulated</div> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right; TEXT-INDENT: 0pt">Amortization</div></td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom">&#160;</td></tr> <tr> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td></tr> <tr> <td align="left" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left">Finite-lived intangible assets:</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" valign="bottom" colspan="2">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="22%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left">Developed technology rights</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">68,416</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(22,417</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">45,999</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">68,870</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(21,223</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">47,647</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="22%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Brands</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,627</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(563</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,064</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,637</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(535</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">1,102</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="22%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">License agreements</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">620</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(148</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">472</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">622</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(119</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">503</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="22%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Trademarks</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">107</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(69</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">38</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">113</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(73</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">40</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="22%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Other</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">425</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(228</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">197</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">488</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(231</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">257</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="22%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left">Total amortized finite-lived</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="22%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> &#160; intangible assets</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">71,195</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(23,425</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">47,770</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">71,730</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(22,181</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">49,549</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="22%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left">Indefinite-lived intangible assets:</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="22%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Brands</div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">12,462</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">12,462</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">12,562</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">12,562</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="22%" valign="bottom"> <div style="DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -9pt; text-align: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">In-process research and</font> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">development <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(a)</font></font></div></td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">4,178</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">4,178</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">5,834</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">5,834</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="22%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Trademarks</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">70</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">70</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">70</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">70</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" width="22%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -18pt; text-align: left"><font>&#160;</font> Total indefinite-lived</div></td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">&#160;</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="PADDING-BOTTOM: 2px" width="22%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><font>&#160;</font> intangible assets</div></td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">16,710</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">16,710</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">18,466</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">--</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">18,466</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr> <tr> <td align="left" style="BORDER-BOTTOM: black 4px double" width="22%" valign="bottom"> <div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: -18pt; text-align: left">Total identifiable intangible assets<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(b)</font></div></td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">87,905</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(23,425</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">64,480</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">90,196</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">(22,181</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">)</td> <td align="left" style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt" width="1%" valign="bottom">&#160;</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" width="1%" valign="bottom">$</td> <td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" width="10%" valign="bottom">68,015</td> <td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 4px; TEXT-ALIGN: left" width="1%" valign="bottom">&#160;</td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(a)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Decrease is primarily related to the impact of measurement period adjustments (see <font style="DISPLAY: inline; FONT-STYLE: italic">Note 3. Acquisition of Wyeth</font>).</div></td></tr></table></div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" border="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 36pt" width="2%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt">(b)</div></td> <td width="98%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; text-align: left">&#160;Decrease is primarily related to amortization of finite-lived intangible assets, the impact of measurement period adjustments (see <font style="DISPLAY: inline; FONT-STYLE: italic">Note 3. Acquisition of Wyeth</font>) and the impact of foreign exchange.</div></td></tr></table></div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">&#160;</div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">&#160;</div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Amortization expense related to acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in <font style="DISPLAY: inline; FONT-STYLE: italic">Amortization of intangible assets</font> as it benefits multiple business functions. Amortization expense related to acquired intangible assets that are associated with a single function is included in <font style="DISPLAY: inline; FONT-STYLE: italic">Cost of sales, Selling, informational and administrative expenses</font> and <font style="DISPLAY: inline; FONT-STYLE: italic">Research and development expenses</font>, as appropriate. Total amortization expense for finite-lived intangible assets was $1.4 billion for the first quarter of 2010, and $610 million for the first quarter of 2009.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div></div></div></div></div> Note 8. Goodwill and Other Intangible Assets A. Goodwill The changes in the carrying amount of goodwill for the three months ended April 4, 2010, false false false Discloses the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subjec t to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain or loss on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each g oodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss. This element may be used as a single block of text to include the entire intangible asset disclosure including data and tables. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 142 -Paragraph 42, 43, 44, 45, 46, 47 false false 1 2 false UnKnown UnKnown UnKnown false true XML 30 R1.xml IDEA: Document Information 2.0.0.10 false Document Information 000010 - Document - Document Information true false false false 1 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDperShare Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 3 1 dei_DocumentInformationLineItems dei false na duration string No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. false 4 2 dei_DocumentType dei false na duration na No definition available. false false false false false false false false false false false false 1 false false false false 0 0 10-Q 10-Q false false false The type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type should be limited to the same value as the supporting SEC submission type. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, NCSR, N-Q, and Other. No authoritative reference available. false 5 2 dei_AmendmentFlag dei false na duration na No definition available. false false false false false false false false false false false false 1 false false false false 0 0 false false false false false If the value is true, then the document as an amendment to previously-filed/accepted document. No authoritative reference available. false 6 2 dei_DocumentPeriodEndDate dei false na duration date No definition available. false false false false false false false false false false false false 1 false false false false 0 0 2010-04-04 2010-04-04 false false false The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements this will be the filing date. The format of the date is CCYY-MM-DD. No authoritative reference available. false 7 2 dei_DocumentFiscalYearFocus dei false na duration positiveinteger No definition available. false false false false false false false false false false false false 1 false true false false 2010 2010 false false false This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. No authoritative reference available. false 8 2 dei_DocumentFiscalPeriodFocus dei false na duration na No definition available. false false false false false false false false false false false false 1 false false false false 0 0 Q1 Q1 false false false This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY. No authoritative reference available. false false 1 6 false UnKnown UnKnown UnKnown false true XML 31 R2.xml IDEA: Entity Information 2.0.0.10 false Entity Information (USD $) 000020 - Document - Entity Information true false In Billions, except Share data false false 1 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDperShare Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 false 2 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 false 3 usd $ false false USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 4 2 dei_EntityInformationLineItems dei false na duration string No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 false false false Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. false 5 3 dei_EntityRegistrantName dei false na duration normalizedstring No definition available. false false false false false false false false false false false false 1 false false false false 0 0 PFIZER INC PFIZER INC false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 false false false The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation 12B -Number 240 -Section 12b -Subsection 1 false 6 3 dei_EntityCentralIndexKey dei false na duration na No definition available. false false false false false false false false false false false false 1 false false false false 0 0 0000078003 0000078003 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 false false false A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation 12B -Number 240 -Section 12b -Subsection 1 false 7 3 dei_CurrentFiscalYearEndDate dei false na duration monthday No definition available. false false false false false false false false false false false false 1 false false false false 0 0 --12-31 --12-31 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 false false false End date of current fiscal year in the format --MM-DD. No authoritative reference available. false 8 3 dei_EntityWellKnownSeasonedIssuer dei false na duration na No definition available. false false false false false false false false false false false false 1 false false false false 0 0 Yes Yes false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 false false false Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A. No authoritative reference available. false 9 3 dei_EntityVoluntaryFilers dei false na duration na No definition available. false false false false false false false false false false false false 1 false false false false 0 0 No No false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 false false false Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. No authoritative reference available. false 10 3 dei_EntityCurrentReportingStatus dei false na duration na No definition available. false false false false false false false false false false false false 1 false false false false 0 0 Yes Yes false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 false false false Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. No authoritative reference available. false 11 3 dei_EntityFilerCategory dei false na duration na No definition available. false false false false false false false false false false false false 1 false false false false 0 0 Large Accelerated Filer Large Accelerated Filer false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 false false false Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. No authoritative reference available. false 12 3 dei_EntityPublicFloat dei false credit instant monetary No definition available. false false false false false false false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false 3 true true false false 102000000000 102 false false false State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K. No authoritative reference available. false 14 2 dei_EntityListingsLineItems dei false na duration string No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 false false false Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. false 15 3 dei_EntityCommonStockSharesOutstanding dei false na instant shares No definition available. false false false false false false false false false false false false 1 false false false false 0 0 false false false 2 false true false false 8066133809 8066133809.00 false false false 3 false false false false 0 0 false false false Indicate number of shares outstanding of each of registrant's classes of common stock, as of latest practicable date. Where multiple classes exist define each class by adding class of stock items such as Common Class A [Member], Common Class B [Member] onto the Instrument [Domain] of the Entity Listings, Instrument No authoritative reference available. false false 3 11 false Billions NoRounding UnKnown false true XML 32 FilingSummary.xml IDEA: XBRL DOCUMENT 2.0.0.10 true Sheet 000010 - Document - Document Information Document Information http://www.pfizer.com/2010-04-04/role/DocumentInformation false R1.xml false Sheet 000020 - Document - Entity Information Entity Information http://www.pfizer.com/2010-04-04/role/EntityInformation false R2.xml false Sheet 000030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) http://www.pfizer.com/2010-04-04/role/StatementOfIncome false R3.xml false Sheet 000040 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) http://www.pfizer.com/2010-04-04/role/StatementOfFinancialPositionClassified false R4.xml false Sheet 000050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) http://www.pfizer.com/2010-04-04/role/StatementOfCashFlowsIndirect false R5.xml false Sheet 000100 - Disclosure - Basis of Presentation Basis of Presentation http://www.pfizer.com/2010-04-04/role/OrganizationConsolidationAndPresentationOfFinancialStatements false R6.xml false Sheet 000110 - Disclosure - Adoption of New Accounting Policies Adoption of New Accounting Policies http://www.pfizer.com/2010-04-04/role/AccountingChangesAndErrorCorrections false R7.xml false Sheet 000120 - Disclosure - Acquisition of Wyeth Acquisition of Wyeth http://www.pfizer.com/2010-04-04/role/BusinessCombinations false R8.xml false Sheet 000140 - Disclosure - Cost-Reduction Initiatives and Acquisition-Related Costs Cost-Reduction Initiatives and Acquisition-Related Costs http://www.pfizer.com/2010-04-04/role/CostReductionInitiativesAndAcquisitionRelatedCosts false R9.xml false Sheet 000155 - Disclosure - Financial Instruments Financial Instruments http://www.pfizer.com/2010-04-04/role/FinancialInstruments false R10.xml false Sheet 000160 - Disclosure - Comprehensive Income (Loss) Comprehensive Income (Loss) http://www.pfizer.com/2010-04-04/role/ComprehensiveIncomeExpense false R11.xml false Sheet 000180 - Disclosure - Inventories Inventories http://www.pfizer.com/2010-04-04/role/Inventory false R12.xml false Sheet 000190 - Disclosure - Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets http://www.pfizer.com/2010-04-04/role/GoodwillAndOtherIntangibleAssets false R13.xml false Sheet 000200 - Disclosure - Pension and Postretirement Benefit Plans Pension and Postretirement Benefit Plans http://www.pfizer.com/2010-04-04/role/PensionAndPostretirementBenefitPlans false R14.xml false Sheet 000210 - Disclosure - Earnings Per Share Attributable to Common Shareholders Earnings Per Share Attributable to Common Shareholders http://www.pfizer.com/2010-04-04/role/EarningsPerShare false R15.xml false Sheet 000220 - Disclosure - Segment Information Segment Information http://www.pfizer.com/2010-04-04/role/SegmentReporting false R16.xml false Sheet 000240 - Disclosure - Taxes on Income Taxes on Income http://www.pfizer.com/2010-04-04/role/IncomeTaxes false R17.xml false Book All Reports All Reports false 1 8 0 0 3 113 true false Pri_20090329 1 DEI_2010-05-10 1 Pri_20081231 1 Cur_3mos_20100404 72 Pri_3mos_20090329 47 DEI_2009-06-26 1 Pri_20091231 39 Cur_20100404 39 true true EXCEL 33 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls MT,\1X*&Q&N$`````````````````````/@`#`/[_"0`&```````````````" M`````0``````````$```K`````$```#^____```````````"````________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M_______________________]_____O____W___\$````!0````8````'```` M"`````D````*````"P````P````-````#@````\````0````$0```!(````3 M````%````!4````6````%P```!@````9````&@```!L````<````'0```!X` M```?````(````"$````B````(P```"0````E````)@```"<````H````*0`` M`"H````K````+````"T````N````+P```#`````Q````,@```#,````T```` M-0```#8````W````.````#D````Z````.P```#P````]````/@```#\```!` M````00```$(```!#````1````$4```!&````1P```$@```!)````2@```$L` M``!,````30```$X```!/````4````%$```!2````4P```%0```!5````5@`` M`%<```!8````60```%H```!;````7````%T```!>````7P```&````!A```` M8@```&,```!D````90```&8```!G````:````&D```!J````:P```&P```!M M````;@```&\```!P````<0```'(```!S````=````'4```!V````=P```'@` M``!Y````>@```'L```!\````?0```'X```!_````@````%(`;P!O`'0`(`!% M`&X`=`!R`'D````````````````````````````````````````````````` M```````````6``4`__________\"```````````````````````````````` M`````````!#1)WC=\LH!K0```$`!````````5P!O`'(`:P!B`&\`;P!K```` M```````````````````````````````````````````````````````````` M`!(``@#_______________\````````````````````````````````````` M```````````#````"E$!```````%`%,`=0!M`&T`80!R`'D`20!N`&8`;P!R M`&T`80!T`&D`;P!N````````````````````````````````````*``"`0$` M```#````_____P`````````````````````````````````````````````` M``````"```````````4`1`!O`&,`=0!M`&4`;@!T`%,`=0!M`&T`80!R`'D` M20!N`&8`;P!R`&T`80!T`&D`;P!N```````````````X``(`____________ M____`````````````````````````````````````````````````@```*`` M````````@0```((```"#````A````(4```"&````AP```(@```")````B@`` M`(L```",````C0```(X```"/````D````)$```"2````DP```)0```"5```` ME@```)<```"8````F0```)H```";````G````)T```">````GP```*````"A M````H@```*,```"D````I0```*8```"G````J````*D```"J````JP```/[_ M___^_____O__________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M______________________________\)"!````8%`$88S0?!@```!@(``.$` M`@"P!,$``@```.(```!<`'``!P``&)R;```!@(````````````````` M```````````````````````````````````````````````````````````` M`````````````````````````````````````````````````````$(``@"P M!&$!`@```,`!```]`2(``0`"``,`!``%``8`!P`(``D`"@`+``P`#0`.``\` M$``1`)P``@`.`!D``@```!(``@```!,``@```*\!`@```+P!`@```#T`$@#P M`%H`3"R+&C@```````$`6`)```(```"-``(````B``(````.``(``0"W`0(` M``#:``(````Q`!P`R````/]_D`$````````&`50`80!H`&\`;0!A`#$`'`#( M````_W^0`0````````8!5`!A`&@`;P!M`&$`,0`<`,@```#_?Y`!```````` M!@%4`&$`:`!O`&T`80`Q`!P`R````/]_D`$````````&`50`80!H`&\`;0!A M`#$`'`#(````_W^\`@````````8!5`!A`&@`;P!M`&$`,0`<`,@```#_?Y`! M`0``````!@%4`&$`:`!O`&T`80`Q`!P`R````/]_D`$``"$````&`50`80!H M`&\`;0!A`!X$-P`%`!D``2(`)``B`",`+``C`",`,`!?`"D`.P!<`"@`(``B M`"0`(@`C`"P`(P`C`#``7``@`"D`'@1!``8`'@`!(@`D`"(`(P`L`",`(P`P M`%\`*0`[`%L`4@!E`&0`70!<`"@`(``B`"0`(@`C`"P`(P`C`#``7``@`"D` M'@1#``<`'P`!(@`D`"(`(P`L`",`(P`P`"X`,``P`%\`*0`[`%P`*``@`"(` M)``B`",`+``C`",`,``N`#``,`!<`"``*0`>!$T`"``D``$B`"0`(@`C`"P` M(P`C`#``+@`P`#``7P`I`#L`6P!2`&4`9`!=`%P`*``@`"(`)``B`",`+``C M`",`,``N`#``,`!<`"``*0`>!'$`*@`V``%?`"@`(@`D`"(`*@`@`",`+``C M`",`,`!?`"D`.P!?`"@`(@`D`"(`*@`@`%P`*``@`",`+``C`",`,`!<`"`` M*0`[`%\`*``B`"0`(@`J`"``(@`M`"(`7P`I`#L`7P`H`"``0`!?`"``*0`> M!%\`*0`M``%?`"@`*@`@`",`+``C`",`,`!?`"D`.P!?`"@`*@`@`%P`*``@ M`",`+``C`",`,`!<`"``*0`[`%\`*``J`"``(@`M`"(`7P`I`#L`7P`H`"`` M0`!?`"``*0`>!($`+``^``%?`"@`(@`D`"(`*@`@`",`+``C`",`,``N`#`` M,`!?`"D`.P!?`"@`(@`D`"(`*@`@`%P`*``@`",`+``C`",`,``N`#``,`!< M`"``*0`[`%\`*``B`"0`(@`J`"``(@`M`"(`/P`_`%\`*0`[`%\`*``@`$`` M7P`@`"D`'@1O`"L`-0`!7P`H`"H`(``C`"P`(P`C`#``+@`P`#``7P`I`#L` M7P`H`"H`(`!<`"@`(``C`"P`(P`C`#``+@`P`#``7``@`"D`.P!?`"@`*@`@ M`"(`+0`B`#\`/P!?`"D`.P!?`"@`(`!``%\`(``I`!X$'P"D``T``2,`+``C M`",`,``[`"@`(P`L`",`(P`P`"D`'@0C`*4`#P`!)``C`"P`(P`C`#``.P`H M`"0`(P`L`",`(P`P`"D`'@0O`*8`%0`!)``C`"P`(P`C`#``+@`C`",`.P`H M`"0`(P`L`",`(P`P`"X`(P`C`"D`X``4``````#U_R```````````````,`@ MX``4``$```#U_R```/0``````````$$@X``4``$```#U_R```/0````````` M`$$@X``4``(```#U_R```/0``````````$$@X``4``(```#U_R```/0````` M`````$$@X``4``````#U_R```/0``````````$$@X``4``````#U_R```/0` M`````````$$@X``4``````#U_R```/0``````````$$@X``4``````#U_R`` M`/0``````````$$@X``4``````#U_R```/0``````````$$@X``4``````#U M_R```/0``````````$$@X``4``````#U_R```/0``````````$$@X``4```` M``#U_R```/0``````````$$@X``4``````#U_R```/0``````````$$@X``4 M``````#U_R```/0``````````$$@X``4```````!`"```````````````,`@ MX``4``$`*P#U_R```/@``````````$$@X``4``$`*0#U_R```/@````````` M`$$@X``4``$`+`#U_R```/@``````````$$@X``4``$`*@#U_R```/@````` M`````$$@X``4``$`"0#U_R```/@``````````$$@X``4``4````!`"````@` M`````````,`@X``4``4````!`"@``!@``````````,`@X``4``4````!`"H` M`!@``````````,`@X``4```````!`"@``!```````````,`@X``4```````) M`"```````````````,`@X``4```````)`"@``!```````````,`@X``4```` M```)``@``!```````````,`@X``4````I``!`"````0``````````,`@X``4 M````I0`!`"````0``````````,`@X``4``8````!`"````@``````````,`@ MX``4````I@`!`"````0``````````,`@X``4``<`I``!`"````P````````` M`,`@X``4``<`I0`!`"````P``````````,`@X``4``<`I@`!`"````P````` M`````,`@DP($``"``/^3`@0`$(`#_Y,"!``1@`;_DP($`!*`!/^3`@0`$X`' M_Y,"!``4@`7_8`$"````A0`P`%<,`0```!0!1`!O`&,`=0!M`&4`;@!T`"`` M20!N`&8`;P!R`&T`80!T`&D`;P!N`(4`+``2#P$````2`44`;@!T`&D`=`!Y M`"``20!N`&8`;P!R`&T`80!T`&D`;P!N`(4`1@#=$@$````?`4,`3P!.`$0` M10!.`%,`10!$`"``0P!/`$X`4P!/`$P`20!$`$$`5`!%`$0`(`!3`%0`00!4 M`$4`30!%`$X`A0!&`+@=`0```!\!0P!/`$X`1`!%`$X`4P!%`$0`(`!#`$\` M3@!3`$\`3`!)`$0`00!4`$4`1``@`$(`00!,`$$`3@!#`$4`(`"%`$8`=2X! M````'P$Q`%\`0P!/`$X`1`!%`$X`4P!%`$0`(`!#`$\`3@!3`$\`3`!)`$0` M00!4`$4`1``@`%,`5`!!`%0`10!-`(4`,@"F.0$````5`4(`80!S`&D```@`&L`90!Y``H``3``,``P`#``,``W`#@`,``P`#,`'``!0P!U`'(` M<@!E`&X`=``@`&8`:0!S`&,`80!L`"``>0!E`&$`<@`@`&4`;@!D`"``9`!A M`'0`90`'``$M`"T`,0`R`"T`,P`Q`"$``44`;@!T`&D`=`!Y`"``=P!E`&P` M;``@`&L`;@!O`'<`;@`@`',`90!A`',`;P!N`&4`9``@`&D`0`@`&8`:0!L`&4`<@`@`&,`80!T`&4`9P!O`'(`>0`7``%, M`&$`<@!G`&4`(`!!`&,`8P!E`&P`90!R`&$`=`!E`&0`(`!&`&D`;`!E`'(` M$P`!10!N`'0`:0!T`'D`(`!P`'4`8@!L`&D`8P`@`&8`;`!O`&$`=``<``%% M`&X`=`!I`'0`>0`@`$P`:0!S`'0`:0!N`&<``!C`&4`<`!T`"``4`!E`'(`(`!3 M`&@`80!R`&4`(`!D`&$`=`!A`!\``3,`(`!-`&\`;@!T`&@``!P`&4`;@!S`&4`@!A`'0`:0!O`&X` M(`!O`&8`(`!I`&X`=`!A`&X`9P!I`&(`;`!E`"``80!S`',`90!T`',`/P`! M00!C`'$`=0!I`',`:0!T`&D`;P!N`"T`<@!E`&P`80!T`&4`9``@`&D`;@`M M`'``<@!O`&,`90!S`',`(`!R`&4``!E`',`(`!O`&X`(`!I`&X`8P!O M`&T`90`=``%0`'(`;P!V`&D``!C`&P`=0!S M`&D`=@!E`"``;P!F`"``80!M`&\`<@!T`&D`>@!A`'0`:0!O`&X`(`!O`&8` M(`!I`&X`=`!A`&X`9P!I`&(`;`!E`"``80!S`',`90!T`',`+``@`&4`>`!C M`&4`<`!T`"``80!S`"``9`!I`',`8P!L`&\`0!A`&(`;`!E`!0``4D`;@!C`&\`;0!E`"``=`!A M`'@`90!S`"``<`!A`'D`80!B`&P`90`F``%!`&,`8P!R`'4`90!D`"``8P!O M`&T`<`!E`&X`0`O``%%`'$`=0!I`'0`>0`@`&$`=`!T`'(` M:0!B`'4`=`!A`&(`;`!E`"``=`!O`"``;@!O`&X`8P!O`&X`=`!R`&\`;`!L M`&D`;@!G`"``:0!N`'0`90!R`&4`0`@`&\`<`!E`'(` M80!T`&D`;@!G`"``80!C`'0`:0!V`&D`=`!I`&4``!P`&4`;@!S`&4`*0`!1`!E`&8`90!R`'(`90!D M`"``=`!A`'@`90!S`"``9@!R`&\`;0`@`&,`;P!N`'0`:0!N`'4`:0!N`&<` M(`!O`'``90!R`&$`=`!I`&\`;@!S`!H``4\`=`!H`&4`<@`@`&X`;P!N`"T` M8P!A`',`:``@`&$`9`!J`'4`0`@`&8`:0!N`&$`;@!C`&D`;@!G`"``80!C`'0`:0!V`&D`=`!I M`&4``!C`&@`80!N`&<`90`M M`'(`80!T`&4`(`!C`&@`80!N`&<`90!S`"``;P!N`"``8P!A`',`:``@`&$` M;@!D`"``8P!A`',`:``@`&4`<0!U`&D`=@!A`&P`90!N`'0``!E`',`"``!20!N`'0`90!R`&4``!C`&@`80!N`&<`90`@`$,`;P!M`&T`:0!S M`',`:0!O`&X`(``H`%,`10!#`"D`(`!F`&\`<@`@`&D`;@!T`&4`<@!I`&T` M(`!R`&4`<`!O`'(`=`!I`&X`9P`N`"``00!S`"``<`!E`'(`;0!I`'0`=`!E M`&0`(`!U`&X`9`!E`'(`(`!T`&@`;P!S`&4`(`!R`'4`;`!E`',`+``@`&,` M90!R`'0`80!I`&X`(`!F`&\`;P!T`&X`;P!T`&4`0`@`&$`8P!C M`&4`<`!T`&4`9``@`&D`;@`@`'0`:`!E`"``50!N`&D`=`!E`&0`(`!3`'0` M80!T`&4`0!E`'0`:``N`"``00!S`"``80`@`'(`90!S`'4` M;`!T`"P`(`!L`&4`9P!A`&,`>0`@`%<`>0!E`'0`:``@`&\`<`!E`'(`80!T M`&D`;P!N`',`(`!A`'(`90`@`'(`90!F`&P`90!C`'0`90!D`"``:0!N`"`` M;P!U`'(`(`!R`&4`0`@`&X`;P!T`"``8@!E`"``<@!E`'``<@!E`',`90!N`'0`80!T M`&D`=@!E`"``;P!F`"``=`!H`&\`0`@`&8`;P!R`"``=`!H M`&4`(`!F`&$`:0!R`"``<`!R`&4`0!I`&X`9P`@ M`&X`;P!T`&4`0!E`'0`:``?``%! M`&,`<0!U`&D`0!E`'0`:``@`%L`5`!E`'@`=``@`$(`;`!O`&,`:P!=`(`,`0T` M#0!.`&\`=`!E`"``,P`N`"``00!C`'$`=0!I`',`:0!T`&D`;P!N`"``;P!F M`"``5P!Y`&4`=`!H`"``#0`-``T`3P!N`"``3P!C`'0`;P!B`&4`<@`@`#$` M-0`L`"``,@`P`#``.0`@`"@`=`!H`&4`(`!A`&,`<0!U`&D`0`@`&\`9@`@`%<`>0!E`'0`:``@`&D`;@`@`&$`(`!C`&$` M0`@`"0`-@`X`"``8@!I`&P`;`!I`&\`;@`N`"``5P!H`&D` M;`!E`"``5P!Y`&4`=`!H`"``;@!O`'<`(`!I`',`(`!A`"``=P!H`&\`;`!L M`'D`+0!O`'<`;@!E`&0`(`!S`'4`8@!S`&D`9`!I`&$`<@!Y`"``;P!F`"`` M4`!F`&D`>@!E`'(`+``@`'0`:`!E`"``;0!E`'(`9P!E`'(`(`!O`&8`(`!L M`&\`8P!A`&P`(`!0`&8`:0!Z`&4`<@`@`&$`;@!D`"``5P!Y`&4`=`!H`"`` M90!N`'0`:0!T`&D`90!S`"``;0!A`'D`(`!B`&4`(`!P`&4`;@!D`&D`;@!G M`"``;P!R`"``9`!E`&P`80!Y`&4`9``@`&D`;@`@`'8`80!R`&D`;P!U`',` M(`!I`&X`=`!E`'(`;@!A`'0`:0!O`&X`80!L`"``:@!U`'(`:0!S`&0`:0!C M`'0`:0!O`&X`0`@`&\`8@!L`&D` M9P!A`'0`:0!O`&X`0`@`'(`90!C`&\`<@!D M`&4`9``@`&D`;@`@`#(`,``P`#D`(``H`&T`90!A`',`=0!R`&4`;0!E`&X` M=``@`'``90!R`&D`;P!D`"``80!D`&H`=0!S`'0`;0!E`&X`=`!S`"D`+@`@ M`%0`:`!E`"``;0!E`&$`@!E`&0`(``H`',`90!E`"``8@!E`&P`;P!W M`"D`(`!A`&X`9``@`&$`<@!E`"``0!E`&$`<@`@`&8`<@!O`&T`(`!T`&@`90`@`&$`8P!Q`'4` M:0!S`&D`=`!I`&\`;@`@`&0`80!T`&4`+@`@``T`#0`-``T`*`!M`&D`;`!L M`&D`;P!N`',`(`!O`&8`(`!D`&\`;`!L`&$`<@!S`"D`(``)``D`#0`-`$$` M;0!O`'4`;@!T`',`(`!2`&4`8P!O`&<`;@!I`'H`90!D`"``#0`-`&$``!C`&P`=0!D`&D`;@!G`"`` M:0!N`'8`90!N`'0`;P!R`&D`90!S`"``"0`)`"0`(``)`#$`-@`L`#,`-``R M`"``"0`)`"``"0`D`"``"0`)`"``"0`)`"0`(``)`#$`-@`L`#,`-``R`"`` M"0`-``T`#0!)`&X`=@!E`&X`=`!O`'(`:0!E`',`(``)``D`(``)`#@`+``S M`#@`.``@``D`"0`@``D`"0`H`#$`-@`W`"``"0`I`"``"0`)`"``"0`X`"P` M,@`R`#$`(``)``T`#0`-`%``<@!O`'``90!R`'0`>0`L`"``<`!L`&$`;@!T M`"``80!N`&0`(`!E`'$`=0!I`'``;0!E`&X`=``@``D`"0`@``D`,0`P`"P` M,``U`#0`(``)``D`(``)``D`*``Q`#<`,0`@``D`*0`@``D`"0`@``D`.0`L M`#@`.``S`"``"0`-``T`#0!)`&0`90!N`'0`:0!F`&D`80!B`&P`90`@`&D` M;@!T`&$`;@!G`&D`8@!L`&4`(`!A`',```@`&$`8P!C`&\`=0!N`'0``!I`',`=`!I`&X`9P`@`&$`0`L`"``=`!H M`&4`(`!F`&\`;`!L`&\`=P!I`&X`9P`@`&D`=`!E`&T`0`L`"``<`!E`&X`9`!I`&X`9P`@ M`&8`:0!N`&$`;`!I`#@``4,`;P!S`'0`+0!2`&4`9`!U`&,`=`!I`&\`;@`@ M`$D`;@!I`'0`:0!A`'0`:0!V`&4`0!E`'0`:``G`',`(`!O`'``90!R`&$`=`!I M`&\`;@!S`"P`(`!G`&4`;@!E`'(`80!T`&4`(`!C`&\`0!N`&4`<@!G M`&D`90!S`"``80!C`'(`;P!S`',`(`!T`&@`90`@`&,`;P!M`&(`:0!N`&4` M9``@`&,`;P!M`'``80!N`'D`+@`@`%<`90`@`&$`<@!E`"``9@!O`&,`=0!S M`&D`;@!G`"``;P!U`'(`(`!E`&8`9@!O`'(`=`!S`"``;P!N`"``80!C`&@` M:0!E`'8`:0!N`&<`(`!A`&X`(`!A`'``<`!R`&\`<`!R`&D`80!T`&4`(`!C M`&\`0`N`"``#0`-`%<`90`@ M`&D`;@!C`'4`<@!R`&4`9``@`'0`:`!E`"``9@!O`&P`;`!O`'<`:0!N`&<` M(`!C`&\``!T`&4`<@!N`&$`;``@`&,`;P!S`'0`0`@`'(`90!L`&$`=`!E`&0`(`!T`&\`(`!E`&8`9@!E`&,` M=`!I`&X`9P`@`'0`:`!E`"``80!C`'$`=0!I`',`:0!T`&D`;P!N`"``;P!F M`"``5P!Y`&4`=`!H`"``80!N`&0`(`!P`'(`:0!M`&$`<@!I`&P`>0`@`&D` M;@!C`&P`=0!D`&4`(`!E`'@`<`!E`&X`9`!I`'0`=0!R`&4`0`@`&D`;@!C M`&P`=0!D`&4`(`!E`'@`<`!E`&X`9`!I`'0`=0!R`&4`0`@`'0`<@!A`&X``!P`&4`8P!T`&4`9``@ M`'(`90!D`'4`8P!T`&D`;P!N`"``;P!F`"``=`!H`&4`(`!W`&\`<@!K`&8` M;P!R`&,`90`@`&(`>0`@`&$`<`!P`'(`;P!X`&D`;0!A`'0`90!L`'D`(``T M`#4`+``T`#``,``@`&4`;0!P`&P`;P!Y`&4`90!S`"P`(`!M`&$`:0!N`&P` M>0`@`&D`;@`@`&T`80!N`'4`9@!A`&,`=`!U`'(`:0!N`&<`+``@`',`80!L M`&4`0`@`',`90!C`'4`<@!I M`'0`:0!E`',`+``@`&4`>`!C`&P`=0!D`&D`;@!G`"``;0!O`&X`90!Y`"`` M;0!A`'(`:P!E`'0`(`!F`'4`;@!D`',`*`!C`"D`(``)``D`(``)`#(`-``S M`"``"0`)`"``"0`)`#(`.``Q`"``"0`-``T`#0`@`$0`90!R`&D`=@!A`'0` M:0!V`&4`(`!F`&D`;@!A`&X`8P!I`&$`;``@`&D`;@!S`'0`<@!U`&T`90!N M`'0`0`@`',`=P!A`'`` M0`@`&8`;P!R`'<`80!R`&0` M+0!E`'@`8P!H`&$`;@!G`&4`(`!C`&\`;@!T`'(`80!C`'0`0`@`&T`90!T`&@`;P!D`"``*`!H`"D`(``) M``D`(``)`#@`-0`X`"``"0`)`"``"0`)`#@`,0`Q`"``"0`-``T`#0`@`$P` M;P!N`&<`+0!T`&4`<@!M`"``;`!O`&$`;@!S`"P`(`!C`&$`<@!R`&D`90!D M`"``80!T`"``8P!O`',`=``H`&<`*0`@``D`"0`@``D`-P`X`#(`(``)``D` M(``)``D`-P`X`#0`(``)``T`#0`-`"``5`!O`'0`80!L`"``"0`)`"``"0`S M`"P`,@`P`#$`(``)``D`(``)``D`,P`L`#8`,``R`"``"0`-``T`#0!4`&\` M=`!A`&P`(`!S`&4`;`!E`&,`=`!E`&0`(`!F`&D`;@!A`&X`8P!I`&$`;``@ M`&$`0`@`&$`;``\`!P@`6P`(`!O`&8` M(`!O`'4`<@`@`&8`:0!N`&$`;@!C`&D`80!L`"``80!S`',`90!T`',`(`!A M`&X`9``@`&P`:0!A`&(`:0!L`&D`=`!I`&4`0`@`',`90!C`'4`<@!I`'0`:0!E`',`+``@`&4`>`!C`&P`=0!D M`&D`;@!G`"``;0!O`&X`90!Y`"``;0!A`'(`:P!E`'0`(`!F`'4`;@!D`',` M+``@`&$`<@!E`"``)``Y`#,`(`!M`&D`;`!L`&D`;P!N`"``80!S`"``;P!F M`"``00!P`'(`:0!L`"``-``L`"``,@`P`#$`,``@`&$`;@!D`"``)``W`#<` M(`!M`&D`;`!L`&D`;P!N`"``80!S`"``;P!F`"``1`!E`&,`90!M`&(`90!R M`"``,P`Q`"P`(``R`#``,``Y`"``;P!F`"``:0!N`'8`90!S`'0`;0!E`&X` M=`!S`"``=`!H`&$`=``@`'4`0`@`%``:`!A`'(`;0!A`&,`:0!A`"``@!E`&0`(`!G M`&$`:0!N`',`(`!A`&X`9``@`&P`;P!S`',`90!S`"``80!R`&4`(`!N`&\` M=``@`',`:0!G`&X`:0!F`&D`8P!A`&X`=``N`"``#0`-`"@`9``I`"``"0`- M``T`20!N`&,`;`!U`&0`90!S`"``80!P`'``<@!O`'@`:0!M`&$`=`!E`&P` M>0`@`"0`,0`N`#(`(`!B`&D`;`!L`&D`;P!N`"``;P!F`"``;0!O`&X`90!Y M`"``;0!A`'(`:P!E`'0`(`!F`'4`;@!D`',`(`!H`&4`;`!D`"``:0!N`"`` M90!S`&,`<@!O`'<`(`!T`&\`(`!S`&4`8P!U`'(`90`@`&,`90`;``%#`&\` M;0!P`'(`90!H`&4`;@!S`&D`=@!E`"``20!N`&,`;P!M`&4`(``H`$P`;P!S M`',`*0`F``%#`&\`;0!P`'(`90!H`&4`;@!S`&D`=@!E`"``20!N`&,`;P!M M`&4`(``H`$P`;P!S`',`*0`@`%L`00!B`',`=`!R`&$`8P!T`%T`*``!0P!O M`&T`<`!R`&4`:`!E`&X`0`@`'0`<@!A`&X`@!E`'(`(`!)`&X` M8P`N`"``"0`)`"0`(``)`"@`-``V`#<`(``)`"D`(``)``D`)``@``D`,@`L M`#8`,@`U`"``"0`-``T`#0`6``%)`&X`=@!E`&X`=`!O`'(`:0!E`',`(`!; M`$$`8@!S`'0`<@!A`&,`=`!=`!@``4D`;@!V`&4`;@!T`&\`<@!I`&4`0`@`&0`=0!E`"``=`!O`"`` M=`!H`&4`(`!I`&X`=@!E`&X`=`!O`'(`>0`@`',`;P!L`&0`(`!D`'4`<@!I M`&X`9P`@`'0`:`!E`"``9@!I`'(`0!E`&$`<@`G`',`(`!S M`'4`<`!P`&P`>0`N`%0`:`!E`',`90`@`&4`>`!C`&4`0!I`&X`9P`@`&$`;0!O`'4`;@!T`"``;P!F`"``9P!O`&\`9`!W`&D`;`!L M`"``9@!O`'(`(`!T`&@`90`@`'0`:`!R`&4`90`@`&T`;P!N`'0`:`!S`"`` M90!N`&0`90!D`"``00!P`'(`:0!L`"``-``L`"``,@`P`#$`,``L`"``9@!O M`&P`;`!O`'<`.@`@``T`#0`H`&T`:0!L`&P`:0!O`&X`0!E M`'0`:``@`&$`;@!D`"``:0!S`"``0!E`&$`<@`@`&\`9@`@`'0`:`!E`"``80!C M`'$`=0!I`',`:0!T`&D`;P!N`"``9`!A`'0`90`N`"``#0`-`"@`8@`I`"`` M"0`-``T`4@!E`&8`;`!E`&,`=`!S`"``=`!H`&4`(`!I`&T`<`!A`&,`=``@ M`&\`9@`@`&T`90!A`',`=0!R`&4`;0!E`&X`=``@`'``90!R`&D`;P!D`"`` M80!D`&H`=0!S`'0`;0!E`&X`=`!S`"``*`!S`&4`90`@`$X`;P!T`&4`(``S M`"X`(`!!`&,`<0!U`&D``!C`&@`80!N`&<`90`N`"``#0`-``T`0@`N M`"``3P!T`&@`90!R`"``20!N`'0`/``;(`%A`&X`9P!I`&(`;`!E`"``00!S M`',`90!T`',`(``-``T`#0!4`&@`90`@`&,`;P!M`'``;P!N`&4`;@!T`',` M(`!O`&8`(`!I`&0`90!N`'0`:0!F`&D`80!B`&P`90`@`&D`;@!T`&$`;@!G M`&D`8@!L`&4`(`!A`',`@!A`'0`:0!O`&X`(``)``D`(``)``T`#0!)`&0`90!N`'0`:0!F`&D`80!B M`&P`90`@``T`#0!)`&X`=`!A`&X`9P!I`&(`;`!E`"``#0`-`$$`@!A`'0`:0!O`&X`(``)``D`(``)``T`#0!)`&0`90!N M`'0`:0!F`&D`80!B`&P`90`@``T`#0!)`&X`=`!A`&X`9P!I`&(`;`!E`"`` M#0`-`$$`0`@`'(`90!L`&$`=`!E`&0`(`!T`&\` M(`!T`&@`90`@`&D`;0!P`&$`8P!T`"``;P!F`"``;0!E`&$`0!E`'0`:``I`"X`(``-``T`*`!B`"D`(``)``T` M#0!$`&4`8P!R`&4`80!S`&4`(`!I`',`(`!P`'(`:0!M`&$`<@!I`&P`>0`@ M`'(`90!L`&$`=`!E`&0`(`!T`&\`(`!A`&T`;P!R`'0`:0!Z`&$`=`!I`&\` M;@`@`&\`9@`@`&8`:0!N`&D`=`!E`"T`;`!I`'8`90!D`"``:0!N`'0`80!N M`&<`:0!B`&P`90`@`&$`0!E M`'0`:``I`"``80!N`&0`(`!T`&@`90`@`&D`;0!P`&$`8P!T`"``;P!F`"`` M9@!O`'(`90!I`&<`;@`@`&4`>`!C`&@`80!N`&<`90`N`"``#0`-`$$`;0!O M`'(`=`!I`'H`80!T`&D`;P!N`"@``5``90!N`',`:0!O`&X`(`!A`&X`9``@ M`%``;P!S`'0`<@!E`'0`:0!R`&4`;0!E`&X`=``@`$(`90!N`&4`9@!I`'0` M(`!0`&P`80!N`',`,P`!4`!E`&X`@!A`'0`:0!O`&X`(`!O`&8` M.@`@``D`"0`@``D`"0`@``D`"0`@``D`"0`@``D`"0`@``D`"0`@``D`"0`@ M``D`"0`@``D`"0`@``D`"0`@``D`"0`@``D`"0`@``D`"0`@``D`"0`@``D` M"0`@``D`"0`-``T`#0`@`$$`8P!T`'4`80!R`&D`80!L`"``;`!O`',`0`@`&,`=0!R`'0`80!I`&P`;0!E`&X`=``@`&<`80!I`&X`0!E M`'0`:``M`'(`90!L`&$`=`!E`&0`(`!R`&4`0`@`',`<`!E`&,`:0!A`&P`(`!T`&4` M<@!M`&D`;@!A`'0`:0!O`&X`(`!B`&4`;@!E`&8`:0!T`',`(`!R`&4`8P!O M`&<`;@!I`'H`90!D`"``9@!O`'(`(`!C`&4`<@!T`&$`:0!N`"``90!X`&4` M8P!U`'0`:0!V`&4``!P`&4`8P!T`"``=`!O`"``8P!O`&X`=`!R M`&D`8@!U`'0`90`@`&8`<@!O`&T`(`!O`'4`<@`@`&<`90!N`&4`<@!A`&P` M(`!A`',``!P M`&4`8P!T`&4`9``@`'0`;P`@`&(`90`@`&T`80!D`&4`(`!F`&\`<@`@`#(` M,``Q`#``(`!A`'(`90`@`&D`;@!C`&P`=0!S`&D`=@!E`"``;P!F`"``80!M M`&\`=0!N`'0```@``D`"0`@``D`,0`@``D`"0`@ M``D`"0`M`"T`(``)``T`#0`-`"``20!N`&,`;P!M`&4`(`!F`'(`;P!M`"`` M8P!O`&X`=`!I`&X`=0!I`&X`9P`@`&\`<`!E`'(`80!T`&D`;P!N`',`(`!A M`'0`=`!R`&D`8@!U`'0`80!B`&P`90`@`'0`;P`@`%``9@!I`'H`90!R`"`` M20!N`&,`+@`@`&,`;P!M`&T`;P!N`"``@!E`'(`(`!)`&X`8P`N`"``8P!O`&T`;0!O`&X`(`!S`&@`80!R`&4`:`!O M`&P`9`!E`'(`@!E`'(`(`!)`&X`8P`N`"``8P!O`&T`;0!O`&X`(`!S`&@`80!R`&4` M:`!O`&P`9`!E`'(```%3`&4`9P!M`&4`;@!T M`"``20!N`&8`;P!R`&T`80!T`&D`;P!N`"``6P!!`&(``!T`"``0@!L`&\`8P!K`%T`@`P!#0`-`$X`;P!T`&4`(``Q`#$` M+@`@`%,`90!G`&T`90!N`'0`(`!)`&X`9@!O`'(`;0!A`'0`:0!O`&X`(``- M``T`#0!7`&4`(`!O`'``90!R`&$`=`!E`"``:0!N`"``=`!H`&4`(`!F`&\` M;`!L`&\`=P!I`&X`9P`@`'0`=P!O`"``9`!I`',`=`!I`&X`8P!T`"``8P!O M`&T`;0!E`'(`8P!I`&$`;``@`&\`<@!G`&$`;@!I`'H`80!T`&D`;P!N`',` M+``@`'<`:`!I`&,`:``@`&,`;P!N`',`=`!I`'0`=0!T`&4`(`!O`'4`<@`@ M`'0`=P!O`"``8@!U`',`:0!N`&4`0!S`'0`90!M M`"``9`!I`',`;P!R`&0`90!R`',`+``@`&$`<@!T`&@`<@!I`'0`:0!S`"`` M80!N`&0`(`!P`&$`:0!N`"P`(`!I`&X`9@!E`&,`=`!I`&\`=0!S`"``80!N M`&0`(`!R`&4`@!E`&0`(`!B`'D`(`!M`&$` M;@!A`&<`90!M`&4`;@!T`"``=`!O`"``90!V`&$`;`!U`&$`=`!E`"``;P!U M`'(`(`!B`'4`0`@ M`%<`>0!E`'0`:``@`'``<@!O`&0`=0!C`'0`0`@`%<` M>0!E`'0`:``@`'``<@!O`&0`=0!C`'0``!T`"``0@!L M`&\`8P!K`%T`/P0!#0`-`$X`;P!T`&4`(``Q`#(`+@`@`%0`80!X`&4```@`&\`9@`@`&H`=0!R`&D`0`@`"0`,@`W`#``(`!M`&D`;`!L`&D`;P!N`"``<@!E M`&P`80!T`&4`9``@`'0`;P`@`'0`:`!E`"``30!E`&0`:0!C`&$`<@!E`"`` M4`!A`'(`=``@`$0`(`!S`'4`8@!S`&D`9`!Y`"``9@!O`'(`(`!R`&4`=`!I M`'(`90!E`"``<`!R`&4`0!E`&$`<@!S M`"``8@!E`&<`:0!N`&X`:0!N`&<`(`!A`&8`=`!E`'(`(`!$`&4`8P!E`&T` M8@!E`'(`(``S`#$`+``@`#(`,``Q`#(`.P`@``T`#0!T`&@`90`@`&4`>`!P M`&D`<@!A`'0`:0!O`&X`(`!O`&8`(`!T`&@`90`@`%4`+@!3`"X`(`!R`&4` M``@`&,`<@!E`&0`:0!T`#L`(`!A`&X`9``@ M``T`#0!T`&@`90`@`&D`;@!C`'(`90!A`',`90`@`&D`;@`@`&X`;P!N`"T` M9`!E`&0`=0!C`'0`:0!B`&P`90`@`&D`;@`M`'``<@!O`&,`90!S`',`(`!R M`&4`0`@`"0`-``Q`#``(`!M`&D`;`!L`&D`;P!N`"``:0!N M`"``=`!A`'@`(`!B`&4`;@!E`&8`:0!T`',`(`!F`&\`<@`@`'0`:`!E`"`` M<@!E`',`;P!L`'4`=`!I`&\`;@`@`&\`9@`@`&,`90!R`'0`80!I`&X`(`!T M`&$`>``@`'``;P!S`&D`=`!I`&\`;@!S`"``<`!E`'(`=`!A`&D`;@!I`&X` M9P`@`'0`;P`@`'``<@!I`&\`<@`@`'D`90!A`'(```````#_`````````0\`_0`*```````7 M`"$```#]``H``0```!<`(@```/T`"@`!``$`%P`!````_0`*``$``P`7`",` M``#]``H``@```!@`)````'X""@`"``$`'0"`6]!``0(&``(``@`>`'X""@`" M``,`'0"`.<5``0(&``(`!``>`/T`"@`#````%@`E`````0(&``,``@`>``$" M!@`#``0`'@#]``H`!````!@`)@```'X""@`$``$`'```TK!`_0`*``0``@`> M`"<```!^`@H`!``#`!P```"60/T`"@`$``0`'@`G````_0`*``4````8`"@` M``!^`@H`!0`!`!P``%2Q0/T`"@`%``(`'@`G````?@(*``4``P`<``!XID#] M``H`!0`$`!X`)P```/T`"@`&````&``I````?@(*``8``0`<``!DH4#]``H` M!@`"`!X`)P```'X""@`&``,`'```I)I`_0`*``8`!``>`"<```#]``H`!P`` M`!@`*@```'X""@`'``$`'```!)9``0(&``<``@`>`'X""@`'``,`'```$()` M`0(&``<`!``>`/T`"@`(````&``K````?@(*``@``0`<``"`4D`!`@8`"``" M`!X``0(&``@`!``>`/T`"@`)````&``L````?@(*``D``0`<```0AD`!`@8` M"0`"`!X`?@(*``D``P`<``!0@4`!`@8`"0`$`!X`_0`*``H````8`"T```!^ M`@H`"@`!`!P``.!Y0`$"!@`*``(`'@!^`@H`"@`#`!P``(!,P`$"!@`*``0` M'@#]``H`"P```!@`+@```'X""@`+``$`(```UJA``0(&``L``@`>`'X""@`+ M``,`(```MJU``0(&``L`!``>`/T`"@`,````&``O````?@(*``P``0`<``#H MD4`!`@8`#``"`!X`?@(*``P``P`<``#(D$`!`@8`#``$`!X`_0`*``T````8 M`#````!^`@H`#0`!`"```,2?0`$"!@`-``(`'@!^`@H`#0`#`"```%*E0`$" M!@`-``0`'@#]``H`#@```!@`,0```'X""@`.``$`'`````!``0(&``X``@`> M`'X""@`.``,`'````/`_`0(&``X`!``>`/T`"@`/````&``R````?@(*``\` M`0`@``#,GT`!`@8`#P`"`!X`?@(*``\``P`@``!4I4`!`@8`#P`$`!X`_0`* M`!`````8`#,```!^`@H`$``!`!P````B0`$"!@`0``(`'@!^`@H`$``#`!P` M``#P/P$"!@`0``0`'@#]``H`$0```!@`-````'X""@`1``$`(0``J)]``0(& M`!$``@`>`'X""@`1``,`(0``4J5``0(&`!$`!``>`/T`"@`2````%@`U```` M`0(&`!(``@`>``$"!@`2``0`'@#]``H`$P```!@`-@```'X""@`3``$`'P`` M`-`_`0(&`!,``@`>`'X""@`3``,`'P`!@$1``0(&`!,`!``>`/T`"@`4```` M&``Q````?@(*`!0``0`=```````!`@8`%``"`!X`?@(*`!0``P`=```````! M`@8`%``$`!X`_0`*`!4````8`#<```!^`@H`%0`!`"(```#0/P$"!@`5``(` M'@!^`@H`%0`#`"(``8!$0`$"!@`5``0`'@#]``H`%@```!8`.`````$"!@`6 M``(`'@`!`@8`%@`$`!X`_0`*`!<````8`#8```!^`@H`%P`!`!\```#0/P$" M!@`7``(`'@!^`@H`%P`#`!\``0!$0`$"!@`7``0`'@#]``H`&````!@`,0`` M`'X""@`8``$`'0```````0(&`!@``@`>`'X""@`8``,`'0```````0(&`!@` M!``>`/T`"@`9````&``W````?@(*`!D``0`B````T#\!`@8`&0`"`!X`?@(* M`!D``P`B``$`1$`!`@8`&0`$`!X`_0`*`!H````6`#D````!`@8`&@`"`!X` M`0(&`!H`!``>`/T`"@`;````&``Z````?@(*`!L``0`<``!]OT`!`@8`&P`" M`!X`?@(*`!L``P`<``!#ND`!`@8`&P`$`!X`_0`*`!P````8`#L```!^`@H` M'``!`!P``*6_0`$"!@`<``(`'@!^`@H`'``#`!P``&&Z0`$"!@`<``0`'@#] M``H`'0```!@`/````'X""@`=``$`'P`!`#)``0(&`!T``@`>`'X""@`=``,` M'P`!`$!``0(&`!T`!``>`/T`"@`>````&``]````UP!"`!0)``!8`@X`*@`^ M`"(`1@!&`$8`/@`P`#X`/@`^`#X`/@`^`#X`/@`^`"(`/@`^`#X`(@`^`#X` M/@`B`#X`/@`^`#X"$@"V``````!```````````````"@``0`9`!D`!T`#P`# M`````````0````````#E``H``0`>`!X````3`.\`!@```#<````*````"0@0 M```&$`!&&,T'P8````8"```+`A@````````````M`````````)0I`0#^+0$` M#0`"``$`#``"`&0`#P`"``$`$0`"````$``(`/RI\=)-8E`_7P`"``$`*@`" M````*P`"````@@`"``$`@``(````````````)0($````_P"!``(`P004```` M%0```(,``@```(0``@```*$`(@`)`&0``0`!``$`1@!8`E@"````````X#\` M``````#@/P$`50`"``@`?0`,``````"V/`\````$`'T`#``!``$`MA@/```` M!`!]``P``@`"`+8$#P````0`?0`,``,``P"V&`\````$`'T`#``$``0`M@0/ M````!`!]``P`!0#_`"0)#P````0```(.```````M```````%````"`(0```` M`````/\````````!#P`(`A```0````,`_P````````$/``@"$``"````!`#_ M`````````0\`"`(0``,````$`/\````````!#P`(`A``!`````0`_P`````` M``$/``@"$``%````!`#_`````````0\`"`(0``8````$`/\````````!#P`( M`A``!P````0`_P````````$/``@"$``(````!`#_`````````0\`"`(0``D` M```$`/\````````!#P`(`A``"@````0`_P````````$/``@"$``+````!`#_ M`````````0\`"`(0``P````$`/\````````!#P`(`A``#0````0`_P`````` M``$/``@"$``.````!`#_`````````0\`"`(0``\````$`/\````````!#P`( M`A``$`````0`_P````````$/``@"$``1````!`#_`````````0\`"`(0`!(` M```$`/\````````!#P`(`A``$P````0`_P````````$/``@"$``4````!`#_ M`````````0\`"`(0`!4````$`/\````````!#P`(`A``%@````0`_P`````` M``$/``@"$``7````!`#_`````````0\`"`(0`!@````$`/\````````!#P`( M`A``&0````0`_P````````$/``@"$``:````!`#_`````````0\`"`(0`!L` M```$`/\````````!#P`(`A``'`````0`_P````````$/``@"$``=````!`#_ M`````````0\`"`(0`!X````$`/\````````!#P`(`A``'P````0`_P`````` M``$/`/T`"@``````%P`^````_0`*``$````7`#\```#]``H``0`!`!<`0``` M`/T`"@`!``,`%P!!````_0`*``(````6`$(````!`@8``@`"`!X``0(&``(` M!``>`/T`"@`#````&`!#````?@(*``,``0`=``!\FT#]``H``P`"`!X`)P`` M`'X""@`#``,`'0``Z)Y`_0`*``,`!``>`$0```#]``H`!````!@`10```'X" M"@`$``$`'`"`1\Y`_0`*``0``@`>`"<```!^`@H`!``#`!P`P&W70/T`"@`$ M``0`'@!$````_0`*``4````8`$8```!^`@H`!0`!`!P`@)7*0/T`"@`%``(` M'@`G````?@(*``4``P`<`(":S$#]``H`!0`$`!X`1````/T`"@`&````&`!' M````?@(*``8``0`<``"XC$#]``H`!@`"`!X`)P```'X""@`&``,`'```K))` M_0`*``8`!``>`$0```#]``H`!P```!@`2````'X""@`'``$`'```RL-`_0`* M``<``@`>`"<```!^`@H`!P`#`!P`@#G(0/T`"@`'``0`'@!$````_0`*``@` M```8`$D```!^`@H`"``!`!P``$Z]0/T`"@`(``(`'@`G````?@(*``@``P`< M```RNT#]``H`"``$`!X`1````/T`"@`)````&`!*````?@(*``D``0`<``"@ M?D#]``H`"0`"`!X`)P```'X""@`)``,`'````']`_0`*``D`!``>`$0```#] M``H`"@```!@`2P```'X""@`*``$`(`"`7^A`_0`*``H``@`>`"<```!^`@H` M"@`#`"``P!SN0/T`"@`*``0`'@!$````_0`*``L````8`$P```!^`@H`"P`! M`!P`@)C'0/T`"@`+``(`'@`G````?@(*``L``P`<``"AR4#]``H`"P`$`!X` M1````/T`"@`,````&`!-````?@(*``P``0`<`,`DU4#]``H`#``"`!X`)P`` M`'X""@`,``,`'```/]9`_0`*``P`!``>`$0```#]``H`#0```!@`3@```'X" M"@`-``$`'```T^1`_0`*``T``@`>`"<```!^`@H`#0`#`!P``+'D0/T`"@`- M``0`'@!$````_0`*``X````8`$\```!^`@H`#@`!`!P``'SO0/T`"@`.``(` M'@`G````?@(*``X``P`<`/":\$#]``H`#@`$`!X`1````/T`"@`/````&`!0 M````?@(*``\``0`<``#QL$#]``H`#P`"`!X`)P```'X""@`/``,`'```>K-` M_0`*``\`!``>`$0```#]``H`$````!@`40```'X""@`0``$`(`!(T0=!_0`* M`!```@`>`"<```!^`@H`$``#`"``J/X)0?T`"@`0``0`'@!$````_0`*`!$` M```6`%(````!`@8`$0`"`!X``0(&`!$`!``>`/T`"@`2````&`!3````?@(* M`!(``0`<``!9OD#]``H`$@`"`!X`)P```'X""@`2``,`'```7;5`_0`*`!(` M!``>`$0```#]``H`$P```!@`5````'X""@`3``$`'```J*=`_0`*`!,``@`> M`"<```!^`@H`$P`#`!P``!*Q0/T`"@`3``0`'@!$````_0`*`!0````8`%4` M``!^`@H`%``!`!P```#P/_T`"@`4``(`'@`G````?@(*`!0``P`<``"XED#] M``H`%``$`!X`1````/T`"@`5````&`!6````?@(*`!4``0`<``#HAT#]``H` M%0`"`!X`)P```'X""@`5``,`'`"`O<-`_0`*`!4`!``>`$0```#]``H`%@`` M`!@`5P```'X""@`6``$`'```&*!`_0`*`!8``@`>`"<```!^`@H`%@`#`!P` M`(2A0/T`"@`6``0`'@!$````_0`*`!<````8`%@```!^`@H`%P`!`!P`@`;( M0/T`"@`7``(`'@`G````?@(*`!<``P`<`("'RD#]``H`%P`$`!X`1````/T` M"@`8````&`!9````?@(*`!@``0`@``!1V4#]``H`&``"`!X`)P```'X""@`8 M``,`(``@+>)`_0`*`!@`!``>`$0```#]``H`&0```!@`6@```'X""@`9``$` M'``@L>)`_0`*`!D``@`>`"<```!^`@H`&0`#`!P`(!?E0/T`"@`9``0`'@!$ M````_0`*`!H````8`%L```!^`@H`&@`!`!P``.>W0/T`"@`:``(`'@`G```` M?@(*`!H``P`<``#XN$#]``H`&@`$`!X`1````/T`"@`;````&`!<````?@(* M`!L``0`<``!.J4#]``H`&P`"`!X`)P```'X""@`;``,`'```5JE`_0`*`!L` M!``>`$0```#]``H`'````!@`70```'X""@`<``$`'```#=%`_0`*`!P``@`> M`"<```!^`@H`'``#`!P`P&O10/T`"@`<``0`'@!$````_0`*`!T````8`%X` M``!^`@H`'0`!`!P``$G`0/T`"@`=``(`'@`G````?@(*`!T``P`<``"4P4#] M``H`'0`$`!X`1````/T`"@`>````&`!?````?@(*`!X``0`<```FMD#]``H` M'@`"`!X`)P```'X""@`>``,`'```Z[5`_0`*`!X`!``>`$0```#]``H`'P`` M`!@`8````'X""@`?``$`(`!PI/E`_0`*`!\``@`>`"<```!^`@H`'P`#`"`` M<.C]0/T`"@`?``0`'@!$````UP!$`*0*``!L`@X`*@`B`$8`1@!&`$8`1@!& M`$8`1@!&`$8`1@!&`$8`1@`B`$8`1@!&`$8`1@!&`$8`1@!&`$8`1@!&`$8` M"`(0`"`````$`/\````````!#P`(`A``(0````0`_P````````$/``@"$``B M````!`#_`````````0\`"`(0`",````$`/\````````!#P`(`A``)`````0` M_P````````$/``@"$``E````!`#_`````````0\`"`(0`"8````$`/\````` M```!#P`(`A``)P````0`_P````````$/``@"$``H````!`#_`````````0\` M"`(0`"D````$`/\````````!#P`(`A``*@````0`_P````````$/``@"$``K M``````#_`````````0\`"`(0`"P``````/\````````!#P#]``H`(````!@` M80```'X""@`@``$`'````$U`_0`*`"```@`>`"<```!^`@H`(``#`!P``(!. M0/T`"@`@``0`'@!$````_0`*`"$````8`&(```!^`@H`(0`!`!P``+![0/T` M"@`A``(`'@`G````?@(*`"$``P`<``"P>T#]``H`(0`$`!X`1````/T`"@`B M````&`!C````?@(*`"(``0`<`(`S\4#]``H`(@`"`!X`)P```'X""@`B``,` M'``0-O%`_0`*`"(`!``>`$0```#]``H`(P```!@`9````'X""@`C``$`'``` M0%;`_0`*`",``@`>`"<```!^`@H`(P`#`!P``-!TP/T`"@`C``0`'@!$```` M_0`*`"0````8`&4```!^`@H`)``!`!P`0##5P/T`"@`D``(`'@`G````?@(* M`"0``P`<```@U<#]``H`)``$`!X`1````/T`"@`E````&`!F````?@(*`"4` M`0`<`*"WY$#]``H`)0`"`!X`)P```'X""@`E``,`'`!`O>-`_0`*`"4`!``> M`$0```#]``H`)@```!@`9P```'X""@`F``$`'```5)[`_0`*`"8``@`>`"<` M``!^`@H`)@`#`!P``$"!0/T`"@`F``0`'@!$````_0`*`"<````8`&@```!^ M`@H`)P`!`"``L./U0/T`"@`G``(`'@`G````?@(*`"<``P`@`.#Y]4#]``H` M)P`$`!X`1````/T`"@`H````&`!I````?@(*`"@``0`<``!P>D#]``H`*``" M`!X`)P```'X""@`H``,`'````'M`_0`*`"@`!``>`$0```#]``H`*0```!@` M:@```'X""@`I``$`(``@_O5`_0`*`"D``@`>`"<```!^`@H`*0`#`"``X!3V M0/T`"@`I``0`'@!$````_0`*`"H````8`&L```!^`@H`*@`!`"$`2-$'0?T` M"@`J``(`'@`G````?@(*`"H``P`A`*C^"4']``H`*@`$`!X`1````/T`"@`K M````&`!L````_0`*`"P````8`&T```#7`!X`(@0``/``1@!&`$8`1@!&`$8` M1@!&`$8`1@!&``X`/@(2`+8``````$```````````````*``!`!D`&0`'0`/ M``,````````!`````````.4`$@`"`"L`*P```!,`+``L````$P#O``8````W M````"@````D($```!A``1AC-!\&````&`@``"P(8````````````)0`````` M``#W-P$`/SD!``T``@`!``P``@!D``\``@`!`!$``@```!``"`#\J?'236)0 M/U\``@`!`"H``@```"L``@```((``@`!`(``"````````````"4"!````/\` M@0`"`,$$%````!4```"#``(```"$``(```"A`"(`"0!D``$``0`!`$8`6`)8 M`@```````.`_````````X#\!`%4``@`(`'T`#```````MCP/````!`!]``P` M`0`!`+88#P````0`?0`,``(``@"V!`\````$`'T`#``#``,`MA@/````!`!] M``P`!`#_`"0)#P````0```(.```````E```````$````"`(0`````````/\` M```````!#P`(`A```0````,`_P````````$/``@"$``"`````@#_```````` M`0\`"`(0``,````#`/\````````!#P`(`A``!`````(`_P````````$/``@" M$``%`````P#_`````````0\`"`(0``8````#`/\````````!#P`(`A``!P`` M``(`_P````````$/``@"$``(`````P#_`````````0\`"`(0``D````#`/\` M```````!#P`(`A``"@````,`_P````````$/``@"$``+`````P#_```````` M`0\`"`(0``P````"`/\````````!#P`(`A``#0````,`_P````````$/``@" M$``.`````P#_`````````0\`"`(0``\````#`/\````````!#P`(`A``$``` M``,`_P````````$/``@"$``1`````P#_`````````0\`"`(0`!(````#`/\` M```````!#P`(`A``$P````,`_P````````$/``@"$``4`````@#_```````` M`0\`"`(0`!4````#`/\````````!#P`(`A``%@````,`_P````````$/``@" M$``7`````P#_`````````0\`"`(0`!@````#`/\````````!#P`(`A``&0`` M``,`_P````````$/``@"$``:`````P#_`````````0\`"`(0`!L````#`/\` M```````!#P`(`A``'`````,`_P````````$/``@"$``=`````P#_```````` M`0\`"`(0`!X````#`/\````````!#P`(`A``'P````,`_P````````$/`/T` M"@``````%P!N````_0`*``$````7`#\```#]``H``0`!`!<``0```/T`"@`! M``,`%P`C````_0`*``(````6`&\````!`@8``@`"`!X`_0`*``,````8`#(` M``!^`@H``P`!`!T``,R?0`$"!@`#``(`'@!^`@H``P`#`!T``%2E0/T`"@`$ M````%@!P`````0(&``0``@`>`/T`"@`%````&`!Q````?@(*``4``0`<```& MH$`!`@8`!0`"`!X`?@(*``4``P`<``"`CT#]``H`!@```!@`<@```'X""@`& M``$`'```0&%``0(&``8``@`>`'X""@`&``,`'```P%%`_0`*``<````8`"L` M``!^`@H`!P`!`!P``(!20`$"!@`'``(`'@#]``H`"````!@``'X""@`(``,`'```J(!`_0`*``D````8`'0` M``!^`@H`"0`!`!P``/!S0`$"!@`)``(`'@!^`@H`"0`#`!P``(!RP/T`"@`* M````&`!U````?@(*``H``0`<`(`4Q\`!`@8`"@`"`!X`?@(*``H``P`<```8 MC,#]``H`"P```!@`=@```'X""@`+``$`(```V+C``0(&``L``@`>`'X""@`+ M``,`(```EJA`_0`*``P````6`'<````!`@8`#``"`!X`_0`*``T````8`'@` M``!^`@H`#0`!`!P``!!SP`$"!@`-``(`'@!^`@H`#0`#`!P``*!OP/T`"@`. M````&`!Y````?@(*``X``0`<```$H<`!`@8`#@`"`!X`?@(*``X``P`<``!/ MT<#]``H`#P```!@`>@```'X""@`/``$`'```/L9``0(&``\``@`>`'X""@`/ M``,`'```-[I`_0`*`!`````8`'L```!^`@H`$``!`!P``-"*P`$"!@`0``(` M'@!^`@H`$``#`!P``.2JP/T`"@`1````&`!\````?@(*`!$``0`<``"`'X""@`2``,`'```(&=`_0`*`!,````8`'X```!^ M`@H`$P`!`"```%G"0`$"!@`3``(`'@!^`@H`$P`#`"```*'*P/T`"@`4```` M%@!_`````0(&`!0``@`>`/T`"@`5````&`"`````?@(*`!4``0`<``"0G4`! M`@8`%0`"`!X`?@(*`!4``P`<```+Q4#]``H`%@```!@`@0```'X""@`6``$` M'```GJS``0(&`!8``@`>`'X""@`6``,`'```HL?`_0`*`!<````8`((```!^ M`@H`%P`!`!P`````0`$"!@`7``(`'@!^`@H`%P`#`!P``"C*0/T`"@`8```` M&`"#````?@(*`!@``0`<````(L`!`@8`&``"`!X`?@(*`!@``P`<``#P`'X""@`9``,` M'```JJ#`_0`*`!H````8`(4```!^`@H`&@`!`!P````@0`$"!@`:``(`'@!^ M`@H`&@`#`!P````40/T`"@`;````&`"&````?@(*`!L``0`@```6J<`!`@8` M&P`"`!X`?@(*`!L``P`@`(#1PD#]``H`'````!@`AP```'X""@`<``$`'``` M`$7``0(&`!P``@`>`'X""@`<``,`'````#?`_0`*`!T````8`(@```!^`@H` M'0`!`"```&!KP`$"!@`=``(`'@!^`@H`'0`#`"```%B+P/T`"@`>````&`") M````?@(*`!X``0`<``#HGD#]``H`'@`"`!X`)P```'X""@`>``,`'```E*!` M_0`*`!\````8`(H```!^`@H`'P`!`!P``'R;0/T`"@`?``(`'@!$````?@(* M`!\``P`<``!\DT#7`$0`6@@``&P"#@`J`!@`-``8`#0`-``F`#0`-``T`#0` M&``T`#0`-``T`#0`-``T`!@`-``T`#0`-``T`#0`-``T`#0`.``(`A``(``` M``(`_P````````$/``@"$``A`````P#_`````````0\`"`(0`"(````#`/\` M```````!#P`(`A``(P``````_P````````$/``@"$``D``````#_```````` M`0\`_0`*`"`````6`(L````!`@8`(``"`!X`_0`*`"$````8`(P```!^`@H` M(0`!`!P`@)G$0`$"!@`A``(`'@!^`@H`(0`#`!P``&!\0/T`"@`B````&`"- M````?@(*`"(``0`=``#`B$`!`@8`(@`"`!X`?@(*`"(``P`=````54#]``H` M(P```!@`C@```/T`"@`D````&`"/````UP`.```!``!0`!@`-``T``X`/@(2 M`+8``````$```````````````*``!`!D`&0`'0`/``,````````!```````` M`.4`$@`"`",`(P```!,`)``D````$P#O``8````W````"@````D($```!A`` M1AC-!\&````&`@``"P(4````````````!`````````!*.P$`#0`"``$`#``" M`&0`#P`"``$`$0`"````$``(`/RI\=)-8E`_7P`"``$`*@`"````*P`"```` M@@`"``$`@``(````````````)0($````_P"!``(`P004````%0```(,``@`` M`(0``@```*$`(@`)`&0``0`!``$`1@!8`E@"````````X#\```````#@/P$` M50`"``@`?0`,``````"V/`\````$`'T`#``!``$`MA@/````!`!]``P``@#_ M`"0)#P````0```(.```````$```````"````"`(0`````````/\````````! M#P`(`A```0````$`_P````````$/``@"$``"``````#_`````````0\`"`(0 M``,````!`/\````````!#P#]``H``````!<`D`````$"!@`!````%P#]``H` M`0`!`!<``0```/T`"@`"````%@"1````_0`*``,````8`)(```#]``H``P`! M`!L`DP```-<`#`"@````/``.`!@`#@`^`A(`M@``````0``````````````` MH``$`&0`9``=``\``P````````$`````````[P`&````-P````H````)"!`` M``80`$88S0?!@```!@(```L"%`````````````0`````````/3T!``T``@`! M``P``@!D``\``@`!`!$``@```!``"`#\J?'236)0/U\``@`!`"H``@```"L` M`@```((``@`!`(``"````````````"4"!````/\`@0`"`,$$%````!4```"# M``(```"$``(```"A`"(`"0!D``$``0`!`$8`6`)8`@```````.`_```````` MX#\!`%4``@`(`'T`#```````MCP/````!`!]``P``0`!`+88#P````0`?0`, M``(`_P`D"0\````$```"#@``````!````````@````@"$`````````#_```` M`````0\`"`(0``$````!`/\````````!#P`(`A```@``````_P````````$/ M``@"$``#`````0#_`````````0\`_0`*```````7`)0````!`@8``0```!<` M_0`*``$``0`7``$```#]``H``@```!8`E0```/T`"@`#````&`"6````_0`* M``,``0`;`)<```#7``P`H````#P`#@`8``X`/@(2`+8``````$`````````` M`````*``!`!D`&0`'0`/``,````````!`````````.\`!@```#<````*```` M"0@0```&$`!&&,T'P8````8"```+`A0````````````$`````````#`_`0`- M``(``0`,``(`9``/``(``0`1``(````0``@`_*GQTDUB4#]?``(``0`J``(` M```K``(```""``(``0"```@````````````E`@0```#_`($``@#!!!0````5 M````@P`"````A``"````H0`B``D`9``!``$``0!&`%@"6`(```````#@/P`` M`````.`_`0!5``(`"`!]``P``````+8\#P````0`?0`,``$``0"V&`\````$ M`'T`#``"`/\`)`D/````!````@X```````0```````(````(`A`````````` M_P````````$/``@"$``!`````0#_`````````0\`"`(0``(``````/\````` M```!#P`(`A```P````$`_P````````$/`/T`"@``````%P"8`````0(&``$` M```7`/T`"@`!``$`%P`!````_0`*``(````6`)D```#]``H``P```!@`F@`` M`/T`"@`#``$`&P";````UP`,`*`````\``X`&``.`#X"$@"V``````!````` M``````````"@``0`9`!D`!T`#P`#`````````0````````#O``8````W```` M"@````D($```!A``1AC-!\&````&`@``"P(4````````````!``````````C M00$`#0`"``$`#``"`&0`#P`"``$`$0`"````$``(`/RI\=)-8E`_7P`"``$` M*@`"````*P`"````@@`"``$`@``(````````````)0($````_P"!``(`P004 M````%0```(,``@```(0``@```*$`(@`)`&0``0`!``$`1@!8`E@"```````` MX#\```````#@/P$`50`"``@`?0`,``````"V/`\````$`'T`#``!``$`MA@/ M````!`!]``P``@#_`"0)#P````0```(.```````$```````"````"`(0```` M`````/\````````!#P`(`A```0````$`_P````````$/``@"$``"``````#_ M`````````0\`"`(0``,````!`/\````````!#P#]``H``````!<`G`````$" M!@`!````%P#]``H``0`!`!<``0```/T`"@`"````%@"=````_0`*``,````8 M`)X```#]``H``P`!`!L`GP```-<`#`"@````/``.`!@`#@`^`A(`M@`````` M0```````````````H``$`&0`9``=``\``P````````$`````````[P`&```` M-P````H````)"!````80`$88S0?!@```!@(```L"%`````````````0````` M````%D,!``T``@`!``P``@!D``\``@`!`!$``@```!``"`#\J?'236)0/U\` M`@`!`"H``@```"L``@```((``@`!`(``"````````````"4"!````/\`@0`" M`,$$%````!4```"#``(```"$``(```"A`"(`"0!D``$``0`!`$8`6`)8`@`` M`````.`_````````X#\!`%4``@`(`'T`#```````MCP/````!`!]``P``0`! M`+88#P````0`?0`,``(`_P`D"0\````$```"#@``````!````````@````@" M$`````````#_`````````0\`"`(0``$````!`/\````````!#P`(`A```@`` M````_P````````$/``@"$``#`````0#_`````````0\`_0`*```````7`*`` M```!`@8``0```!<`_0`*``$``0`7``$```#]``H``@```!8`H0```/T`"@`# M````&`"B````_0`*``,``0`;`*,```#7``P`H````#P`#@`8``X`/@(2`+8` M`````$```````````````*``!`!D`&0`'0`/``,````````!`````````.\` M!@```#<````*````"0@0```&$`!&&,T'P8````8"```+`A0````````````$ M``````````E%`0`-``(``0`,``(`9``/``(``0`1``(````0``@`_*GQTDUB M4#]?``(``0`J``(````K``(```""``(``0"```@````````````E`@0```#_ M`($``@#!!!0````5````@P`"````A``"````H0`B``D`9``!``$``0!&`%@" M6`(```````#@/P```````.`_`0!5``(`"`!]``P``````+8\#P````0`?0`, M``$``0"V&`\````$`'T`#``"`/\`)`D/````!````@X```````0```````(` M```(`A``````````_P````````$/``@"$``!`````0#_`````````0\`"`(0 M``(``````/\````````!#P`(`A```P````$`_P````````$/`/T`"@`````` M%P"D`````0(&``$````7`/T`"@`!``$`%P`!````_0`*``(````6`*4```#] M``H``P```!@`I@```/T`"@`#``$`&P"G````UP`,`*`````\``X`&``.`#X" M$@"V``````!```````````````"@``0`9`!D`!T`#P`#`````````0`````` M``#O``8````W````"@````D($```!A``1AC-!\&````&`@``"P(4```````` M````!`````````#\1@$`#0`"``$`#``"`&0`#P`"``$`$0`"````$``(`/RI M\=)-8E`_7P`"``$`*@`"````*P`"````@@`"``$`@``(````````````)0($ M````_P"!``(`P004````%0```(,``@```(0``@```*$`(@`)`&0``0`!``$` M1@!8`E@"````````X#\```````#@/P$`50`"``@`?0`,``````"V/`\````$ M`'T`#``!``$`MA@/````!`!]``P``@#_`"0)#P````0```(.```````$```` M```"````"`(0`````````/\````````!#P`(`A```0````$`_P````````$/ M``@"$``"``````#_`````````0\`"`(0``,````!`/\````````!#P#]``H` M`````!<`2`````$"!@`!````%P#]``H``0`!`!<``0```/T`"@`"````%@"H M````_0`*``,````8`*D```#]``H``P`!`!L`J@```-<`#`"@````/``.`!@` M#@`^`A(`M@``````0```````````````H``$`&0`9``=``\``P````````$` M````````[P`&````-P````H````)"!````80`$88S0?!@```!@(```L"%``` M``````````0`````````[T@!``T``@`!``P``@!D``\``@`!`!$``@```!`` M"`#\J?'236)0/U\``@`!`"H``@```"L``@```((``@`!`(``"``````````` M`"4"!````/\`@0`"`,$$%````!4```"#``(```"$``(```"A`"(`"0!D``$` M`0`!`$8`6`)8`@```````.`_````````X#\!`%4``@`(`'T`#```````MCP/ M````!`!]``P``0`!`+88#P````0`?0`,``(`_P`D"0\````$```"#@`````` M!````````@````@"$`````````#_`````````0\`"`(0``$````!`/\````` M```!#P`(`A```@``````_P````````$/``@"$``#`````0#_`````````0\` M_0`*```````7`*L````!`@8``0```!<`_0`*``$``0`7``$```#]``H``@`` M`!8`K````/T`"@`#````&`"M````_0`*``,``0`;`*X```#7``P`H````#P` M#@`8``X`/@(2`+8``````$```````````````*``!`!D`&0`'0`/``,````` M```!`````````.\`!@```#<````*````"0@0```&$`!&&,T'P8````8"```+ M`A0````````````$`````````.)*`0`-``(``0`,``(`9``/``(``0`1``(` M```0``@`_*GQTDUB4#]?``(``0`J``(````K``(```""``(``0"```@````` M```````E`@0```#_`($``@#!!!0````5````@P`"````A``"````H0`B``D` M9``!``$``0!&`%@"6`(```````#@/P```````.`_`0!5``(`"`!]``P````` M`+8\#P````0`?0`,``$``0"V&`\````$`'T`#``"`/\`)`D/````!````@X` M``````0```````(````(`A``````````_P````````$/``@"$``!`````0#_ M`````````0\`"`(0``(``````/\````````!#P`(`A```P````$`_P`````` M``$/`/T`"@``````%P"O`````0(&``$````7`/T`"@`!``$`%P`!````_0`* M``(````6`+````#]``H``P```!@`L0```/T`"@`#``$`&P"R````UP`,`*`` M```\``X`&``.`#X"$@"V``````!```````````````"@``0`9`!D`!T`#P`# M`````````0````````#O``8````W````"@````D($```!A``1AC-!\&````& M`@``"P(4````````````!`````````#53`$`#0`"``$`#``"`&0`#P`"``$` M$0`"````$``(`/RI\=)-8E`_7P`"``$`*@`"````*P`"````@@`"``$`@``( M````````````)0($````_P"!``(`P004````%0```(,``@```(0``@```*$` M(@`)`&0``0`!``$`1@!8`E@"````````X#\```````#@/P$`50`"``@`?0`, M``````"V/`\````$`'T`#``!``$`MA@/````!`!]``P``@#_`"0)#P````0` M``(.```````$```````"````"`(0`````````/\````````!#P`(`A```0`` M``$`_P````````$/``@"$``"``````#_`````````0\`"`(0``,````!`/\` M```````!#P#]``H``````!<`LP````$"!@`!````%P#]``H``0`!`!<``0`` M`/T`"@`"````%@"T````_0`*``,````8`+4```#]``H``P`!`!L`M@```-<` M#`"@````/``.`!@`#@`^`A(`M@``````0```````````````H``$`&0`9``= M``\``P````````$`````````[P`&````-P````H````)"!````80`$88S0?! M@```!@(```L"%`````````````0`````````R$X!``T``@`!``P``@!D``\` M`@`!`!$``@```!``"`#\J?'236)0/U\``@`!`"H``@```"L``@```((``@`! M`(``"````````````"4"!````/\`@0`"`,$$%````!4```"#``(```"$``(` M``"A`"(`"0!D``$``0`!`$8`6`)8`@```````.`_````````X#\!`%4``@`( M`'T`#```````MCP/````!`!]``P``0`!`+88#P````0`?0`,``(`_P`D"0\` M```$```"#@``````!````````@````@"$`````````#_`````````0\`"`(0 M``$````!`/\````````!#P`(`A```@``````_P````````$/``@"$``#```` M`0#_`````````0\`_0`*```````7`+<````!`@8``0```!<`_0`*``$``0`7 M``$```#]``H``@```!8`N````/T`"@`#````&`"Y````_0`*``,``0`;`+H` M``#7``P`H````#P`#@`8``X`/@(2`+8``````$```````````````*``!`!D M`&0`'0`/``,````````!`````````.\`!@```#<````*````"0@0```&$`!& M&,T'P8````8"```+`A0````````````$`````````+M0`0`-``(``0`,``(` M9``/``(``0`1``(````0``@`_*GQTDUB4#]?``(``0`J``(````K``(```"" M``(``0"```@````````````E`@0```#_`($``@#!!!0````5````@P`"```` MA``"````H0`B``D`9``!``$``0!&`%@"6`(```````#@/P```````.`_`0!5 M``(`"`!]``P``````+8\#P````0`?0`,``$``0"V&`\````$`'T`#``"`/\` M)`D/````!````@X```````0```````(````(`A``````````_P````````$/ M``@"$``!`````0#_`````````0\`"`(0``(``````/\````````!#P`(`A`` M`P````$`_P````````$/`/T`"@``````%P"[`````0(&``$````7`/T`"@`! M``$`%P`!````_0`*``(````6`+P```#]``H``P```!@`O0```/T`"@`#``$` M&P"^````UP`,`*`````\``X`&``.`#X"$@"V``````!```````````````"@ M``0`9`!D`!T`#P`#`````````0````````#O``8````W````"@`````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````$```#^____`P````0```#^________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M_____________________________________________O\```4"`@`````` M`````````````````0```."%G_+Y3V@0JY$(`"LGL]DP````4`````,````! M````*````````(`P````!````#@```````````````(```"P!```$P````D$ M```?````"````',` XML 34 R7.xml IDEA: Adoption of New Accounting Policies 2.0.0.10 false Adoption of New Accounting Policies 000110 - Disclosure - Adoption of New Accounting Policies true false false false 1 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDperShare Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 pfe_AdoptionOfNewAccountingPoliciesAbstract pfe false na duration string No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false No definition available. false 3 1 us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock us-gaap true na duration string No definition available. false false false false false false false false false false false false 1 false false false false 0 0 <div class="BWxbrlnote2"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <div> <div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><a style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline" id="xbrlnote2" name="xbrlnote2">Note 2. Adoption of New Accounting Policies</a></div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">&#160;</div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">The provisions of the following new accounting standards were adopted as of January 1, 2010 and did not have a significant impact on our consolidated financial statements:</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 9pt; TEXT-ALIGN: left" width="1%" valign="top"> <div style="DISPLAY: inline; FONT-FAMILY: symbol, serif; FONT-SIZE: 10pt; FONT-WEIGHT: normal; TEXT-ALIGN: left">&#183;</div></td> <td width="99%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">An amendment to the recognition and measurement guidance for the transfers of financial assets.</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr valign="top"> <td style="WIDTH: 9pt; TEXT-ALIGN: left" width="1%" valign="top"> <div style="DISPLAY: inline; FONT-FAMILY: symbol; FONT-SIZE: 10pt; FONT-WEIGHT: normal; TEXT-ALIGN: left">&#183;</div></td> <td width="99%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">An amendment to the guidelines for determining the primary beneficiary in a variable interest entity.</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div></div></div></div></div> Note 2. Adoption of New Accounting Policies &#160; The provisions of the following new accounting standards were adopted as of January 1, 2010 and did not have false false false Represents disclosure of any changes in an accounting principle, including a change from one generally accepted accounting principle to another generally accepted accounting principle when there are two or more generally accepted accounting principles that apply or when the accounting principle formerly used is no longer generally accepted. Also disclose any change in the method of applying an accounting principle, or any change in an accounting principle required by a new pronouncement in the unusual instance that a new pronouncement does not include specific transition provisions. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 154 -Paragraph 2, 17, 18 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 28 -Paragraph 23, 24 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 01 -Paragraph b -Subparagraph 6 -Article 10 false false 1 2 false UnKnown UnKnown UnKnown false true ZIP 35 0001157523-10-003143-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001157523-10-003143-xbrl.zip M4$L#!!0````(`*F%K3S]\NWB1IX```FN"P`0`!P`<&9E+3(P,3`P-#`T+GAM M;%54"0`#WF3L2]YD[$MU>`L``00E#@``!#D!``#L76F3HSC2_KX1^Q]XZWUW M8S9B7(6XJ9Z>#7<=O=[I.J;*,[VS7SHH(Y?9P>`7WF4#Y*/4IE2BGQP]]?YC;WA#W??WU-.DH&/7 M>X1G>?&$W'XP?!P_OO0'CX:Q6+U!GU[Z)]%U\I(^X-%`1/$;'IX6EJ^,7WSPZ"8L)>3MQG0"_!)QEOC\Z6WI?XB=#6:O'L!-8P6MT M;775,LGUJ84]CN))\]['D^-']^GD;/33T8\\^4_50%D_G&1?CD6=Y,B*)"VP M9[DF(Y\V5/#CNENM"H_NI$M.E!)?BNI?I));S_I"V@H)T%+=4@D0#`E`L%VK MA+!$G+M^MZ@"=?>"<[#C$5D0_(E+6=_+O(0=,_%*DE_QG5WP*U(FK_.BH'=. MF:$=VTB9Y!5Q(.C[4":4KG6QLVK[Z:RQ_>H,M5+V*\627:GD_&+T)>S0\@#Q M'5-*#'L_2B$J5P:"TC&EQ+!WH92E8X4:^>7^/*.&.3;\I8=_C)R]4W@B+BB^ ME2R0.U9-9(7KY=S$N.XWNKF MII5.*CJ_Q(2X<^RX<\LI%UBEB*Q$MM#X;J+>K/:BP.GT%GQE['G8O`_^_ M&O824W5:YI>IZP:.&^`OV,;S+TA!LJ*3`,[$$VMNV.#E#Y0C+N+2'7&Y4UXC M1X31RY12"J*]`7IPB>@TMC-W/G>=*F`BTA5%0$UQ29*8!9:5FT8U-$TK@`#: ML&\-RQPY9\;""@R[0&N:I"FRKC5%I_*2KF;Q%2!@E+?`CF^0!X>.^0'"^:D5 M^&-OZ0=%+2SPJJ"I3;$.1#%/E84HTGC''B7Y:U5S2[(@JKK<%*2`%%'(HF1E MI['=X<"P'&Q>&)YC.8_^<#)9SI:1(/SZ!5K"<\6XWIP=00R MP(@7<$/6)!&Z=F-JL"S.RJW2&.C87I*YOUO7H_TS"#SK81D8#S8>N]>N0[!X MKFW#(^5U$31%EY'6F.!K=Q7QANZ\8WV%JP!-<+L6J\H(JRHU]2$&0 M&*M7B:30`I0B)0.>(&F-60OF0I!+NGP^.-=Y'&-O3OI=)4E5519%?8MNA73& M7?6-IQ$[:K`@ULC\\T-JB+J#`\V@Y6N$O4_;ET_ M\'!@>1#2.T&FN,VJAT11%0%X8_((;%#2'"/3?#3H@BZ^28UX">E(;5PCI&IB MSO!2#H49<[PE-D//D!JH*M"@1EY3I,:F,0*<'7D*4>20:I,^H6HZ+S0&*RN( MB;"+(10:Q:(86^,U66D^)!)CR%J;M=A,[&KX,Q@:R5_$%WHR;(#L#X,SP_-> MP;DK"0]EQ&L\:AQO(YU,UV5BV#IH,L[V##Q48DA'SA,XH:2S%FA6X!550TKC MZ0OBFS+MGB<^WX&[PQ,,-8)A'N*LT@%10Z(FR8TC*20I$C,>EJ%(X[T&',1- M_N0:3N+QCQY$B.7C.`B40,&-<2.=@5T#3!H]:08G<+U7J%X!3%&6>=0\'$1@ MZIC^E12;:7[?QX%_,SVW_(7K&S9`7RY6X15<)7(M!PS=S8+,9\)06D!?&89R MH&!C+T1GXKX&V/(J5Q&3:)HJ"9SQH*H,KR-16:[?F`XCQ9H-:0'(+UXB;A<`1*" M'4U'S2?<81QD3%<=.'F]J<@M4"#,08VM5O[$2"@Q1&%BZ_3Z/@M%Y)61E7`&$#S#'CDF M?OD)OU:)H(T6K6T6%K*6$9G%2S#?AOT;-KR:RAK$^0%EA62K\AG;]D^.^^S< M8\-W(40:^?X2>U6R?B,K;I6E9(7]ZMK@PQC>ZZ5E8\^O$G+M)F5D7F;:)*SP M'5Z0&4_G\3XP@F6EB$P]\@O)BJ(`SD"9C^`P5$GX9'B/F`/W#(5>XQ4%B:+&ZRD>E8C+A#\`'QQC\#Z7Q*,OT1/+K:RR M%%5F_(!,^=F%3S^XF9+!C,ZK8^_)FF#_WK7-H@A!EL!3*5U1K(0IB3SC$!0# MR6@+TQ6+,.':AD>'YMQRJ*4.K"=\\4)64`O"7?"_55G22SV9:O"2R*Z^U`*5 M72;UP29/")'/H7%LE_IFT:,K-V,X`8)[9`H%W#E0B$_TE%\[15)422X-YBLK M)PAY2ZB-@6:W5#@3B:]+SLQTXF`-=]],8'KL MQM)+P&^G,7;43A6^:1^#X/J#X5L3ZKDFD`D;`5MGF/+'@KQ)[TG);^HML[LF MF,5\36%BBYUZRXA7$01>E;-2Y3`EGEUE.8"WK`JR+(B5N8.EV`6-G?IKA;.L M:KHFZ5LVC,HSANKMG>5*V#*[:%?'5]ZI1UH-4DYY?H?R2"MQ#60UB:LS'FEE MQ40M;TFL,QYI#6//1F+M]$BKC:HJ-`@>6N.1UFBJPWJD-10N,K-JA_!(-]?4 M@3S21A0]A$=:`2SID4IH1Q[I)NS*'$;R:#/[3P$R)72@!/G MEKV$4?\-XY0D@JUXL>NJ-&9&<8VRK18]N7=V1'+28#YCZW$&5X=/4(='?+V< M/V#O9LHLMF0)O$ETG5CB84SM1O)K04\JOF!UJA%XDK1>#WP1@L*=ANM,_:BI MR)HW$TX@+7>;8:'0O=OE^L/+6]OEA@/A8>WR)B`W\G4/;Y>+DN^$/8Y0TX(0K;V.4M\M5%7E=5I);F2:;. MIV)F[&0F+-EKPCH2!:3JY1F_I8#EG)T`^TA81T@1!%4O39TM!2KF[*@X0,:Z M"@KBM=)YW#+8.F+#U#WDJR,>`N+R?1:ERN41NX'Y`/GJ0`E)4QO#CI-5#YVN M+O)(*=]]4XY:1P5I]CO.5AI>]JMCQ1-E_CFP$1>8-?B:NS6K[W= M'08>7M&:FQA5858X][7;702VR6)SO@EQ#MO^M[MK,$:`[6V,5-8%9BVJ"MLN M-I(C\"7!#6GL/H.+E[VDUP055'EE>91 M&0_A(^LB%NXDKW6$G`!FFA>JMP"4)-`S,?CNSI`#ET5!Y0>\E`YXO"2SWO^> MCI#CD:QL$:D,-'8R8^J%Y&]=D@'0I;SYF_X?(P1`L$F(V-O^ZPD[2[>84.5'0:.#9G!Z, MY7J[8^3`%X,PNOE<*.A88R:5VG.,'`(_56X\QN0'GYL>(@>=8V)16PJ_;1P9 MU62RY'99V^PD2!V9V;GH<)F.I#ZN;?]6>S=8]RM?2+Z#NX?=))I4Z,/62N$; MFO]91G-AA+"&/QL%>.Z/W3L,."86G9=>V[^Q2QA1.;6S&'33VO+[@"<.[RUC:&#K$9Y[6$ M5N"\,KS?,1V([C'$5UO30).K8>;)7*>;TVQ^;-+U?+*1!)1^99"D]>#U9AK/ MS.\:-D)"*B>],8A\=5^Z7K+$*..=M-'N^E]\"D&.YFN*KV4V=@Q;%W5F&J^^ MY)TZ&W4RA1ER'\#9J,2EYAS'MD]?HWKC";O;LQ.^1O7.%2'G]+"..!N5E=/T MO!T1AWH M[F?K*<=6NAK55A!IA8[SV[D:-6"+BKBULY%M,G)$%_F$I4_2(Z,^00^S)A.` MR0?O\"+24>;)L+7)S,]XYF%\!76:^3?>IRT/34':^LCJ@X).;G6M?/O*]?!X M9B1+H2`.K2U14<2DM@X,/3MUORXA>4#Z3@]>*!*2;U9NIC>>:3F&][K*4-WN ML"%V9KU$%)-LM2)HPNY06W,)+X+3M:OPA`UF-Y-=R\[M&/-`%-@TTOJB,XDH MTRF>`*DO7B9`]4=\9P3XQLG/]]T*=,YW%C80W2[;7&0:G>;3:+?YQ!2'5,A=I;A#8:0ZLF0]@TAE9AU MA3T^ZHU'D!IS,PP=-A]!5CD@N<^$YR5G)T6V`JVIC*(WD;T7U#7FFMDUM^:H M$PEI)#5HV^-;>9F='6)%,$GH=-$]L[MK\S,@6=.=+'J+>E<38#NJ=?6$ M1H[D;*77A_K>+A]L:W)INT:JOGK>B<&KSR0SC1PO=A"IN66OQ<:GG:\/\;Z$ M*Y5G6I-?Z>/2,P4420@Y7TO&SRA/0J*`M;L6)30G\D[#;0#0Y^C(46=3CZ1) MNEA]=&\ANV4^-:.P$:1U3:Y=I]Z;E6FG8(60)#??I22*J46_!L#*VB>=*1,F MBX4/57_]2!0DN>+3Q^6[FL3U>05;H,O?I57G8W&*)I.=58VSR#6A>%M6V;?B M:G]=6I`E,&5J\YSEG*F!@J]+[ZC[(I7LW"W?2ECZ>0Y=:57W%20D(TDL[;[E M7_+1E'9V7Z3K2*[8JUK^#1U9$W?6?2L7&59A\*Y7.A05I:Q0.-OQLJ\K*+RK_>5;VO(F*_-/QA[/YEAF=83-[$-'^KZX?/+ M@V<3=0A'?WT,WOWY3_$#?O!JX_='ES?7X\']Z-\7IQSB%\$[CEZX'%Z-/OUV MRHVM.3`"<'-W[MQPTD44_R,N_'QT?_MI".4\$.CON*OAW#3Q>7XE*/2 MHBMWHX__B"^-+_XU'HRNSR^NXRNDO@/#MAZ=4\[&TX#"(*(,1I#EV):#RVL1 MW64J_?DB1/'@VF8$X_SB[.9N.![=7)\",4SLD=*/*-/6>N4<8XZ3%P@\LK>? M$XZYH>DN:.:*.Z4(UHW+W;K@A0/524U.C+A.)P=4)DG)L*:OH3Z-^>+=_R*% MWPS%AHK>)0/&,\PMR#P+V0?H$P6#?>>FKFV[ST2_#N`PUNJF)YD8GNESSQ!U M<09I&&QR!GWSGX:S-+Q7#GW/D;[$P:.<"?$>-"@W,Y[@<>+?&A+DWYP9QK.]!@V$1B$O?MT(Y5FJ[^B^X-WLBZ@L+A<785/ M41M;K^<'M"F)"KVR/E/P.!A8;-L^*`DT__Z(/^*>+3.8O3\",_67\.;",,WH M9@*@QSU1Z%`-=Y&\8<:P/X_.Q_\XY?0548:?1A^OHZJNQ("0_(+R])YK-/S7 M.1B"[SD?PLQIE17\'9JJ*$7I=_TL3Q-5-MF.3,70X M(_[^&A>XM/MY>.)"/Z$FCW2B.=U^1;L!][B$/@(C'O11CSY,OGGF3\G'N:`+ MKCN.0?W/XP)MA3^]]4]"ZHVM9]_)VM/)^MY5MW>1'H0).)_V(1,'X#Y;9*\@ MO;WPP,6%4>R!IHM"7X+?%A0#S>19E)96O-$+TYG`-O6Q37\G\GAWZF%G9DK" M8P;BZ#&]/3_>]$I.$[)=8N>V]]/UWD_?BY^N9_UT?>VGZ\=G M>I.4TZ;.^I;#3@D_'6)#(]`3SB!RN?_)?C^V.J M66I^'"/A87@0<=L.A[?#\_/1]4%H9@!_>]QH?["CV['4\`F0'=Y?(9`%%@)T-D(*N"`4S/*4VH^# M>#833+H^11>;VK4]+7':WJS-:SJ^/7GW#ELI8[S2K`YD`%G.(;(@8-O+GH0? M7F;)6VNJ6T[G*F-;AWKMMK7$\VKN61X:[<]+N#:UL%ES5&AOQ^T[0LNHU:V. M<+]<+&P:_QAV=U!_=^TZ@U4?_EO?B;^F3MRPS@54&24G`GJB?$U$:8,E2L_@ M=<>";A(2M[<[5$4M43%A^9M1LR@:V76ST@N_#N]&0])D_MRP[<'$6/B[G4O] M;F[9=IR\8+JV;7A^W6&S7&';![5))GCD4S$[L4"L]EA5Y>BSJK+%8-72Z;(W M-F5)Q`5K!,.%9]F<]'T[;%@-P&2)JX44WO4$7L?ZW;?;@:X,[Y@3]"YU(%[O MO`MP<*3]$-4/4?T0U0]17>Q`_1#5#U']$-4/4?T0U?(AJN]W_-T^W:M?Z MNPCVYE-L#*&&]3B(BW-`OZMOIKZ9^F;JFZEOIKZ9^F;JFZEOIKZ9V@/AJVJF MKR/*K(XD[['W9$TPW71?%4+F)=^VEK[[X\O_'0A+>K(L)[&>`-"E%FFFO+EZ M^K2//K+>(LWT].D:?;06*:9G3]?8([=(,3U[NL8>A6^19GKZ=(T^4F]]>OHT MIX\@M$@S/7VZ1I_6.\[?ROQ7_"&M?@*L99FC&W)U/.H14W681Z)G5%1SZ,V\PCU'E*+VJR[1%);'[[V/.H"C^0^>:%%3=9= M'HFM7PKZ5J;3+EX6>$*^9>CA8.DY7/2)ENB[;/W\6H<[V7<"WZ8UC[_U!&H/ MJ'H$0JA-?F-/H!:!JD6@P:`S*NIYU/.HY]%7SB,8T'J/Z.W;JL,$TI06Z:CG M3XM`U>1/BU34TZ=%H.K1IZW6YUN9+1O.72^P_J#?,N+<:>?/\/G6.M#7IJJ> M0CV%>@JU"%1/H9Y"/85Z"O44ZBG4$KWT%.HIU%.HIU!/H3=7U;=3ZO<#]=-MZ MNNW6LUR/\Q,?#_!/OIO\E[UK[6T;9];?%]C_0`0M3@K(J60[=IQM"[A)WMT< M=)LB]=G@_530$IUP5Q>7E)IF?_T94K['%]GQA;3G2VL[$C6<>68X,QP-!0MX M*M]@[LUB-41S;I+([,41MIHQ2&+VPNC8)!SA*PX&$87P0?@@?!`^"!^$SY[" MQZ24",+'(*+LMC[6)-(:11)II<;,3-I%)E+*PXC%J20T!N:S-`V9_EXJQ0P/ M'+!:ORHF]65&^VP04<6.$#)I><<4F;4X,G:=1_C8`!^L)C)(8O;"R"0CA#"R M%D8F-=1#&%D+(ZQB,$ED]N+(^$."E\JE]0C_TKR\O/[\>^GC3:MU\^/O2]#_\>;V\NIV,&P[I/X_ M:G`BDY`'OQ$C`+E+HHLYJO/2+G:Q>!IX-SL#ZR"QQSC>9/9YB@G;G=^#EM=X MH@LAMC'OF":[6(R6]X!QO-'@$BTO(G:KR5F[.(R&%V&,=A?M[LZ)?O$K]G9Q M&.WN`<-XH\=<;<[PKI(;G\K[*O`^2+)VR*S.DW]F*>DRP9.`^_T$>?[N]BI9 M\@6<,E?]UT?C\CA]90JQQ?1^[HF_QC%W32L88GBO,'PZ;P_7..8BAA'#4_PO MM,.(8;LQ7$$((X3MAG!]7JF\<;Q%"".$GU%;16<8(6PWA.M+5Y$@A!'"1D'X M=)OY].HF\NGY1PKL&WSKI8\7)L`GD]5'_1':XNUP@,+#C7&GI;GS&;ASNX5\ M>NN!D8#Y@E')0%H@E5GY=?77%*[N<"%3^"08(U$2IP^2)!U2=CT7KHNZ5+"` MI,G<2]T&Z22"))D@_W?R]81\SX"L#H<;NR&-)7FDDG0%CZC@X1,)!/_!8M)^ M(OZP%P6YISS.&U*$R2,3(VTIB/]`Q3WPD$J9^)RF,.XC3Q_(W1-+'TJ"A?HG MP60J,C_-!(_O87(\A4OA2?)D!#B#3XI/U/^><;PI"$YCI.X-`#]&R`G MEKPGK=GHEW->$0&1^\E]S/\%RM1S^[!C/YF?:50K2`'EZ0"Y113A,!'S'V#@ M4+8@)P$L'T+@D8TI?0<6,2WG>Y"%`/GDZD9>G=5)Q,-0B0G`HJ[0&IQ+#JX; MD[I#7M6\R>N718ZR$J]J[N0P70`WF`0N[H6O#U[WCP,3<)NL&3!O6VPH#1@VGYI2(&=598[S"18 M(\4.&B696D%'U2_(>3T3F"T>_XEYU\S#FY`?N++F"`^ M]I:V2R[],)&98"W0M8^*P@^__D+(N_XHOR=)\`@0A&&N04SQ/0>7OJG9/>5> M+2?XVDS#H/?3RZN+F MMMFZOH$G9W'`A!K]B/#@_=&0KR2F$1O]01?ZP"=R=D+ZTM4JJ6%"AE(FN9@U MNNC>1G$CDIO'UAD3:@YY>"#DM[9TDA.#S?"X?ICH(O7R)RCT4LR.+4R;S+C^" M>"`,99?Z,.7W1^XP<^*ZK_,_=FD0]/ZX2JUAZ^9+/ROEG9QVTWZ9Y_PRT`$= MU>IV*A'U#W\U;Z^;"A\RHF%8\FE7KM?].^XY1#H4#``C5*QVH,RB(MH%S#%]"R":DCI,0V`CL_0&V#D$0T@CI_8%T2Z4;5X!TQ`*> M121.XC5L0._N%:KU]JN;%<`3WSEB>A@%+L6P\_E!/*">6$ZM./#%F8I%9[:89+,+`:2AZN[03*S&$B-LVT&J[,S(+\1E?8H2?XOT[F2 MXNP\;N.1C`815=!^.:YK?)"[E'/9(WS>!K6-CN>@HF&->4Y_4WE.8^H(L!WK MR\S#\>G<)@A&E!.\<-5!K!I/=$&L&G],$2(5D:J1ZIUN,FQ$K")6UX?5>L7X MPS!&L;I*K%"T%;N-<<.@:&+LK;A57'UL%[7FO:0=MHN:N6'I.:<-[-R'.+8< MQ][9/`?+..XBB!'$4ZM'SN:6L!G'8,0QXGAJ!4NMNLV`=]>-*,WL)M%.1,#$ M4HTE!GSJ;QE,2N[N^K+UQSFIU$94K?QZ05"THI17BHK&"KKG!#P]VAMG&R)^ M*B3&&U<6W-QI_?<3C,I3&,R?>->UOY$S[)*2=P\<-(Z;VAM3=ZV41&;MO_O] MSW0;%I+%*42,NI%>U`U9RG3#%=7#4"BPJ!'4#[V>67ILU7-1=_ODM,U#>%#> MX#.+^BWX\D<>2[;Z?#^KGD.5$]*<,IDQ-KS)NXK1$()P.C[G`8-HE/3ZDCUK M]:`G,O*&/)'L7G?](@]4ZB9Z3ZJS)V/Q@$&!0]I92O3([2'?\LZF7/7Z9'`3 M%0/6C4PA`$&=S(`IFJ%"9LBKGE17-D2%9Z0M2MMTBW++.B&HL\Q[W48@`-T_ M*6)4-5K+>^CI_JJ$!G]G,LV1O2W%1)Q;@G/?=)Q_&?3@%=,1WTD$@YL)^YDO M:^O%WO[T8UNF6]W'D[E-_O:?65.;UXTU#^G/7?!2K"S73&?J0[#^8L< MRVR'&=4I"*&YY]"<^GJ[!5U_-EG.NZ3$-R%D_8.9;4FW4CVRN:J6*2EEFSMU M_2X2N9PCO$MJ+WI-EJTAN*F;01=4B8V;ONEX+:P:IM-W8*K;]/TLRO2).S;I M@TCYOSK#C5J!6K%^A%V/Y#*L48MA:LH:DIN]W%#(+/(?T&0:89),I^_`3";& M`!@#H.I:J;JXH!F!.M/I.S"MP!A@^S$`05-DXO[$FIK8[*H'MB'/-:3?MB'< M0"F8P`V4@@G<0"F8P`V4@@G<0"FLOZ1DVQT<&D4J0DJ-F24A_^$Q3UDIY#]T MD>A$*>E8-2@"TS!@HA10"B@%E`)*`:6`4C!-"DNYC?VW[::<';=Q%]([>Z$/ M>(/WB`@"W8J9XZC4;#(/:@_;$.0["&G6VTO3QB:.\Q=%SVG'+9I!-,<`VS M!3O5NE.KFN3^V!VC%MKF<&=&J!\%C0,,1NTX36J&1GE.K6R\0B&6K,#2\6D- ME_7="\MB!'F.6ZM:PR;$DME8JE5P93-(;!9CZ?BTLLVS7G%EVSL$>8[GEDUG MTZ$$KI^XSV+)"+T73#?6Q2#6:N6JE3$G;9#0+$;2L;?18R]PH=][!%7KQB_S MB"0KD%0K(Y(,$IK%2#KV/),*/W!5,XBH8@@Z=4W*[!]T\-H2-&`1%?]@T&JU M2GDN9J<-$IK%2#JNX>J^>UE9#*"*23D/M$3V`LGSC'<3$4E6(.FX;A*2<$TS MB*B">5CCMX26"EA[A$\]LLGB8'9X$O):XMCBDYC'R+6?/+^V`WTVI)W;)+J@ M]I8W66]3L/OD=KP+Q*SQ1!=^.7>3<=1:0/M"1P:Q:CS1!0.UQB:3CVA?$;,; M\`G.C#>OB%G$[(1/4/%,!RWZ!(A516'YU$Z?P)J-_W*]2+)D3DNP5I+2D-#\ MN`86D,Y(F]E%211,4!J6H-PW7B&&$$.((9.(0@PAAA!#B*%=$X480@PAAO9P M\]\M$L_.WOQ7E'62.)W"I/[/9/@[>7:."M8-8`YK@NRZYW@-+!U`V)I"=.%M M`L>"DA?<*4"XZIW8NE/?:!MHM+((VXTX!_4*PA9A:PK1Q0_]\,ZPC`#A:@5< MJPWGM+K)%U*QDN#%Y]->QP'K&'%&K6%I1LQ]&L,KQ!!B"#%D$E&((<008@@Q MM&NB$$.((<30/H>NLVL&\,PQ^[7**SO5&O:V-4AN%H.I5+*&1P@DDX&$5LDT MN=D-IE,$DTERLQA,N,29)#.+@62'5=IJ*#L6FWIG+]Q750]3I>MK@GZ^55OJ MBL1G4A+!)*/"?R`0`FLF#:ODU__<@/U@8=)5IZ,M-7S=??T;^>OJMG5]T?S4 MQX)F5IIT\WH6^F:,^N=?,+(WCJB"M1^.5\=>T@:)S6(LH==CDLPL!A(:)8=\CG$Z^W+\JV8$;3L(SFOO$*,8080@R91!1B"#&$&$(,[9HHQ!!B M"#&TAZ4";I%P=W:I0)%@%QOB[QJIYJ>UO)I3]^Q,;2%L#Q>VN(&`D#6&:+2T M"-O]A>V94ZW5$+8(6T.(1@/FE$G&\_SA>?"BB<1PN?`82XG?_\5NK.M6S>0DAXQB, M=AAQ_)SN$2^^ZI4K*EJY`\UD8RB[U>7S__L@](NU$!$SH MCP.!*8FIZ[HT"'K7C>;*!GSJIW(F)7=W?=GZXYQ4:B.J5GZ](`VVHI17JE+* M#6BO<>>/A'!0IJR@*0)21_@ M;Q%(,R5)AT1P;2:8[G':98(G8%R#OS.9JE\D.9:,%>U]VOKO)R"2IT";KXGZ MG*2,5$Y(T_^><!B,P2@T M5!>!1L(S0/-Y[(=9H`E<61V;$X9B>H'RH'Z9PE-3TF8QZW#@0Y2%*>_"M>U, MPE.D))TL]M58$C3\A?RE0G]/?*[O>.3I`Z$$GG,/%_:?LRX^7"126QA)0P82 M^`HJ*;3N`]S6;`4D$<8[I5W4B6`Y5#=J^Y15KC#!;#H>T9% MRH1B5=GU7$<3^:KFN21:?+W;.%G*.$Q=G=4];?%V.,"8_5_B\[NWF2S=4]H] M_SU)@D<@OQD'UP.&-#4_+KGTPT2MABVP(1\571]^_860=_U[KZB(`2GR"Q-? M'^C(9=H^P)=;UGE_=)&);Y4HD=\4T]RJ6SWZT)^['P+G(7J]^]D680RKH^=. M]RGF^W,3MG-\B-E?EF8]+>;B+#;E^H>[J]QNMY,PZ#WT\NKBYK;9NKZ!Z!5L M(!-J]"/"@_='(QPB,8W8V"\#Y\)S3TA?*@3$0K1<2#/-#:WVJ,'\7"11!'#5 M?WR`QS.1*Q9=VD]8#J8F+XD?J>1^;UT*,V5U69^1L.H0J1EY?/7EZQORR."C M6JCT90GYQ%]OR"LF$$.H5S`&T%"OBA9NJ+9S[X!$SDE4T/`D*R/V'! M>9#D"HQFT?XIHPR,6,"SB,1)O(9LUYL<]CTPNS&8LSS(C=B>>,^LY9Z:P;]',YJ3YIU`[-!3E'1N*49)G M."5-B!%"4G56]T>V3+!REPN:,G,MEI45Y*AN5:Y$[ ML-ZF%B]RLHUMK+$\"05TU9[F%2@G.^2TE.>_99=^G8[[U9>OY',6,4'31)1* M.BES_B)#C=C=-7913G;(R1H;4^ADR^"=9A0M1HR55O;,"'U&G4@2Z68Z;J)E/Y< MG\'???8+^R>LQ1;,>W/#W)02(O9P$6MIDQIKPI:7=_'8>."BJEI499" M+F+M#,37L8Q5#V$9^PRK%<]CGIT%-B]J6H#=*@SH5J'")#N;52!<#Q*N]7+# M2K@N6M>P9M&XB'KWB8=]XQ5B"#&T!QL::ZCUO&1Q$O%XGZH]4;,LYQ5B"#&T MYXF9%UKN(GF9.Z8$SX(2_<$$O6Z9X]:VF8(X&/3CTX#`*0`R9'@58[.E/O(][F;=& MPQR-.43MFV8AAA!#!V.=\96`?=9CTUY.Q?>;$4+X`H`5+P!L(4&/]?]838WU M_XC8?4=&6SN7AW"]2#ABN7_N+6,B6=+>848 M0@SMP>;%NLO_<7/9.*+V3;<00X@AM,_[4N2/>KI_U?BXBWPX6-ITA;PQB?B= M;R=OI\XH/U:XE!^5R[YG'*;)XE2>D[QU=M+5.\Q.[RN7,M.Y>GW4,6%1-TR> M6'ZR+HNEWHX>72P6QP.!`$E'[QBO$$&)HO5'"@C7J M$"*&KZ,Y3)(^T)0\T("PGTSX7*JL&/>!ZGO!:`J!!%P0PS^,]`.,B(I_6)I? MIL*,)!.]8&*I).>.&;6>!&;Q!'`OU[E$4K/NOOZ-_'5UV[J^:'[J*XN>3)IT M]22.Z9L7YRPW[+39YUCNLSM,S8CF`T=SM6[G205VHC"E5\O<+]6E/)*A49CB^^<];9'>^-L M0\0O\&Q:#TRR0198>RHC>5[RR`0;RPH'F5#_*5^OPX5,R?>,"G`!I?+RRJ[G MZKQQV74;#FEG:3Y`G.CWUL(L8`%\T'EBB"F4[B?(H$^5F M,L&30)(V\VD&W^%&+O*AI+KQ,4=L^OJ(B!]?(+$U]5/KX%@OVH M2/CPZR^$O.MVV/E%(M-;%F2^XNIUS%-.%1MD,PZ:/DA5?]T44FOE6B1'Y3HG6K;O7H0Y\=?DBE!)M_][,M0I`P MJTX'\'SCT=(`_@P`OAULP0^&F/VE4%7$&FH":3$UG)C%+(MY=Y53T4["H$?& MY=7%S6VS=7T#BX6.#-3H1X0'[X^&?"4QC=CH#XJ\S_")5$^(DF-I('4R(G:M MBB."+_4DKV_)]W#HAN&^7(2WF(WKE.\=RRT'F),L+_"`O_,.]\&&@!(`BY2M M`FV(6<[:1YX^]")98+D8L)R/L/Q8,A4"AQ#Z)O>"1K+_5SU^#-$PV,;3-UHT M:B@Z%(\R@W=/3#TC)C=^FJ@M.N_4T=;TY$"%]%7S3*<6IG#*620.G;G0:Q"- MXR2#L0+%W?^E,2Q;3Z1<J^TXO4OU:!I,Q;K M=[%%-Q%:NCQ.$T+U`((]0$BO%B`5T*O7L^&/[%Y=E]/]/W*D"8E#[EG,]!_5 M3/Z?O6]M;MM(UOZ^5?L?4*ZDCEP%2;Q*HIVD2I:579W7CGUD;;R;+ZDA,"0G M`0'N`)#,_/JW>P8@00J\`^2`ZJK=F"*!06/FZ>OT=%LA>T0YKS=@V2@"X6R% M8[BB+Y"G'1F$8:I"NR`MU#;MB/GC,PL@C3NUO<`!_8A5KV!V0`<&$K`,K\V< M@>"/>G/78B.`Z$B*Z7,C"3,8J_ME_@,."<+#8CKWZ5\SPD-91('G!4\XOPO% M!_.\:3QL(6QQZ1=A_LW2US33`UC7[%_B5#Y\^IQZE/6S]B@J*E\F-SEI1P?X M&&A=GJ?T[+&`9EQQ^.+"U,,>#G@T7"KJ'@:2<^LC&+J#T+H%L\M=Y:;E3-J0 MNR(>@M;P"XALK)DGM?=MC\4K7L8JJR]^O;Z_N\85#(<@+4]!!8;%VA0G0^%Y M:F,#'4^0V4R&*_WTPZ7OE95IN/I14Z9N')BILV0N4,;78,MX5LO>VP;3K@2C M2[TFZ@R3+GLGCSAA$V!]9/+,:G2JQ`FU3C4Y896>+2ASY5`9,X8\=Y[[#I1^ M8LALT"K0T?6,-?L@F1\R'4-PTL"N6?DC+S!QSZQ:UF763Z-#[$!M7NF1'Y7#/TSUY^R_GF.NMM195UQ&3/C9])M3F>1.3IPNTGHD03)D7];VV5.#M!YA=G?, MMMME]L@T1.M5V)^[=EVE?)AGN7PDN2-4X._TE(4ACRR956`%NWDNQ0&/)WK3 M,;[P+`&I&D`JLU3@BW:("MTCPB,L0^Y'Y6T3<8H"&B4*S+,M3T\K:5H29%\N M9*]>@#=4A1)7NR;$!1'SMM%(5!BFX$PE`^O!7':6;4X9-[M4W8A`G`/B4M,Q MJ*A17A!ACT6-L"0A%37:I:C1?$J\)3%\&H)+;,&=7&)$5?_@"LF=R!M;Z?Y> M%"15@](R1[D5.G"7<"3%D$D!]R:UC6#L$?==@3440E5$HLJGEF?8F[6'`I$LR#T9.2`;H@@RXKD-0< M2$HIS11BTG68:AU=]:+'>9A]-69]UVB3,>H#W64W4$PO5S]A-5<_#_\8^UT^#GQB&QF,O2BLMJ-J; MOJY$JLI>?(.5BSA0\UVC=5:;S`;\#!@1L'"Q'W*89!C;#R(>SL[T@'F]=)J+ MK2U%HLXP4=\/AO$IC-W)VYUY( M(3YS>:(J&*N$3*1EWI,H66?%S!8EUTXD'D4T/AX!DER?[`D:CK/GB_E\Y7*6 M=Y/2?,EB5P.R,S0O*EGI.#)>G:MB/&(+RT#*"4HL,.]*.9!(E6?STQ#,%@MS MQ%9!*E`=6]-$V-XI)18['&*I0"ZQF+&YZD><8(^MCTXGZH+P2RK"6(G[,)!! MW!]41D-4UFHL\%!B?;-#B21P2."8PP_7&!.H#/>2N'E[TC@R<;/39N[&U1A* MV+\.UKD M'NCM<.0%8\XG!_AF:A11D;F*]89IM8UO#4``,AE`]6;;H+DA`%4.0%=V_=+X M_E0$(9,AU+8;EV66[R8('3V$&G:G9GR9W9?B8URK^MAB.&)"8MD#N* M>BP1B"L.XGK[TA2""<3&3'/50%RSFY<-4V@F'!LSS17#\:7=O%@6MC%N?@G& M!./GY#;M6FV955&T5WSHSHWS;NR,7XJMO[9L*#3KJAK4,N=Y"ZA5W7,F*_"L M`U3R_6SUWZ0?5&>3KFE[JKZQK/=3_?4R5%,:WQE;$;:G]$KHBT;\1ORF^*WQ`O@-*5NWFL\:V,JP,#84 M53.5EO:QUGS6PW\^P,-$!%/JJ`%O%,M'Q0SF\AY7;5\C]LWR!.L*3T0"!+GQ7*/@ M5MMNU6H63YX8VM:0`778%!4^^7&/)9-L6R'S$J;$AV(K9!L?\#00SF!NU,:5 M7<^.:@W8(\XL][/MC9DJ%S\S9V>ESQEBI,]]+E779LD=5+4NO`7WD[;8NMTS M7@>OU%5&`+XT(`Y>+_TK;9_)L-4!W!_R1Q@2>S%W8?">B&`F1]P/D0K5;18H MD3P2NEUMYB*8Y/%T&H=L#+]9(R:PF71DN1K@(RY%X`)1/>2$S!MN/U_Y1\DF MT_2\.V[*9-@N6XJ(@[_YY.,4`7'1&-[68T"%FJG_QF*D7A.N[<'X:)S$?'M: MIXFEB^D+DP;`V.?\FX@FW;P9OJ>&+=.=5$".G^U3LKZXKKZF-[]V3>_8>PW3 MC]S-/,M%$>\(+]1]YVFU2[\)-&@X? M2://M78;'7*"[JB6O*UV4>@^4$F/LAC/JIF2B M1B[V;/9.=JZQY\-?>,596J=JK--&QOY[:]11^+Y!#EH3C50#<'0I?A)%4F\!J MV]4/28B;Y`UOP8UE]NXD:?Z"@&3Z%&T3\MYFJZAJ$O\^26I1,M[EC]P+=!)# M\0+>_+">$4@UOQA`H^(=GPFR+P^RU2RY4MA&;4[YBGUIL,++5VRCD>@\WO&? MQ^LL"RT8-[ETII0PG(/A?9I61A\HW4Y3X%D]T1OG44J)RA5)5.:F)RK?#4>> M2O#-'+=(TXUS3N_4.IDC*S`RES[S,,3JZ&,1S$N&<(7D3J3.9TQ.\XCT6>K$ MS^(S.2,I`HDW8&(R<_X;BU#,'/^Q]8&,9P<XUEN=WGNV]Y@Y1U=O6DFJW^OM#S!M&3W/ MD-&J%4#&>B&=["'"Z5,+.$-XHC/>7Y^[*5#S#Q"N&\150R>E\#< MK7Q]\O*5.JFXV7";?O[A?-3C;Y!E[M-5O)M*FVO?O9Z*F'LM-/#B\+T('2\( M09@\@*1[AZ3^]/>_6=8/<7C:9VSTYLY_!"@&_- M81#^CHF/M5:M]>JG=$8,EM]1E5]\?564]$-O#1]\?WMS:?[ZX>[3V#XQ2".)8[^RA+NCZ^F M\VKY;,BS7R!YO\`GZ_+,2M'0,]IX[9U:S7B4&6_L\Q*&/ M+AIV.N)0:>Z&/->0E'I#9H-6H?+9LD6:[3]C^&[`7:L?!"YEO58Q];QEMTOM M%D7YKD;K,6AB/1IZ@4P<'YUKS4KCK=O.BFDT(";4O M&K675Y5$[38*ZNC/'F1W]9'4=1.9+FO?O[5^O;U_N+NY_I`NC7I,FJQYPO3> M;S;%B4XY4(;X,X%2L^M-:@)'.*XZCAMVJU:FQV_::0P49N=[=N\ MI(K3W/,"F!OHDK!$F,G,=V,^[>.19,NB`>NF?1$6=@F!7UAD M/;%0GP#`//P>-OA0!P"4?SU@KFY(,6D!`3=,FQ786*?\"99>=:D8<9GFL$\. M'823K/]IQ?6T)1;_IFNOGUDW:1N"81#GI$/JE'Z\'H\58,,1GUMCSN3_A#H" M,,YM5@+S&/+TKG1HW;$BG3L615)T8\U0,(E=$7A!7SAA9BH7S4W^E$S>%^;: MCY(6/3/=-+#XNP@CS+!_$C`67NQC_K^73B$>W1@[0!$>/XB=P928,PM>"D;# M$?U`D8`=-53GG3'`(HSQ<6$88#%\;-B1/"#,TF-2WOJFGW\X7R:0UQ?D(E$2^8Y)Y#"Q%L#\8"!&NN@\BNH4?JSY-J7@.E<1O7IS5OE?7+&DBA1GJZG@6 MB,;&U5ECZ0VUCI).U@#L.>R_DZ5CL0J:465)TZK80SVQ//V]X.4TT]K:W<1* MOE_9U[!>C,$5CH?`[38>YQ.]K%ESU7R;IZ+7M<0Z)AT[77R$.($^V!HR2D\] M)AVA[`S,L^@]6 M?#<4[ECI0MW@#KT0'CI2C!0GNS+&\]IHS/?!K=)*$-6VE3]Z^S+F37@ MS(L&ZB$>[XNDI;#%?:;:&\*ER7%IU+(@2!PN_=0;Q+>*P+]4?8KU.X,3DQ(Y MM264ZH9KT=<*,ST?=8>]]]SAPRY\:-957\(&R1"2(4>NX9/Z!6+:+'7"D&F_ M3\4Q#@@/`>.`7B:F(*8X?J90Y4F2@*4?^*=)-0?$T#3GU[W[6A7K4GY]Z/PN?^0XLPY=)4\]" M@XX41V]ZVE[*$E6ET MJPMF!B]]]X4XLD^T3T!6WR5Z1=1,,AR)4U:-.OMS>O%9B#/O7 M2S'$NED8>?'[9]:U$EI#$:E6OKCL2?1#QAY&8U(YUPN""%<<'BRM0%4DFE*< M*DD01_`UGYJQ^(JZYSR.U5?&3*IV]DG8&&^P_/2%'\11+KK(QZ,"<<4)I9G,!\2-YS^-I&`))2X?&O=O,I;,/6K$9T8TC MX+UHQ1;$"T79/=C2?HSKF59MLR? M_D(7\BM/."@<89X`^D_IW,0^BUVQ4*=FBQY&`S!8W,")\:=%R1'+!0:HK30M M([W-T]1!@DT7%[(A1QG92V4>X<[YSW`Y/.#T_\!\"&+/ MU:S)TDVG/V)_;M=IM4FGRE8Z:L?8'^/:::LJ2PXN^;7OQW#C886?F4)5[FU,F=]2^;4_^R"795CO$WYU[.('(K>.XV MYUL4RC[HHF^TPCDFNG629V>_5I;[9(<>561B,*$;A>6.E4$%/T?CJ1F/B8W* MSCV%"T[#"/DGDLP/F1*RMDX<5'F$>0_%[^=V'B^NK*Z.ZIU97P<";`3])#]X MPH0:9CT-P,$>GP9//M963CT_1=/GGOB+2VW1@<_9UT8?+!%(9?V;$N5Z0)ZF M,*()!SI"U7Y&KU%:+O?86,OU-/RGC$`_S0&=S4'`,?'WODS55&(YSJ4J8$9G M]P]P'C#0F/A("5^DC]&THO^1FB;]V&,J5S/H`EJT=[&#)*\XJ\P0L!VWS'40 M6\E!]RH75B&C!VZB\CNN)VP":_0AXX#`[V"7NOO2M!463,I(GX;*](Y!\^2[&FX70O<(6=H8ZCM(!UBRC[KM4XN7'Z1Y0I7 M>9H#!LXELT)8(=$3X/%&D_QS;8;.V+,9*U9EGN.^@&UULP$V%1[,Q"I0IOOC M"0D8J(FFWC(H"44!DB)Y)(-PI#,J,!*HR$W"/GF6]#0=G@,?#Q6%2D.$2?@Q M`@LY4K=Z:HU/0LY!.`-=NAX[7I45HBIP:B(YCR/J>,W%=W)2##J6,4D=!#'PF09-/:9/\GE7QS=VIM-ON5P MV\GX;4F;%SO9W?JYO?+E&^O;;.W/;+_G[;CG5H-+G]O./':W^LZ+IZ18(5^` M7,_?C<^I&ZU/)RTL\KSA0=\%I50SQ]<*6XAB)RB/IV;>?>Y],_4/%[[MQ=JO MN[5L(R72<:XGZB(?9L=._Q7;5UE'75WX-N.M[W/6%X,H,_HLNE M[#4,V'%W,V$TSY#@H$HV^O&5_K=P<91S8/?P`HH$\O.W;9%`+F69/F;S1(:)E`*"&!D%!])*Q2:>ON MXJM&O3[SD7A@`5/Y\2B9*I!%QMNA46JD\5:OV;5VZZBE`Z'ZQ:F\ MD_IEE34>66]F$GT(*'?LJZMFA;%,UMNZ@387S\KW!-,53^>J^F?V3Q=:FT+RJ,:;(AS23Z(.F13;MS466'B&S(-2?JDVKX MX0>Z"2INNJMP+1ENA\:GD89;PVYV:+.=0'U4RHX.NA#*CQ_EQR^ZR:)30WX( M_/YIQ.70MVN7]$)`4+S,>@VLN`(Y<>/\B.6V62ZJ2'? MZ<[DV28^9+\9+PL.8K\U;5!QQR@*",PO3K&1^48H/WZ4'Z_()NM-#?D+CZR( M?5,]@.--"]>3''@QIENC95]>5CE!EVPW,XD^A%:[O*BR2B-#S9#9-0G2**!K M]2IGOY5NJ:6TYG1GJ+H5]RPA+M,HN`R+;M54FLF7SSIW5*E!TAK6X';M?,H0 M1G6[4ROCJ,1!&ZL49D$2]QCS4DT#N6=OD47#VQ016Q%;D5(ZM-5<<>_L9#2D38\0GS6;MV-QR2H$]/MXQ,:A%*;#$5L16I)),2(!=NHHM6$4WB,$$ MK[ISH1-EP7@.A,]:T_ M8IAZO=!T9F)4;#LA>S,J+8=[WHBYV+O]QU>UZ0S6T*3''\,1<](?NX$$HU=] MQ%#S`-O`X__PV%B6'CE9J+23Y&0%$RJ_WKU_^.<;JWD!EGKZS,9\EDE>#/O0 M]G]N2\PE-OZB#:3TI3M7"]YZ_QA]&'!KR%D82Z[:BXZX%`%(>?>/.(SPF]#J M!?)9U]$%-#S\YP,0(M'A,*9#&W@A[@5$8,KDE3>S+#A[8UDL)WQ(AYWAA^6-U651.D M[ALR*>"N*+"Z/(JXG!`&/_S)88J8C`2.K6^+AR-5V-=BW2".@$@'-Z!@>$=( M)QZ&0!0\VN+?!+R(WX=;D'I\,T5Y*)0[Z<(;GF5$QR8+Y`H7A&*$+Q=[0`&L ML][=>>0^/A%>$R\+XV[(_QOC(/!N^02L@?(-I=<"_WZ>FR=([\KSZ0!K#[>= MN'@F6G=DM0?%:K\`J]U/8PQ:`D7`\[`:>;87`Q[VL,+YJOLWC_XT43ZI?.H5J MU71"4.*(WK@LI91NWJ.^R(OW0T#B0J*@;] M!^_!$%%8`6EF"-LT7CC;K+37"N6G_;DB68[R>%_'L-$(X6`;*2LIX26E6N;X M*8@E&"UL"%^KKY`-^93)$AMF!)P&2DD$^$5/>*#D'!9R8KZUF:])S'?TS`>^ M2##DNIATXFB`311+'P:% MYWBQNA5,1O@Z\8Q<$3I>@"Z$?I8;@&,"^E1QLHT>R1.`$_^-M+7*Q2C"1PH? MJ!]JAE=N!3Q-C1Y'@T!J8I\&`ORI(1LGUN?$,4L=-_W,K*<4A]PE`;&N@&B] M<`%1::,6W3_@Q<"9:,U^;O)Q+A@7^+WB&?_/3WOUG6#^D]<"U(F@'W0_'([Y3X^B6(IE]'U_=Q/+WYC`(?V_4`,JM6NO53^D:.1XP_H^OWGW]UI6>#R-*91G MVB:CBK(J)D^K)+M&#Y\^IUM&];,V&`E)FM9RX*]^D;RDO/F-G]G`]1)3\HAH M79X>]WP#U@EPQ>&+!6)V*=>M?O4"N,[A&)E.^$YR;GT$13((K5L0:^Z:OD)V MTH;<%?$0ZWOS4I8VQV%8>[$S>GIUFMU:"9&YSRYZE=47OU[?WUWC"H9#L%]. M'38*BY6Z)T,P@I0[``+7!:'*9**+ULV>6S.%=#=0[,S:&Z2V+F;GQH'9.4OF M`M5_/9+"LUKV]EI_SP1/%Q'-UC5%CV$29BEC&*7HMHS6O#`F^LCDF=7H5(>) M&K5:IYJLLTHY%Q,#V)I?CN2Y\]RW`PWK(Z4`>4JK<,!5V,9NSE56B<=[V?I^ M+X9SD>8Q%B]*M@VZO!?(F3!B%%A+3W-O:$&78BAD8L]E6=#%(W0YT=\90FMB MZ$SB.?G4-NQ:LWUX?;P+#@BL+P>LE\GYRZJ!=2-E56&%I/OH+8F,OUFE>@JR M;0K@U7WSXMZ)6H_ICFVN"$.$H2,0U(W+=23UJ;YLX:;T)(<@/^O"NE'M4)VQ M/LGN)4E^DV,%*FDG0)E?G$=!_+E__CP!RZIU:=`\O28,F4/4FAAJ7K4,FJ77 M)-07"76,&L6^Y)C)S5VKSX0?:O.UUNOE1E3*QRKE0FT[7K\-ZGNGE4X.J/I_+`)N!01 M.0"3MBXO#)HEBJD91-2ZF:P7#9/R+<@GV<4GT7T%;Y8HA[E>@W0P@RS"M95- M)U>^FV004A2.,#NKWBJ)V&WTW:K6%57V>391:)][XB\NL6;4V38Z;&6_B5WK MM=VJPB\QP]>=-CV>4XVOQO-CEI-?]RJ M/.K,ZVQ5H[#0>HJS+WI,+['IYVD%SU75.&=K=W[A?] MGF_;+`\W4?W.E?4[86+G"G@F4XT+;=7K9U:RK&"(38HR*[2\Y-*=7[D5C+`E M*T_;!4T[I$1/`5:^!@[`ID+!<,BE.NT0R#[SDT+WH9W4K\;FKI&(8A@("]_C MO=VD;*X5ZHD/E]?\+'B2JUU"='&5ZN3[1#4G+Y%?LWKY-)=8F;J,:O6[6A$; M5^U"LI:@<'6=ZZP<4[>]$\%HP$#T.#R.L"O1;*A4]4<.HTE[J\^JE=;8NF&2 MV[J7$?.B].]/H,6\H#^VK=L0`2W"`7?AGL"-TP9:M\"QV&O.^J@:;X66$X=@ M#W%YV@L%S^1C$(`/&8<2'>(%JAP=7,!D-,(E>/W_$ MA(_U]WO<`;D2ZR\E#T<"A%,`LS`=.I9!G_LB:2GMBD0..=@G3-H6'_/)Q;KI MAN\&CH1UF7FZ*AZNO0(:B)^9ZT4^9_MH'6>Q9_^0@ M@01$_`"C>C`V2%UP&51/0W!$P'A2[8!PQ)F>(X_,<=!BLK%%(L/^)(YP M$VG!_$B<)N(1!GQKW8#0BT&6)S0Y24N\#%T)\58`+W<*\N/4P88J<,<@YXXP M1@$6*CF,-Y)XS MSP.U,[:PWZ*KNB3!?R-49&$\&GEJ6/ARP(>!E(-`N"C'EA'0703(+_JLN/[A(6J[Y#RKM29;J3+*A)WTK5V2ABW^!]IO=-Q-FP3?>ND/N M32!'`3JPYY\FQ58F\COPO?&9]3!0*Q8-`E>9S+B`8##I`Y_=\8RX"](>;=J/ M3;F>PRS?,IC6E-UQ1'4;\A2*ZXA[8UWSI=<#=@.AA_\FX-'\J/M)X71.?\RP MMZ\:3>DUQ]F"CS!J7Z3-X`[$?L?#S?>HI^-$KLZR-*`@75G%E:IQF`PCZ[\Q M^"FXGL`X&-Y3]V+19NICLK?>("OVB8WM:5+VH ML!8$1UJ)[+?%8$MS->$%B:)/X@]K.5(BA M-[*`*IRCFKJ[.ZVS`2>@-B=A#7%R;">R:)T.O4XO1:RDCG?.1$PK*>5F.M"A MWETR?P]1WSX9@J2V<42M>RZCWBJS MN`])[Y>#I8N.\4C:9F/#N)(,>Y#O.0D3!>ZC=3?;1Z,#\"_N`'P%JGA1T0;" M[`S9EV6V!3%KKS_GM&VE5:*N3B?7C(7O@[=;9?(VG5M?7Q%=V)?M??;,+>[@ M.N'U)>*U9E\M+1-B+EY7*:)B_?V=$D4IYF!*S.'8YHHP1!BB+8C<(U4%!Z&< MK9*YB6N):TGR$X9(\E/BD$EXKU[2QZ7=J1N?\T$0,AE";;M5.ZXN`$Z7@Z3Z19D[_<;LD%+2T.Y)0[9UXE+FD%'RPKPLC).VW6@9 MGSQ$[2H)K0JM=?MRK]NU^VU8N=X^>:45HTX=>K9100U<*#=CGMRF7;]83."0)["4")PL7A^C%63D?SYHLI/7-6XY8]8Q=\;ZPXXNOAP255>[>2] MG@IZ5B:2?;9.2()$SU&(GN[K]8OE'T8(E<`[TWKE29?*&U5S,PQBZ?"4I3,U MS;&IAQ/-5BQ74J8;>W]:<]THG`$?ZK846,W\K)P2SZH=U-9#+\Q&FSZ`>6$P MG8*TZG92I/O\A'\;<3_DJ@9^0J:5?!=:)_RL?Y;]A;E#X0M5V1E+/*NBV7"K MZD/R;,CT=LF9KE7=9\+70AWI1&4P5R(<2U8+'QL.J"K[*`5=WM7U\;'X=(1E MCIU8JBKR2')2.!SDNNJ)Y3O\5%`(1ITM-WM'PT9!;P-8FIK*7A7 M2.^"66.IE*8$+[P%`0FP8Q9@KNF^[\]YG1'2Q@AV.>R3&EYOK!/Q>A?A@==] MUSB[LKJZK'>V\=(S2P,<7!DE+2[G!F,T#/^(4ZL-!D4CSE=][]3CL-.,DL[Z8:I#4."YEJL-<-7U M1[GF;V&:8)XV:=Z"\W+9Z5C#=%Y&JN^@\,9+WGSRXNJ!\,1U;$7=A>E$/+X& M%$934SKY65'2JM=22LZL)8"K=2H!N';K8CJQZP).16V41Y!@9OTU>0:]!!#+ ME[_9N=QQ^63F$9=T6,)Q MZ_6+0W3#VJY+]V%[\>0^_4N&0Y*X8R8VJEJ4):UR5O3_-=,>J5JOG"KUQSE0 M4YPC;(13@58UA^Q/\[)[TFP^8[OOY9O?>J+*[2:H?\S>Q-'^,SB)=YU!']0UYKB$-,PR9#5J%XHWL?5G/7V^U>.P&GENLV?RLJL`D0^K- M3J*58$K"XOA782-A<#D!_$2$2!W,;G?H$'D\VJ*=&P+]O& MUY0@"!D.H<9Q=<(X=H%]ZWK*\PEL)A)+RKS'*7#>-K&!&2*H&DBZLRFPB1]"[<<>CU M^+>@Z%)7C"S[XV'IRSIUQS9HT2J,)++L*Z4;;KC'NY)_(_%=9:9K7U*E6X,6 MK4J)<9_">0C"QT2WU5FNN;%564FB9!D,I):5Y1_7R7Q_=OX,:!] MTDJS7*-#MK=!BU9E)%T9GTU+PGO9/FF]21NEIB+7!/:F?$B#%JW"2**-TDKI MB=^"<.R?/["_`D?XI"%,Q>SA^;IA?J(<(:D22"(-42D-\9Y',O#.]3_6AVL2 MXU5FOL:%\4%80E(UD'1E?'H6R?&,'/\21QP^DO2N,L^UC>F"(UIJ+6`-9N4RS?H$6K,)(H4E,I'?$/'KB!?_X;]UQ* MW*DVYS7,/[%"2*H&DIK&'X$F(3XCQ/T@DL%([\:2!*\LW]7("C=HT2J,I'J' MCCU528+?#)@?B6_G\.]P),@0KS;SF;_+14BJ!I(N28Q728S_VN/^RA;=Q')& ML]P5G5TU:-&JC"3S:Q&1\,X([W?@R(Q!BU9E M)-4IOZ5*\ONWP`MZ9'U7F^>HK89)BU9E)-6-]^-(>F>D]SU_9)$(2'Q7F^F, M=WD)215!$E6%K)+X_LA=&7@DO2O-,SXH2DBJ!I+,WZ@A*3ZS._HS5TA#7GF<%T8#+@I6#2\KA>'BZ8;<;Y$(8M&P5 MQE+=OFP97XAN(Q61$/[Y^OW[NU_^]:)\"W0*]:_SKZ<6QS&YR@ MKN@I$KZ,A!2/R2V%:*/UEV89/';AX'>?[M_?WD^&[7K,^1,'M\+`$^Y;RPA^ M.B31ZXJE6JW,V$;.\A].[Q%JC2=Z/=2VK\ILFE(>9H]"O];6T:_UJX7Z]2&( MF&>]$\%HP.20.3R.A`/?C&3@QDX4DI8B?I_74BV[76H99U)3!-LR-B#M>JGM MO0S15'O61NJ+K[=:]70#S]U&0=46ZJ?WXI'+4/0$=R!6TSV,B=@_/YU?F1^8)295`4KMI M?-XXJ8K,0;[`#^,AEXFR<)CD92D,RAH[(C:_N*"T`(,6K<)(HK2Q*NF+7^)( MBD@$/FD)XNV5O-UJ&U_6@9!4"20=F9:H],[VCAX'&X5QGWL%ZPU>EMZ@O4CC MB5ZW<1:E>1%F32':A,Y0+W/SO$B%IS.Y\O;+R7&ILKG9L.NM>F6FB;!D,I8N M.L8CB7R7Z.U-($>!9!$__Y2>BB0'@HRQO553(0>",%L\9BOJ\VZCD'(GOP63 M[P9QU^.55D[:STB/6FZCFU;,SJ[8+(]]BJ-Q#T.*^RUWK>B2%9[5LJU&KU\ZL#[GW M8R*@'T1`ON/%>%=2U2%GO(],.@.KT<$!:YVS!3-'G'$4G-&M$&>X0G(GLD+F MP9`Q8%5:GG"X'W*+]0'&0[@*R`78WXJ0B3/K)@!VB%R"\%%#V#$=PI_B*!0N MSZNB0]`\:FBZID/S3IL#$ZOC^-YQXQ&9$,$6*5 M:<*7N:SR68I`GHXX_.-:;!C$?L(.:0:<;3T-!`#VB:M#-_Q1!'$(N'<\%B;9 M!(!U)'J-/+F'_WP`PD0$]#AY^UFVFJ%)%IXV[Y\*>E8F`>)LYCF%LN!\/#87 M%WA/5YY/!SC4<#-@>E!@^@7`=+\L2C+_]/NTMEYW;/5YT)=L!(C!Q6.`),\+ MGMY44&BM*ZF61*L>/GU.0U7UL_8H*FJ#9=ENUD4!(<%#T%TBVXVP1AQ8-+?7%K]?W=]<(FW#(/._4`:5>[)[?R5!XG@A\L(9[E@O2 MGLEPJP*FY>Y*%R)GGL_;\TG*FNADPO\]-41BE6;O%9NOOY*(:>V)@[[*;YG;D)0B9#J&5W+CH&S0Y!J+JU#EI'6?SY6-7_;2R#T+6=2@8V015 MYKV&?6$^^Q&6*H&ENGW9I"+N!BU;A;'4-KYGS$8V04+X-F=&JFXOZ,/(YQ]8 M)'SK>LBE<-CY=4_]\U&XKL>M6Q9&Q9D1QAR%H8)TN^J33J>:#:$)M2\9M?5V MF9$10JUYML"ACWHLVO&MIO36K+=Z,-+.I6KOUQC- MD,*UNU67VO3S#^=Q>-IG;/3F"^]C6=-[/@ID!"SP7H2.%X2QY`^P9.^0F)_^ M_C?+^F'4XV]^%C[S'<&\.S^,9(PWACDW6`[,&OQQSWL_OKJ)Y>_-81#^CDM2 M:]5:KWY*7UT5$P-Q_?5;5WJP!KR=#[[EC#]7*VMVB,5_+)KXHD/C;#T66EWQ M2WWQ]593T0W^/WO7VJ2VD;7_2E?*J8VK!(O$W:E\F/4DFZGRVBE[WKCV8R,U M@]9"(BTQ8_+KWW-:"(G+@``)6N)\B,-`2VJ=?LZE3Y^+EV1TW__Z_M/GN\>' M3R#H5=%:O/L/S'5^^2&E*_/Y5&2_P.E]A$^LVV2K9669=55PX27C]K@=]V$: MY5^\G53+O;!W3?9%>,+&;(B4>G=A*%"B^`[[X/*1Z[F1N[Y7KPWY#I/HP06J]SL?!?,(%*V,.$C78,R"N63C%=UX2CJ.FM3.8MTV\J..X@08Q$;,Q=Y7B9"X:F M(Y/"GDL)QA,;\=`-\Q:=/K&0*GN7$T;GA@E>*TE?S\1\3:A!JU"(:*I>Y\RL MF$H$S([77TF)1\EQ/\="%$[Q=K5@N30ZKL`S13)KF"IO]B@4G@!T#H`&VA?K M(%UP]\Q=#WV-C7$@&]@]CCEB%&5T0\&JP2;5H&O0Y@G)=VVC/]"^#`:!J1)@ M:EM&6__TNT,J8U=HE6( M0RJD/EQO&AW][43"4B6P9!E=_:N[54:!7""U=H?V$'_-W6B1V7\83'S'Z#;T M6)6N6FAW4B=QT-$^!Y^05`TD#4S=B42NK'LAW6<>N<\BQ1!)NR5I&5@ED?06R8`]>JMG M]$H]BB351;`M83??,X:=,MUHFI3RK9Z.6D5KQ>V0PM>2G`L^(Q_3&7FUO2IU MHQ5AB#!$2B#/+N7+))`@R86<,B_@?F@PFTOIQN4O["",BLXE?Z*0W/KP_-#4 M/CZ?D%0)))F&.=3^C)`41ZHX?A>>`U*],>419G8L-O/,UQ0)GV)%W[_A#U0I M!6L42O*HD1SH= M]!577OO7*]NU4%T6=[/?&RJWMETK;C/XBH8]_CV.W82Z)6U"J6/T_EE7K/.Y M-30&%]V!%M\'E$EQ.AVRRP4K5/HJI&ZT(0X2A6U4.>7R.>6J!\I5R6:R*@1:L-_Y'>H-X7B=:$88( M0Z0WKE9AZ`:94J^>A.VN]B%9!""=`62UM6]WI[,4-P?G^X:H7'/M3"3+(K&L MT:)5&$E=2_OH_7,.WV\J<*R@JLX41G8K`3G],OM]40P90;8$RZ?,&@9Z!I#= ME`ZCX&<2`07#)NB!E,&+ZS^M%S28N&$42-<&%3*3@2V$`[_SD'$'-T+" M*5B7C-\:[">/JNG41S#TC7Z/2GYJM&P5QE+7Z.B/I:/T2VW=9"=6U,&2H-?4 M/U/4/SY5W"%'2.Z`LH%A44<>\M]I,^FT1HQV!C]=OA.,;P/'0Z'2K658IH^3BCQQHN.E5V])* M.S7!\J7Q!LFXHSSQ1SON;>%YX8S;KO_TRP^M'_"(S!%2?5PM&*X8CIMQQUF. MRRKT%9T2#^/FRGU]N'_\_1UK]S*L9OUX0%>?N,HG[3K7ZM_LT;'+N0\')4U^ M]]YW!;G?5N6`0L:E8(Y`?S(\R,%Z0/!OX*N?.19Y@)O9$]_]"P?;/!)/@52M MIGC(QH'G!2_A._9!/`N/F5ASR`]9-!%L'@H6C-E?\P`-D9ET;8'C)7,=X4?* M1;U98,)6!2BF7'X34?CS\IY6GGN&[M3UN-Q_1^QKLF\ZK]\GN4$TP5Y;0"\_ MB)*;PU6*@JX$D\M;X-^NG_XU"H5\YDH2QN_3WGZ?N9\.@XMG\RALLC]=&`?W!4,)=;Q1,9]YU3:SZIIR?'AR>B.#B>^VF$4Q M)5S?]N8./`Q)_SDXS<#5<@5.8!KY8+`G+QG-?'50`'=\, M@4"NY^&C`6#P]#M8+(]U#&:US)9ZX3?]_L:8>V&+Z4A(UC9Q7&N(7[K^LPBC M>!'5?-,7-O.^<)-]A(F60GY\6_6S`Q/#KQ-\+*>VZ^T!7%NOVGQ%UI`NJ84N M&>FN2QXE5QR=\KF"]D1X2C"`'`TC)6D]\<3M!?MCPN44EI;#%<]"`D,)-A*^ M&+L@]@C+=<:RK3N6_RV#$!2C+P6,01OGB8,I$(MY^&4);=3^(=S"'8/=X$<$ MVEJ#UCD(VN4<7]T!EH;FK2>NH_DAML\`M+.9#+Z[4S#>P9Y\8S8M-EK:3V!B M;)MB*^$M0EL&+RP*8ND.AI*0$;`$7O9U(:+)/T(VXPNTL<#4A>56)A1R$*"% M@4!GYG`X9!_5UT`-P=Y[8#JQ.UN96E]$%'E"77WW)(7Z9+"7B6M/P%P">PSF M#L]&XRJ^,^.*(:/XX5A<"";DH_;!9X&2F<)C7P2Z"1K(L!@%X\SM"(S+S\*9 M?U><_$<`]CEL=MA/H1!YP_L?__L!R.Y&@&E;D?DC;"18]]]-EA9??4AW#>_8 MO^<<=%LDQ-MFGO@8$A:U$!9"=PUW+U!S\2C>OT^$\Z2X)T7N:HN')EO"[N/- M(C*KLEZXJ7+BO&PR(`MP\SC@E0+Z\,;NM=)L'?+MU M0U7B8/>U[=Z^7>3/1]_/;/7VS^7HEVME7BXZ*LDH!TOBFK^R420Y5(0706'I)6U,\Y[2YV;F MZ[]:*@(^`>>&:4I5O,E>:Q8;>]:!2<0#FG4F18@[_.QQS/+8Q7/'@%C;C4T`N"H*)'G3:FV8 MNI4P3(4MP5K$P]C7&]Z20(6?LZHN2P;X!8[XM\3 M%UK(IMP1"7.,71E&[*\YEW`=W@0-3LSF"@.8! M./$=^!`'PL3BV0MUY]AYQFU@UKB-`_'<>3S7:79.YKJC]O1)APQ]V>?Z_B66 MW[_4/]F_U+=.\"\=[2.RK-,=8()R/W[V7@CHP5*GJ0QF-0VG$0T%917-"0 MFS)*4.1!O[0J7,YMF.F*W-DA.7='A MDFC<'P"'%(K3G$UYU# MT*Q:YP`\(//62L8@AM]TS&9_`_,[&*/3R\0*760GL>GCW+D.>,U(_C.]0>[; MK5'[45'[(U#[\]E0R81AO3+IK[%KB">A5BHJBX-(B8(T`2-V_6PMX,$33OP; M;N@MXANHO`P59R^B2>`L?P_#^72F(K3>'46TA3J+Y]9+S26SZUKE$H[',!%KR8IP0I+4D(XX@ MCBB.(Y0=D.6'3`K:DB?67"?$&\0;1_/&P<#XZS/-8;/M;CNS<8MYHHDKG<:, MRP@#Z2/I?F^@1HD3'1WAK?(/P[6(LF6FGX/=U_&$$:-<\%0$/3ZPR5(>RE$V MB31A38='/`Z(D\)Q`?K+^HX;[DZ8X#-Q+G%N[;7:#A[=SFI9TW%D\!%KD%([ M(UU_7>DEV@[Y2Y564`H/OO5M=Z:J&,2N#XSA#$(WBAT;Q(X:L./V0=[^8C8G M8'N-!8_,8[QE+KT7*JX2RXRD#L!L;9*?=GL#WS8:[!HF:7/72GV=8#(%^B;A M"7"!@1[*4,2S"--C_?$\4AFF/)RPL1>\K(("XNH8\6,:R_(TF_52EE$#\5G, MM@F<1@NM8F_4IM9(XFI4X!!^#F=!E"T/LSQ@EIM-3C*03)**"+O?A>4T"I"R?&!'AEA61F`^Q'M]T:F/`5!S6 MD51^B_/.7H*Y!S)!Q`'YH,WC("PAES%8R>A$]2\SR9;&A#J"#?D4C`PQY:X? MFR_14HY5)Z^,CFI)MEQ9MOSQ6F)9H['<420U^Y#GP/KVL!/27&0IDI=E3$S9,JD)>:$VFBH[-9%(YP)&PT7F).Z5_'Y M.61:$/M7A/UW=MS+Z]`OYBH72' M+9,'GR$[HVPTV(M@$_XL,I"0PA:N6BVPUY3[*9JD18YWE'F-<9%8D8B#33/2 MT-N.),@<@LRC"C!Q(^J2XNL8#@GM+Y MX42(N')O4AB[QIISE[+$6*8B**O0024CP^-J1*P3]]7>0@>(KT^;B]/@L;F9AD?*ZVQ\_ MA1QRXXSYG%%96RFRG&LBWK9Y//XFZQ2\J"1:*TZ^/:DS1=%[ M]('$Q5?A`SKBX;TP>N64;8NV+%`>Y/9US[M\<[SVH,RNQ==J4$P`NAB`>KV> M1K2IC+6X3T87X([U#G>U_[*S!B$)\;+MNS*9T>P:W5:[,G0B,.D,)JMM#(>F M[G0BX7Y`N*N31Q+K5>;$H3FL#)$(23HCR33,85=W,I%(WR72/ZS"6;(EP^/8 M)Y+P5>=+RV@-M+>U"$S5`%/;,"U+=SH=DO)K&+NPR"\T:R*';$_&'."EK::C M[Y?1AXX8"XF]S+![1":`+8@F0JYB%'EZB)CM^IOGQ\?WM]] M2)9?O7(2*_T3?[MU=]))514C;9,\21HM6H61U+4J?T:0*\RRBGKJV&W(J:KJ M8^#;N;25GPXL7V&-SE=8AZ+B]`FM+6F*)8FI2TXZYU'GH$PQ=J505@I_V:SO_6C?F_#AB_I M^,2F\_[ZV'T=LU,9(A&2=$92FS2-?EN'#[0-J`^##0R+PH5U6K<*@ZG3-LRA M]J%^-3@.OMX.XM-F9-6%]@<.A5=1J$K^?.,R-1H=9Q-F2]"=5C4Q>XXV[0#! MG6`^\@1%5^VFB[Y:J;@Y7B!BI:S)YF3MGM';FRNM'8%/KE-+.*XSCH=&IWO) M0,%.&5HJ_IBK.X:>9?1'@72$+*5';[N7837KZFU<-DL1)UFA.=K+#TJ:_(%V M9G>J_'Y29IUA^7(CVZPUVZ*51]D^(7'@A5BUDUVVAUTD/60;J_ZR-NR!);>Q M2>\;:]!AR\+_;Y/F'NN7AR]\ID8.UP=R-=-[88OI"';T;1-GVQH:)TZDVVKG MG4@ZL-A>-L2MFG'KZ`:Y-4%YNV^N\\-Z8]?5,+-[+ELFM^KW.WF>:/5[Q'^W MP7_V#?+?7B75[IHYE52O7:JVM-K]G!,QVQ:QZVVPJW.#[+J">7>01WGUSV;+ ME>(=]G)IRVY)W+?IOCRS5>I>;^BC6OB/HM1V>%EOZ%?L*_@T][CT%DP@!)"F MW/.2CK=;/?*P)Z$[G0%B$#Y-]AO^G2E.Y_HJUD2MU%;'7@-;,?J,PQ`;<8^C M4_`!&,9PW0+^'ZXZ-6+H8X#M$U6P8R,"$=V(Q'062"YA)/UUZR*HQQ_^O[3Y_O'A\^?7S'YO#B,I;`.4M[_:O)'M;A?I_` M_=<8[E]6<*\E^7*UV5S94'.0'&F_TJ1)-W_FKH?\T`!QT@@Y,`82<"(\IQ$% MC>4%BUB29+ME[])K<9_-FVFSN>YUOFB[N3/=^768ZZ%8HXW'I@V1>KH>CMK8 MW5:JV?T7=$'>_%\]FC@2(B\RUY/Z>EV[QV`I14ESAAQ>*GR\/LV*SSUU+BN^ M:,?AZP'FN)Z,S]$C]*L;3HE6&#.C>9UXQOCS(R+QU5:_7S&(F->-A.,_%NVZ&SX;MY M=]:ZY?>Q7*L641$[IN*C&C6A!JV"#M2@52A>5"]=N+U70EPU]/<=U:3DJP@C M(?UDZ$F+LXO2R0-^G(.I2J M7CD(64:WKWT'$8*0SA`R3:/?KGR1@QLT-]A^LX`_J0`QL@ZJ7H7$,GK]067( M1%C2&DL]LA8T6K0J(\D8=K2OBE@9J^&T`D@KJ^%](#'4-Q(K=4^M2W7$X_79 M=C@D!:#1HE482:8Q&.PK`J(7F0A+.F/)`BQI7[2S,L:$.^SV8"O8!DW#^$\CHB3\)EI@CV&8#?1/)T(_J*_B0C,S:$@=)4O0[IN]U MQJ>\77_S"A45)A"&@>TNR8?Y9(T1M[\))Q,G0!99;62?V2JS!!%IT=M!DF5T M2RT42EBZ)2SUZ%"H2H="G\6SD"$FJL_FTIYP^+A*B@X+]@B-R"-4'TXW#:NG M/:<3EBJ!I4:C,C0B(.D,I$H(I8N:'V78$P7Z+/*8*/_7_-+,1J@D;J%[,0M" M-V(/?CB7W+?7'$BOW*R$5WB:`4E`J@203(OB9#5:M"HCJ:M](B`9 M!ZEQ\%[(2!6?CT1<&30^Z""SH,H\6&K'2!+FMP,D.I72:2LYWZ9O21A5OM)Y\0L(980J\FD.X[11>PLH\K8$44:70&]>J(HFMH1JYN M*8WA,2:'^&N.P9JIJ\%@XKOMS94#8K<]_!432.]<(%3:X*@ M%L2Z90A2X,3-!4Y8G3(/$D6+VO6!:HGHC;AF'"LA8N(0%UP;(J&6+9Z1MLJT_NT:7IURC"]XH_H MF=D\EMFRE7::+,N7QALDXXYRAQ[M/;6%YX4S;KO^TR\_M'Y@HT`Z0JJ/JP7# M%<-Q,^XXRW%9,W-%I^1T:G/EOC[7@WA#Q9-!!N[/O=MEWLL%/+9M6$JH;"C0#9?>6M"=2Y4#YOM[LFX MSOU&"J`CW0'ZIY`+%DX"&34B(:>9_DWPP.?`>T9?]&83A=1C34BLM7RU=8?O M>Q"7+DA.`&DPSN`R(W!1DFX"&)-=78`X?Q(@8#$15BH)+.?X,SQ.W0-'R7TM MSC(L@D\)^10%>2+90S81GE,LAVQZ:W8N&UXSDO],;Y#[=FN+\Z@6YR,LSN>S MD77_Z_M/G^\>'SZ!T3;W@9UB,.3,:W[?9%^4B'I$$?6O0,K@!8@>ZO%NA^?_ M)96OH]7D`2EXU@=XF@9S1,L80&@'TZF02N?/^$Q(1/6;=M-D(]?SXMZ\^-7= M3+H>ZQC,:IDMA5,8--P8="]L,1W!/=HF#FP-FP2MK:6Y;[(/@?\4(^M^H[Z^ MSIAZ\-E__I^]:VUN&U>RW[=J_P/+FZUKU\HRWR*S,U/EL9U=TM2N. M!#%[`1')%/3XX(.6,7?X`*K81F!HE\``^/?PF#(-R$",(<2M."7P`L2YH:,T M$-VX+0WI[<)B3@<)-J&Y!G0*1A]"&A3SE,/U98Z$^0@!QN2>OU3ZE(H?89^! MT-DGF1)IM&1,ZVO%9SM*G/;_@G0'Y1[0*"'0/_HPH%.>(W64"9GG5<I9.<1*0L`X6`*SM"&L>#!!]\;,^#>G0YT+PH@"_8*JQ M1,U5\+GH`E9R2P,U*Y^*//6RX%""/?V=>B-D1S"V_OW*:9HVPRM*]O3FWS\O M1,U],$#^V"<64:A(N7@`KAB.J'+CQ]]YG_-]O\>G2@PE^!4LZ)W`##*W1F1` MNAFF?"<0B4).$U"/(4V6B"58]#!KB0P!H'U^FPL@%0`IB\'LT6>X`$ME:2Y5 MA.6[RI_@.I1^Q]*@42##7(;5TM`'CKR(9N@V$4M'8X6!@^2_3#.A!'U24!J^ M?0GKPQ<@$3@Q7E$/4'(,WAX!Y9X7'<5J(YIA$LBQ7&K`XLR2EC_G=]\_\2PH M!3!39*GX--C../#@R=$@@114)@`\$.ZUB+(B.#C7#1_`MDKQS%\ M!W$KC#,E^2'4R,'-8T%`(LX3KP6J!75)3"?C"`/&F&L M`1065B"8+-:YHL\G]33.H((AYQW"\/*D;D5SW,`AZ'%K_V":72>/C$*J)]N! M``GC[T-9DA`':9X%M-^[_P>!`7KIB>8F!,)T.@'< M"$?`J5#E`%,*9IK*;.P#=8&H3B):=&^8)M#$JGX&)!XKPX#-8F'2(`4,%;KC M![UK%M%_T;ZXA4#<^`CU@LBZ:CB[!:L7`,R_4LB^A_-U,^W[B_*7(?(8\+8; M-'^$^.,EC+]*<3I!E#GN`Y*+$2J\M:,$#-R)6U0I(40[*9&>O`:.UAR0EA!; MU,?KP-I*AHT98'E.C^%\5.3SS:>\KCZ)_?A_E3&;X>P&A_8`5WPX&G!/2]:! M))AR]BTT(N2NMAI@+H6-`J3Z#]0KM==5/D5L(OP#Q,=_.WC[V*.X#$UR#IEY M">(9`"*F)'G$9&D"C%S4P5VB#R"!FA,ZAY:>A(3`_TXKVHYG9+HC\WOWS@2V MR17/\[AM]`YEJA@LECT>1!6+\8C1//`[7A[G[N@$,X!D,,XGW[+8@^X`II5- M"%8>V2)P+9O!DUW`(.1V]1UCD.AU*0Z+)!A"3MEK.$G8R^1CF]D-B)`305I( M'WQ.B,J$].50,NB-<"*XXA3'3`8$($_/JJE=BY2 M;+LR\A\;/=LSWS^_HTFY'Z!;2>;Q'Y\?^UBM6B- MYB!THE'`!W9;[RH=\!#!I?LL//J+\.C=-GURY4VHYP/W#EGX`MM?FMOF6\N^ MZA?UN->6\?6VI^^1^]R-(TJ5WR#E&,?*!4[2;NE";]=3MMYHN#K>F\S^I<>8 M?_#'Z0-U7UKF??/>O9='M/;8^GXC45?17;&V^>:M;Z?84G/0>,G0\.2Z MG!\JGX@?*7^0(*5\A8XJ-]DJ2CSVIV_^PKO=1=C"4_?M?+$M/6+WO@&0 M['8#H+QYZ\E#D?6?>90_H"OMYSGV$-Z4K:D+2AO5X^DY1_'Y?H6N$=[;_'[E5S"[FN)TWV%=(9K>TF^QXSG&W6 M`,_PP,FG@,WV<0E0DM0WKBMI0]*&Y*+%-AD,/T5R%U$2I]&\6^O+#H?1G$]H>GRFC6IC%[PX9TJ%DM4I(,:QO#6D#BV!_Z$-B&>!T0A#:\ MPN,U$32X@2$.2,4(N($C_EOXM`\5>&I+>=A7M%">VNFKJ/823M[;J(.\) M?"^7KK7^SC5Y3:"TV&6+5=^DR;Z7!&N;^P*_T@0^NJ=Q@A_)2P/W@+CNFZZD M#4D;DF#^0^OD\DQ=NX3:-^>3-B1M2`*X7!+?;Q=OUTUO;;KG3:YOO#GS.6S3 MNL8/GXZ0RQGUK(ZOA(MW=)V@7'EY-_/8CM3-8RWJ3)OI=D[\FE MEZ\L4I%C>;V(9&8MTY6T(6E# M\DC@^TH"Y$+T>UG5.W3N9MAW(%NO5";[N1S'K-Y.;%;?6]9#Q?67@L M3_ZUP&4E497)3IN$VC<;>B^`_F-KT6,6019"HXG29U'$9GXXDH#>'J'VS1FE M#4D;DH#^KJ:EWJ&+MVMQ45YU*.UGO^U'1@1YV*^>PW[O$(Q:RE<-><"]16/V MA@U)>]7K"65\>^TIK("%(S&#Y=%^(N>N6B/4OLT[2!N2-B217,Y=21>7DQ"2 M[DM#:D6,>&S?ESE]4#R6]@/ZWF)):W\`ZHEQ:N\FW9>3L;B<:MS/K M&]`@B*=DX(>CGP_4`]RBY=&(ORQ&"X<+RTV)YV7ERLRAT%,>RJHC]^?E^=W? M/RJ&77(X_;^?(`4_.,H_Q`J6DKE'PFTFN^N\DO#KN4EAH&O)ZK9$PCY=`/!VQ"CTX\ZJ4#OL'Z^#BD27>9[."/D3VW*6AG&M$Q M#6/<_2W:/3FD#U/XA!Y5UN&(TBR$Q>TVF5 M8WY8(PTC"L]A*H3]C$\.L9LT/E)`G*?ZN>3WVZL&,`K^*0Z)K-&/0D(/#\SC MW^7U&URU@?^5[SC$Y\&QRJVT0+_'QV>YS$E$PECT3B'>7ZGH]S),OR@X5M/Q MM1Z+S_2CDT4%6U>WY)=WW"^_@E_>U)#=HXGY(5C%)%-GGZ7"?8?$YUB:4O1; MECYMBAUN9?BL/P$,3]#B\;DS%GHXA!Z^XB?AN*7]F@6U6PQJ\'!,Z0\;T%>6 M4,4Z[:X_2/51N:4!6"XTNOC^%+PR$8[QQ2=]/_`3G\:56']&HX2CU8H&RBY( M(KQ\XIY&T$!_#BX4,V@"FQO`1WYR'*=3]!B%C")*Q3/)F("G$J@I*Q/Y\?=C M[K3X'`@`+HC>/*0D20%6,R>%+Q,&S@T,A7*9.!>@T91$*/_?%/`7%L,#6`R_ MQWI1?H\.21I@K3@N)`-O-J->5[F#,2,C$&X$K5=&'L8SIIMZSGN!W0<=$27( M]#@'?(C]'"`^&):A3/P@@/<=#D*SL3\8*S,J^@]E19<#['L$0P.M?M`<)W\( M*T>K"M%*`^QP%'/1^FD,1H%!Y(X+6:@JPR3^5$3_F?H1USJJ9$I@@(`XH'2\ MLJ+5K!5ZCR6A=@+IWBP<1<3CW1/C#V`9$50B-'K)E1-A-V#<*0V7'H&V^A3# M%0F5T^PAM(Y;'D'Q[S4&0=XD2`CZQG87Y7YCS)O_+#X MG4XC/U#,CJ*KFMI!7IXQ^TGE8H&'I;4D1F.,N& M)8RD5(IX]^B^&/4'%,0''!6>`"P`;/UY`>%V<3`F8`#VF[%];[#Z_.+LZN;T M[O(*TNT4`#,2"MH6Q[O*&<<1Y0;\O1T]>EKJJQ"MDH4CQHV>Q'[,;3FB]SZ( M@+XAT'$&YC#FOBYLM6R9N;WFU*:X#PBAW<>"X#_H6+2,O_BEQP!3$D1,"`Y8 M#>`&5$04!%I_Z`\(6"[2-_$KU("+`0(K8D,X7R/%E$882<7P<>D7#7+_@8?1 M0T*VU`*`_8#BU46A0W$K@]Z5U/Z&19X`/N\NP2^#H)CJ(]&XL>X.\K8'XV#.5U5]!"K+V`,,=N!U2]-)Q:O; M9U.$7]?6NX$UE`Y>`Y:=(_BCV5P`L$*,NZ5@+)PT+',&C'`0"'RHR.^G>>*# M8[?@Z'%W+S'L:8^_#!5@-1A`.EGP!(80LJ4HC0HL!1INC`,@^9`.1.!'?P?. M`B;9>3HU0E^C#S!,:*W"*2<$R$:$&1./LR5`X"ZT7(^?\.$K^$6I-!(T)(;3 MB-W[,?=;SH7X>XC^PRRTYX2HTB=@(1EE]BBD-U[&R@+H6,"])V=Q'1&*,SP0 MY"!GVR5C>^"@) MRA.._[FK?$X)).X)I>WHSU9@)5Q'^,V?7+F7+(7QYU,$:.P4;GD$=A M9A:G_=CW?!+-T4*NA_Z_`&LNPT%7.11OX!'*&0EG)HP[QQU\,E9.`0\\#G^' ME0^.E*R@YKJN2L)`KY1!"X,1(;Z,R,XG+5,2=%X-,X3PZ.<@/IZ`/'I6O(]?V) M'W:5:\C24B*2KC7=[.3J6=('YBA%!^#]*#<9(12D0POWQ^\GY#N@1):DYZ!: MXE]K%0.D!9N"AP&2TDF6"XNLLVL51.BPL-X@5`2+2!%N%_\2\ M@*U@LP@+$$ERJ,AE7T#&FE[$*>3$>1=$@U7+R(%_(0@"(!C=7QE_+;#V7D`Y MOO\]]'&X;Q,8]1C,!VD)E#X#Y$V*,'7!PV*X^!K-EX9A/`\@R_,);YKWND]Q M6JXT%3@$^^>`*7J0-_^:!&?7US^=3(?T8T'R2AP/^CL(>*"]`P#X%87YY3__ M0U%^2N/C$2'3C]<1&U#JQ9^`A%S&:-`#>C7\`@-Y!^-X+B9/!Q#9@OCG@V/[ M@$^WYP>_Z"K_\]/)]LT)\0!Z MOW\<,I9`_D*_P!OE@7^4S*>@76@?3(9Z!]FG$4.=CY-D^O'D9#:;=1_Z4=!E MT>@$!#!.\.L3+'C`*\^K!V4LU0KO2<*BO-)QA-WX+]_[ELOQC8*K?3-4R]0< MT\K+!:1/`]`%BY.KX6?&O/@T]+*IC/B6!=XWW=%ZCFOV#DZ6VL^K71("SJ\0`:'[W(O0G<2D]^6B%C$C M^7'3%]V?3I;TLE99I]'RH)%HD.L"7CZACJS$R1`8V'%)+:(%,,GMAC$7@*T; MEVQ!3^NJE>'^07.S3;MG6D[%'FZ`KD-OQB#C.7)J-D5WOQ!+"7Q4D=:=#L04 MV67(_2Z.L7??=,MV>YIN;S#'U];PBXA>ZQ#HEMFS3%>KC,$MA3@:CCZ+=`^Z M<^I!4,0`P[E^UJ-OFNT8/<-T&U+WKE+6JEE-[6F.IIO;8VE/U2S-,!I2YA:" MU:J_GFY9NE$-15L.N:ZKKML8#.PH9+UJ=5S'=*M6^1S@LFW7M*VW"+FYY+4. M@*&ZO9[6ZU5Q@<38!_SGHEA2BD^3,Q)%<^C!'SCK`E(Y/3":EV!;FF:ZNED8 MPC/9UN\A`45#LM(.IK.3,M<-?Z&=%P\+AJ[UW$6K.:[A+!;F"8MY:T@]#-71 M#:W:1#9,HPT MSZ/%NV*`\TH:XL<_)FRM>@9$,9U>U1B%9%?#LI@$GW'M]S)?'\%I-+YC M*:7>U92*E6P(4Z9E.V93K.Y9(M=KVH:JV;:]5N6%,6BJYKBJV:@R5X2I5TT. M!#QK$?`R/>6SHR6&`?ZT0/@8,V:E6I)&0XX!/)_!H( M>@*B(@/F21$*JKFVH9E-6>)6HM4B.V_Y2.O!3B MJCVSYQA-Q=0=!*Q7GX9N6J5<9^.\0TGB/'AEA4K?+*IKRPS$CF+7JGO'="&T M5.AIXB1]2[U<:PHOD&@^FLA#SSM)XET0W5$VS7;TI%OBCTM;+%FW=<'I6U4(Y M[%RS.(EHDAT#J'1G8S\`(FRKL4G&%Q"\9DNW+=?NK;+U=?&@)*QNZ+;A-!6U MMA:O5EWV3-URU)5IV\$@2G&7`.Z3Y;2PG+RJJNMJ>E,L=3O9ZC5(US(<=64S M"?>K]6.M@=I=M=<4S&XC6;V0:O2,GFI7U[7+[$VW#,-U]*;VV*T5I5X=6::A MN[VJE5U'&;#<)FSP7>SH*(HV-;W]B$@U3^Q8P(K6;.2>3%A8ELZTX4]C$7BS M//4&`\>U-;6ZCG):'+B_)C[@[AF9XK&S;SA/IS>W,OJ$5#4S$LVR5U<_85AQ M^QU?EH6\-&-3\5V4QGQE7.VI;E,A8#O9ZI[U,7OZ"J^^H7@RBGH7A)_DBH$` MI).43[`@31WX(*]CJX[9&+7;1<)ZX4]U#5/3JF'U+J(D3J-Y"7#`[7%#7E.) M]&,2U:LQO>Q2^9HG046_L!C7'J^&P$EQ2=KA2RV-<>0?$[=F MTN<8H.OJ^BBW@3$+H+%87%/`17"UQK:Q;Q:H9GQT;$M;T==O?L@B$.HRNR8$ M;-@T'<=H*D';+$^],5F#`;)6]I>O#F:QG>I:'(P_3<2E%[@,G\->XG*':6H,4?7OY:M4EX(&CKFR[ MW6[?OVZ;/7.S1I?$>>H4A0%]=S2W&-5G'J-87+!1<'#-_ M.P!=H]1[-7SC:N/=:`V\<=O:D]VH_+5*_:',UP3*L:/QX_ MSJ!9F@XY3"N/6N2RU:M%0U55T]%6-WIMP7<=M*OX\1^*Z@[KC_+NZ<\F-)`;!\)'&8#`XFB/,,2:+VG8BJ&Q:ZI;2^HMV`05\1,B-E3T>!QI>XAZXQ;N4X!`N7:BZKM(9DF&, MX)>T"<9+$H.=JC*#TIP7[2,-B,05LR+Y.6W!9@1II;MB]S*5#R8)M&>9S.L( M-@\2:H>YV7D*]ABM1B#-NG>O:0R.&F1/`52_`[M8ONKG8!?SU4=EZ]`$$>9L M_9UXP,:M4LNZT6<5T1EZ+P5=@^H!=Z#:\XK9:TJB$ST295?UWV(<>&SS2%_V ML*4JV'18X-,FL8_#-9:+O_[_.XDTK_'@*HI"WLJ1:QICK4I44=V4R!H\(I8[ M2-JB@CU%L1:3@E)YSF6.81&1JEGUF[/J@N-%[\!^SI[5R4'>Q. M1<;@XQR)-B"(BHS-[K=[H1F+JN`4$%O'3^G^-@6DQ,`]K>ZP+2@XR%A"6F2N M;EW$0V!42&H:I_:LVF"76JM4P#D%_P(4@IVYV''_>3C+HCSX)R@$'<0_!1T0 M(X!=M$A6BG!>7[2SM<2XD>M&[($C6JAE]FT/E06[7]%><+;@'C92"[/FWO,' MRJ*+/EJ4W4CX0QK'@@!Y\.J:E&#'UX";Y]+7^!$8$_::1IWM2HH^6;TU=#L$ M9X3$#N!8<9R526[KB3YB:'FDPZ+W\0>+6LAIZPW.2`LVHI(V[FZAX@:#@\`* M]K!X,S1HD14<2WG4G.9YUQ7B@:H"I`VX[@@*+C,T2\+)E6U/0#8FAWK)"A$7 M!,87'WIS39:KD$@%,5.D[0=[4FVPHV2+S>68.;!'(\`F]\$'%D&Q]F*EVMT< MHR-(``LBI742MO4$>T9MG4%GS_A=,`@26&YQGS/YM:L(_FFJN=CJ"I:'U$BK MXU].9:6:I^4%>X7"`J[Z<*HG^O&G-V[;3E=WDA.:*)<_]L8^__UK:/SW,E[M M[1M02P,$%`````@`J86M/)X6*^31"@``B98``!0`'`!P9F4M,C`Q,#`T,#1? M8V%L+GAM;%54"0`#WF3L2]YD[$MU>`L``00E#@``!#D!``#=76USXC@2_GY5 M]Q\X]C,AF9>[S=1DMLC;%%7)DDJ8N_MVI=@-Z$9(G"03V%]_DC&$$-F699#% M5FU-%I#D[GZZ6ZU6R_KZVV)*6G/@`C-ZT3X[.6VW@$8LQG1\T?XQO.W\VO[M MV]>_=3JM[T"!(PEQZWG9NDP$IB!$ZU^80ZO3^?:58/KSB_[G&0EHJ5&I2#]> MM"=2SKYTNR\O+R>+9TY.&!]W/YR>?NRN6[>SYHMW[5\^IJW/SL_/N^FOFZ8" MFQJJ8<^Z_[Z_>XHF,$4=3(5$--(/$/B+2+^\8Q&2*;.E=+5R6^A/G76SCOZJ M<_:A\_'L9"'B]K>__J75:JT$PAF!1QBU]-\?C_TW#YV-\!_`3R(V58.>G79. M/ZG_NKIE]TDJ04^!RL&HK]"8:@[2\28<1A?MV4@_].ST]-/I)_W(7R)&8Z`" MXBM&!2,XUCAM!A&[H\CE#"[:`D]G!-K=_=)[BZD2.4;D@0FL!7U%D!!XA"%V M8>(2$8W@TP1`"A_T7R$QN27L1?1IK'0[DO5$SUX'+*<^0B1*2*J>=^ISUEY3 MN$]&5L^'A01%^5I=-S00%KUA.'NN1`M&V12#6)E"(KJ)Z(P1FFF+..\"D9MO MM$&<=T[/,H/X)?OZ/S>CD2)C,+I91!-$Q_"H:!U036>/QOK/S?\2/$=$RVU- M+$'/0"[:Y)DX=5_Q2K3-,[X6M@]>S60]`,/1.[=ZZP*Q%5R33:3IJ!RO-6_@ MD7:501@X]^D`99T7? M",L[)DPXOO\QS!G6P7>R8@X]HW`-,Q6?XI1']?\$4A'2N#=E7.(_TN\-^%3I M%N:,Z8Y<==X]8_HT01PN4;HNFL[4`BD/Q>*&8:LYHY=);:]N]`1<*X9T7F>(5K<++1VP2504"[> MZ#VM>KB`^#E@$"NQ[1G$7OS?1,@T;?0[HY%BL*^X%T/V")'ZC`DHOE>$ZSE[ MR"QE,)`3X`85\/(\%P7Z>\`*Y%%H_H/A""`6MTI*?2$2G7<=C.X8'0^!3Z_A MV>1&[#L=U51>M%!A;IS[1A,M4R4=LEZD5F\<%+U*Z^3R@2`JU1RFUW3I#&9" MM7+GVDNCCD]XB_(-K)X(FH;Y::)6`%H#5SQ.H_X M3Y#HF<`31`G/2SY5ZE<[0@\>UW+NO:^V9AF-I5-K6=/C0L]B1K5CN"%#'(P& M/%8\\.4UUHS1N,C\"EK7#HA#@\V:YX:0NV5\.U9+`VV['1O'$5P0_O48W*J3 M'&Q0?U=5H;YXXPXV\[/V!_=(*E=.QWUZSS@,)X@.U3!PSZB<",7E8&31=:O+ M@-_E);H:H<`MW/HMZD^(@(KY5P^5R]?YR38LJSN6VV3_N9G5 MLXU+V8]`3.!:&,@Q"6.C]?N)94M5?9W+V#6XU!RW&^[)R7I_]E'MXCHFHCP( ML,'LY%8\DL8@=G49CB/4CN8"5I?*8O`,^FZ9R5;F_`K-L$3$@+-]I^,*U"TV M)ZJR?IC8R&K&L@V.*DQ_.T!^[>[">*<^'ZS>VJ+PO;'*ZYX0(,55PKDYWV_\ MO;':Z14UN62&/8_OT,A*!>S9I:YCZZU$M[*W1X@`S[5QZ6670?15NH59;&4& MICI?_N,>\[:3&2>;YF'NQ)KQL>?',R[?&8M?,#$%(+L_A5D(99:WF7;O89]$ M=(R5^:V(5%C?+"*2Z%.)!7*OTBW,NB8S)M7Y\HR7N5*\IZ)8SI>*R'\BDMB? MWV]Z*()8J(U[A#KP'SPW6+YB%/ M\CFPV+/E^S@0DZ##PCN&Z!9UWSD3!8NJ"KU"CA!RP*K,G?<88JY(8'QICI-- M/X<<$^2@D,^&;P^64CD876,Q8P(1I0?)K$^S*$5]&S$J,4T@SC)2QL,@-49Q M`>\?#?N[NMSZ#A8DBWY.&%&R$SJ>D!VXL;W6'T3,F:6)2.<;W3)G2*I9=P@Q^K:EGA\.Y<1NP MTN>P<=PS+KEH-XK6*<76R:AYD(L#(62]Z\G[>0"%.(;Q"G:M83 MO2A*IEJ&$%\K$B/CV6C[3F&>;BW'JRJ'_O.A:W+2NB2M7APF2L/P'%X/UZ95 M;4.T,*=(748(,XM@X1[KL.N[`N%UU5B\(@X[@JBZ^,UEK#GQY^>N\QN%&5&; MA/M>[B'DI;"M/UB8X7P!U/MBV;\EI]D2 M%=I4L%VK+F%N"A9;:P7&FK#/2O:W=W`.'ZZ7V5=XL.A).3\8-/P:?!28L^6: MRTI#!3\/:*F3\^6E/N:&P4>!)94^15SY-H'U.PO>TJ26=L732(5NP0=^>493 MF4?/V*FI#LI-J:!5\'%:#C*E+'D&XF8Z(VP)\`AI*LHJU6#=)_A(+`>DB@SZ MMAU]4##AR\*]O?Q&M4$YS!'*\G1<&4O^`P*>;+V6M"0TMFGNMC=QZ+T_&F@E[LJ6;] ML`\*4P$,&#-_TFA4DXRG,8H*4%RZAYG.LT6]"H_!>85+&#$.6TN/W3IH-3&_ M'66UK+P'.='7816=GFW@Z6'ZCP-["6M?="!Q^SZ*@@B(1YB#,CCS(<><%L>J M'/N'C5G(R7M1L5`.4[_6(2TK`S['$8@G1F(#P.6-`WUU?X-@V\K,MS5#ZM16 MMZP3?95;/,44"ZGE,8?LFB*3D5?J6'L/ZD^G#R[R\U[$;KIY+*-L\RJ8[,J# M>',CF=9T@\+L8;1`KQYH4(OV)E3?^PY;%T;JW,[;-PV9=AZL.@2Z+=2@@E21 M6Q#NI:$;(#U<=1&;?\RKP\)V@;X:N4$L+<352%;+YK+7`USR M&L0B<7_IHK!N@GVST^*X0>$\1J#:4+C[5)/9X-+1#\`ODE^X4TK9.$)C MNZ#K<\:*JO45Z#@R%0,6M0LS;UE,LG5.N@"O$+7S&I-$Q2VU]-,T1C`:FA%G MH:,[+8]#2W>)KJ*G^;@%O$5;S:,ZC!7FYJV#=W+F/6ST*WDLI]&.0P.L++\& M_S:5:=D/^I]G)$!]\W]02P,$%`````@`J86M/#^G,[,)$```)_T``!0`'`!P M9F4M,C`Q,#`T,#1?9&5F+GAM;%54"0`#WF3L2]YD[$MU>`L``00E#@``!#D! M``#M76USX[81_MZ9_@?5_:R3G;NTN9LX&9U?,I[89X_M).VG#$2N)#84H0*D M;>77%R!I2;8!$``I<&^JF9NS+2W`??;!`MC%"[__\6F1#AZ`\81FQP='[PX/ M!I!%-$ZRV?'!+_?GP^\.?OSA^[\-AX.?(`-&/GG\<$\SY>?1J/'Q\=W3Q.6OJ-L-OKF\/#]Z%GZ MH!:7W\;YNL"V\+>CZLNUZ)NJ']^7LD7-")Y:9=&"`.MA/QK^"PVE!\-C[X9OC]Z]\3C@Q_^ M^I?!8%#9CM$4;F$ZD#]_N;UX\=#E-/D3V+N(+D2E1X?#PP_BWTA*CNYRPD+X_#REC_PBBP4MD;166?6\1S6+(.,0G M-.,T36+)[KH^3C<5/E>4KY9P?,"3Q3*%@U&WVI\GF2`@(>D-Y8DT^TE*.$^F M"<0^.#Z35/)Y-P?(@^A_(=QF`>U,_KJ6SO4]R_(D7UUD4\H69=MNT!=T\GK- M"(N>E:M_W=9O[1Q)EH_B9#&J948D35_JHO&HYYY`NM*WI8Y;)3O7*J8+DF3# M!2PFP#SU4];1O::):$&R%Q]6S_-55E--Y_K.184L*B8P7#_24V5#39W[SRF- M"NFI]AX4ZTOLL@W`E!1IWKX1O*Q'K[$03+*RV[X4?];B4BG#X%GJ7`_56]7# M4PZBEWP>'=>/2&FD@I.3)YK110*\JK[@HX(/9X0LY5,^CC(!H_PKAD1"_#@\ M/*K'W[^+CWZONL33%ZT])1-(CP_22:K\NM(SE=,#RI[ML&L]+V%&TDJ;\5/" M%:IJ),S:;H@;LVA`60RLG@<^;3?%%HUORNC"K"!M,K5XQKJYC13MS;TE^OEX M+PUT1\3O2%N%]>[))`6%VDVB@1JN8?S8--U&7:D%%5O-^*OKU7;13[QX?+?= M1%O[0IJO/WEMW_KCWV\($RWBA"Z6)%M=O9C>;9G:(!7*XJH)Z,;<2GM22^4# M-FF%"XH>'BY$[*3J%&W$O0DH)TR?HI2*4.[X(&<%;#ZD62Y&B+.T#.G$;`EF M\A=GUK;"&F,W]!84=>E>>R#P7CS80-CVUS@\Q,?J;U$$M/18:!!++QP-W0"G!Q+.$QZ1]-]` MV+GXQ#0N:"0]B/B`@P@CH-ZHJ)J''1D*60\ZOL5$AQ92'Z/!*?"()(*[PV^0 MIC]G]#&[`\)I!O$%YX5RW+:2QY%?<'4/*U#!J?F5ID66$[8Z3U)@^D%=(X)Z#UGE.F' M<*64!PO_[)\%`Y3@QK\I)FD2G:>4Y%K3*V0\#/]=_X;7`@EN]DLQAQ;^9\X3 MJ:7098LT:J+,&3VKVAQ=:R6_TM!:CX=:-KGP`S9=+&AVE]/HC[LY8<"OBUP> M?9`G/O3#MD4A3)&W)2_VL(*N%6@/%>S7"JRRK&O[Z08"M0"F,4"C(EO+4(A]/Y"I%I+)ZDRB.98%F\]OAZ(&'Z^E/E,92M3M@ M#TD$_(ZFL88)LS`.5VBT-'7#$[HC@E14/*N.Q:="LW&\$':3&/+D`6I4JO[) MJ2`.O['ER@=;8-YN@8-XY%PH=RIZV90N97]0:W;V%*6%#/_&T7^+A$%\D=TP M*IH;EQ90D-E!;3C6Z6P9[@QP8-K'"YF=_[/,:,JX6H3YLT1,9L:<;UT0\&([ MI$T!',MYMN2Y8$+AENOV8^UZ;TK@6.5KYUX:4#84O3F0+CZ03Q'A19073/CJ MR9RP&4CE2J^M+M^XA51>35&JK;:]1P4XUO<BEO0!*&XY]A2AE4)JI^H$$2Q_3$EM@&&.AZ`2%137=OY+1*6#'/63(I#M_F03CF/UWX=GLK]-J"3A,>5:@@WH`28]WU5#3\QG9A M5QS'%,N5;1=LH==?&!4=D514M>SRYDL<4Z]F^^LT#VQ=0?&F)7AVG]YUX-AO MUU<^$YY$AO49*WF?A8'#/GAP M0(-NUBAT+M4M%?>:#BIKP+&H8T>,]93/@!3Q7,Z-88^Z<"P*M>#:&S.&7M:V M=\6577%BRP)/STR<)FF10^PPXFE*^/2;O6P,<<*#<=2K%6XU[JGJP#GRZ>AQ M&?OT:'&/?DY,>]6&'[#`3O$;)+.Y;#8/PG5G\*60:*^G;PZ2Z*:,7N5Q#G6- M_-#6D'&0N]TC-QR<\JP!Y[C6DF`[T,'WU*X/?YTF#TD,6;S&*U]\Y: M^V(^WMK+NKH[J"VR@AZ(LWA+T/Z4W/Z4W/Z4W/Z4G&*Y=G]*;G]*[O_BE%RU MH=L0.ZH%<'A!LZ5-VH>>1HKIT3B+Y0^YD_"!I'+WX#@_(8RMQ!SW5Y(6RMO; M7,KAX$5C=>H-*'2/-:V,.^_-8GA",_,1#3K'[HSBB):""5N(0+1+D3? M^`7R^M8L5==D(8XCD6CFP1Y'Z!TZ-"]/,EQ2DFUI]Q.CG.MI<2B%8]>QF1UG M.,%77!Z$"I2MU.<_5%_CV.EK-KM>;^\,>LW6*4Q!_!+?DZ=:A2PN\U;57_J& M[54>QS[;AA'9'U@OTU69*.1+RDDJO+!8KK=[*Q?*M'-:KUIP;-MM&$_:PNN% M5,,XWY%?[6!/K@T1&/SFDF:S5S,]X=R;T8RK!P^78CAVYIH)<<<3_A"!<,E\ M=9.23)Y`DP%2>;!7S8^-.)*MNF9B[($$)D3>)O*8;-(\6\9__162_6%F0ZN5 M#CYE?7F?@"!Y?2&$P>`NQ9!L86B:X[H"\I[[?J&9W2Q/'A0QA';>M2!9XFR* M]5KBZV7FI)TRM;%]\#@;P=4BEPF9)&GY?AMY@91_#6ERUZ(X M\H/-"70_7(%Y.X6)(4VH^!9'FMS9MK0!4$_IVANRDI/GYD2M6A"'*_B288,M MM#NL=^:\T$G`,@[N+L5PI-6]'<@9:6`&RPM)&MW*((4CL>[+3R.PT-O:%\N4 MK@#J:YRV8.G)L2Z#(QGO2Y4CS`YS]R\U+N?FM=#6-U99?*>:<.3S?>GJ!'Q_ MLW*]NW7J7SO(V/L2UH5#[2"/+*>@QLF$61!'\MZ;$PMLP2,@83*(Z]NP;JK- MFC*9NH71//GSJ@!'SM\_CO+'')C?LE^^H0('Y`F#ZG7U+[1WX+I]94C6%'R) M[\H`X9U<,6HWN;55$21K%RT\V0%F^#0)*R#>NFK22)F-.)+5C18Y$TN(?72S M3MUHYUZ%*$UB"["_>,`<""!;_N@@!.AY;T+=RY:JZ[:K&Z1\>$"4ZFA$%OI` MP>8LIO;L@$;$APE,60PCK-##>QR7MB*I//QZD9V099(3U?Z%!DD?4A!E*JS0 MA7<1>4MTN<51@*EG]_R>%OW>BV8A_*$64C=F$,9-L\S5DE8Q$?7/`>4H?^446)PQ>;S[=7^BTO]!I?Z'3_D*G_85.N^X_+O<7.C5W MF*%3GLK;=6Z`)?*MA9',,\$I5#\-YUG:5(/#HRPNLVR-,3"W\EH8>OQY]0N7J^CU*7[Y,NT\>:AF;WIF_2O!P6LKUF@W-@B^\KKK5\OM@*<6-N[@ MU7/*3>3C^#]%?>S_GMZ"BI+QL:9/=JUX+.TY+ZPD;Z0)844$GWHA%)1R' ML-JW&5SV#+Y!<"G"X:1$)7Y/H5[E&R]D9N9/W74X+L5P]"UH6*:^%@P]9:_? MS23?0;]9`%9-VXV".'H);.S;V"SX`BX'\4@Y43J%!TAI>9G*12901J"<1EB6 MP''P$UL+<#)>3[O&[5\5;UD"QQE3;$W!R7C!MZJM;24M(("6<;'.;O?4TA;E M!&_#K&WU)3O_72OA".\[W8FI.K_=`FQEHEQ'!- M@MJSZHL`(>G:8]K2V0?"EO57=`XXC`9F!]I9(Y8J?:V$< MJ8T6'-%VR/MFU_*M"T[E$?8'E'N\[B"27ZH'U_:5H1YL72CLR!)]NZDM\2[E<*02=N"FW=#I M[J;/5Y1TX:4V=>$(PG?LI/:&Z,E'SRG;!E#&Z@KP!F]UK`%'L-R=WWK!1QL- MM8J"6E"\@T.I[2GV18Z#W?IMMNUB78M*<$RV=ACK6MN@DW'Y@O-"/`[XU@RO MO#5,GB';%KR%9=T%O9*L1A^9S;L7SX0KFN5S?LTNU8MXP9^-.F:VX5HQ[@S:= M0B2F:&=/D9BXS>"6Y'"=J<-9!;\^Q7&,I5U$[/[H$1^Q4[#L4QS'&-P%R_[H M4;`\%OT08RO1Y6CO7'0IAR.<]3TJ:005^H1#L5Q6IW])^GQ!Q$4VI6Q1W76G MSY8ZEL01;EJ<2?:!Y9V0:GA:.7B3)#XM$Q25MXLIFC\KEA7BR$^Z4F''H),) MPF_2?;[:6ZJH?GNQ7NBKH,W6_M0.;7"&JNW!4AK/Y7\3,5T1G_P/4$L#!!0````(`*F%K3Q7N:*1RS```&'N`0`4`!P`<&9E M+3(P,3`P-#`T7VQA8BYX;6Q55`D``]YD[$O>9.Q+=7@+``$$)0X```0Y`0`` M[)U;;^0VEL??%YCOH/4^3`=HMT51UVPZ`\?N#HSQM(VV,YE%L`ATH6RA56*- MI/(EGWY)2JJ;2195+IH*L"^)VZ:DO\B?#LG#P\,?_O8T*ZT'5#<%KCX>@0_V MD86J%&=%=??QZ)?;S\?AT=]^_.$_CX^MGU&%ZKA%F94\6S\MFJ)"36/]6M3( M.C[^\8>RJ+Y]3_^3Q`VRR%VKAOWSX]%]V\Z_/SEY?'S\\)34Y0=+YO@NCN<`^&B.`7K>IH$8-7M1I MQQ-Y!D485<>_W!S]>([3Q0Q5K751Y;B>,0*LW\@[(^NB1;/F?W\X60G;?@&< M\MJBC9]PA6<%:CYLMR91&9U4N.K^E:&"-DUT;(.A:I@<3CVI M%.^JH:2$XWIHX\V&.*U3"]<9JON/O;LPKM,===Z7.$DQ^9[F[?%&]>1A??8_1[R!.`4PC$4Y.:'NN&\`WX(F6-,?.+7FZA)7U/T^'C0U5 M6-)LBC`DP,F21,0"`#X`7A#I8^&4O%3&8,C+^.[M85@^_S-Y/*<:N'\WCP-? M%I8TG:IQ",(TSEVA<7#]"+J1\P;&88[J`F=D0)59&>F*S=F):R;D4Y6=$QD2 M@\$M9QX5N3PL:5Q%9.(\#5+AZ(1`2$:@[IN8D`PU:5W,:<=IT)*%%2V<\=/;V]O1TNLZ8K!NJZH:)NEIIXM29^D7FR1JA%4N(4.4,!#ET8Z%1 M"J'KAXZOG;/+HFG)JS6&ITN=FD&,;*:TH^14.!(+Q))F5H0G!#&,`A$[H1OY MMJ-Q>K2%SGLR[6[:NAL4_7;Z5)@':"6(RME)$;_XU%`2J,3BIE>U12ER?4\X MI(:V$WD^U&B+UODYQ[.XJ`P0M!+12>!4AZB(>5*$RK"D(97QR!$,A.8&VJX- M8*1Q_/RBJ[J-DQ(9-S),Q4[;LE'*/"@R<5C2JHJLY#"V?2A"!7B1[T,[T([* M;[?HJ;5^(A7]S1@F5`)3($3D18FIX/%2&):THJH9LTN M/!%RY!JQN,65EXM\)XB%XQ,G\(FY&?`'=SJ^+F5\ M(2J$X/"+3049@3HL:5=%6C(GR'-?:'-@$'D0A/K]>V2H7L=$596A)^L;>C;F MT>N$7%`=?T?/8B<>O]Q4@!')PY+&520F31,8>F)B7.!!G>.6LT5=L_7'HDD) M,<\HK@TN.O5J/C,Q_T.TB->==A4US\Y.A5C2TJK=DP.`&XB7G\+(]8#.Y:?> MXCRBLK2^5?BQLAH4-[A"F54TS0+5IDS/KT31WZF@FU[/!9,C-$$[RIO'24TF MEK2^\B(X]$"0"H<\+H1N`/2O'CS@-V88RA%"Z2<(;&W:VS`:0=(`:@[5Z4.:+I"Q2*R]QW)K" MY)II^$PE""'AE)D*(CQI6-*6JH2X*822D0P(`@"@1D(NJA3/D$5-).I7L!/J M>4A;#0Y`5+;+WVR3TO_Z]T[04L^@AE-#.TJ:)V>70"QI:55^,IC$D7A<8_MD MRA9H'->L@:-K64&%FJ4,T=H"OX!Y1@2ZL*015=('GA8[&72DK M,FY25,5U@;5%QXPB9%`C"(V1EIL0+UQY6-+"RA;%"V)?.&8A(/I!H#,R;\VB M7.I$4*SJW/1157:1&7 MUC5NBFXUT_!09JGO*E^J&\1)QC5C+IL082IJL1@/Y?U0N1,+8_4`\'T0A1K7 MKS:8.XN;>XO,"1Z;*;%&53%1:HP)BT^*+;%*+&E_57<.A-`7+G&%7A1"G?LM M?XJ;HJ$\79-"Y&WC_:W7/*<[MH%MN[;+^""_^)W=_RI?O[L$#872YLE0$8G% M;:C:O_DH#863*^#9#H0:;$R656-*.RN-H%P2A>%-OY#NAHW-3[T7U0-X-UX>U*&MW ME;KQA*7,$R`3AR5-I!I;8]LY$/MH'"_T@U"CC^9GC+/'HBRMN,JLJ_8>U<0\ MM*1$D93(.FT:=%`C,3SNM,K8PU;/ZAXEH63LI>;1&:T82YI>E:<\\L)!.F-MXKIB>U2N"4EL`ZEUVK9UD2Q:ZMZT6FQU.TR[/][CDE2_*F$;%A/Y M82KQ>X,P]-U0H\6\079GN M7>B;;#;G,@:F6\66@+W_3V"8GHUIYD-"<_-GYGQ5?M^)N^W>KW5V^V,%!ASL7FF]]",)=0I&V;/ M\6412XYO>SHCELYP0Z8<=#J"GN:H:E#SO1G@F!`R=O_4RY#@M:NH>9AV*L22 M1E9$)\J3Q!''^=NN'P)7XVK@5T2FZHM]'1@')&<0(B%&5,0\*4)E6-*8REM! M4I`AH7$!D>^'KJ_9N%!G>A.7E!-@"!`JXRJG_@'Z3=Z@^J%(47-#AML"XR(O M;!X:!8U8TM"J!@;9> M\MXJ5IZDN'-?Q]FLJ-BNZ;9X0,OAHSDSWVOM4LM3-_#IAL*^^KD.O3$7FO\( M1^K%$F)4HX!L+T.A"$,`/#*+#S3&*!+#@8C(>P9>1H9,)9XS=[!YZ@9II!G. M5\+Z-OCTU,__F8FK47917=>8]-4-M7#\?N&U=S//YR%>`DOX4H46.F+3&4`8 MZ-SG<3JC#I\_XB&>I%@M\\5L.NRKO+M)3).9:E=8)XY19U8B(!R8$D, M/4>82-4AH+I:-[:N#9:.AS%M41W/NV_(JD66LA\73\E(+K]\94/XX@KSX*D* MQ1)*5!.+9TZ`Q-$+@-U38WS<)7F?[^GPE0#'1K3QEC.[VG1F%[TSVQ!TDE6* M3:_[X'0?MTHCOX=Y,/>7CB54*:+JNR'@AM]MJ-(^_Y*P>IT7?W1SLP\3P'-7 M34T4JVUD9*VK.FJ+PXQGXX@]S8OVK:E)$)GV$GC*LC_I:WIF;E4QTEJ;#D$< M37A'&RNO#&>AE_'&_)NK>^=%DW8+?"A;K>^19K_*;^,G[7RM/]["R^=;QU:% MF+^<8/&>@-;&Y106?^6U]ZG&K\9+-8^@G0#/WEG9O'7K91!"'X.@ M,A;0_@WT/E$6/)&N@B=67\,4R#]4;;Y9LTWU:SKX^W&_.TWPJ\8")TZ6BT^. M@Q!X6M,+D\[SH:`GKUIDR$*[$'J$3]4/9$Q^3<3F];Z_GU"%2`H3+PA"S]9YS'QGQ4PSCWO8)[&?85C"1W*,=UD`B`^L\AV_2@,-<9T,_L^*>!>5#>3J(Z; M_/K)PK9#]G9P^#H5(S*AVI*#27S;=S5&=+%43EGQ4&2HRLAP+BZR%V,Z4]'B MRR-YSP=]0P=#55\3J9QJ&W.9>>Q&J=W>@+H&ANJL(?#R7)B-Q0L<'^A,QK+3 MV2Q;'=Y`LM^C.U7G-&E"9BA8.^[E=>;>P3RO^PK'8LR4=^@E<@EO/A$[EQ^(A$XT[&Q MW%I2K!%WW?#< M]\+`=C1N]!%DJ;Y%3ZWU$VG!;X:Z@:OZ+J[ZG5:D]AM<%EF78:[*UJ6NY:=? MYA5O5HLS]#W8:W!J6-;)U_1> M6(RH\@$\818ZO-B#,SR;D\$"JIKB`77=SA?*]<%$-_(<`9I)UNA!"H//`N8U4Y<:!&]0\JPTD5(J;!TU) M)9:TNJJELQTO#81[UX$?01#IS`>FEO[<.&1KF<2W$PFH8;??#V7U.C38:>E,MKW+0U:HNZ.W:J#_2WKLD%4X"SESID MN=]4VXM5Q/2UMS(/[*O?`(LI4^Z?\]07)V6`8>0$0&,@S;Y'`!@'>=OK+R-U M9UGS*.Z6B"5AET6<%&71%GUJU_7.[*_6IW\OBO;9#"UKRF@R7AI2V>OJ5$DX&GNI M><)&*\822E3W823(Y?JE=XG1[I^[I2DZK'(+S68#331A-/>HTS\/BML(CJ1% M-5U1F.:!,+(9.`"`P-&XZW_=+IK>K+U>PVI&;]+V37Y>W&;#JM+B(CL4+K$! M$'HP\C32LD[]T&O^F4^I>?D5[Y/O0WINMXX'F.=.GS"Y(=Z[S^9_-`<%5A<;NILN#8F7A/ ME@N=,-(9FG=S3_K(8]('SJP2QZ9RU='@`CJ5N:02OJ(4%0^TL_ZYQDUSMJAK M4O&<&AIQE7E\QHC%8@*4O>MN"!U>[].[4EW@1+[.$+@NY(EF<1]>];U5TK3N M-`'M8TSJBB5WR_`B:?,%&:7T%Q@:I_1/7S4,^Z89]&3I+_T;G<0URR6,KV+*[K9S)=^V=<+O1O86(9':C_,Z4_ MH)400Z&)*I6R;V5.A[IQWI7*J=IA`6[S`#"$`P-:YH(BKNQ?='[-?!H?T5-16%T*^T]50 MI.'/_<9<9AZM46JQ!`KEM6MH9Z'D&%P[<%V=N8ZN:[I'D7K:Y^3W;7?:-K&[ M[*2@88"?IHO9HCO.*4-S,@$H6'2-L3,EF&(:]-C2X/"%20M.8R\R3-DHMEB"C MO*4M3A,@/(N`]J*^K76=>>5<2'!=XT<:&4L/$1X6FH>1^;Q?<,8Y&78-`[(, M)=(3DO71>$Z>+!ZJ<_YJGBV>*"QI;%6$PC`/0N&^,\<+/.@&&FW9TAJF@PX:1"%V+B,N,P\3J/48@D&RCV:E]JIT%T.[2#TM,;9]9NONV-UC/)U M2R7LM$>24N;ID8G#DF95GH"Y!!9>QK0.P<@/@*\3%F)L:YK(BR!#M^IWVV3H MK']Y8'.+9J82',[F)7Y&Z&LG92TL0PR3\C7FT5*7BB5(J&9,B5+`P^SE4]_8 MX3VEV"4Q5E/F:#Q(/PMD9QLZB?5Z93_X"I?Z3)SN[E M:RO5S71XDFC#BBVK&JR7N2X2QVEZGAOY@<9#*;^B-J:.$`OUF0/-$#/(&/(7 MGJ["`ZFG)BUXMDG](O-$C="*)0"H4N6ER.?M4E][+)M+2RA3'4*$J1/S=M7IRGLQ9Z]VT\9U>[D?Y-LI,*C[,4%W156Q$TMSJWN$ M#.KU&@@\WTOV3E:Q=PU\JK(#OC\BOQ_]YJ3_SY%P8=WW0KKTH=-'\X"JA:E% M]!M2>4TO@;_Q6E#"O,T0"(5!FP;==V68617W0+]-W4MC\@ MCU]ETG+F*TXN#TL*[3DP2-,D<7C!42H/4?GB,IPN9L.YINICY_NBL5#9Q??5 M-"%"PPS)N^([BP@CDSB6I75&-[51L]*YL/JSH-F4C@I_3V9ZK44N?BCPHBF? MB6%JT1V9K_R!LO?=2=)L*P:Y);%0].RWSZT^F)$!4"2QN!1-[7F;:-HC,U" M,`;7\+>4I,!:GEL"YBTGK,@ZX6FWF'82,UIPQ`P7Z#4093Q3;,C&OHY/8?&Y M#$;T^4X>`*_;A)5)*+_/JMQ3II9B4F_1"H;PSFXDV$5QA(K``3V)^6MO=3=] MLB2FI;+[7F_]_($",<+#Q;*,3LU3UMI,'H5KXM_HX1&UF:(BR>C&X>O=S#W& M"T[F4\0"KADP6`(:_,`!/M<6YH/-P[0HF,^Y,`73V@W7QUIU^OE^EM16Y,RX M==>VM1B_69'Q2+PN_!1E^P3(^.\T.>X+-P,VC>+31X-B]E37 M)MU'F7ZE]"$^:8"--A@=TR>JD`0QJN.:F^6(%8!N?5A;692K#G^\P"*;08^V M#\NU:6OWXO3X:TEOT@`.?F*3Z4EJ,ET=W'-!VMM"4[ZP$(7C;:[;*JB#5NJ MZZY&W`#E4@U3ZL>BRD$4U!7LKWMH>EPUT)8TS*5NVKQMKE>UD5?.REVX]JCX MX$KI9`7/V-=1KDI4G/]Y#GA04)743YJ^XDX=4E\RR%T[IF./6:?LN-]S'Q,< M3M7(@SI0K(DJIHZ5K5[7L&A]>#&08'C-4JHB1,]W7OSCUI,T01_-9 MZ+.11#(/>KK9$:ZSL!>UJ3VNN[:L,0^1N/9* M4I$#?RM1II!7F]>FQU4K:I-Z1.AZ\5P2V/6==K"LJNVZ(V9P?Y**N8%^41_* M-6UUM^(R1X1QBKH+2KAIO3$'I.D1FC3@03?[P'+-^IX^MFTN%V.VJ2M*N]UP M[V^I3DQ5(Z<@`+44H.DW#*"MTVWN$TU]A?'9K-F.][WI`7T9-I-ZY.HW^7#, MAH)*6U%=4F5+ MY>_D1=AL+)PNI;7-`T='\W?X_2/!L'O,GFIJ)3E1"01M4?62\WS@W('FI">J M=,O0ADO;57F\SSZL:E9^621G,^H_KR6>KF*=,7!U6M9W@8YVI*!M62N5F^GL MH]](^A=E>?&_8UK59?2("EZWJG[1,X&K2CI=I3ICN#:26P=7#>1HZ[Z$6D25 MEY9_]$N2PH[N4QJP)!>107EVUSDZ<+G1&!47X5-KO"WETU_"\P-Q6\*3(9"E M"VQG97G*CC+Z]_>7,^J.&<]DG0^\]:742\3S`74'FIL-NN&@;#D;ZJMJ6LO+ MY[GCR@S_H7BS`DR>_D<,Q97=S]P`G^BV)#X_97?J5 M9A=02P2!!E)H%+P8=Z'!:#202`.I9)?D\.OJ&R53JE=RSO`:G?%F<.:,N]1` M]OK>GE]L'J;$P'R6ZN593J9=;[JUY2SJ$-61-^=]HFLI#>,D,V'C)UF!&#E@\:CW#%/%L[\I(7KV#O]>," MJVY$)_3']"#J:_#!D^.A'+TB@+Z?TJY^82[LC56;/VPNUM;:'3%\MC@K>'64 MXG2IF,#3-8I4+<^[4.ZZJ+FFU2_-<\.NH36IQX5N#P?+-:DJ5%O>T.1O7T"Y M@04?[5E+$*&D)/$LD%B=?6H=%"L%,?1P*F?42^'R@VX'F9A_'Z_#2/;1MC]#:MEWN2=E,YV[24N2ZOEQ'[3M-/T?9XH`&+4)Y!";[3O@%E-\RW&)C..AM* MY=V-GT`_8Z"QB$W%#^':CM)?6167LFQ5T;^CO^!`M\[HUU;2DTF29793&-7D MEW:!8Y_:1'41G#?M`0X9:X+-+AQBP=!V'.+AS,LLM@6"-M^6M5&6-V[7ONQT M9RS7PKN8/F!54'UGD783,YD/R[."M:J..AJ+[_:Q1S+#=&7:RKY'O:-6QN*W M=>Q*97Z)[R_63>`>(.QA0,Z[!3]4+Q'7ODE5.LPL+@<&E%71+JS M:SS,M>7F!`MUGG,7=^*0BZ&G4_'$/>^ZRA[M'9U8`_+9TI55G;N0^%ZM56FM M3==>.(LV)W,[99PO6YY)!;.$F^9D70?3HY1:1%E&QC%-U1',.H]/;PUJ49DT M3+AN^TO'])3M+S4VP6])2N_!5I4V0[:7SC((0S^(`MDRD*]J.(4(S9@V&./" MLS(]+N:S(J=B7'&Q<_GUJ.U,"E:VTJZ:T78RNIZB5,RTSW6/.!M7=<5[6G%. M2JOZ2/;1@6S'OWH3+F/0/@DOH8\6Z#8B7K1E&OMU[DLB95%S_A!H.:C?PXQ- M6.3W%?EU$OI\=J@6M"8=(:6[#X26:HKT<>VT MI-`H21PR-+B5;(:4\WSVW_XL*$)Q^V!.]W[:"T)E1[DV5UI_OSLL<;YZ[<#K("/<:;0TH"UB,..R/=')*;_/5K'(L\D6B+[]R$27J# M7[@R`F[NLO9WK"ZR]I;K+*F]4*;R7W#'G?>$E0[/&*@CU2]+*1&C&&1=^;J.3E6O1OE#6CZ`H;*E(?WRM?4AM%[PUL M+RG=Y*#]A"[LXOX.IKN<5GPA4^!\A]$(*HH^XOWPWQ"`O@U:RFG[%5!Z:]]<[,(5=?H/R@.YG-] M'JS-%*Q-+$A66I,_.`T?L47GY(AZP]J&2B1C4!72G$.&=2AEZS\3?PI@9R`H M,X.*4`F#*:WY>F3]Z"+NZ@TX0,!LWC&YJ_N2TE\P=TPQ3]ATL29JN'UXHK&5 M--_X2(7@S-@?4[P7.^"L$KQA?DC)CO=7!:;QGCD6A.0E+OD>MB,Q>6`2N19V M`R`2`(%-6X6;@$;\C@"8@V-[3X5*GY-UC`&U!_(7C7$\,$3XELCV+GQGAY]& M80AA,IJ*MX$X(`C;IM)`ZN(J.1YN^5\S?)"`44?BO]A6OH53 M8PLB]7V$#5NN<1GS@*\$$9PEAVH'V6;Z*UUC89IB_$*$QK]HI<('ANF)X@-] MX%H5GWO.F&BVJ_JR^I/7@N7Z=KI[M-R8W%@'QI>,]?4M>94I*0&LO<4L37-I MJ_+%YMV3MD/4T_B-:2M;MTL]Y57[ZW(M>CI^YXV2;Z48K;H:NC,1H:YTO,!: MNZH*EZ#4AM$!I7/Q4#@Q^Z2LU`VK-JY6ZH[RDL6ZC*YM$BH#R"IE[^84]J>M MYU*7+@.567@:V_B!9)$_)Q;[1#:N";"MNG;@[5D_\JOGRW![SWK%B]MNH53K M1S^Y`5&IEIR/2S+0DO"`$M=4Y9%^+4V)":=!,FBTHV57P=)3G1421Y=DI0,+ MON4'OLKH98&^8HWQX_^2G,B+7E[M_R7,2>TXX,UJX:@J))VS-]_3FXNDCQC, MD)(E\9J1"EK?M),NP9?IR;TX7H3+,%25?!^U+FS'HZ\AXZYMF5A9",'"]%KD M&PY31:F/""3&WQ7BZ!4ZN_:H->5R>!2TS;NL6#2A:2G7OMQL`1:_J%6> MW:?'3CM;M\2'S[O]-GFAJ,:SSQL'_+PV<_9F$]2V=K.LC>6,6)J"AXC.)R=6 MOEF08N$9F7J)L1U'F-?=9!O"DUJX:#=]\$*Z4>VR_>*9AHS"'C^JJ7J1L@I6 M5OVB7"Y==^F,V$3YD_"!P\K,?-`K6/1("+\<85EB(P3V4T"CTV4)O_J_G)8O MC)3_!4J^("$*X;SRY/1+[#4"DX9)UBU_[@2>6=^GQ[46R\6((?^GP"EN+&8` M'=Z55P\\BF?G!A\5B4G]7&OB)R"^K[+VV#\==VVZE]AVI&;AQL][M!\;LZ_' M18]$#".E`3QUC\X'.[44)K7SK(DHGID=('6%)PRQJ:WA.:)%Z?6;M+!;.8D0S(T?% MIV1'HG@"7'`"^.=5]P:*/T^/""552R!Q^9/WTKLGO_B=%LB$V?%] M;^K:+3/Q':-HJ@CT&)P$%H?.G3_B%^+AO@'GK2305X+S68'=R$[ZHT9;.?17 MR@)G8R-V^&@^GZ3I"_-5\JA=DN6I*1[98O4((WND]&`$&-F+%5GRO+\="5A5 M!A(\L<=$&!^[L2]BFEC,31Z(]AQMMX9'Z^,"14*+G.`C)?*+.95K-0]O[C+&2HCE($L$4"6OS1PS-&SN&;'LDBOG,^T!A8P'X%0D/$N.N#?6;"B06/"GL8GM^0Y>V^0\(!1LEP,(@A0A-K` MQ0A;/"[9Y0GFR@X2:\Q>"/%]Z@(`N2(P^`WZF!5*C8-DG+*(PNP6FA'[HKE1FTC^36$\:90F(\>N< M`F1;G?`E;7T/^0[B&$:H\SGP^Q"?#`4J7?U]'2PM1WF'?!%<#ZX#\#,V/CTU M7SL8JT?JJ1[QGY.SYN1$L0UW2KXUY![O9Q$S8BO/'HE0O;;PFRB,4&Y9L:\G MJ3S_(#K,->2G8/Z""*05TYZ;>6QX?#W_[@L33IDK`T!#-,4/;XW;ZB%3OH&) M6VRY;`!/MBL M(FI23#N15X,*R9(:T[A@-%09:8[4VHQ(7>+=QQ0#'5G\;)ZW@E*$;3F+@CSH M^ZUTJ!5:0"IQ#6][5&`0,9*R`6`W"@2X"]7]C:[N?J6?0[4(%Y:JQ,)EMMT. MOA-)FLT*UMG,:D3 MOPWP-)4QQ]R00-E0>I05,&@I);F-$28K\QT!-@DX1KB>U+D2[-\&+^(>KEIY M0'/NU^'25I:YO.3FU^%8J,Z\/-\LR)DAH7<-8,MQ`^6EU"6K#8PGG'X%@X,- M<5:JR(=S/:(:#\]+A/.'^N5T=+M[4*K0N;)?==9HYGYTNX70DLIP\IW/2=F7 M@=H[BBXXT]TG+7-CJQ3GRZ%]^'N+&C]_W0+)#7H8XK@5U0/(?K]]*5S8\`-8 MN2S'$%YE#6.$S0T_\]\K'15[?@TJC$1*X"-_PHZ9!9&?YY[FV?Q%#11@*_&V MT4-NBNYYH0V\.X&/H:VN(WX:7&SCTT5==NU<(6-F1I M9&N M?#P_FE7^%:R*?G87.H)#Q73"T*_OX[JV'7O,"$FC0F-3/GVX#3&(&2J-*&&KFTEFYK4K$ MM51TD^Q@_,AO"N"$P.*7F$3&]UP9,R(6RF#!4`,"!\HYP7X(-W_"F&#C[#FRD]!#Q,F:&2-`VL%6;[@EX$J&S<7QE[9C@ MSZ-PJMTG/RBNDFA+*Z6.>-&PVZ+(4EU)#!A`O\)"SL*ED"3QR>_=!:?,[N]2 M3BKW&;0LX/`/[2F#Y6LJ4]I.BS4QYTVY2"\NVC]H]/`(:^^&P.OD@?+J'9G! M9,),Q*W/^AN6\9][WN6PJ.BD+Y70\U:N2CL8KU1K!]]V08PA4=-I5[+6FXVR MF(EH;8?`_7S<&[YNKMY)`3\WK;JTA2N+FBJ,SZ*[W7!X>+6Y MG38<;'.S5&64_'[<[[>BYB5NP5^VR;.4,\EV91(%GY@<\A3YLD\DS M6&\X)+"2+\M^BS0:G$B#4VD`F0/:?/WD-+C@YZ,`#\1',@(<-55>U]G8GJKL M^L771J<]56.)W/#?,[?A665>=.8VGJ-:`3-?<&C8*K3MI,N%QY]:GV MB\7"<4?,IK[/ZP*+HKC#G2ILY+N8C]NP/AJ?FWXA-).7U,^5+N`=QPR4^A[[ MI[5:NYO5:L2;B#,$='.T#=NZC=?BUO.ZZ3P^/8ZTJ$P:9EX73[8=F%1E'>$Y M"?LY_@^K63Z1+9H%_&P_K MOFZA'Y]HYJ?1/K\EKI MIW0MHA8.O%6"D;'>:R+/G>Q9#DOV`D\\L#M;@'M6MEA9+LUSP3&=<4ODY@-%[`C![LPPW\;+K0PJO2B* M()[&M@RJK@O%D$P.8@+S1@S8U^4-:R(3[7)M>="/YZ/FW1UJL+@'&:1Y/`._ MT);FF4D3'MF1--J6G758SE'`2^K)'^4=(L1+B8_])K(#_$32(/H7*084H1.$ M>XE9W"B+S,EH^A3Y7#)/5P8)`D8$AE6@''#FT4/.PS\J.#N3%X!@YS-W MNL@T5IE^0?6%LW!JVZ19&\M=.`L``00E#@``!#D!``#M'=MRZ[;QO3/]!]=]]K&=2YN3R4E'OF4T]3G2V$[2 M/F4H$I+04(`*D+:5KR\`4A(E`2``DB#L:J;3)-8"W"NPNU@L?OC'ZR(]>0:$ M0HP^G5Y^N#@]`2C&"42S3Z<_/]V=?7?ZCQ]_^,O9V,$FO;PXN_B&_>^<0YY?X\62 M@#E`%#Z#(9/'`MR^+ME_`:_&5I^@5T!KDX"%DZ]C<0<0D#J-TR&1/\@5`61U:4\V0UO$; M<]%@-$#)&+.O@8S9#__B%;.N*0_/("4KQ0-G.-\8IC+M$?41F$8)_"-NX9FBR[R7B/_B:2@!EO(L*O#;;R2/["S#9 M39A'`.EH6IVFNX5AC=1H>AW1^5V*7^@0)9"SOW;910EW"Y(M_2#9$HFW$_K` M?L-FMJ.)Q?0ZC2B%4P@2%SJNHI2[?8]ST*4Q5O`O?*!F+-^?I?W%FAE7MI)L M"ZK56@7?.F8W.,X56Y8"MT0]0HW=LF*3]^P/Y0".0@N8%M\%KQE@8EY'`9MO MISC>H:C\7!:]8H07;+$K(HR799SQ M5_:GW];X/+&/KQ%)HPE(/YVFDU3ZS**T<$,&KU"V M\"L@0MFSGGBD:K9?[8`&O%?MXHD-Q.!180H4;O`B@C)CE?T<"JM5+,1UJ+?( M7I!FF[_LL[?\\V]C005/.$=H]1DL)H!(.*V!"H7A4HYB0_1E3._5J9&:I;E; MW(-_?4*2$E$W``$=:V M=(@>KN6T=S_K'E*>?M=KA1PJE/2`";=U%'CGN6%"K!ZX1^M\`#/&41*A[$NT M4"N.'"PL.S798NJI\:Y%UXPPP@L8$O#Z3[!2BD`!%Y;UFLM`2XY'(5SGA.PX M@>HL7QUH*(D^3=)'X%:?I/A%_0(X@H1B`94II+8ULC^%!R?[8F8D26 M=^'\@M.-PG`W947\*%H:*)J`.XGD M;_V+Q(0J[Y(1ZG'-UM!9I=3G0"!2*"&IW/+4[GMKU$B*K;-$T81<`"8I\J.NBXCL6UF)O MY"UX/PQ25@YW>MJH-Y41]PAXW=5BGN15*,[=:"]TC":\EM,'+U'0)YA#.@C MWFK6'A5ZX%",H);?V(XBWQ8!4C;QK+@HS2^'#9(%1.*4B%]IW+N(6[42JX&A MQ"*FTG*ASK/D'AC/V"?G#+D;\`Q2O.1K5HG9[6NW?`[^**(PUCI41?&_>U3YV-S#-,Y!8T*,884?1 M8>.'*3CXDKA_?@-IG&*:$ZTW:SNT-_[_"N!LSMGWS!R&&?B2\\S/:'J01A9: M(R'4:7PH/K"UE'!CHCTO%@I,2YLQ.3IQG"$4Q[EE$9N1[5G(13[C'E-ZQ^B^ MQKRQ0\Z0&BUY$RG>&X)1+W1QIW'(0>+&>H90[5B^Q>$6:.U5LEQM"W1!LL7V M"V#Q^5/T:B=CA[E"-6D+:3M3':)%5]%NU>RW*2`LZ+POT%`*6D@Y M`X0"`=FUAJA<1)L50+CN[O?R^8,07($8Z3_T/$5LG@317[CQ'*-66]:)K2*+%"G%YT0=] M%LD\&UIZ6:NM$GF>S:U247D#GV$"4++!DW?K&T=0?OQK/LQM4^W@W,ED8[(E M*[AXZ0I,,0&5_LF?(<)$E(T5"P';=W=GN?UOSG[^#+(Y3G@O4)KMM*2TBK1: M_[K[F:6ESXVS*.W$YS;=AGM@:W#*RR"*0]TQ/SID,G7;_[O]D/L9WWM2R>8< M##B=T#!_T$A3_A92PL!64VSXXKNZG6`6VW!$)=(]_-']SMO;L7(5U7V&?'7A M7"/Y?'Q;\M$0WG,M1AG"F%=K!KQH48IA MW3GL,A8_7CH\7CH\7CKL]\Z;WACKKMN8*(RT[/`!\*>QXBPGQ7LO9&;R0M-N M4:[#!&\_*K.H[G7FCTU6W>&,^QF0">XM:'6K6G56]/(]I\K#>?)3:2V.E6UM\)6S5U)W;#`O%0[#"^7@WM[7K6.*^D4:7 MY`#!:8UR-]/A[UE'[F$T@:GH8,$OT?*#U/+9Q>)`2B,%VZ&A5.G6R\>-,M^% M`!'EM\#X/SA6SU'*SPL'V75$R(KY2K]$:2[M/6HS+A29*2P&.Y/D>RF>8Y(] M`;+0G]?KP$))!.E%44^!9\Z7#XK2!Q`#IAEL3V:>:=GO4;:U&("'4B^HEX0Y M);Y/CW`FUM5['*$*=C\13*E:,!:C0KG3JY>/-4'>C]_+5X;EH:_LYU#:O^H9 MK\;\S3`WG[B#`E*]2.Q)\E^+L`0D6XW3"/':+>YF MB)OWKN$_?L_N;':NQLK1]O[LK_;]H.)>=.Y M1<-RFV'!U!?7[1.V)/EV;05:_.HW76(:I;,C]I99(TBV.&N_6W MVFHA;K#9AH`A3)KZ'$(]9I$UQ#4D^AXCA:<:>C/DB4`X82?KB*PX0Z MWR:QN=NQ@Q,CB],@=\Y]2N@'K`8$)05RF9D.?=>YM" M!)+R9O88(,K8QX/G"HWZ3PMQ M-Y\LF'#:5?1ML<"_I8LB+;:O6]BVT1`WD085TMD0VH?]6MEG!\(**'0P)=%[ MSKU4(D&)JIQ!`^4FF("<;+LM**M+%"!NLO@8CBSTA/G.5"6)*$*, M4M[@8HBNHR7,(EE>O@;2K;ZG@_-!YV25"7V^,QT$1#0G*ZVAJ('<9*(KZ=^G M1,A#X'*.P"RJW&[L6YQU7/$LR0>01=P/75\_&,1QOLA%1H![J+&TVYCY(#=) M!^2YVY+J67S[354.NCJP3KF-*[ M(%OJ*MCNQ&X*\RY,O@M&]K?"2TG7+_O:(6Z*\=U[4`P[%OG/5O-.!`7GT?HL MD3Z17+I:F("[B=KA!1*1EH//W31U:)`"-^10BY(^-M8Z-M8Z-M8Z-M;R4\+> M4V.M,@:N5$V4N0^4B,/YNI2%,CMGV8,X^6B'?_QG6^FRS0(_M803, M>:'J,]AV?=9TI'>&Z;72-^9"&)(O.ZTVD[S!)*'D?SN4O#$7?)_,]-^Z MLDL/*U\N4[$_1^G:,QRB*2:+J*Y'LMW(4/I^&#Q^[4*812;8H9_]4A@80YUD M/?6T?P-=2]UBAT^O`(6[@S+;P9)XT"3Q(_I.7 M/0J?\`.(,=MA16_5;2:K>/UUD`K^,1ZI*F+8!*T$/J&@U-N6>P.82L904,;^ M/05EB<)@P\XAQ@A`I_7L6W)VS("W&LJ7?,NOM> M*/TF0U-$C\SW'\S%`"3B`?L$,$]872` MX>>(_`[$7:M'$.=$561H-<[=G7W/NE#/L9YTX0Z3ZN96OK]Z0*A&*RQG:+U: M_"WKAQ/OO&=!EB6VM:YA'>C[71LL?$DS)O6T'(RF(Y(P6LAJTP=>8_H::/=@ M\AV)VIA/SH=(567:^!M/O0_291?:"@:/+J;Z<\A;UJU?>AU'E)NA:$99EZL M_6#W%RD"UPP+_]65:V%HAF2%;501VEEH$XIF6&Q)KESSK!FWTRF(V39X^QJS MS7$&'M@&/T+R\BN);K@,=]Q1K*_3IETH1AO%Q>Y,Z_%8I!*IB^C<;.UPG,$Q M:&K].FZ[!R;6#/`L[GW]K7@XZG[HYH/>0<(KM!-96^:WJ%#'-D+'-D+'-D+' M-D*>;\3X;2-4W;T?F4/&_+,B+92M*MDBT]/#QI/Y\IR[:T33PHE12USL1B?6 MYQAMJ(3)7.Z.\O^)1I@SL=O;<5WV[&JULB^`^RZMF.:Z.FT_K2^2_E7`EHY_ MO'^[]>*S4$R_83FB!Z8[*VC-M5W!C0@F-P*-(JETAXG[!6?#"7N[9E9YJX6C MR40ESS`H@$)QK%N2`C:CUWM6J%C8.2Y2Z1S^',K5KK;EHJ+4-C8*QW6P[2-@ MUG[`:MGQK,XV"7R)NKL,;[W:R_MQ6!NG'NZO8E5J_\D`.A0GPP15[$,\WLUQ$,"#VKW'!6[[^%20,414&,AFP#97J;*Z; M#[1@<8,$+PMMVD6,:5U@-YMDN?G$!/#JG?#VV!BMG69 M@+=@%.O/Z`U``Q6*LNM0Q+8L]:ZF/V&M+>" MX#YN9OKL-D$+&E['6HW:VPX-Q1:L\<;-9>3=9-9/C[/(3+2BZ=U$]A'264,M M;`N*O_^-W:?ZKO%B@9'XH>SEKS&$IE.%8AB-Z;V$?(;*^P&-6"G91?,^S46@LU=KZ]R"A&@E%GH!*(HC$A: M@I29>ML-;"/RY7?:*2QBP5]7()OK@MU:X%`TW`!3[,YQ[TI^C2FSP207B:(A M8G1%_"50'FI7*'T`XCT=#NQH`O(7KJP_;J;KK<[;@BG8XZ-[4Z3Q9+Z*([H\ MFVN!"[@S9?%NQ6/^NE61P68($I!!(C)F91<\WFRH_ZUKBZ2(#Z68&AIXTZE: ML&D3EFNLV&5X*%N@$^ZX394F6236]F"98C6U!\V1=8X.+Z2E&/7@+AB!X,T+%US06H(4+94W7 M([E??!>>NDI>^2P[`?>NO1+4ON"L)H`Q&])*;")]'E4;@!B->!]1AAFIV$5L M1C92_L+_;Q)1P/[R/U!+`P04````"`"IA:T\FQDL@3\(```01P``$``<`'!F M92TR,#$P,#0P-"YX9.Q+=7@+``$$)0X```0Y`0``[5S= M;^*X%G]?Z?X/7IYV'RC0SJRF5=L54#J+1*$J5'/?5B8Y@.\$.V,[+>Q?O\=. M0E)"@4"FY8J.1AKB')^OW_'Q\4?F\L_9U"-/(!43_*I4.ZF6"'!'N(R/KTJ/ M@]ORE]*?UY>_ELOD*W"05(-+AG/2"!3CH!3YQB203Y[$3(<>6T6JU5_GO7Z5M:E.;!%+B^%7)Z`R,:>/JJ M]".@'ALQ<$M$4SD&W:534#YUX`5'?\3^`7GBB"ERK57+U4_XMQ2)]QC__H)Z M-I1>K,%9Q;P>4@4QN3_*P3M0Y3&E_J*#91VH2M1N))R7J[7R62W50\]]4*NZ MV!QR1N&^Y&\0"CD3!,4X[@ M+G`%;E-P)3SF&G%]Y&=SD^J-VI@3IQAIIM?C0WMSJ@@57[!8<$@K8G1Q8<0X M,WJ'HWB;E'5=Q3]G55(F"_[XN]GKWK2Z_=:-^=7O==HW]0$^]`?XSUVK.^B3 MWBUI=YN]NQ;Y[;%;?[QIX_O?+RN)"LO*64<%Z)8>O[:_'>HY@6?=W,'GRTJ: M8E/G1$[^OKX$A69NEAR]B-'=@+LKG,"XKXTA(J>6>VZ,;U;P*`SEFD$YEI#^ MF9)VU`@B2Z;G^^#7RG`H#+W3)?1"41_8KJ9R;D_`=!JGX1[RS@R8M2[ M%\K:W?2H4F%961C"G[;,PHUZI]YMMDC_KU8+,_%'_MUJWA6C)E636T\\[Q4) M"R9M[N)RQ='%X?]YIUFX6>__16X[O6\?D1!'`KJ489UUG^*>&_*>'%/._K&= MDX#"ASIWTXQ3N2&)M<)BHE:U69\IQQ,J,*MCTC#&$3$B:2V.&F[J"C^$H@O/ M=<<1`4Z-?'R/D#FX,,D-?<*B.:%\#`HA;TDI9%-(,^)15($(US((UR-[#,AH M$4GT(;%-QXVW\R-@X32<']QXLZDIID,9H%,U'6X/EM#GIRU.@YPO/H M4$CD^P1U*D'<`.;'=M&.>L@DSI3 M(^`!/%.4-9%X%[ASBR@L#CZMB`.ERPMU2$H?0KF;'O;E2"7;Y;BCA!84"C\= M[\_K\O@'H*EA/T7.$UQV8>2'NY*MF6]683L,[U=9%0;K'RN&<4HJ"<62WSI" MJ>->0HWB14V;*RV#W2;HVU5,BANCGY?!7,@C*8%'#2/C3\A5R%V60>VH[[PX MR+YDQE\[4?"H@1H+X3XSS\-BIJW2'E>W]-DR+0OTTNS$5 MR;>@O]2`1"H0J\-1(P]4VTJDKZ%C;VL]N3 M5@"Q&Y-&WI&,_,M*YII>U+1TH\]>YXMN"Q,ZQ&*5.OJJI&6``6,K]!'\W<@> M(],O;$$6 M.+.WL=W8AQ%J6S&VF7`'ELX-9%@^5')85%]_4KILW?;D!V?IJJVG9?,VT!R< M3:F]DF535K\Z.`LV;4HLFY6#_N!L[6`(!H&V,]R)Z96UQKOK\>YI!M5U`%QU*\6TK51@\,;JLC\14@_`?-,V MU&B9J3<3P@?PZ3SZLN0%Y1T-,T^;#W#Q`W?HJ(GJR0ZH189Z2X$'-R*2Y+[1 MGCN,N\&$INVR;MG']V\O]B4?D= M;+G0!\>\LX>:V4#.R^!@`W/5^B29-`V= M[IJ!E/A\`R/`'^Z`SJ*J/JKVPZ>(*K8R;Z?W0#?\*%2O-1ZGKNU,,7/<2Q?L MUO70'/%JO;5V+"_2W<[98!.'@TT'6K-ZP-GV^[O,F]L M%SI+M6RRLNJ-[$WK3)6YCN(`EAXO[ MV(J?,O?&UD#W5MJMD)EMEWVY')Q?MKGYL>R%G'W>?6V4/Y+7E$I%,7OG0NJU M>+"'/ST>KIR7@7_MY<%%]8H+P687()OB-I&]F67A65/XOU'@X[]02P$"'@,4 M````"`"IA:T\_?+MXD:>```)K@L`$``8```````!````I($`````<&9E+3(P M,3`P-#`T+GAM;%54!0`#WF3L2W5X"P`!!"4.```$.0$``%!+`0(>`Q0````( M`*F%K3R>%BODT0H``(F6```4`!@```````$```"D@9">``!P9F4M,C`Q,#`T M,#1?8V%L+GAM;%54!0`#WF3L2W5X"P`!!"4.```$.0$``%!+`0(>`Q0````( M`*F%K3P_IS.S"1```"?]```4`!@```````$```"D@:^I``!P9F4M,C`Q,#`T M,#1?9&5F+GAM;%54!0`#WF3L2W5X"P`!!"4.```$.0$``%!+`0(>`Q0````( M`*F%K3Q7N:*1RS```&'N`0`4`!@```````$```"D@0:Z``!P9F4M,C`Q,#`T M,#1?;&%B+GAM;%54!0`#WF3L2W5X"P`!!"4.```$.0$``%!+`0(>`Q0````( M`*F%K3RTA$65-A0``#\W`0`4`!@```````$```"D@1_K``!P9F4M,C`Q,#`T M,#1?<')E+GAM;%54!0`#WF3L2W5X"P`!!"4.```$.0$``%!+`0(>`Q0````( M`*F%K3R;&2R!/P@``!!'```0`!@```````$```"D@:/_``!P9F4M,C`Q,#`T M,#0N>'-D550%``/>9.Q+=7@+``$$)0X```0Y`0``4$L%!@`````&``8`%`(` '`"P(`0`````` ` end XML 36 R17.xml IDEA: Taxes on Income 2.0.0.10 false Taxes on Income 000240 - Disclosure - Taxes on Income true false false false 1 usd $ false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDperShare Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 2 0 pfe_TaxesOnIncomeAbstract pfe false na duration string No definition available. false false false false false true false false false false false false 1 false false false false 0 0 false false false No definition available. false 3 1 us-gaap_IncomeTaxDisclosureTextBlock us-gaap true na duration string No definition available. false false false false false false false false false false false false 1 false false false false 0 0 <div class="BWxbrlnote12"> <div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <div> <div> <div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left"><a style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline" id="xbrlnote12" name="xbrlnote12">Note 12. Taxes on Income</a></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: left">Our effective tax rate for continuing operations was 36.0% for the first quarter of 2010, compared to 28.2% for the first quarter of 2009. The higher tax rate for the first quarter of 2010 is primarily the result of:</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr valign="top"> <td align="right" style="WIDTH: 9pt" width="1%"> <div style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;&#160;&#160;</div></td> <td width="99%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">higher amortization charges, primarily related to intangible assets acquired in connection with the acquisition of Wyeth, and the mix of jurisdictions in which those charges were incurred;</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr valign="top"> <td align="right" style="WIDTH: 9pt" width="1%"> <div style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;&#160;&#160;</div></td> <td style="TEXT-ALIGN: left" width="99%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt">the write-off of the deferred tax asset of approximately $270 million related to the Medicare Part D subsidy for retiree prescription drug coverage, resulting from changes in the U.S. healthcare legislation enacted in March 2010 concerning the tax treatment of that subsidy effective for tax years beginning after December 31, 2012;</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr valign="top"> <td align="right" style="WIDTH: 9pt" width="1%"> <div style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;&#160;&#160;</div></td> <td width="99%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">the expiration of the U.S. research tax credit; and</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="text-align: left"> <table style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" cellspacing="0" width="100%" cellpadding="0"> <tr valign="top"> <td align="right" style="WIDTH: 9pt" width="1%"> <div style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: symbol, serif">&#183;&#160;&#160;</div></td> <td width="99%"> <div style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-INDENT: 0pt; text-align: justify">the increase in non-deductible in-process research and development charges.</div></td></tr></table></div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div> <div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left; TEXT-INDENT: 0pt">These factors were partially offset by $410 million in tax benefits for the resolution of certain tax positions pertaining to prior years with various foreign tax authorities.</div> <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br/> </div></div></div></div></div> Note 12. Taxes on Income Our effective tax rate for continuing operations was 36.0% for the first quarter of 2010, compared to 28.2% for the first quarter of false false false Description containing the entire income tax disclosure. Examples include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information. This element may be used as a single block of text to encapsulate the entire disclosure including data and tables. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph h -Article 4 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 109 -Paragraph 136, 172 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 109 -Paragraph 43, 44, 45, 46, 47, 48, 49 false false 1 2 false UnKnown UnKnown UnKnown false true -----END PRIVACY-ENHANCED MESSAGE-----